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Preface to ”Synthetic and Biosynthetic Approaches to
Marine Natural Products”
The ocean is the natural habitat for abundant multicellular plants or animals and unicellular
bacteria. These organisms are excellent producers of secondary metabolites that have important
biological properties. A group of marine natural products of special interest is the heterocycles. The
chemical structures and biological properties of this compound type have attracted the attention of
the scientific community, which has attempted to synthesize and biosynthesize this class of molecules.
This Special Issue of Marine Drugs collects a series of papers describing synthetic or biosynthetic
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of the Furanosesquiterpenes Structurally Related to
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Abstract: Here, we describe a general stereoselective synthesis of the marine furanosesquiterpenes
structurally related to pallescensins 1–2. The stereoisomeric forms of the pallescensin 1, pallescensin
2, and dihydropallescensin 2 were obtained in high chemical and isomeric purity, whereas
isomicrocionin-3 was synthesized for the first time. The sesquiterpene framework was built up by
means of the coupling of the C10 cyclogeranyl moiety with the C5 3-(methylene)furan moiety. The
key steps of our synthetic procedure are the stereoselective synthesis of four cyclogeraniol isomers,
their conversion into the corresponding cyclogeranylsulfonylbenzene derivatives, their alkylation
with 3-(chloromethyl)furan, and the final reductive cleavage of the phenylsulfonyl functional group
to afford the whole sesquiterpene framework. The enantioselective synthesis of the α-, 3,4-dehydro-γ-
and γ-cyclogeraniol isomers was performed using both a lipase-mediated resolution procedure and
different regioselective chemical transformations.
Keywords: pallescensin 1; pallescensin 2; dihydropallescensin 2; isomicrocionin-3;
pallescensone; furanosesquiterpenes; stereoselective synthesis; lipase-mediated resolution;
cyclogeranylsulfonylbenzene isomers
1. Introduction
The furanosesquiterpenes are a large family of terpenoids that have been isolated from different
natural sources. Among these compounds, those possessing a chemical framework consisting of a
mono-cyclofarnesyl moiety linked to the 3-furyl moiety (compounds of type 1, Figure 1) constitute a
small subclass whose components occurs only in marine environments.
The first studies of these natural products date back to 1970s when pallescensin-1 (2) and
pallescensin-2 (4) were isolated from the sponge Dysidea pallescens [1], together with other structurally
related sesquiterpenes. Afterward, these compounds were also detected in other sponges [2,3] and in
some nudibranchs that feed on sponges [4]. Moreover, the pallescensin-1 isomers isomicrocionin-3
(3) [3] and dihydropallescensin-2 (5) [2,4–7] were isolated contextually to the above-mentioned studies
as well as during the course of researches finalized to the characterization of metabolites derived
from marine organisms. In addition, the ketone derivative pallescensone (6) was obtained from
the dichloromethane extract of the New Zealand sponge Dictiodendrilla cavernosa [8], and later, from
different nudibranch species [9,10].
Almost immediately after their identification, both the chemical structure and the absolute
configuration of the pallescensin-1 (2) and of the pallescensin-2 (4) were confirmed by chemical
synthesis [11]. Thereafter, several new synthetic approaches [12–19] provided compounds 2, 5, and 6
both in racemic and in enantioenriched forms. Curiously, isomicrocionin-3 (3) has not been prepared
yet, whereas pallescensis-2 (4) has been synthesized only in racemic form.
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Figure 1. Representative examples of natural furanosesquiterpenes showing molecular framework of
type 1.
The reported syntheses were studied in order to confirm a proposed chemical structure or to assign
the absolute configuration to a given metabolite. Overall, the preparation of the sesquiterpenes 2–6
was studied on a case-by-case basis. Therefore, a reliable and general synthetic approach to this class
of compounds is still lacking. In addition, some of these sesquiterpenes have shown biological activity,
but the limited amount of the available natural material precluded their comprehensive evaluation.
For example, compounds 5 and 6 were isolated from nudibranch mollusks and are thought to possess
antifeedant activity against their predators [4–10]. This ability was experimentally confirmed only on
the whole dichloromethane extract of the mollusks [10], thus the determination of the real antifeedant
contribute of each furanosesquiterpene could not be determined. Similarly, the antibacterial activity [3]
of the pallescensin-1 (2) and the inhibitory activity against human tyrosine protein phosphatase
1B (hPTP1B) [7] of the dihydropallescensin-2 (5) were evaluated only for the natural occurring (S)
enantiomers. Since the enantiomeric composition of a given compound could affect its biological
properties, it is clear that the reported data are not enough to give a proper characterization of the
biological activity of these metabolites. Overall, the aforementioned considerations point to the need
of a general and stereoselective synthetic method for the preparation of all the isomeric forms of
these furanosesquiterpenes.
By taking advantage of our previously acquired expertise in the enantioselective synthesis of
monocyclofarnesyl terpenoids [20–23] and cyclogeraniol isomers [24], we decided to devise a synthetic
procedure that could comply with the above-described requirements.
Our synthetic plan is exemplified by the retrosynthetic analysis described in Figure 2. Accordingly,
we envisioned to prepare the target molecules of type 1 through the reductive cleavage of
the phenylsulfonyl derivatives of type 7, which can be in turn obtained by alkylation of the
cyclogeranylsulfonylbenzene derivatives 8 with 3-(chloromethyl)furan 9. The latter lithium salt
can be prepared by reaction of a commercially available alkyllithium reagent (e.g., BuLi) with the
cyclogeranylsulfonylbenzene derivatives, in turn synthesizable from the corresponding enantiopure
cyclogeraniol isomers 10. Of course, none of the above-described chemical transformations should
involve side reactions, such as the double bond isomerization or the racemization, which could end up
with decreasing the isomeric purity of the chemical intermediates, and thus, of the target compounds 1.
2
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Figure 2. The proposed retrosynthetic analysis for the stereoselective synthesis of the
furanosesquiterpenes possessing molecular framework of type 1.
Herein, we describe the accomplishment of this synthetic plan, whose effectiveness was confirmed
by the stereoselective preparation of some selected furanosesquiterpenes, namely (S)-pallescensin-1
(−)-2, isomicrocionin-3 (3), (R)-pallescensin-2 (−)-(4), and (R)-dihydropallescensis-2 (−)-(5). The limits
of the presented approach were also discussed as highlighted with the stereoselective synthesis of
(R)-pallescensone (−)-(6), which again required a building block of type 10 as starting material but
with the use of a different synthetic path.
2. Results and Discussion
According to our retrosynthetic analysis, we started with the stereoselective preparation of
the cyclogeraniol isomers 10. The α-cyclogeraniol enantiomers were already prepared using both
asymmetric synthesis [25] and resolution procedure [26]. Since racemic α-cyclogeraniol is easily
synthesizable from ethyl geraniate [24], the lipase-mediated resolution procedure is the most suitable
approach for the preparation of both the enantiomeric forms (Figure 3) of the alcohol 10a.
In order to find out a proper enzyme to be employed in this process, we investigated the reactivity
of (±)-10a toward irreversible acetylation using vinyl acetate as acyl donor in the presence of lipase
catalyst. We checked three different commercial enzymes, namely porcine pancreatic lipase (PPL),
Candida rugosa lipase (CRL), and lipase from Pseudomonas sp., (lipase PS). These preliminary experiments
indicated that only lipase PS catalyzed the esterification reaction with an enantioselectivity acceptable
to perform a proper enantiomers separation (enantiomeric ratio E = 9.2). Our findings agree with
previous reported studies on the same enzymatic transformation [26], which assessed an enantiomeric
ratio of 12.9 for lipase PS.
Accordingly, our resolution procedure furnished the enantioenriched alcohols (S)-(+)-10a and
(R)-(−)-10a that were converted in the corresponding sulfones (S)-(+)-11a and (R)-(−)-11a, respectively.
This chemical transformation was accomplished by means of a high yielding, three steps procedure [27],
consisting of the reaction of alcohol 10a with tosyl chloride, nucleophile substitution of the obtained
tosylate with potassium thiophenate in dry DMF, followed by sodium molybdate catalysed oxidation of
the resulting sulfide using an excess of hydrogen peroxide in methanol. Other synthetic methods, usually
employed for the transformation of a hydroxyl functional group into a phenylsulfonyl group, afford
sulfones 11 in inferior yields. For example, the reaction of the diphenyldisulfide/tributylphosphine
reagent [28] with 3,4-dehydro-γ-cyclogeraniol or with γ-cyclogeraniol give the expected sulfide
derivatives close to a significant amount of elimination side products. For this reason, we decided to
employ exclusively the above-described thiophenate displacement procedure for the synthesis of the
four sulfones 11a–d.
Concerning β-cyclogeraniol, we selected β-cyclocitral 12 as starting compound. The latter
aldehyde is commercially available since it is employed both as building block for carotenoids
synthesis and as flavor ingredient [29,30]. The reduction of 12 with NaBH4 in methanol afforded
quantitatively β-cyclogeraniol 10b that was converted into sulfone 11b according to the general
procedure described above.
For the stereoselective synthesis of γ-isomers 11c and 11d, we used diol 13 as a common starting
compound. According to our previous studies [24], the latter racemic diol is preparable in high
3
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diastereoisomeric purity starting from α-cyclogeraniol. The following lipase PS mediated resolution
procedure afforded diols (4R,6S)-(−)-13 and (4S,6R)-(+)-13 in high enantiomeric purity. Each one of
these two enantiomers was transformed into the corresponding enantiomeric forms of the acetates 14
and 15. Accordingly, the chemical acetylation of the diol 13 enantiomers afforded the corresponding
diacetates that were submitted to two different chemical reactions, aimed to the cleavage of the
secondary allylic acetate group. The regioselective elimination of the latter group was accomplished
refluxing the diacetates in dioxane, in presence of calcium carbonate and palladium acetate catalyst [31].
This process allow the conversion of the diols (−)-13 and (+)-13 into diene derivatives (+)-14 and
(−)-14, respectively. Similarly, the diacetate derivatives of the diols (−)-13 and (+)-13 were reduced
using triethylammonium formate, in refluxing tetrahydrofuran (THF) and in presence of the palladium
catalyst to afford γ-cyclogeraniol acetate enantiomers (+)-15 and (−)-15, respectively [24]. It is worth
noting that both reactions proceeded without appreciable formation of other isomers deriving from
double bonds isomerization.
Figure 3. Synthesis of the stereoisomeric forms of the cyclogeranylsulfonylbenzene derivatives 11a-d
starting from the racemic cyclogeraniol derivatives 10a and 13 and from β-cyclocitral 12. Reagents and
conditions: (a) TsCl, Py, CH2Cl2, DMAP catalyst, rt (room temperature), 4 h; (b) K2CO3, DMSO, PhSH,
rt, 12 h; (c) H2O2, MeOH, (NH4)2MoO4 catalyst, 0 ◦C then rt, 8 h; (d) NaBH4, MeOH, 0 ◦C; (e) Ac2O,
Py, DMAP catalyst, rt, 8 h; (f) CaCO3, PPh3, Pd(OAc)2 catalyst, dioxane, reflux, 5 h; (g) HCOOH, Et3N,
(PPh3)2PdCl2 catalyst, PPh3, THF, reflux, 6 h; (h) NaOH, MeOH, reflux.
4
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This aspect is of pivotal relevance in natural product synthesis, where the biological activity
of a given product is often dependent on its isomeric composition. Finally, the obtained acetates
enantiomers (+)- and (−)-14, (+)- and (−)-15 were hydrolyzed using sodium hydroxide in methanol, and
the obtained alcohols were transformed into sulfones (+)- and (−)-11c, (+)- and (−)-11d, respectively,
according to the general procedure used for the synthesis of compounds 11a and 11b.
The obtained sulfones were then used as chiral building blocks for the stereoselective synthesis of
the marine furanosesquiterpenes structurally related to pallescensins. Although we prepared both
enantiomers of the compounds 11a, 11c, and 11d, the isomers (−)-11a, (−)-11c, and (−)-11d were those
available in higher enantiomeric purity, according to the resolution procedures of alcohol 10a and diol
13. Therefore, we decided to use the latter sulfone enantiomers for the furanosesquiterpenes synthesis.
As described in the retrosynthetic analysis, compounds (−)-11a, 11b, (−)-11c, and (−)-11d
were treated with n-butyllithium (nBuLi) and the resulting lithium salts were alkylated using
3-(chloromethyl)furan 9. The obtained derivatives 7a-d were not isolated and were treated with
lithium naphthalenide at low temperature (−70 ◦C) in order to remove the phenylsulfonyl group
through its regioselective reduction. Both alkylation step and phenylsulfonyl group cleavage proceeded
with high chemical yields and compounds (−)-11a, 11b, (−)-11c, and (−)-11d were efficiently and
stereoselectively converted into (−)-pallescensin-1 (2), isomicrocionin-3 (3), (−)-pallescensin-2 (4), and
(−)-dihydropallescensin-2 (5), respectively (Figure 4).
Figure 4. Use of the cyclogeranylsulfonylbenzene derivatives 11a–d in the stereoselective synthesis
of the furanosesquiterpenes (−)-pallescensin-1 (2), isomicrocionin-3 (3), (−)-pallescensin-2 (4), and
(−)-dihydropallescensis-2 (5). Reagents and conditions: (a) nBuLi, THF dry, −60 ◦C, then 9 in DMPU,
rt, 2 h; (b) lithium naphthalenide, THF dry, Et2NH, −75 ◦C, 1 h.
The proposed synthesis of compounds 2, 4, and 5 compare favorably over the previously reported
stereoselective methods [11,15,18,19] since the overall yields are higher, the approach is operationally
simple, and it afforded the target compounds in high stereoisomeric purity.
Isomicrocionin-3 was not synthesized before. Therefore, the comparison of the analytical data of
synthetic 3 with those recorded for the natural sesquiterpene isolated from Fasciospongia sp. [3] allows
us confirming the chemical structure previously assigned to isomicrocionin-3.
Furthermore, as mentioned in the introduction, pallescensis-2 (4) was synthesized only in racemic
form [11] and the (S) absolute configuration was tentatively assigned to the dextrorotatory isomer.
This assumption is based on the observation that both (+)-pallescensin-2 and (−)-pallescensin-1 were
isolated from the same sponge (Dysidea pallescens) and the absolute configuration of (−)-pallescensin-1
was already assigned by chemical correlation with (S)-(−)-α-cyclocitral. (S)-(−)-2 and (+)-4 most likely
possess the same absolute configuration because they were formed through a common biosynthetic
pathway. According to our synthetic procedure, we established a chemical correlation between
(4S,6R)-4-hydroxy-γ-cyclogeraniol (+)-13 and (−)-pallescensin-2 (4), thus confirming unambiguously
that (−)-pallescensin-2 (4) possesses (R) absolute configuration.
5
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The very good results described above prompted us to investigate a possible exploitation of the
sulfone alkylation approach for the synthesis of pallescensone (6), a sesquiterpene ketone structurally
related to dihydropallescensin-2 (5). As described previously [27,32], the lithium salt of a given
phenylsulfonyl derivative can be acylated using anhydrous magnesium bromide and the alkyl ester
of the corresponding acyl moiety. The following cleavage of the phenylsulfonyl group by means of
lithium naphthalenide at low temperature provides the acylated derivative. Unfortunately, we found
that the reaction of phenylsulfone 11d with 3-furoic acid methyl ester afforded the acylated sulfone in
very low yield.
This disappointing result is most likely due to the steric hindrance around the new formed bond,
which does not allow phenylsulfonyl and ketone functional groups to adopt vicinal conformation with
formation of the magnesium complex, whose chemical stability secure the product formation.
For that reason, we decided to study a different approach for the stereoselective synthesis of
ketone 6. Taking advantage of the above-described process for the preparation of the enantioenriched
γ-cyclogeraniol derivatives (Figure 3), we selected the enantiomeric forms of compound 15 as chiral
building blocks for pallescensone synthesis. More enantiopure isomer (−)-15 was used as starting
compound (Figure 5) and the devised synthetic procedure provided pallescensone (6) after six steps, in
good overall yield (43%).
Figure 5. Stereoselective synthesis of (−)-pallescensone (6) starting from γ-cyclogeraniol acetate (−)-15.
Reagents and conditions: (a) NaOH, MeOH, reflux; (b) TsCl, Py, CH2Cl2, DMAP catalyst, rt, 4 h; (c)
NaCN, DMSO dry, 80–90 ◦C, 5 h; (d) DIBAL, toluene, −70 ◦C, 30 min; (e) 3-furyllithium, −70 ◦C, THF
dry, 20 min; (f) IBX, DMSO dry, 40 ◦C, 4 h.
Accordingly, acetate (−)-15 was hydrolyzed using sodium hydroxide in methanol and the obtained
γ-cyclogeraniol was treated with tosyl chloride and pyridine, in presence of the DMAP catalyst. The
nucleophilic substitution of the tosyl functional group with the cyanide group was performed by
reaction with sodium cyanide in dimethylsulfoxide (DMSO), heating at 80–90 ◦C to afford cyanide
(+)-16 in 85% overall yield. The latter compound was then reduced at low temperature (−70 ◦C) using
DIBAL in toluene. The resulting aldehyde 17 was not purified and was treated with freshly prepared
3-furyllithium in THF. The obtained crude carbinol was dissolved in dry DMSO and was treated with
an excess of IBX [33] to afford (−)-(R)-pallescensone (6) in 51% overall yield from 16.
The 1H- and 13C-NMR spectroscopic data of the synthesized compound 6 were superimposable
with those reported for the synthetic [18,19] and the natural [8] sesquiterpene, whereas the measured
optical rotation value, [α]20D = −34.4 (c 1.1, CH2Cl2), show comparable value and opposite sign of the
naturally occurring (S)-pallescensone, [α]20D = +36 (c 1.0, CHCl3).
Finally, it should be considered that the enantiomeric forms of γ-homocyclogeranial 17 were used
as a chiral building blocks not only for the synthesis of pallescensone, but also for the preparation of
other sesquiterpenes [18,34] or sesquiterpene analogues [35], thus expanding the prospective utility of
this synthon in natural products synthesis.
3. Materials and Methods
3.1. Materials and General Methods
All moisture- and air-sensitive reactions were carried out using dry solvents under a static
atmosphere of nitrogen.
6
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All solvents and reagents were of commercial quality and were purchased from Sigma-Aldrich (St.
Louis, MO, USA) with the exception ofβ-cyclogeraniol, 3-(chloromethyl)furan and IBX.β-Cyclogeraniol
was prepared by reduction of β-cyclogeranial using NaBH4 in methanol. 3-(Chloromethyl)furan was
obtained starting from furan-3-carboxylic acid by means of reduction with LiAlH4 and reaction of the
obtained carbinol with mesyl chloride in presence of s-collidine and LiCl [36,37]. IBX was prepared
starting from o-iodobenzoic acid, according to the literature [33].
Lipase from Pseudomonas cepacia (PS), 30 units/mg, was purchased from Amano Pharmaceuticals
Co., Tokyo, Japan. Enantioenriched α-cylogeraniol 10a and cis-4-hydroxy-γ-cyclogeraniol 13 were
prepared by means of the lipase PS-mediated resolution of the corresponding racemic compounds, as
previously described by Vidari [26] and Serra [24], respectively.
3.2. Analytical Methods and Characterization of the Chemical Compounds
1H and 13C-NMR spectra and DEPT (Distortionless enhancement by polarization transfer)
experiments: CDCl3 solutions at room temperature using a Bruker-AC-400 spectrometer (Billerica,
MA, USA) at 400, 100, and 100 MHz, respectively; 13C spectra are proton-decoupled; chemical shifts in
ppm relative to internal SiMe4 (0 ppm).
Thin-layer chromatography (TLC) involved the use of Merck silica gel 60 F254 plates (Merck
Millipore, Milan, Italy), while column chromatography involved the use of silica gel.
Melting points were measured on a Reichert apparatus equipped with a Reichert microscope and
are uncorrected.
Optical rotations were measured on a Jasco-DIP-181 digital polarimeter (Jasco, Tokyo, Japan).
Mass spectra were recorded on a Bruker ESQUIRE 3000 PLUS spectrometer (ESI detector, Billerica,
MA, USA) or by GC-MS analyses.
GC-MS analyses involved the use of an HP-6890 gas chromatograph equipped with a 5973 mass
detector, using an HP-5MS column (30 m × 0.25 mm, 0.25-μm film thickness; Hewlett Packard, Palo
Alto, CA, USA) with the following temperature program: 60◦ (1 min), then 6◦/min to 150◦ (held at
1 min), then 12◦/min to 280◦ (held 5 min); carrier gas: He; constant flow 1 mL/min; split ratio: 1/30; tR
given in minutes.
The values of tR for each compound are as follows: tR(2) 18.70, tR(3) 19.14, tR(4) 18.47, tR(5) 18.48,
tR(6) 21.81, tR(9) 3.90, tR(10a) 10.59, tR(10b) 11.32, tR(11a) 25.85, tR(11b) 26.03, tR(11c) 25.71, tR(11d)
25.86, tR(14) 14.02, tR(15) 13.86, tR(16) 14.71.
3.3. Stereoselective Preparation of (R) and (S) Enantiomers of 3,4-Dehydro-γ-cyclogeraniol Acetate 14 and
γ-Cyclogeraniol Acetate 15
3.3.1. (R)-3,4-Dehydro-γ-cyclogeraniol Acetate (−)-14
A sample of diol (+)-13, (0.5 g, 2.9 mmol; [α]20D = +29.5 (c 2.8, CHCl3); 98% ee by chiral GC)
was converted to the corresponding diacetate by treatment with pyridine (10 mL), DMAP (50 mg, 0.4
mmol) and Ac2O (10 mL) at rt for 8 h. After removal of the solvents, the crude diacetate was dissolved
in dioxane (20 mL) and treated under N2 with Pd(OAc)2 (50 mg, 0.2 mmol), CaCO3 (1 g, 10 mmol), and
PPh3 (270 mg, 1 mmol). The resulting heterogeneous mixture was stirred under reflux for 5 h (TLC
monitoring). The mixture was then cooled to room temperature, diluted with diethyl ether (100 mL), and
filtered. The filtrate was washed successively with saturated aqueous NaHCO3 solution (50 mL) and
brine, dried (Na2SO4), and evaporated. The residue was purified by chromatography (n-hexane/Et2O
95:5–8:2) and bulb-to-bulb distillation to give pure 3,4-dehydro-γ-cyclogeraniol acetate (−)-14 =
(R)-(6,6-dimethyl-2-methylenecyclohex-3-enyl)methyl acetate (480 mg, 84% yield) as a colourless oil;
[α]20D = −69.9 (c 3.3, CHCl3); 99% of chemical purity by GC. 1H NMR (400 MHz, CDCl3) δ 6.08 (d, J =
9.8 Hz, 1H), 5.70-5.63 (m, 1H), 4.95 (s, 1H), 4.86 (s, 1H), 4.23 (dd, J = 10.7, 4.6 Hz, 1H), 3.93 (dd, J = 10.7,
9.1 Hz, 1H), 2.21 (dd, J = 9.1, 4.6 Hz, 1H), 2.05 (d, J = 18.6 Hz, 1H), 2.02 (s, 3H), 1.83 (dd, J = 18.6, 5.2 Hz,
1H), 1.02 (s, 3H), 0.92 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.0 (C), 143.3 (C), 127.5 (CH), 127.3 (CH),
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114.2 (CH2), 64.2 (CH2), 50.0 (CH), 37.0 (CH2), 31.8 (C), 28.4 (Me), 27.3 (Me), 21.0 (Me). GC-MS m/z (rel
intensity) 134 ([M − AcOH]+, 52), 119 (100), 105 (24), 91 (54), 77 (17), 65 (6), 53 (5).
3.3.2. (S)-3,4-Dehydro-γ-cyclogeraniol Acetate (+)-14
The reaction sequence described above was repeated using sample of diol (−)-13, ([α]20D = −26.8
(c 2.5, CHCl3); 90% ee by chiral GC) to afford pure 3,4-dehydro-γ-cyclogeraniol acetate (+)-14 =
(S)-(6,6-dimethyl-2-methylenecyclohex-3-enyl)methyl acetate (81% yield) as a colorless oil; [α]20D =
+61.1 (c 3.0, CHCl3); 96% of chemical purity by GC. 1H-NMR, 13C-NMR and GC-MS superimposable
to those described for (R)-isomer.
3.3.3. (R)-γ-Cyclogeraniol Acetate (−)-15
A sample of diol (+)-13, (0.9 g, 5.3 mmol; [α]20D = +29.5 (c 2.8, CHCl3); 98% ee by chiral GC)
was treated with pyridine (10 mL), DMAP (50 mg, 0.4 mmol) and Ac2O (10 mL) and set aside at rt
until acetylation was complete (8 h). The obtained diacetate was dissolved in dry THF (30 mL) and
refluxed under a static nitrogen atmosphere in the presence of formic acid (0.75 g, 16.3 mmol), Et3N
(1.65 g, 16.3 mmol), (PPh3)2PdCl2 (140 mg, 0.2 mmol) and triphenylphosphine (0.25 g, 0.9 mmol).
After the reaction was complete (6 h, TLC analysis), the mixture was diluted with ether (100 mL) and
washed with water (50 mL), 5% HCl (50 mL), satd. aq NaHCO3 (50 mL), and brined. The organic
phase was concentrated under reduced pressure and the residue was purified by chromatography
(n-hexane/AcOEt 95:5–8:2) and bulb-to-bulb distillation to afford pure (R)-γ-cyclogeraniol acetate
(−)-15 = (R)-(2,2-dimethyl-6-methylenecyclohexyl)methyl acetate (0.81 g, 78% yield) as a colorless oil;
[α]20D = −10.1 (c 3.8, CHCl3); 96% diastereoisomeric purity, 99% of chemical purity by GC. 1H NMR
(400 MHz, CDCl3) δ 4.75 (s, 1H), 4.53 (s, 1H), 4.19 (dd, J = 11.0, 5.3 Hz, 1H), 4.15 (dd, J = 11.0, 9.2 Hz,
1H), 2.16–2.06 (m, 2H), 2.03–1.92 (m, 1H), 1.94 (s, 3H), 1.54–1.44 (m, 2H), 1.42–1.32 (m, 1H), 1.29–1.20
(m, 1H), 0.91 (s, 3H), 0.80 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.0 (C), 147.0 (C), 109.7 (CH2), 62.7
(CH2), 52.1 (CH), 37.8 (CH2), 34.2 (C), 33.3 (CH2), 28.6 (Me), 25.0 (Me), 23.3 (CH2), 20.9 (Me). Lit. for
1H and 13C NMR [38,39]. GC-MS m/z (rel intensity) 136 ([M − AcOH]+, 80), 121 (100), 107 (43), 93 (89),
79 (33), 69 (49), 55 (9), 43 (50).
3.3.4. (S)-γ-Cyclogeraniol Acetate (+)-15
The reaction sequence described above was repeated using sample of diol (−)-13, ([α]20D =
−26.8 (c 2.5, CHCl3); 90% ee by chiral GC) to afford pure (S)-γ-cyclogeraniol acetate (+)-15 =
(S)-(2,2-dimethyl-6-methylenecyclohexyl)methyl acetate (74% yield) as a colorless oil; [α]20D = +9.1
(c 3.1, CHCl3); 96% diastereoisomeric purity, 95% of chemical purity by GC. 1H-NMR, 13C-NMR and
GC-MS superimposable to those described for (R)-isomer.
3.4. Synthesis of the Enantiomeric Forms of the Cyclogeranylsulfonylbenzene Derivatives 11a–d
3.4.1. General Procedure
A solution of p-toluenesulfonyl chloride (1.5 g, 7.9 mmol) in CH2Cl2 (4 mL) was added dropwise
to a stirred solution of the suitable cyclogeraniol isomer (0.9 g, 5.8 mmol), DMAP (50 mg, 0.4 mmol)
and pyridine (2 mL) in CH2Cl2 (4 mL). After 4 h, the mixture was diluted with ether (100 mL) and then
was washed with 1 M aqueous HCl solution (50 mL), saturated NaHCO3 solution (50 mL), and brined.
The organic phase was dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in dry
DMSO (5 mL) and added dropwise to a suspension of K2CO3 (3.2 g, 23.1 mmol) and thiophenol (1.7 g,
15.4 mmol) in DMSO (20 mL). The resulting mixture was stirred vigorously at rt (room temperature)
until the starting tosylate was no longer detectable by TLC analysis (12 h). The reaction was partitioned
between water (150 mL) and ether (100 mL). The aqueous phase was extracted again with ether (100 mL)
and the combined organic phases were washed with an aqueous solution of NaOH (10% w/w, 50 mL)
and brined, dried (Na2SO4), and concentrated in vacuo. The residue was dissolved in methanol (50 mL)
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and was treated at 0 ◦C with (NH4)2MoO4 (80 mg, 0.4 mmol) followed by the dropwise addition of a
solution of H2O2 (35% wt. in water, 10 mL). The solution was then warmed to rt while stirring was
continued for a further 8 h. The reaction was cooled again and a saturated solution of Na2SO3 was
added to destroy excess oxidant. The main part of the methanol was removed under reduced pressure
and the residue extracted with AcOEt (3 × 100 mL). The combined organic layers were dried (Na2SO4),
concentrated, and the residue purified by chromatography using n-hexane/AcOEt (95:5–8:2) as eluent
to afford the suitable cyclogeranylsulfonylbenzene derivative.
3.4.2. (S)-((2,6,6-Trimethylcyclohex-2-enyl)methylsulfonyl)benzene (−)-11a
According to the general procedure, (S)-α-cyclogeraniol (−)-10a =
(S)-(2,6,6-trimethylcyclohex-2-en-1-yl)methanol ([α]20D = −102.1 (c 2.4, EtOH); 90% ee; 97%
chemical purity) was transformed into (S)-((2,6,6-trimethylcyclohex-2-enyl)methylsulfonyl)benzene
(−)-11a (85% yield); [α]20D = −83.9 (c 2.1, CH2Cl2); 96% of chemical purity by GC. 1H NMR (400 MHz,
CDCl3) δ 7.97–7.90 (m, 2H), 7.68–7.52 (m, 3H), 5.33 (s, 1H), 3.23 (dd, J = 15.2, 4.3 Hz, 1H), 2.91 (dd, J =
15.2, 3.9 Hz, 1H), 2.25 (s, 1H), 2.06–1.84 (m, 2H), 1.62 (br s, 3H), 1.23–1.16 (m, 2H), 0.91 (s, 6H). 13C
NMR (100 MHz, CDCl3) δ 140.4 (C), 134.8 (C), 133.5 (CH), 129.2 (CH), 128.1 (CH), 121.8 (CH), 58.6
(CH2), 42.9 (CH), 32.2 (C), 31.3 (CH2), 27.0 (Me), 26.2 (Me), 22.8 (CH2), 22.5 (Me). Lit. for 1H and 13C
NMR [25]. MS (ESI): 301.1 [M + Na]+.
3.4.3. (R)-((2,6,6-Trimethylcyclohex-2-enyl)methylsulfonyl)benzene (+)-11a
According to the general procedure, (R)-α-cyclogeraniol (+)-10a =
(R)-(2,6,6-trimethylcyclohex-2-en-1-yl)methanol, ([α]20D = +96.7 (c 2.7, EtOH); 85% ee; 97%
chemical purity) was transformed into (R)-((2,6,6-trimethylcyclohex-2-enyl)methylsulfonyl)benzene
(+)-11a (81% yield), [α]20D = +77.8 (c 2.8, CH2Cl2), 98% of chemical purity by GC. 1H-, 13C-NMR and
MS superimposable to those described for (S)-isomer.
3.4.4. 2,6,6-((Trimethylcyclohex-1-enyl)methylsulfonyl)benzene 11b
According to the general procedure, β-cyclogeraniol =
((2,6,6-trimethylcyclohex-1-en-1-yl)methanol (96% chemical purity) was transformed into
((2,6,6-trimethylcyclohex-1-enyl)methylsulfonyl)benzene 11b (82% yield) as a colorless oil,
97% of chemical purity by GC. 1H NMR (400 MHz, CDCl3) δ 7.97–7.90 (m, 2H), 7.67–7.51 (m, 3H), 3.97
(s, 2H), 2.06 (t, J = 6.3 Hz, 2H), 1.68–1.58 (m, 2H), 1.67 (s, 3H), 1.52–1.46 (m, 2H), 1.04 (s, 6H). 13C NMR
(100 MHz, CDCl3) δ 141.7 (C), 139.2 (C), 133.2 (CH), 129.1 (CH), 127.8 (CH), 125.9 (C), 57.7 (CH2), 39.5
(CH2), 34.4 (C), 33.3 (CH2), 28.8 (Me), 21.8 (Me), 18.9 (CH2). Lit. for 1H and 13C NMR [40]. GC-MS m/z
(rel intensity) 278 (M+, 1), 137 (100), 121 (10), 107 (6), 95 (45), 81 (28), 69 (8), 55 (6).
3.4.5. (R)-((2,2-Dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene (−)-11c
(−)-γ-3,4-dehydrocyclogeraniol acetate= (R)-(6,6-dimethyl-2-methylenecyclohex-3-en-1-yl)methyl
acetate ([α]20D = −69.9 (c 3.3, CHCl3); 98% ee; 99% chemical purity) was hydrolyzed using NaOH
in methanol, at reflux. After work-up, the obtained crude alcohol was submitted to the general
procedure to give (R)-((6,6-dimethyl-2-methylenecyclohex-3-enyl)methylsulfonyl)benzene (75% yield)
as a colorless oil; [α]20D = −89.2 (c 3.7, CHCl3); 96% of chemical purity by GC. 1H NMR (400 MHz,
CDCl3) δ 7.92–7.86 (m, 2H), 7.66–7.60 (m, 1H), 7.58–7.51 (m, 2H), 5.96 (d, J = 9.9 Hz, 1H), 5.65–5.58
(m, 1H), 4.82 (s, 2H), 3.22 (dd, J = 14.6, 2.4 Hz, 1H), 3.04 (dd, J = 14.6, 8.1 Hz, 1H), 2.53 (dm, J = 8.1
Hz, 1H), 1.90 (dm, J = 18.7 Hz, 1H), 1.79 (dd, J = 18.7, 5.0 Hz, 1H), 0.91 (s, 3H), 0.85 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ 143.1 (C), 140.3 (C), 133.4 (CH), 129.1 (CH), 128.1 (CH), 127.4 (CH), 127.1 (CH),
115.0 (CH2), 56.7 (CH2), 44.8 (CH), 36.3 (CH2), 32.7 (C), 27.2 (Me), 26.7 (Me). MS (ESI): 299.1 [M +Na]+,
315.1 [M + K]+.
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3.4.6. (S)-((2,2-Dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene (+)-11c
The reaction sequence described above was repeated using (+)-γ-3,4-dehydrocyclogeraniol acetate
= (S)-(6,6-dimethyl-2-methylenecyclohex-3-en-1-yl)methyl acetate ([α]20D = +61.1 (c 3.0, CHCl3); 96%
of chemical purity) to afford (S)-((6,6-dimethyl-2-methylenecyclohex-3-enyl)methylsulfonyl)benzene
(74% yield), colorless oil; [α]20D = +78.8 (c 3.1, CHCl3); 96% of chemical purity by GC. 1H-NMR,
13C-NMR and GC-MS superimposable to those described for (R)-isomer.
3.4.7. (R)-((2,2-Dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene (−)-11d
(−)-γ-Cyclogeraniol acetate = (R)-(2,2-dimethyl-6-methylenecyclohexyl)methyl acetate (([α]20D =
−10.1 (c 3.8, CHCl3); 96% diastereoisomeric purity; 99% chemical purity by GC) was hydrolysed using
NaOH in methanol, at reflux. After work-up, the obtained crude alcohol was submitted to the general
procedure to give (−)-(R)-((2,2-dimethyl-6-methylenecyclohexyl(methylsulfonyl)benzene (89% yield)
as a colorless oil; [α]20D = −11.7 (c 3.7, CHCl3); 96% diastereoisomeric purity, 95% of chemical purity
by GC. 1H NMR (400 MHz, CDCl3) δ 7.92–7.85 (m, 2H), 7.67–7.49 (m, 3H), 4.74 (s, 1H), 4.56 (s, 1H), 3.35
(dd, J = 14.7, 9.4 Hz, 1H), 3.24 (dd, J = 14.7, 2.5 Hz, 1H), 2.44 (dm, J = 9.4 Hz, 1H), 2.07–1.93 (m, 2H),
1.55–1.44 (m, 2H), 1.35–1.28 (m, 2H), 0.90 (s, 3H), 0.78 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 145.6 (C),
140.0 (C), 133.4 (CH), 129.0 (CH), 128.2 (CH), 110.9 (CH2), 54.4 (CH2), 47.8 (CH), 37.2 (CH2), 35.3 (C),
32.9 (CH2), 27.8 (Me), 24.9 (Me), 23.2 (CH2). Lit. for 1H and 13C NMR [41]. MS (ESI): 301.2 [M + Na]+.
3.4.8. (S)-((2,2-Dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene (+)-11d
The reaction sequence described above was repeated using (+)-γ-cyclogeraniol
acetate = (S)-(2,2-dimethyl-6-methylenecyclohexyl)methyl acetate ([α]20D = +9.1 (c 3.1,
CHCl3); 96% diastereoisomeric purity, 95% of chemical purity by GC) to afford
(S)-((2,2-dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene (84% yield); ([α]20D = +9.8 (c 2.4,
CHCl3); 97% of chemical purity by GC. 1H-NMR, 13C-NMR and GC-MS superimposable to those
described for (R)-isomer.
3.5. Synthesis of the Furanosesquiterpenes (−)-Pallescensin-1 (2), Isomicrocionin-3 (3), (−)-Pallescensin-2 (4),
and (−)-Dihydropallescensis-2 (5)
3.5.1. General Procedure
nBuLi (1 mL of a 2.5 M solution in hexane) was added dropwise under nitrogen to a cooled
(−60 ◦C) solution of the suitable cyclogeranylsulfonylbenzene derivative (2.2 mmol) in dry THF
(10 mL). The resulting orange solution was stirred at this temperature for 15 min and then a solution of
3-(chloromethyl)furan (260 mg, 2.23 mmol) in dry DMPU (1 mL) was added dropwise. The reaction was
allowed to reach room temperature and after two hours at this temperature, and it was quenched by the
addition of a saturated solution of NH4Cl aqueous (50 mL). The resulting mixture was extracted with
diethyl ether (3 × 50 mL) and the combined organic phases was dried (Na2SO4) and concentrated in
vacuo. The crude product was dissolved in dry THF (15 mL) containing dry Et2NH (1 mL). The mixture
was cooled (−75 ◦C) and was treated under nitrogen with freshly prepared lithium naphthalenide
(8 mL of a 0.72 M solution). When the staring material could no longer be detected by TLC analysis
(1 h), the reaction was quenched by the addition of a saturated solution of NH4Cl aqueous (50 mL)
and diluted with diethyl ether (80 mL). The organic phase was separated and the aqueous phase
was extracted with ethyl ether (50 mL). The combined organic layers were washed with brine, dried
(Na2SO4) and concentrated under reduced pressure. A large part of the naphthalene content was
removed by crystallization from hexane. The liquid phase was then purified by chromatography
(hexane/diethyl ether 99:1–95:5) to afford the desired furanosesquiterpene.
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3.5.2. Synthesis of (−)-Pallescensin-1 (2)
According to the general procedure, the alkylation/reduction of
((2,6,6-trimethylcyclohex-2-enyl)methylsulfonyl)benzene ([α]20D = −83.9 (c 2.1,
CH2Cl2); 90% ee, 96% of chemical purity by GC) afforded (−)-pallescensin-1 (2) =
3-(2-(2,6,6-trimethylcyclohex-2-enyl)ethyl)furan (73% yield) as a colorless oil; [α]20D = −93.2
(c 3.2, CHCl3); 94% of chemical purity by GC; Lit. [10] for synthetic 2: [α]20D = −89.5 (CHCl3); Lit. [3]
for natural 2: [α]20D = −23.5 (c 0.07, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.34 (t, J = 1.7 Hz, 1H),
7.23–7.20 (m, 1H), 6.27 (br s, 1H), 5.31 (br s, 1H), 2.50–2.40 (m, 2H), 2.01–1.91 (m, 2H), 1.76–1.63 (m,
1H), 1.69–1.66 (m, 3H), 1.62–1.39 (m, 3H), 1.19–1.10 (m, 1H), 0.95 (s, 3H), 0.88 (s, 3H). 13C NMR (100
MHz, CDCl3) δ 142.6 (CH), 138.6 (CH), 136.5 (C), 125.6 (C), 120.2 (CH), 111.0 (CH), 49.0 (CH), 32.6 (C),
31.6 (CH2), 31.6 (CH2), 27.52 (Me), 27.46 (Me), 25.5 (CH2), 23.5 (Me), 23.0 (CH2). Lit. for 1H and 13C
NMR [3]. GC-MS m/z (rel intensity) 218 (M+, 8), 203 (2), 162 (3), 147 (15), 133 (13), 121 (14), 109 (26), 95
(41), 81 (100), 67 (7), 53 (13).
3.5.3. Synthesis of Isomicrocionin-3 (3)
According to the general procedure, the alkylation/reduction of
((2,6,6-trimethylcyclohex-1-enyl)methylsulfonyl)benzene (97% of chemical purity by GC) afforded
isomicrocionin-3 = 3-(2-(2,6,6-trimethylcyclohex-1-enyl)ethyl)furan 3 (78% yield) as a colorless oil; 99%
of chemical purity by GC. 1H NMR (400 MHz, CDCl3) δ 7.34 (t, J = 1.7 Hz, 1H), 7.24–7.22 (m, 1H), 6.30
(br s, 1H), 2.50–2.42 (m, 2H), 2.27–2.19 (m, 2H), 1.93 (t, J = 6.2 Hz, 2H), 1.64 (s, 3H), 1.63–1.55 (m, 2H),
1.47–1.41 (m, 2H), 1.02 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 142.6 (CH), 138.4 (CH), 136.9 (C), 127.6
(C), 125.7 (C), 110.9 (CH), 39.8 (CH2), 34.9 (C), 32.8 (CH2), 29.5 (CH2), 28.6 (Me), 25.6 (CH2), 19.8 (Me),
19.5 (CH2). Lit. for 1H and 13C NMR [3]. GC-MS m/z (rel intensity) 218 (M+, 64), 203 ([M −Me]+, 47),
185 (4), 175 (10), 162 (18), 149 (25) 137 (77), 121 (18), 109 (20), 95 (100), 81 (85), 67 (15), 53 (16).
3.5.4. Synthesis of (−)-Pallescensin-2 (4)
According to the general procedure, the alkylation/reduction of
(R)-((6,6-dimethyl-2-methylenecyclohex-3-enyl)methylsulfonyl)benzene ([α]20D = −89.2
(c 3.7, CHCl3); 96% of chemical purity by GC) afforded (−)-pallescensin-2 (4) =
(R)-3-(2-(6,6-dimethyl-2-methylenecyclohex-3-enyl)ethyl)furan (79% yield) as a colorless oil;
[α]20D = −65.1 (c 2.9, CHCl3); 96% of chemical purity by GC; Lit. [1] for natural 4: [α]20D = +39.5.
1H NMR (400 MHz, CDCl3) δ 7.33 (m, 1H), 7.19 (s, 1H), 6.25 (m, 1H), 6.03 (dd, J = 9.8, 1.8 Hz, 1H),
5.69–5.59 (m, 1H), 4.91 (s, 1H), 4.74 (s, 1H), 2.53–2.42 (m, 1H), 2.33–2.22 (m, 1H), 2.05 (d, J = 18.5 Hz,
1H), 1.81–1.67 (m, 3H), 1.35–1.23 (m, 1H), 0.96 (s, 3H), 0.86 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 145.6
(C), 142.6 (CH), 138.8 (CH), 127.8 (CH), 127.3 (CH), 125.4 (C), 112.8 (CH2), 111.0 (CH), 51.1 (CH), 36.4
(CH2), 32.6 (C), 28.3 (CH2), 28.2 (Me), 27.6 (Me), 23.0 (CH2). Lit. for 1H NMR [13]. GC-MS m/z (rel
intensity) 216 (M+, 8), 201 ([M −Me]+, 2), 173 (2), 157 (2), 145 (2), 131 (2), 122 (55), 107 (100), 91 (17), 81
(10), 65 (4), 53 (5).
3.5.5. Synthesis of (−)-Dihydropallescensis-2 (5)
According to the general procedure, the alkylation/reduction of
(−)-(R)-((2,2-dimethyl-6-methylenecyclohexyl)methylsulfonyl)benzene ([α]20D = −11.7 (c
3.7, CHCl3); 95% of chemical purity by GC) afforded (−)-dihydropallescensis-2 (5) =
(R)-3-(2-(2,2-dimethyl-6-methylenecyclohexyl)ethyl)furan (71% yield) as a colorless oil; [α]20D
= −7.1 (c 2.5, CHCl3); 94% of chemical purity by GC; Lit. [15] for synthetic dextrorotatory isomer:
[α]20D = +4.55 (c 0.1, CHCl3); Lit. [2] for natural 5: [α]20D = +6.0 (c 0.3, CHCl3). 1H NMR (400 MHz,
CDCl3) δ 7.34 (m, 1H), 7.19 (s, 1H), 6.26 (m, 1H), 4.80 (s, 1H), 4.57 (d, J = 1.9 Hz, 1H), 2.45–2.34 (m, 1H),
2.25–1.92 (m, 3H), 1.81–1.40 (m, 6H), 1.30–1.17 (m, 1H), 0.91 (s, 3H), 0.84 (s, 3H). 13C NMR (100 MHz,
CDCl3) δ 149.1 (C), 142.6 (CH), 138.7 (CH), 125.5 (C), 111.0 (CH), 109.1 (CH2), 53.5 (CH), 36.2 (CH2),
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34.8 (C), 32.4 (CH2), 28.3 (Me), 26.7 (CH2), 26.3 (Me), 23.7 (CH2), 23.3 (CH2). Lit. for 1H and 13C
NMR [15]. GC-MS m/z (rel intensity) 218 (M+, 72), 203 ([M −Me]+, 14), 189 (6), 175 (10), 162 (5), 147
(12) 133 (13), 124 (13), 109 (85), 95 (65), 81 (100), 69 (49), 53 (21).
3.6. Synthesis of (−)-Pallescensone (6) Starting from (R)-γ-Cyclogeraniol Acetate
3.6.1. Synthesis of (R)-2-(2,2-Dimethyl-6-methylenecyclohexyl)acetonitrile (+)-16
(−)-γ-Cyclogeraniol acetate = (R)-(2,2-dimethyl-6-methylenecyclohexyl)methyl acetate 380 mg,
1.94 mmol, ([α]20D = −10.1 (c 3.8, CHCl3); 98% ee; 99% chemical purity) was hydrolysed using NaOH
in methanol, at reflux. After work-up, a solution of p-toluenesulphonyl chloride (570 mg, 3 mmol) in
CH2Cl2 (3 mL) was added dropwise to a stirred solution of the obtained crude alcohol and DMAP
(20 mg, 0.16 mmol) in pyridine (2 mL). After 4 h, the mixture was diluted with ether (60 mL) and
washed in turn with a 1 M aqueous HCl solution (50 mL), saturated NaHCO3 solution (30 mL), and
brined. The organic phase was dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in
dry DMSO (20 mL) and treated with NaCN (1 g, 20 mmol) stirring at 80–90 ◦C until the starting tosylate
could no longer be detected by TLC analysis (5 h). The mixture was diluted with ether (80 mL) and
was washed in turn with water and brine. The organic phase was dried (Na2SO4) and concentrated in
vacuo. The residue was then purified by chromatography eluting with hexane/ethyl acetate (95:5–8:2)
as eluent to afford pure (R)-2-(2,2-dimethyl-6-methylenecyclohexyl)acetonitrile (+)-16 (270 mg, 85%
yield) as a colorless oil; [α]20D = +12.1 (c 2.2, CH2Cl2); 96% diastereoisomeric purity, 92% of chemical
purity by GC. 1H NMR (400 MHz, CDCl3) δ 4.96 (s, 1H), 4.75 (s, 1H), 2.56 (dd, J = 16.7, 4.4 Hz, 1H), 2.41
(dd, J = 16.7, 10.8 Hz, 1H), 2.26–2.15 (m, 2H), 2.14–2.02 (m, 1H), 1.70–1.50 (m, 2H), 1.50–1.31 (m, 2H),
1.00 (s, 3H), 0.81 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 146.2 (C), 119.7 (C), 110.4 (CH2), 50.3 (CH), 37.7
(CH2), 35.0 (C), 33.5 (CH2), 28.6 (Me), 23.5 (Me), 23.2 (CH2), 16.4 (CH2). GC-MS m/z (rel intensity) 163
(M+, 3), 148 (7), 134 (1), 120 (21), 107 (9), 91 (11), 79 (18), 69 (100), 53 (11).
3.6.2. Synthesis of (−)-Pallescensone (6)
DIBAL (0.9 mL of a 25% wt. solution in toluene, 1.34 mmol) was added dropwise under nitrogen
to a cooled (−70 ◦C) solution of nitrile (+)-16 (200 mg, 1.23 mmol) in dry toluene (10 mL). The resulting
solution was stirred at this temperature for half an hour and then was allowed to reach rt. The reaction
was quenched by the carefully addition of diluted HCl aqueous (50 mL), followed by extraction with
diethyl ether (2 × 50 mL). The combined organic phases were dried (Na2SO4) and concentrated under
reduced pressure to a final volume of about 4 mL. The resulting solution was added under nitrogen to
a cooled (−70 ◦C) solution of 3-furyllithium (10 mL of a 0.25 M solution in THF), which was previously
prepared in situ by addition of nBuLi (2.5 M solution in hexane) to a solution of 3-bromofuran in dry
THF. The resulting mixture was stirred at this temperature for 20 min, then was quenched by adding
saturated aqueous NH4Cl (20 mL) and was extracted with ether (2 × 60 mL). The combined organic
phases were dried (Na2SO4) and concentrated under reduced pressure. The residue was dissolved in
dry DMSO (2 mL) and was added to a stirred solution of IBX (1 g, 3.5 mmol) in dry DMSO (6 mL). The
reaction was warmed at 40 ◦C for 4 h and then was diluted with diethyl ether (80 mL) and washed
with water (2 × 50 mL) and brine. The organic phase was concentrated in vacuo and the residue was
then purified by chromatography eluting with hexane/ethyl acetate (99:1–9:1) as eluent to afford pure
(−)-pallescensone 6 = (R)-2-(2,2-dimethyl-6-methylenecyclohexyl)-1-(furan-3-yl)ethan-1-one (145 mg,
51% yield) as a pale yellow oil that solidified on standing; [α]20D = −34.4 (c 1.1, CH2Cl2); 97% of
chemical purity by GC; Lit. [18] for synthetic 6: [α]20D = −31.8 (c 0.57, CH2Cl2); Lit. [8] for natural 6:
[α]20D = +36 (c 1, CHCl3). 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.44–7.42 (m, 1H), 6.77–6.75
(s, 1H), 4.71 (s, 1H), 4.44 (s, 1H), 2.91 (dd, J = 15.8, 9.8 Hz, 1H), 2.81 (dd, J = 15.8, 4.2 Hz, 1H), 2.66
(dd, J = 9.8, 4.2 Hz, 1H), 2.28–2.17 (m, 1H), 2.13–2.01 (m, 1H), 1.65–1.34 (m, 4H), 0.98 (s, 3H), 0.84 (s,
3H). 13C NMR (100 MHz, CDCl3) δ 194.5 (C), 148.9 (C), 146.7 (CH), 144.1 (CH), 128.1 (C), 108.8 (CH),
108.5 (CH2), 48.7 (CH), 38.8 (CH2), 38.6 (CH2), 35.0 (C), 34.4 (CH2), 28.9 (Me), 23.8 (Me), 23.6 (CH2). Lit.
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for 1H and 13C NMR [14,16,18]. GC-MS m/z (rel intensity) 232 (M+, 5), 217 (5), 199 (2), 189 (3), 176 (3),
163 (3), 137 (3), 122 (22), 107 (24), 95 (100), 81 (12), 69 (13), 55 (6).
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Abstract: Thirty-four new benzo[d]thiazol derivatives 2a–2i, 3a–3r, and 4a–4g were synthesized and
investigated for their potential antidepressant and anticonvulsant effects. In a forced swimming
test, 2c and 2d showed the highest antidepressant and anticonvulsant effects. 2c and 2d displayed
a higher percentage decrease in immobility duration (89.96% and 89.62%, respectively) than that
of fluoxetine (83.62%). In the maximal electroshock seizure test, 3n and 3q showed the highest
anticonvulsant effect, with ED50 values of 46.1 and 64.3 mg kg−1, and protective indices of 6.34 and
4.11, respectively, which were similar to those of phenobarbital or valproate. We also found that the
mechanism for the antidepressant activity of 2c and 2d may be via increasing the concentrations of
serotonin and norepinephrine.
Keywords: benzo[d]thiazol; synthesis; antarctic-derived fungus; antidepressant; anticonvulsant
1. Introduction
During selective evolution, microorganisms in the polar region are distinct from other microorganisms
with respect to genomic composition and have unique molecular–biological mechanisms, including
metabolic regulation. Tan et al. reported very rich microbial resources in the Arctic and Antarctic [1].
In addition to extremely high species diversity [2], the structures of secondary metabolites of polar
microbes also show diversity. Therefore, the Arctic and Antarctic regions are considered to be valuable
natural products pools.
In an investigation of the secondary metabolites of the Antarctic-derived fungus Penicillium sp.
44.42 ◦W, 60.54 ◦S, 239 m underwater, water temperature of−1.16 ◦C), Jiao et al. reported the isolation of
nine compounds from the fermentation broth of Penicillium sp. [3], including benzo[d]thiazol-2(3H)-one
(Figure 1). Benzothiazoles are heterocyclic aromatic hydrocarbons containing phenyl and thiazole
rings, as well as sulfur and nitrogen atoms in their structures. Benzothiazole derivatives display a
wide spectrum of pharmacologic effects, including anti-inflammatory [4], antibacterial [5], antiviral [6],
antioxidant [7], and immunomodulatory properties [8]. In addition to the central nervous system
(CNS)-related pharmacologic effects, benzothiazole compounds have been reported to display
selective inhibitory effects against monoamine oxidase [9–12], as well as anti-Alzheimer’s disease [13]
and convulsions [14]. The antidepressant effect of a series of benzothiazole derivatives has been
demonstrated through animal models such as the tail suspension test (TST) and forced swimming test
(FST) [15,16].
Several reports have described the antidepressant and anticonvulsant activities of benzothiazole
derivatives [15,16]. For this reason, we synthesized thirty-four new benzo[d]thiazole derivatives 2a–2i,
3a–3r and 4a–4g (Schemes 1 and 2) and investigated their potential antidepressant activity using the FST
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2a = -CH2CH3 2b = -(CH2)2CH3 2c=-(CH2)3CH3 2d = -(CH2)4CH3 2e = -(CH2)5CH3 
2f = -(CH2)6CH3 2g = -(CH2)7CH3 2h = -(CH2)8CH3 2i = -(CH2)9CH3  
3a = -H 3b = 2-F 3c = 3-F 3d = 4-F 3e = 2-Cl  
3f = 3-Cl 3g = 4-Cl 3h = 2-Br 3i = 3-Br 3j = 4-Br 
3k = 4-NO2 3l = 4-CN 3m = 2-CF3 3n = 4-CF3 3o = 4-CH3 
3p = 4-OCH3 3q = 3,5-(CH3)2 3r = 3,5-(OCH3)2   















4a = -H 4b = 4-F 4c = 4-Cl 4d = 4-Br  4e = 2,4-2F  4f = 2,4-2Cl  4g = 2,4-2Br 
Scheme 2. The synthetic route of derivatives 4a–4g.
2. Results
2.1. Synthesis
Target compounds 2a–2i, 3a–3r, and 4a–4g were prepared as shown in Schemes 1 and 2.
Commercially available benzo[d]thiazol-2-ol was the starting material; the derivatives 2a–2i and
3a–3r were obtained through the introduction of an alkyl group or benzyl group by a one-step
16
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nucleophilic substitution reaction. Compounds 4a–4g were obtained through a two-step reaction.
The intermediate 2-(2-bromoethoxy)benzo[d]thiazole was synthesized and underwent a nucleophilic
substitution reaction with 1,2-dibromoethane, then the 2-(2-bromoethoxy) benzo[d] thiazole formed
was reacted with substituted phenols. The structures of 2a–2i, 3a–3r, and 4a–4g were determined by
infrared spectrophotometry, 1H and 13C NMR spectroscopy, as well as mass spectrometry.
2.2. Antidepressant Activity of 2a–2i, 3a–3r, and 4a–4g in the FST
The antidepressant activity of fluoxetine, 2a–2i, 3a–3r, and 4a–4g, as indicated by the immobility
time in the FST, is displayed in Table 1. Most of the compounds, except for 3h, 3k, 3l, 3r, 4c, and
4e, induced a significant decrease in the immobility time at 30 mg kg−1 and showed a marked
antidepressant effect (Table 1). In particular, 2b–2d, 2f, and 3q possessed the highest antidepressant
effect and induced a significant decrease in the immobility time compared with that of the control
group (p < 0.001).
Table 1. Antidepressant effect of 2a–2i, 3a–3r, and 4a–4g.
Antidepressant Effect
Compounds Duration of Immobility (s) TID a (%)
2a 122.5 ± 9.2 * 31.64
2b 59.3 ± 8.8 *** 66.91
2c 18.0 ± 2.4 *** 89.96
2d 18.6 ± 6.8 *** 89.62
2e 104.2 ± 9.7 * 46.32
2f 26.7 ± 7.4 *** 85.10
2g 67.7 ± 10.7 ** 62.22
2h 76.0 ± 13.2 ** 57.59
2i 93.0 ± 9.0 ** 48.10
3a 81.2 ± 9.4 ** 54.69
3b 84.8 ± 5.6 ** 52.68
3c 61.5 ± 3.3 ** 65.68
3d 75.2 ± 8.2 ** 58.04
3e 132.2 ± 8.5 * 26.23
3f 68.2 ± 11.5 ** 61.94
3g 80.3 ± 11.9 ** 55.19
3h 141.3 ± 8.5 21.15
3i 66.0 ± 8.1 ** 63.17
3j 99.3 ± 8.7 ** 44.59
3k 153.8 ± 11.0 14.17
3l 172.5 ± 5.4 3.74
3m 125.8 ± 13.6 * 29.80
3n 124.5 ± 14.3 * 30.52
3o 130.6 ± 5.4 * 27.12
3p 71.2 ± 7.0 ** 60.27
3q 26.3 ± 10.3 *** 85.32
3r 143.2 ± 11.4 20.09
4a 67.5 ± 7.3 ** 62.33
4b 130.5 ± 7.9 * 37.56
4c 141.7 ± 9.1 32.20
4d 116.2 ± 7.0 * 44.40
4e 151.7 ± 14.1 27.42
4f 129.5 ± 5.4 * 38.04
4g 124.2 ± 8.1 * 40.57
control 194.1 ± 11.1 -
fluoxetine 31.8 ± 7.7 *** 83.62
a TID: percentage decrease in immobility duration. Significant differences versus control values. * p < 0.05, ** p < 0.01,
*** p < 0.001.
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To better understand the antidepressant effect of 2a–2i, 3a–3r, and 4a–4g, the percentage reduction
in the time of immobility (% TID) was calculated using the formula
% TID = [(X − Y)/X] × 100
where X is the immobility time (s) for the control group and Y is the immobility time (s) for the test
group. 2c, 2d, 2f, and 3q reduced the immobility time and showed higher TID values than the other
tested compounds (Table 1). The % TID values for 2f (85.10%) and 3q (85.32%) were similar to that of
fluoxetine at a concentration of 30 mg kg−1 in the FST. However, 2c and 2d showed higher % TID values
(89.96% and 89.62%, respectively) than that of fluoxetine (83.62%), suggesting that these compounds
may have superior antidepressant effects compared with that of fluoxetine (duration of immobility (s):
2c = 18.0 ± 2.4; 2d = 18.6 ± 6.8; fluoxetine = 31.8 ± 7.7).
2.3. Anticonvulsant Activity of 2a–2i, 3a–3r, and 4a–4g in the MSE Test
The phase-I test study comprised two parts: MES and toxicity. The toxicity was measured
by the rotorod toxicity experiment. Compounds 2a–2i, 3a–3r, and 4a–4g were assessed for their
anticonvulsant activity. The phase-I test was a qualitative analysis, with three doses of the test
compounds administered (30, 100, and 300 mg kg−1). A protective effect was observed in mice through
intraperitoneal administration of 2a–2i, 3a–3r, and 4a–4g in the MES test (Table 2). Except for 2f–2i, 3h,
3j, 3k, 4a and 4f, other derivatives displayed an anticonvulsant effect. Compounds 2a, 3a, 3l, 3n–3q,
and 4b displayed the highest anticonvulsant effect at 30 mg kg−1 in an MES test. Compounds 2c–2e,
3b, 3e–3g, 3i, 3m, 3r, 4d, 4e and 4g were active at 100 mg kg−1. While 2b, 3c, 3d, and 4c showed the
anticonvulsant activity at 300 mg kg−1. The rotorod toxicity experiment indicated that 2a–2i, 3a–3r,
and 4a–4g did not display toxicity at the test doses. In addition, all compounds were excreted or
metabolized in ~4 h.
Table 2. Anticonvulsant activity of 2a–2i, 3a–3r, and 4a–4g in a phase-I study.
Compounds Dosage (mg·kg−1)
MES a Rotorod b
0.5 h 4 h 0.5 h 4 h
2a 30 1/3 0/3 0/3 0/3
2b 300 1/3 0/3 0/3 0/3
2c 100 1/3 0/3 0/3 0/3
2d 100 1/3 0/3 0/3 0/3
2e 100 1/3 0/3 0/3 0/3
2f 300 0/3 0/3 0/3 0/3
2g 300 0/3 0/3 0/3 0/3
2h 300 0/3 0/3 0/3 0/3
2i 300 0/3 0/3 0/3 0/3
3a 30 1/3 0/3 0/3 0/3
3b 100 3/3 0/3 0/3 0/3
3c 300 1/3 0/3 0/3 0/3
3d 300 1/3 0/3 0/3 0/3
3e 100 3/3 0/3 0/3 0/3
3f 100 1/3 0/3 0/3 0/3
3g 100 1/3 0/3 0/3 0/3
3h 300 0/3 0/3 0/3 0/3
3i 100 1/3 0/3 0/3 0/3
3j 300 0/3 0/3 0/3 0/3
3k 300 0/3 0/3 0/3 0/3
3l 30 2/3 0/3 0/3 0/3
3m 100 2/3 0/3 0/3 0/3
3n 30 3/3 0/3 0/3 0/3
3o 30 1/3 0/3 0/3 0/3
18
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Table 2. Cont.
Compounds Dosage (mg·kg−1)
MES a Rotorod b
0.5 h 4 h 0.5 h 4 h
3p 30 2/3 0/3 0/3 0/3
3q 30 3/3 0/3 0/3 0/3
3r 100 2/3 0/3 0/3 0/3
4a 300 0/3 0/3 0/3 0/3
4b 30 1/3 0/3 0/3 0/3
4c 300 1/3 0/3 0/3 0/3
4d 100 1/3 0/3 0/3 0/3
4e 100 1/3 0/3 0/3 0/3
4f 300 0/3 0/3 0/3 0/3
4g 100 1/3 0/3 0/3 0/3
Valproate 100 3/3 0/3 0/3 0/3
a MES test (numbers of mice defended/numbers of mice detected); b Toxicity: rotorod test (numbers of mice showing
toxicity/numbers of mice detected).
Next, the effect of 2a, 3a, 3b, 3e, 3l, 3n–3q, and 4b were evaluated quantitatively for their
anticonvulsant activity median effective dose (ED50) and neurotoxicity median toxicity dose (TD50)
(Table 3) in a phase-II experiment. 3n and 3q showed the greatest effect, with ED50 values of 46.1 and
64.3 mg kg−1, and protective index (PI) of 6.34 and 4.11, respectively, which were higher than those of
phenobarbital and valproate.
Table 3. Anticonvulsant activity of 2a, 3a, 3b, 3e, 3l, 3n–3q and 4b in a phase-II study.
Compounds ED50
a (mg/kg) TD50
b (mg/kg) PI (TD50/ED50)
2a 90.8 >200 3.20
3a 105.9 >200 2.89
3b >300 >200 1.89
3e 147.2 >200 2.36
3l >300 >200 2.04
3n 46.1 >200 6.34
3o 84.3 >200 3.37
3p >300 >200 1.13
3q 64.3 >200 4.11
4b 74.5 >200 3.69
Phenobarbital c 21.8 69.0 3.2
Valproate 247 >200 1.6
a ED50: Median effective dose affording anticonvulsant defense for 50% animals; b TD50: Median toxic dose eliciting
minimal neurological toxicity for 50% animals; c data from Krall et al. 1978 [17].
2.4. Effects of 2c and 2d on Monoamine Levels
Monoamine concentrations in the mouse brain are shown in Table 4. The concentration of 2c,
2d, and fluoxetine was 30 mg kg−1. The neurotransmitter concentration was calculated as ng g per
brain region wet weight. 2c and 2d did not alter the dopamine concentration, but increased the
concentrations of serotonin and norepinephrine in mouse brain significantly in the FST, and these
effects were similar to those of the positive control fluoxetine.
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Table 4. Effect of 2c and 2d on monoamine concentrations in mouse brain.
Groups Serotonin Norepinephrine Dopamine
Normal Vehicle 325.1 ± 28.3 298.4 ± 22.4 357.4 ± 29.8
Stress Vehicle 202.4 ± 38.4 c 207.3 ± 25.7 c 218.7 ± 20.0
2c 334.5 ± 31.9 b,c 309.5 ± 20.6 a,c 201.5 ± 19.2
2d 329.0 ± 27.8 b,c 310.7 ± 24.9 a,c 206.0 ± 18.7
Fluoxetine 340.3 ± 32.5 b,c 321.8 ± 29.1 a,c 202.6 ± 17.8
Values are given as mean ± SEM (n = 8). a P < 0.05, b P < 0.01 vs. stress vehicle; c P < 0.05 vs. normal vehicle.
3. Discussion
The FST is a model of depression. It mimics the condition of hopelessness and has a good
predictive validity in mice. In this model, mice are limited in movement and cannot abscond, which
results in motionlessness [18]. The immobility displayed in this model has been assumed to correspond
to a behavioral response to hopelessness which, in turn, might correspond to a depressive disorder in
humans [19].
Nine benzo[d]thiazole derivatives (2a–2i) containing an alkyl group with 2–10 carbons displayed
antidepressant activity. Among them, 2c (n-butyl group) and 2d (n-pentyl group) exhibited the highest
antidepressant activity. Although alkyl groups are not a functional group, they can play an important
role in the binding interactions of a drug with its target. Alkyl chains are hydrophobic and can interact
with the hydrophobic region of a receptor through Van der Waals interaction in the binding site.
Varying the size of the group allows exploration of the hydrophobic region [20].
Among 18 benzyloxybenzo[d]thiazole derivatives 3a–3r, most of the compounds, except for
3h, 3k, 3l and 3r, induced a significant decrease in the immobility time at 30 mg kg−1 and showed
marked antidepressant effect. Interestingly, 3q, which has two methyl substituents on the phenyl ring,
displayed the highest antidepressant effect.
However, the reduction conditions needed would be quite harsh and might not be feasible without
causing drug degradation [20]. The position of halogen atoms affects antidepressant activity on the
phenyl ring.
Comparing the F-substituted compounds 3b, 3c and 3d at different positions on the phenyl ring,
the sequence of effect was 3-F > 4-F > 2-F, and the sequence of effect for Cl-substituted compounds 3e,
3f, and 3g was 3-Cl > 4-Cl > 2-Cl. The sequence of effect for different Br-substituted compounds 3h, 3i,
and 3j was 3-Br > 4-Br > 2-Br. In addition, among the compounds with electron-withdrawing groups
(i.e., 3k, 3l, 3m, and 3n), only 3m and 3n (with a –CF3 group) exhibited the antidepressant activities.
For compounds with electron-donating groups, 3o–3r, the sequence of activity was 3,5-(CH3)2 >
4-OCH3 > 4-CH3 > 3,5-(OCH3)2. Of seven phenoxylethoxylbenzo[d]thiazole compounds 4a–4g, except
for 4c and 4e, the remaining five compounds 4a, 4b, 4d, 4f, and 4g induced a significant decrease in the
immobility time at 30 mg kg−1 and exhibited antidepressant effects. Among them, 4a displayed the
highest antidepressant activity.
Nervous stress can cause impressionable individuals to develop epilepsy, and depressive illness
is a general comorbidity related to epilepsy [21]. Nevertheless, understanding the heterogeneity
of depression and epilepsy is difficult [22] Antiepileptic drugs might ameliorate the symptoms of
depression, as indicated in clinical studies. Curing depression will have positive effects on epilepsy
and quality of life.
The anticonvulsant effects of 2a–2i, 3a–3r, and 4a–4g were evaluated using the MES test. The most
efficacious compounds, 3n and 3q, exhibited ED50 values of 46.1 and 64.3 mg kg−1 and had PI values
of 6.34 and 4.11, respectively, which were greater than those of phenobarbital or valproate. Therefore,
3n and 3q might be useful candidates as antidepressant drugs for curing depression in patients
with epilepsy.
A disruption in the release of neurotransmitters in the CNS, such as serotonin, norepinephrine,
and dopamine, has been proposed to be a characteristic of depression. The metabolic imbalance of
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monoamine transmitters is considered to be a fundamental neurochemical feature in patients with
depression. Hence, patients could be treated by increasing monoamine concentrations in the CNS [23].
We found that 2c and 2d increased concentrations of serotonin and norepinephrine markedly without
altering dopamine concentrations in mouse brains, in a similar manner to that seen with the positive
control fluoxetine in the FST. A cure for patients with major depression is deemed to include an increase
in levels of serotonin or norepinephrine [24,25]. Thus, the antidepressant activities of 2c and 2d could
be reflected by measuring levels of serotonin and norepinephrine in the CNS.
4. Method and Material
4.1. Reagents and Instruments
Positive drug: fluoxetine (purity > 99%) was purchased from Sigma. Melting points were measured
by the melting point apparatus (WRS-1B, Shanghai, China). Infrared spectra (IR in KBr) were recorded
using FT-IR1730 (Bruker, Switzerland). 1H and 13C NMR spectra were recorded on an AV-300 (Bruker,
Switzerland), and the chemical shift values are in ppm relative to the TMS or solvent peaks. Mass spectra
were recorded on MALDI-TOF/TOF mass spectrometer (Bruker Daltonik, Bremen, Germany). Main
reagents were purchased from Aldrich Chemical Corporation (Shanghai, China).
4.2. Synthesis of Benzo[d]thiazol and Benzyloxybenzo[d]thiazole Derivatives 2a–2i, 3a–3r
A solution of benzo[d]thiazol-2-ol (3.0 mmol), anhydrous K2CO3 (3.0 mmol) and 5 mL DMF was
stirred in a round-bottomed flask for 1 h at 60 ◦C, then, 1.2 mmol of alkyl bromide or substituted
brominated benzyl compound was added slowly to the reaction solution. The reaction solution was
refluxed for 5 h, the reaction was monitored by TLC. DMF was evaporated under reduced pressure,
the residue was washed with water, filtered, dried and the crude product was crystallized from MeOH.
The yield, melting point, and spectral data of each compound are given below.
4.3. Synthesis of Ethoxylbenzo[d]thiazole Derivatives 4a–4g
A mixture of benzo[d]thiazol-2-ol (3.0 mmol, 0.5 g), 1,2-dibromoethane (3.0 mmol, 0.6 g) and
anhydrous K2CO3 (3.0 mmol, 0.4 g) was refluxed in DMF for 1 h, after the completion of the reaction
(as monitored by TLC), DMF was evaporated and the precipitated product was washed with deionized
water, dried. Then, 2-(2-bromoethoxy)benzo[d]thiazole (3.0 mmol, 0.8 g), 10 mL of a mixture of NaOH
and substituted phenol was refluxed in EtOH for 2–5 h. After the completion of the reaction (as
monitored by TLC), the solution was filtered and washed with 10% HCl and water. The crude product
was recrystallized from MeOH. The melting points, yields, and spectral data of 4a–4g are given below.
4.4. Experimental Animal and Compounds Treatment
Male ICR mice (20± 2 g) were purchased from the laboratory of animal study of Zhejiang Academy
of medical sciences. Before the experiment started, mice were tamed for 1 week. During and before the
test, mice were kept at 23 ± 2 ◦C for 12 h, at day and night circle, and tap water and standard food
granules were provided. The procedures were adopted according to the National Institute of Health
Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of our
Institution in this study. All the test compounds were dissolved in PEG-400 (polyethylene glycol-400).
Other drugs were dissolved in 0.9% NaCl (isotonic saline solution). Fluoxetine, phenobarbital, and
valproate were used as positive controls and the vehicle as the negative control. All the test compounds
and other drugs were administered intraperitoneally for 30 min in the FST, the volume of the drug
solution and vehicle was 0.1 mL/20 g of mice.
4.5. In the FST
Male ICR mice were randomized into groups. On the day of the experiment, mice were placed
one at a time into a Perspex barrel (elevation 20 cm, 10 cm diameter) including 10 cm water about
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22 ◦C. Mice were arranged into different groups (n = 8). Next, a mouse was placed independently into
the perspex barrel and kept in the water for six minutes. After two minutes of fierce struggle, the mice
were immobile. The duration of immobility was recorded during the last four min of the six min test.
The immobility course was treated as the time that the mice floating on the water without struggle and
maintained only the movements necessary to provide their head above the water [26,27].
4.6. In the MES Experiment
Convulsions were initiated in mice with a 60 Hz alternating current for 50 mA. The electric
current was implemented via corneal electrodes for 0.3 s. Protection against the spread of the maximal
electroshock seizure-induced seizures was defined as the abolition of the hind leg and tonic maximal
extension component of the seizure. At 30 min after the administration of the compounds, the activity
was evaluated in the maximal electroshock seizure test [28].
4.7. Experiment of Neurotoxicity
The neurotoxicity experiment of the compounds and drugs was evaluated through the rotorod
experiment in mice. The mice were trained to stay on an accelerating rotorod of diameter 3.2 cm that
rotated at 10 rpm. Trained animals were given an intraperitoneal injection of the test compounds.
Neurotoxicity was indicated by the inability of the animal to maintain equilibrium on the rod for at
least 1 min in each of the trials. The MES and rotorod tests were carried out according to the standard
procedure described in the Antiepileptic Drug Development Program (ADD) of the National Institutes
of Health (USA) [29].
4.8. HPLC conditions and Sample Preparation
The dosage of 30 mg kg−1 of 2b, 2c and fluoxetine was used for testing the action on MOA
neurochemical levels in rat brain. Mice were randomly divided into five groups (n = 10). 2b, 2c and
fluoxetine, normal vehicle, stress vehicle oral gavage once a day for seven days. After the end of the test,
the mouse was immediately sacrificed by cervical dislocation, then the brain tissue was immediately
removed, and quickly frozen and at −80 ◦C until used for neurochemical analysis. The brain tissues
were sonicated in 0.1 M NaH2PO4 aqueous solution including 0.85 mM OSA, 0.5 mM Na2·EDTA
(ethylenediamine tetraacetic acid disodium), centrifuged at 13,000× g at 4 ◦C for 15 minutes. Then
serotonin, norepinephrine and dopamine were analyzed by High-Performance Liquid chromatography
coupled with an electron capture detector. The mobile phase was made up of 0.1 mol L-1 anhydrous
sodium dihydrogen phosphate containing 0.5 mM EDTA and 0.85 mM osanetant (OSA) and 11% MeOH
and regulated to pH 3.4 using phosphate acid buffer solution and filtered by the pore size ultrafiltration
membrane of 0.45 μM. The external standard curves were used to quantify the amounts of serotonin,
noradrenaline, and dopamine in each sample calculated by area under the curve. The injection volume
dose was 20 μL. The detection limit of the analysis was 20 pg·g−1 sample.
4.9. Statistic Analysis
All analyses were performed using the GraphPad Prism program (GraphPad software, Inc.,
San Diego, CA, USA). The statistical analysis of the behavioral tests was performed by analysis of
variance (ANOVA), which was followed by Tukey’s post hoc comparison test. All experimental
results are presented as mean (s) ± standard error of the mean (SEM), with a p-value smaller than 0.05
considered statistically significant.
5. Conclusions
Thirty-four previously unreported benzo[d]thiazol derivatives 2a–2i, 3a–3r, and 4a–4g were prepared
and assessed for their potential antidepressant and anticonvulsant effects. 2c and 2d decreased the
immobility time markedly and displayed the highest antidepressant effects in the FST, and also showed
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anticonvulsant activity. 2c and 2d did not change the dopamine concentration but increased the
concentrations of serotonin and norepinephrine significantly in the mouse brain in the FST, similar
to that observed with the positive control fluoxetine. These results suggest that 2c and 2d may be potential
leads for the development of therapeutic agents for the treatment of depression and epilepsy.
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Abstract: Haematococcus pluvialis is widely distributed in the world and well known as the richest
natural source of astaxanthin that is a strong antioxidant with excellent commercial value. The pathway
of astaxanthin biosynthesis in H. pluvialis has been documented as an enzymatic reaction. Several
enzymes have been reported, but their isoforms or homologs have not been investigated genome-wide.
To better understand the astaxanthin biosynthesis pathway in H. pluvialis, eight candidates of the
geranylgeranyl pyrophosphate synthase gene (HpGGPPS) predicted from Iso-seq data were isolated in
this study. The length of coding region of these candidates varied from 960 bp to 1272 bp, composing of
7–9 exons. The putative amino acids of all candidates composed the signature domain of GGPPS gene.
However, the motifs in the domain region are varied, indicating different bio-functions. Phylogenetic
analysis revealed eight candidates can be clustered into three groups. Only two candidates in Group1
encode the synthase participating in the astaxanthin formation. The yield of astaxanthin from these
two candidates, 7.1 mg/g (DW) and 6.5 mg/g (DW) respectively, is significant higher than that from
CrtE (2.4 mg/g DW), a GGPPS gene from Pantoea ananatis. This study provides a potential productive
pathway for astaxanthin synthesis.
Keywords: GGPPS; Haematococcus pluvialis; astaxanthin; Iso-Seq
1. Introduction
Astaxanthin (C40H52O4), a keto-carotenoid, has been well known as super vitamin E due to
its hydroxyl and ketone functional groups and multiple conjugated double bonds that can reduce
the reactive oxidizing molecule. Thus, astaxanthin can be consumed as a dietary supplement or
aging related-cosmetics. Meanwhile, astaxanthin also has been used as an aquaculture consumption
due to its additive of the blood-red color, contributing to over $500 million a year in the market [1].
Astaxanthin can be produced chemically in the factory or naturally from organisms such as the
microalga Haematococcus pluvialis and the yeast fungus Xanthophyllomyces dendrorhous [2]. Compared
with chemically synthetic astaxanthin from the Wittig reaction using asta-C15-triarylphosphonium salt
and the C10-dialdehyde [3], the naturally isolated astaxanthin has 20-times higher antioxidant activity
and is capable for human consumption [4,5].
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As the most important source of natural astaxanthin, it is imperative to understand the biological
process and the regulation of astaxanthin formation in H. pluvialis aiming to improve the productivity
of astaxanthin. The pathway of astaxanthin production in H. pluvialis is complex but still has been
described, which is originally started from pyruvate and glyceraldehyde-3-phosphate (GA-3P) followed
by a series of enzymatic reactions [6,7]. Briefly, isopentenyl diphosphate (IPP), the precursor
of carotenoids, was synthesized through methyl-d-erythritol 4-phosphate (MEP) pathway using
pyruvate, GA-3P, and enzymes of DXS and IspC-IspH [8,9]. Subsequently, IPP and dimethylallyl
diphosphate (DMAPP, an isomer of IPP that was formed by isopentenyl pyrophosphate isomerase (IPI)
or 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (HDR)), were used to form a C20 compound,
geranylgeranyl pyrophosphate (GGPP), with the help of geranylgeranyl pyrophosphate synthase
(GGPPS) [10–13]. Carotenoids were then initialized using GGPP, in the main order of phytoene,
ζ-carotene, lycopene, β-carotene, cathaxanthin, and astaxanthin, with cooperation of enzymes of
phytoenesysthase (PSY), phytoenedesaturase (PDS), ζ-carotenedesaturase (ZDS), lycopene β-cyclase
(LCY-b), β-carotene ketolase (BKT), and β-carotene 3,3′-hydroxylase (CrtR-b) [2,7,13]. Thereby, the
GGPPS, a key enzyme defining the initial GGPP availability, is crucial for the subsequent flux of
carotenoids biosynthesis, theoretically. It has been reported that the mechanism of the enzymatic
reaction converting IPP to GGPP is conserved among organisms from bacteria to human [14,15].
However, the number of GGPPS paralogs were varied within species, as high as 12 in Arabidopsis [16]
and as low as one in Chlamydomonas reinhardtii [17]. Specifically, three GGPPS genes were found in
H. pluvialis based on a RNA-Seq transcriptome analysis (Genbank accessions: KX236181–KX236183).
With the advantage of obtaining the full-length of transcripts to identify isoforms, alternative splicing,
fusion transcripts, LncRNA, and new homologous genes, the single-molecule real-time (SMRT)
long-read isoform sequencing (Iso-Seq) developed by Pacific BioSciences (PaciBio) is more preferred to
discover more paralogs over the RNA-Seq technology [18]. As one of successful examples, more than
113,000 novel splice isoforms were discovered in a Iso-Seq data of Sorghum bicolor L. Moench and some
of them are functional which confirmed by additional experiments of gene cloning and RT-PCR [19].
Since the whole genome sequence of H. pluvialis is available [20], it is possible to discover more
reliable novel GGPPS genes from the Iso-Seq data. The main objectives of this study were to explore
more GGPPS paralogs in H. pluvialis using an Iso-Seq data, to determine their evolutionary relationship,
and to characterize their performance on astaxanthin biosynthesis. By comparing the productivity of
astaxanthin using different GGPPS genes from H. pluvialis, it is expected to arrange a more efficient
pathway for astaxanthin biosynthesis.
2. Results
2.1. Cloning and Sequence Characterization of HpGGPPS Genes
Using three reported GGPPS genes of H. pluvialis retrieved from Genbank (accession nos. KX236181,
KX236182, and KX236183), eight candidates were carried out from the Iso-Seq data by BlastN analysis
with e-value of 0. Using designated gene-specific primers, the full-length coding sequences (CDS) of
eight putative HpGGPPS genes (HpGGPPS1-1, HpGGPPS1-2, HpGGPPS2-1, HpGGPPS2-1, HpGGPPS3-1,
HpGGPPS3-2, HpGGPPS3-3, and HpGGPPS3-4) were successfully isolated. Sequences were submitted
to Genbank with accession numbers MN689792–MN689799.
The nucleotide sequence analysis revealed that eight putative HpGGPPS genes are ranging
1011–1455 bp in length and varied from 960 bp to 1272 bp in CDS region (Supplemental Table S1).
Their deduced amino acids are ranging 319–423 aa with putative molecular weight of 36.27–45.75 KDa,
respectively (Supplemental Table S1). The alignment of nucleotide sequences of eight HpGGPPS genes
suggested 39.9–100% similarity in the CDS region (Supplemental Figure S1). Clearly, three classes were
presented according to the similarity. High nucleotide sequence similarity was found within classes,
including 98.6% identity between HpGGPPS1-1 and HpGGPPS1-2, 97.4% identity between HpGGPPS2-1
and HpGGPPS2-2, and 99.1–100% identity among HpGGPPS3-1, HpGGPPS3-2, HpGGPPS3-3, and
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HpGGPPS3-4. It is noted that In-Del variation was found between sequences of HpGGPPS3-1 and
HpGGPPS3-2 (sharing 100% similarity with each other), and between sequences of HpGGPPS3-3 and
HpGGPPS3-4 (sharing 100% similarity with each other). By contrast, low percentage of nucleotides
identity was found among classes, which was lower than 49%.
By the local BlastN against H. pluvialis genome sequences, HpGGPPS1-1, HpGGPPS1-2,
HpGGPPS2-1, and HpGGPPS2-2 hit different scaffolds, revealing different genome region. Differently,
HpGGPPS3-1 and HpGGPPS3-2 hit the same scaffold, as well as HpGGPPS3-3 and HpGGPPS3-4.
By considering their 100% sequence identity, they might be isoforms from alternative splicing.
Further sequences alignment of HpGGPPS genes with corresponding genome scaffolds confirmed
that HpGGPP3-1 and HpGGPP3-2 were isoforms from modified splicing of intron, while HpGGPPS3-3
and HpGGPPS3-4 were isoforms from exon exclusion (Figure 1). Gene structure analysis suggested
that HpGGPPS1-1 and HpGGPPS1-2 were composed from nine exons, as well as HpGGPPS3-1, and
HpGGPPS3-2. Diversely, HpGGPPS2-1 and HpGGPPS2-2 were from seven and eight exons, respectively
(Figure 1). Due to the missing nucleotide information in the scaffold, the gene structure of HpGGPPS3-3
and HpGGPPS3-4 is not complete.
Figure 1. Schematic diagram of HpGGPPS gene structure, which was predicted by aligning with
corresponding genome sequences. The slash indicates incomplete genome sequences resulting partial
gene structure.
2.2. Molecular Evolution of HpGGPPS Genes
To predict the function of isolated HpGGPPS candidates, the domain of their putative amino
acids was analyzed. According to SMART online prediction, the deduced amino acids of seven out
of eight candidates contained the full domain of Polyprenyl_syn (Pfam accession: PF00348), which
is associated with isoprenoid compounds synthesis. The excluded candidate, HpGGPPS3-4, has
incomplete Polyprenyl_syn domain, because of the missing exon in comparison with HpGGPPS3-3.
By aligning the deduced amino acids of eight HpGGPPS candidates from this study and four from
Genbank (KX236181, KX236182, and KX236183 from H. pluvialis; XM001703117 from Chlamydomonas
reinhardtii), motifs analysis was performed and results revealed that all 12 genes contained the signature
asparate rich motifs, SARM (DDxxxD, which x refers to any amino acids) and FARM (DDxxxxD,
which x refers to any amino acids), commonly found in GGPPS gene (Figure 2). Unlike the SARM
domain conserved among aligned genes, the variation was found in the FARM motifs. In detailed,
HpGGPPS1-1, HpGGPPS2-1, KX236181, and XM_001703117 have the traditional motifs of DDxxxxD,
while rest genes have a modified motifs of DDxx–D. Moreover, HpGGPPS1-1, HpGGPPS2-1, KX236181,
and XM_001703117 have the additional CxxxC motifs, indicating they might have different bio-functions
from the rest of genes. Besides, GGPPS genes from H. pluvialis (HpGGPPS1-1, HpGGPPS2-1, and
KX236181) have the modified TxxxC motifs, comparing with the GGPPS gene from C. reinhardtii.
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Figure 2. Alignment of Polyprenyl_syn domain region in the deduced amino acids of GGPPS genes.
The motifs for CxxxC, FARM, and SARM are red squared. The sequence of XM_001713117 is from
Chlamydomonas reinhardtii, while the rest of 11 sequences are from Haematococcus pluvialis.
To further evaluate the evolutionary pattern of HpGGPPS genes, a phylogenetic tree was
constructed using GGPPS genes obtained in this study and retrieved from Genbank which originally
from other species including Planta, Bacteria, Archaea, and Fungi (Figure 3). Eight HpGGPPS genes
were clustered into three distinguish groups, paralleled with the three classes identified according to
sequence similarity. The Group1 genes, composing of HpGGPPS1-1 and HpGGPPS1-2, were clustered
with GGPPS genes from Plantae and were more close to Euglena gracillis and Thermosynehococcus
elongatus belonging to photosynthetic unicellular species, compared with other high plant species. The
Group2 genes, composing of HpGGPPS2-1 and HpGGPPS2-2, were in a distinct cluster apart from
the cluster containing HpGGPPS3-1, HpGGPPS3-2, HpGGPPS3-3, and HpGGPPS3-4 (Group3). It is
28
Mar. Drugs 2019, 17, 696
interesting that six putative HpGGPPS genes from Group2 and Group3 were more likely clustered
with GGPPS genes from Bacteria, which implied that their function might different from HpGGPPS1-1
and HpGGPPS1-2 that are close to Planta evolutionarily.
Figure 3. Phylogenetic relationships of the deduced amino acid sequences of GGPPS genes obtained in
this study and retried from Genbank. Numbers in parentheses are accession numbers of GGPPS genes.
The phylogenetic tree was constructed by MEGA version 7.0 using neighbor-joining method. Bootstrap
values from the percentages of 1000 replications are indicated beside each node.
2.3. Functional Identification of HpGGPPS Genes in Escherichia coli
The function of isolated HpGGPPS genes was analyzed by hetero-expression studies in E. coli
targeting the astaxanthin formation. The transformed E. coli cells with pFZ153ΔE/CrtE, a plasmid
containing astaxanthin biosynthetic gene cluster originally from Bacteria as the positive control,
displayed orange-red color in the cell pellet as a result of pigmentation of astaxanthin (Figure 4). Served
as the negative control, E. coli cells harboring pFZ153ΔE (NCK), a plasmid without GGPPS gene but with
all rest genes (CrtI, CrtB, IPI, CrtY, CrtZ, CrtW) for astaxanthin production, displayed slight yellow color
in the cell pellet. Similar as the positive control, the E. coli transformants harboring pFZ153ΔE/GGPPS1-1
(1-1) and pFZ153ΔE/GGPPS1-2 (1-2) also displayed orange-red color, but relatively darker, which
might be explained by more pigmentation. By contrast, the pigmentation was not observed in E.
coli pellets harboring pFZ153ΔE/GGPPS2-1 (2-1), pFZ153ΔE/GGPPS2-2 (2-2), pFZ153ΔE/GGPPS3-1
(3-1), pFZ153ΔE/GGPPS3-2 (3-2), pFZ153ΔE/GGPPS3-3 (3-3), or pFZ153ΔE/GGPPS3-4 (3-4) (Figure 4),
indicating that they might not encode proteins associated with pigment production. Therefore, only
proteins encoded by HpGGPPS1-1 and HpGGPPS1-2 have GGPP synthase activity to participate
pigment formation.
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Figure 4. Hetero-expression experiments of pFZ153ΔE/GGPPS in E. coli targeting astaxanthin synthesis.
E. coli strain BL21 (DE3) was used as the host. CrtE refers to the GGPPS gene from Pantoea ananatis,
served as the positive control producing astaxanthin; 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 3-3, and 3-4 refers to
corresponding HpGGPPS genes isolated in this study; NCK refers to the negative control, which is the
BL21 (DE3) containing pFZ153ΔE without GGPPS gene for production of no astaxanthin. Colors of E.
coli pellet are representative of at least five transformants with similar results.
To further confirm and quantify the astaxanthin production in E. coli cells, a HPLC analysis was
successfully conducted. The chromatographic profile of astaxanthin was generated using commercial
standards (Supplemental Figure S2a). As expected, an absorption peak of astaxanthin was detected
in the positive control and but not detected in the negative control. Similarly, the pigment in E. coli
cells harboring pFZ153ΔE/GGPPS1-1 and pFZ153ΔE/GGPPS1-2 have a peak at the same retention
time as astaxanthin standard, indicating the existence of astaxanthin (Supplemental Figure S2b).
Consisting with the color evaluation in cell pellets, astaxanthin was not detected in E. coli cells
harboring pFZ153ΔE/GGPPS2-1, pFZ153ΔE/GGPPS2-2, pFZ153ΔE/GGPPS3-1, pFZ153ΔE/GGPPS3-2,
pFZ153ΔE/GGPPS3-3, and pFZ153ΔE/GGPPS3-4. Besides, no other absorption peaks were observed in
their chromatographic profile. Meanwhile, the quantity of astaxanthin was measured using a standard
curve constructed from a set of astaxanthin standards. Results showed that E. coli cells harboring
pFZ153ΔE/GGPPS1-1 produced as high as 7.1 mg astaxanthin per gram of dried cells in average from
three independent pigment extraction, which is slight more (but not significant at the level of 0.05) than
E. coli cells harboring pFZ153ΔE/GGPPS1-2 (6.5 mg/g DW in average). Notably, the positive control
has significant less yield of astaxanthin (2.4 mg/g DW in average), compared with E. coli cells with
HpGGPPS genes (Figure 5).
Figure 5. Astaxanthin content in E. coli (BL21 DE3) transformants with plasmids harboring astaxanthin
synthetic gene cluster, according to HPLC analysis. Specifically, HpGGPPS1-1-opt and HpGGPPS1-2-opt
refers to the bacteria codon optimized HpGGPPS1-1 and HpGGPPS1-2 gene, respectively. Data were
the mean from at least three replicates and the standard error was presented as the bar. *** indicates the
significant differences at the level of 0.001. NS indicates no significant differences at the level of 0.05.
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3. Discussion
Astaxanthin is one of the strongest antioxidants and its natural format is being demanded by
increasing market looking for natural products [1]. Thereby, the topic of improving astaxanthin
production from natural sources is attractive for the industry. Lots of effort has been made by scientists
trying to design an efficient protocol for astaxanthin production using natural source [7]. As a major
natural source of astaxanthin, Haematococcus pluvialis accumulated as high as 5% dry weight of
astaxanthin [21] and its dairy supplements can be used human-friendly [22]. It was found that two
specific enzymes, β-carotene hydroxylase (CrtR-b) and ketolase (BKT), are crucial for astaxanthin
formation [23–26] and many researches were focused on aiming to improve astaxanthin content [27–29].
However, as the important precursor to initial the carotenoids synthesis in H. pluvialis, limited research
was conducted for the regulation of geranylgeranyl pyrophosphate (GGPP) on astaxanthin production.
It was recorded that GGPP synthase (GGPPS) plays an important role on GGPP formation [6].
In Arabidopsis, a well-studied species, 12 GGPPS genes were found and 10 of them have the ability to
produce GGPP [30]. Research suggested that GGPP formation was regulated with different pattern in
Arabidopsis [30].
Previously, there are three GGPPS genes from H. pluvialis in Genbank and one (Genbank accession
no. KX236181) have the activity to catalyze GGPP formation [31]. Unfortunately, no further information
was reported regarding the other two GGPPS genes (Genbank accession nos. KX236182, KX236183).
With the expectation of discovering more paralogs having enzymatic activity, this study screened an
Iso-Seq data covering transcripts from the control and stressed H. pluvialis cells. The stress condition was
high light and salt which was normally used to induce the astaxanthin formation [20]. Eight candidates
were found and their gene structures were illustrated in this study (Figure 1), using the available
genome sequences (BIG Data Center GSA Database accession no. PRJCA000614) [20]. Generally,
two conserved aspartate rich motifs, FARM and SARM, and flexible CxxxC motifs are presented
in the domain of amino acids of GGPPS genes [16,31,32]. Based on the domain analysis, FARM
and SARM motifs were presented in all eight HpGGPPS genes while CxxxC motifs was only found
in HpGGPPS1-1, HpGGPPS1-2, KX236181, and XM_001703117 (Figure 2). It has been documented
that FARM, SARM and CxxxC motifs are important for GGPP biosynthesis by affecting the IPP and
DMAPP substrate binding process and by affecting the physical interaction between subunits of
heteroimeric GPP, respectively [31,32]. Proteins with features of conserved FARM, SARM, and CxxxC
motifs displayed the function of catalyzing GGPP formation [33], indicating similar function might be
employed by HpGGPPS1-1 and HpGGPPS1-2. Differently, the CxxxC motifs was not found in other
six HpGGPPS genes (Figure 2). Such proteins with conserved FARM and SARM motifs but without
CxxxC motifs was shown to be involved in the production of medium (C25) to long (C45) chain
isoprenoids [34]. It is noted that six HpGGPPS genes isolated in this study (HpGGPPS2-1, HpGGPPS2-2,
HpGGPPS3-1, HpGGPPS3-2, HpGGPPS3-3, and HpGGPPS3-4) and two previously reported GGPPS
genes (KX236182 and KX236183) have modified FARM motifs (DDxx–D instead of DDxxxxD). The
effect of this type of modification on their bio-function has not been reported. The feature of modified
FARM motifs, conserved SARM motifs, and lacking CxxxC motifs was also observed in GGPPS genes
from other species, such as Linus usitatissimum, Ricinus communis, Physcomitrella patens, Zea mays, and
Vitis vinifera [16].
According to the nucleotide sequence similarity and phylogenetic tree analysis constructed
from putative amino acids, eight candidates can be grouped into three classes with more than one
member in each class (Figure 3). To directly evaluate their function on astaxanthin biosynthesis,
hetero-expression in E. coli was performed using candidate genes together with other genes that
are essential for astaxanthin biosynthesis. It is not surprised that two candidates, HpGGPPS1-1 and
HpGGPPS1-2 that closely related to GGPPS1 (Genbank accession no. KX236181), could promote the
formation of astaxanthin in E. coli (Figure 4). Sequence similarity analysis showed that HpGGPPS1-1
and HpGGPPS1-2 shared 99% identity in nucleotides of coding region and only one amino acid
differences. By contrast, big variation (90% identity) was found in the 5’UTR region of HpGGPPS1-1
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and HpGGPPS1-2, indicating there are two functional HpGGPPS in H. pluvialis rather than one as
previously reported [35]. No astaxanthin or other visible pigments were observed in E. coli carrying
the rest of six HpGGPPS candidates, indicating they might not directly associate with astaxanthin
production. Similar findings were also found in other species, such as Arabidposis having AtGGPPS5
and AtGGPPS12 gene with GGPPS domain features but without the function of converting IPP and
DMAPP to GGPP [30,36]. Additional in vitro studies could be conducted to investigate the potential
function of these non-astaxanthin-related HpGGPPS genes.
Furthermore, the yield of astaxanthin in E. coli carrying HpGGPPS1-1 and HpGGPPS1-2 genes is
about 271–296% increased than that carrying CrtE gene (the GGPPS gene driven from Pantoea ananatis
as the positive control). In general, codon optimization is considered as an essential step to produce
heterologous protein in E. coli to overcome the impairment of gene expression from the codon bias [37,38].
Followed by this conventional strategy, we expected more GGPPS proteins in E. coli transformants with
codon-optimized genes, thereby leading to more astaxanthin production, theoretically. Nevertheless,
E. coli with codon optimized HpGGPPS1-1 and HpGGPPS1-2 produced significant lower amount of
astaxanthin (Figure 5), comparing with non-codon optimized corresponding genes, but produced
similar amount of astaxanthin as CrtE (Figure 5). A possible explanation would be that excessive
GGPPS might inhibit the astaxanthin biosynthesis in E. coli. This hypothesis is partly supported by the
evidence that no change or downregulation of GGPPS was found in the salicylic acid and jasmonic
acid stressed transcriptome analysis in H. pluvialis during astaxanthin formation [39]. Further research
can be conducted to test the suppressive role of GGPPS during astaxanthin biosynthesis.
In conclusion, this study found two HpGGPPS gene having the synthase activity to participate
in the astaxanthin biosynthesis. Non-codon optimized H. pluvialis-driven GGPPS genes produced
significant higher amount of astaxanthin in E. coli, compared with bacteria-driven GGPPS gene. This
study improves the understanding of the role of GGPPS in astaxanthin biosynthesis and thereby
contributes to the design of efficient pathway for astaxanthin production.
4. Materials and Methods
4.1. Microalga Culture, Treatment, and Sample Collection
The microalga Haematococcus pluvialis strain 192.80, originally purchased from EPSAG
(Experimental Phycology and Culture Collection of Algae, Goettingen University, Goettingen,
Germany), was used in this study. The alga cells were grown in a 250 mL flask containing 100 mL ESP
Ag medium [40] at 22 ◦C under continuous illumination of 25 μmol photon m−2s−1 in an incubator.
For the stress treatment to induce astaxanthin production, a final concentration of 45 mM sodium
acetate was added into cultures when alga cells reached to the logarithmic phase (OD730 = 0.8), along
with the exposure of continuous high light (irradiance at 500 μmol photon m−2s−1). To maximize the
transcripts in the following SMRT sequencing, alga samples were harvested from the control (0 h) and
at the time points of 1.5 h, 3 h, 6 h, 9 h, 12 h, 24 h, and 48 h after treatment. Alga cells were collected by
centrifugation at 10,000× g for 5 min and frozen immediately by liquid nitrogen. Samples were stored
at −80 ◦C until use.
4.2. Discovery, Isolation, and Sequencing of HpGGPPS Genes
Equal amounts of algae cells collected from different time points of stress treatment were pooled
together for the total RNA extraction and sent to Gene Denovo Biotechnology Co. (Guangzhou,
China) for SMRT sequencing to get the Iso-Seq data. To obtain GGPPS paralogs in H. pluvialis, a local
BlastN against the Iso-Seq data was performed, using three reported GGPPS genes of H. pluvialis
deposited in NCBI (Genbank accession no. KX236181, KX236182, and KX236183). To clone HpGGPPS
candidates, PCR was performed using gene specific primers (Table 1) designed using the target
nucleotide sequences from Iso-Seq data. The cDNA template for PCR was from the total RNA that
was used for SMRT sequencing. The PCR reaction was carried out in a 20 μL volume containing
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1 μL cDNA, 4.0 μL 5× SuperFi buffer, 4.0 μL 5× SuperFi GC Enhancer, 1.6 μL dNTP mix (2.5 mM),
1.0 μL each forward and reverse primer (10 μM), 0.2 μL SuperFi DNA polymerase (Invitrogen Life
technologies, Carlsbad, CA, USA), and 7.2 μL ddH2O. The PCR was implemented on the Bio-Rad
T100 thermal cycler (Bio-Rad, Hercules, CA, USA) under following conditions: 98 ◦C for 2 min; 35
cycles of 98 ◦C for 10 s, 60 ◦C for 10 s, 72 ◦C for 1.5 min; and a final extension at 72 ◦C for 5 min. PCR
products were run on 1.0% agarose gel and target fragments were purified by E.Z.N.A. Gel Extraction
Kit (Omega Bio-tek Inc. Norcross, GA, USA) according to the manufacturer’s instruction. Purified PCR
fragments were treated by A-Tailing Kit (Takara, Japan), ligated into pGEM-T easy vector (Promega,
Madison, WI, USA), and transformed into E. coli Top10 chemically competent cell, as described in
manufacturer’s instructions. Positive colonies were selected by the blue-white screening strategy on
the LB agar plate containing ampicillin (50 μg/mL) and sent to Guangzhou IGE Biotechnology Ltd.
(Guangzhou, China) for sequencing.
Table 1. Primers used in this study.
Primer ID Sequences (5’–3’) Used for
GGPP1F1 CACTGCCTATCCCCGTTTCCAATC Cloning of HpGGPPS1-1 and
HpGGPPS1-2GGPP1R1 GCACCTGCTGACCCGCTCTG
GGPP2F1 GGCGACGCGGGCAAATCAGT Cloning of HpGGPPS2-1 and
HpGGPPS2-2GGPP2R1 AAGCGCCAGGGAATACCAAACATA
GGPP3F1 GCTCTCTTCGCACTTCTTGG Cloning of HpGGPPS3-1, HpGGPPS3-2,
HpGGPPS3-3 and HpGGPPS3-4GGPP3R1 TGATGCCTAGACAGCTCACTT
fGGPP1F2 GTATCTGAATTCAAAAAATGATCCGAGCGATGCACA † Subcloning of HpGGPPS1-1
GGPP1R2 CATAGAAAGCTTTCAGTTCTTGCGGTATCCTA
GGPP1F3 GTATCTGAATTCAAAAAATGATCCGAGCGATGCACA Subcloning of HpGGPPS1-2
GGPP1R3 CATAGAAAGCTTTCAGTTCTTGCGGTACCCT
GGPP2F2 GTATCTGAATTCAAAAAATGAGGGGCCTAGCGGGCAA Subcloning of HpGGPPS2-1 and
HpGGPPS2-2GGPP2R2 CATAGAGCGGCCGCCTATTTCTTTCTGCTCAGGACTC
GGPP3F2 GTATCTGAATTCAAAAAATGGTATCGGATGTGATGCAAG Subcloning of HpGGPPS3-1
GGPP3R2 CATAGAAAGCTTTCACTTGCAGCGCTTGTAAATC
GGPP3F3 GTATCTGAATTCAAAAAATGGTATCGGATGTGATGCAAG Subcloning of HpGGPPS3-2,
HpGGPPS3-3, and HpGGPPS3-4GGPP3R3 CATAGAAAGCTTTCACTTGCAGCGCTTGTAAATC
CrtIB-F2 GTATCTTCTAGAGTAAGGATCCTAACATGAAACCGACCACGGTGA Subcloning of CrtIB
CrtIB-R2 CATAGAGAATTCATGTCGACAAGTTACAGCGGACGTTGCCAC
CrtE-F1 GTATCTGAATTCATACCATGACCGTGTGTGCGAA Subcloning of CrtE
CrtE-R1 ATAGAAAGCTTTCCTTTACGACACCGCTGCCA
† Restriction enzyme sites are formatted in italics.
4.3. Sequences Analysis and Molecular Evolution of HpGGPPS Genes
The ORFs of obtained nucleotide sequences of HpGGPPS genes and corresponding deduced
amino acids were predicted by EditSeq module of DNASTAR software (Lasergene, Madison, WI, USA).
Multiple sequence alignment was conducted by MegAlign module of DNASTAR software to determine
the sequence identity and divergence. By aligned with genome sequences of H. pluvialis (BIG Data
Center GSA Database accession no. PRJCA000614) [20], the gene structure was predicted and the
schematic diagram was displayed by Gene Structure Display Server 2.0 (http://gsds.cbi.pku.edu.cn/).
The domain of deduced amino acid was predicted by SMART online at http://smart.embl-heidelberg.de/.
Phylogenetic relationship was analyzed by MEGA7 software with the neighbor-joining method from
1000 bootstrap replicates [41].
4.4. Plasmids Construction and Heterologous Expression
The plasmid used for heterologous expression targeting gene functional analysis was adopted
from pFZ153, a plasmid has astaxanthin synthetic gene cluster (CrtE, CrtI, CrtB, idi, CrtY, CrtZ, and
CrtW) and produces astaxanthin in E. coli [42]. To investigate the function of HpGGPPS genes on
astaxanthin synthesis, the pFZ153ΔE plasmid was constructed (Figure 6b). Firstly, CrtE, CrtI, and CrtB
genes were removed from pFZ153 (Figure 6a) by XbaI/EcoRI digestion. Secondly, the coding sequence
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of CrtI/CrtB gene was amplified from pFZ153 plasmid using primers CrtIB-F2/CrtIB-R2 containing
XbaI and EcoRI restriction sites, respectively. Finally, the gel-purified fragment of CrtI/CrtB gene was
digested with XbaI/EcoRI restriction enzyme and then ligated with the pFZ153 fragment without CrtE,
CrtI, and CrtB genes to form the new plasmid pFZ153ΔE.
 
(a) (b) 
Figure 6. Structure of plasmid pFZ153 and pFZ153ΔE used to confer the function of HpGGPPS genes
on astaxanthin biosynthesis in E. coli (BL21 DE3). The plasmid pFZ153 (a) was modified to construct
the plasmid pFZ153ΔE (b) by removing the CrtE gene. In this study, HpGGPPS genes were inserted
into the plasmid on EcoRI/HindIII or EcoRI/NotI site to complete the astaxanthin synthetic gene cluster.
The CrtE gene from pFZ153 was served as the positive control.
To complete the astaxanthin synthetic gene cluster, HpGGPPS genes were inserted into pFZ153ΔE
to form plasmids pFZ153ΔE/GGPPS. In detail, the coding sequences of HpGGPPS genes were amplified
from the sequenced plasmids containing HpGGPPS genes, using primers listed in Table 1 containing
either EcoRI/HindIII or EcoRI/NotI restriction sites. Similar as described above, the target PCR fragments
were gel-purified and ligated into pFZ153ΔE plasmid in either EcoRI/HindIII or EcoRI/NotI sites.
Additionally, the coding sequence of CrtE gene amplified from pFZ153 with primers CrtE-F1/CrtE-R1
harboring EcoRI/HindIII sites, was also ligated into pFZ153ΔE plasmid to construct the positive control
(pFZ153ΔE/CrtE).
The procedures of PCR amplification using Platium SuperFi DNA polymerase and gel-purification
using E.Z.N.A. Gel Extraction Kit are the same as described above. The ligation process was performed
by T4 ligase (Promega, Madison, WI, USA), as described by the manual. E. coli Top10 was used as a
host during plasmids construction, as described above. Restriction enzymes used in this study were
purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA).
For the functional analysis of HpGGPPS genes, plasmids of pFZ153ΔE/GGPPS and pFZ153ΔE/CrtE
were transferred into an expression host, E. coli strain BL21 (DE3). The transformed E. coli colonies were
selected on the LB agar plate with ampicillin (100 μg/mL) and then cultured in 15 mL culture tubes
containing 3 mL LB liquid media supplemented with 100 μg/mL ampicillin (LB+Amp100 medium)
overnight. The aliquot of 0.5 mL was added into a 250 mL flask containing 100 mL LB+Amp100
medium. The flasks were incubated at 30 ◦C under dark with shaking (200 rpm) until OD600 reached
0.7–0.9, followed by adding IPTG to a final concentration of 0.1 mM. Three hours later, 50 mL of each
culture was harvested and pigments were extracted as described below. For each plasmid, at least
three independent E. coli colonies were selected for pigment extraction as replicates.
4.5. Pigment Extraction from E. coli and HPLC Analysis
The E. coli BL21 (DE3) cells expressing plasmids constructed in the study were harvested by
centrifugation at 12,000× g for 5 min at 4 ◦C. The pellet was washed by ddH2O twice and dried using
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a freeze-dryer. Consequently, the pellet was crashed into powder, weighted, and resuspended in
1 mL acetone for pigment extraction. The suspension was then incubated at a water bath at 55 ◦C for
15 min with vigorous shaking every 5 min. The supernatant containing pigments was collected by
centrifugation at 12,000× g for 10 min at 4 ◦C. The pigment was subsequently dried using a vacuum
evaporator and dissolved in 0.5 mL solution A (methanol/isopropanol, 8:2, V:V) for the following
HPLC analysis.
The HPLC assay was performed on a Series 1260 system (Agilent Technologies, Santa Clara, CA,
USA). Pigments were separated at a flow rate of 0.6 mL/min on a Phenomenex Gemini-NX C18 column
(5 μ, 150 × 3.0 mm, Phenomenex Inc., Aschaffenburg, Germany) using solution A and solution B
(ddH2O). The gradient elution was 85% A, 15% B at 0 min, followed by linear gradient to 100% A at
10 min, maintained at 100% A to 12 min, returned to initial condition by 12.1 min, and re-equilibrated
at initial condition by 18 min. The injection volume was 5 μL. Column temperature was maintained at
35 ◦C. The standard astaxanthin (Aladdin Chemistry Co. Ltd., Shanghai, China) was used to identify
the target in the pigment. The detection was carried out by UV absorbance at 475 nm. To determine
the concentration of astaxanthin in the testing sample, a calibration curve was constructed using a
serial of plots with 500, 200, 100, 50, 20, and 10 μg/mL standard astaxanthin. The linearity between
concentrations of astaxanthin and their corresponding peak areas was figured out to calculate the
concentration of each analyte. The final astaxanthin productivity of each constructed plasmid was
calculated by the formula, astaxanthin productivity = cal-con. × 0.5 mL/DW, where cal-con. refers to
the calculated astaxanthin concentration in the analyte from the calibration curve, 0.5 mL comes from
the final volume for each pigment extraction, DW comes from the amount of dried cells used for a
pigment extraction. All organic solvents (acetone, methanol, and isopropanol) used in this study are
HPLC grade.
4.6. Statistical Analysis
The data were processed by Pearson t-test to compare two means with replicates. The statistical
significance was determined according to the p < 0.05.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/12/696/s1,
Table S1: Sequence characterization of HpGGPPS genes. Figure S1. Sequence similarity and divergence of eight
HpGGPPS genes in the coding region. The alignment was performed by Clustal W using MegAlign module in
the DNASTAR software. Figure S2. The HPLC chromatograms of pigments extracted from transformed E. coli
cells. (a) the profile of standard astaxanthin purchased from Aladdin Chemistry Co. Ltd (Shanghai, China); (b) an
representative profile of the extracted pigment from E. coli harboring HpGGPP genes and CrtE gene.
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Abstract: Tetrahydropyrans are abundantly found in marine natural products. The interesting
biological properties of these compounds and their analogues make necessary the development of
convenient procedures for their synthesis. In this paper, an atom economy access to tetrahydropyrans
by intramolecular acid-mediated cyclization of silylated alkenols is described. p-TsOH has
shown to be an efficient reagent to yield highly substituted tetrahydropyrans. Moreover,
excellent diastereoselectivities are obtained both for unsubstituted and alkylsubstituted vinylsilyl
alcohols. The methodology herein developed may potentially be applied to the synthesis of marine
drugs derivatives.
Keywords: tetrahydropyrans; acid mediated cyclization; stereoselective; marine drugs analogues
1. Introduction
Tetrahydropyrans are interesting building blocks present in a great number of bioactive marine
natural products. Some representative examples include 2,2,5-trisubstituted tetrahydropyrans such as
malyngolide [1], antibiotic collected from the lipid extract of cyanobacteria Lyngbya majuscula which
shows activity against M. Smegmatis and Streptococcus pyogenes, or 2,5-disubstituted tetrahydropyrans
such as rhopaloic acids A and B, which have been isolated from the marine sponge Rhopaloeides sp. and
show potent inhibitory activity against the embryonic development of the starfish Asterina pectinifera [2]
(Figure 1). The interesting biological properties of these scaffolds together with their scarce availability
has prompted scientists to develop approaches for their synthesis. Moreover, total synthesis has the
advantage of enabling the introduction of structural alterations in the molecule for the preparation of
analogues with potential biological properties.
 
Figure 1. Illustrative examples of THP-containing marine natural products.
The synthesis of these marine products and analogues requires an effective procedure for the
stereoselective construction of the tetrahydropyran ring. Different strategies have been devised
for the formation of these six membered rings including nucleophilic substitution ring formation,
epoxide-mediated annulations or alkene-mediated cyclizations [3,4]. Within the stoichiometric
alkene-mediated cyclizations the most common electrophiles used to activate the alkene addition
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are mercury salts, halogens and seleno reagents. However, few number of approaches have been
described on the intramolecular trapping of an alkene by an oxygenated nucleophile in the presence
of an appropriate Brønsted [5–7] or Lewis acid [8–10]. Although this protocol could be considered a
very efficient atom economy process, the strategy has generally proven to be of limited utility due
to frequent side reactions and lack of generality [11,12]. Moreover, as far as we know, most of the
described methods are focused on the regioselective formation of tetrahydropyrans with no more
than one stereogenic centre. However, very few examples examine the stereoselective aspects of
these processes, usually representing specific key transformations in a total synthesis rather than a
general established methodology. For instance, Yamamoto has used this protocol in the synthesis
of natural caparrapi oxide, where the key step is the stoichiometric acid catalysed cyclization of the
corresponding γ-hydroxy alkene [13] (Scheme 1).
Scheme 1. Towards the synthesis of natural caparrapi oxide.
In another example Nicolaou [14] has reported the formation of the cage-like structure of natural
platensimycin by the acid catalysed cyclization of the corresponding alkenol (Scheme 2).
Scheme 2. Towards the synthesis of natural platensimycin.
Therefore, there is a need to develop a general and efficient method for the stereoselective
synthesis of tetrahydropyrans through the acid-mediated cyclization of alkenols.
For many years our research group has been devoted to exploring new synthetic approaches to
the synthesis of carbo- [15–17] and heterocycles [18,19] using the chemistry of organosilanes. Lately,
Hosomi [20,21] and our group [22,23] have reported an efficient synthesis of tetrahydrofurans by
intramolecular hydroalkoxylation reaction of vinyl or allylsilanes. In this paper, we report the extension
of this work to the stereoselective synthesis of polysubstituted tetrahydropyrans by the acid-mediated
cyclization of activated vinylsilyl alcohols.
2. Results
The δ-hydroxy alkenes needed for this study were readily prepared in three steps such as:
silylcupration of alkynes and reaction with α,β-unsaturated ketones, formation of the epoxide
derivative using sulphur ylides and final SN1 opening of the epoxide with trialkylaluminum
reagents [24] to obtain the corresponding primary alcohol. Unfortunately, primary alcohols 1 showed
to be unstable under chromatography conditions, which made necessary to perform the following
cyclization without previous purification (Scheme 3).
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Scheme 3. Preparation of the starting vinylsilyl alcohols.
We used vinylsilyl alcohol 1a as a model study to get the optimized conditions for this cyclization,
using various Lewis and Brønsted acids. The results are shown in Table 1.
Table 1. Optimization of the acid-mediated cyclization.
Entry Acid 1 Temperature (◦C) Solvent Ratio 2a/3a 2 Product, Yield
1 TMSOTf −78 CH2Cl2 Complexmixture
2 TMSOTf −78 Et2O Complexmixture
3 TiCl4 −78 CH2Cl2 Complexmixture
4 ZnCl2 −78 CH2Cl2 n.r. 3
5 SiO2 r. t. AcOEt n.r. 3
6 BF3·OEt2 −78 CH2Cl2 n.r. 3
7 BF3·OEt2 0 CH2Cl2 67:33 2a + 3a (69%)
8 SnCl4 −78 CH2Cl2 50:50 2a + 3a (63%)
9 CSA reflux CH2Cl2 n.r. 3
10 p-TsOH reflux CH2Cl2 >95:5 2a (77%)
1 1.0 equiv. of acid is used in every example. 2 The ratio of isomers 2a and 3a was determined by 1H-NMR analysis.
3 n.r. stands for no reaction.
p-TsOH showed to be the most efficient reagent for this cyclization (Table 1, entry 10). The reaction
in the presence of TMSOTf or TiCl4 gave a complex mixture (Table 1, entries 1–3), while no reaction
was observed using ZnCl2 or under a suspension of silica (Table 1, entries 4 and 5). BF3·OEt2 was not
effective to promote the cyclization at −78 ◦C, although a 2:1 mixture of both possible stereoisomers
was obtained in moderate yield when the reaction temperature was increased to 0 ◦C (Table 1, entries 6
and 7). Similarly, SnCl4 mediated cyclization provided at −78 ◦C a 1:1 mixture of isomers in reasonable
yield (Table 1, entry 8). Regarding the use of Brønsted acids, the reaction in the presence of CSA
resulted to be extremely slow, while the best results were obtained by refluxing the alcohol in the
presence of p-TsOH for 1 hour (Table 1, entry 10). Under these conditions tetrahydropyran 2a was
obtained in high yield and excellent diastereoselectivity (a single isomer was observed in the reaction
mixture).
With these results in hand and in order to broaden the structural diversity of the tetraydropyrans
obtained by this methodology, we decided to apply the optimized conditions (Table 1, entry 10) to
different vinylsilyl alcohols. The results are summarized in Table 2.
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Table 2. Cyclization of vinylsilyl alcohols 1a–g.
Entry R1 R2 R3 R4 Time (h) 1 dr 2 Yield (%) 3
1 Me Ph H H 1 >95:5 2a (77)
2 Me Ph H H 4 >95:5 2a (62) 4
3 Me Ph H H 4 >95:5 2a (67) 5
4 Me H H H 1 2b (71)
5 Me Me Me H 1 2c (70)
6 Me Bu H H 1 >95:5 2d (73)
7 Me iPr H H 1 >95:5 2e (79)
8 Me Ph H nPr 1 >95:5 2f (71)
9 Et Me H nPr 1 >95:5 2g (70)
10 Me Ph H SiMe3 3 n.r. 6
1 All the reactions were run at reflux temperature except where indicated. 2 The relative stereochemistry of
tetrahydropyrans 2 was assigned based on the 1D-NOE experiments (in every compound 1D-crosspeak was found
between CH2-Si and CH-R2). 3 Yields over two steps from the corresponding epoxides precursor of 1. 4 The reaction
did not go to completion when 0.5 equiv. of pTsOH were used. 5 The reaction was run at r.t. and partial desilylation
of the final THP was observed. 6 n.r. stands for no reaction.
As shown, the process is high yielding and very stereoselective (both for unsubstituted and
alkylsubstituted vinylsilyl alcohols) under p-TsOH mediation at reflux temperature. The short reaction
time needed to reach completion may indicate the benefit of the gem-dialkyl group (Thorpe-Ingold
effect), since the only example of preparation of a THP (a non-substituted one) reported by Hosomi
required reflux for 96 hours [21]. The use of stoichiometric amounts of p-TsOH was proven to be the
best choice, since under lower loadings of acid the reaction is slower and a certain amount of the starting
vinylsilyl alcohol is always recovered (Table 2, entry 2). Moreover, at room temperature the process
requires prolonged reaction time which results in lower yields due to partial protodesilylation [25] of
the cyclization products (Table 2, entry 3). Furthermore, the reaction seems to be dependent on steric
effects, since reaction of alcohol 1h bearing a vinylic bulky group, such as Me3Si, did not react under
the shown conditions (Table 2, entry 10).
We then decided to study the effect of a phenyl group β to silicon in the rate and selectivity of the
cyclization. Vinylsilyl alcohol 1i was chosen as a model substrate for the cyclization process (Table 3).
As expected, the cyclization rate is significantly enhanced by the introduction of the phenyl
group in the starting vinylsilyl alcohol. Thus, at reflux temperature the cyclization of 1i under
p-TsOH induction provides only the corresponding desilylated tetrahydropyrans (Table 3, entry 3)
while at room temperature a mixture of both silylated and desilylated tetrahydropyrans are obtained.
Finally, at 0 ◦C the reaction is fast enough to produce the cyclization products in 10 min, without side
desilylative processes (Table 3, entry 5). Even CSA (either at room temperature or at 0 ◦C) is reactive
enough to provide in good yields the cyclization tetrahydropyrans without any side product (Table 3,
entries 6 and 7).
We then studied the scope of the process employing different starting alcohols under the optimized
conditions (Table 3, entry 5). The results are shown in Table 4.
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Table 3. Optimization of the cyclization of aryl substituted vinylsilyl alcohol 1i.
Entry Acid 1 Temperature (◦C) Solvent Time (min) Product (yield)
1 BF3·OEt2 0 CH2Cl2 60 Desilylated THP 2 (52%)
2 SnCl4 −78 CH2Cl2 90 Desilylated THP (48%)
3 p-TsOH reflux CH2Cl2 60 Desilylated THP (69%)
4 p-TsOH r.t. CH2Cl2 30
2i + 3i + Desilylated
THP (55%) 3
5 p-TsOH 0 CH2Cl2 10 2i + 3i (71%) 4
6 CSA r.t. CH2Cl2 30 2i + 3i (70%) 4
7 CSA 0 CH2Cl2 60 2i + 3i (69%) 4
1 1.0 equiv. of acid is used in every example. 2 Desilylated THP accounts for 2,3,5,5-tetramethyl-2-phenyl-
tetrahydropyran. 3 A 2:1 mixture of the silylated and desilylated tetrahydropyrans was obtained. 4 A 78:22
mixture of 2i:3i was obtained.
Table 4. Cyclization of arylsubstituted vinylsilyl alcohols 1i–l.
Entry R1 R2 Time (min) Product (Ratio 2:3) Yield (%) 1
1 Me Me 10 78:22 2i + 3i (71)
2 Me Ph 10 79:21 2j + 3j (65)
3 Me iPr 10 91:9 2k + 3k (72)
4 Et Me 10 86:14 2l + 3l (73)
1 Yields over two steps from the epoxide precursor of 1.
Although the cyclization of alcohols 1i–l occurs in good yields, the stereoselectivity of the process
is decreased, obtaining mixtures of both possible diastereoisomers, in which the stereoisomer with
the silylmethyl group anti to the R2 substituent is always predominant. The best stereoselectivity
is obtained when a bulky R2 is present at C-3 (Table 4, entry 3), which indicates that the reaction is
influenced by steric effects.
A mechanism that could account for these cyclizations implies an initial protonation of the
alcohol, which in turn would deliver the proton to the alkene moiety. The formation of a stabilized
β to silicon carbocation will be followed by intramolecular attack of the hydroxyl group to form the
tetrahydropyranyl ring.
Regarding the stereoselectivity of the process, one single diastereoisomer is obtained when R4 is
either a hydrogen or an alkyl group. However, a certain loss of stereocontrol is observed when R4 is a
phenyl group (Table 4, entries 1–4). In either case the unique or major isomer is the one in which the
silylmethyl group is anti to the C-3 substituent.
In accordance with Fleming [26,27] and Hook’s [28] models for the reaction of electrophiles with
alkenes bearing an allylic stereogenic centre, two different chair-like conformations (Ia and IIa) could
be drawn for vinylsilyl alcohols 1a–e. In the preferred conformation Ia the allylic hydrogen is partially
eclipsing the double bond (“inside”), while the largest substituent is antiperiplanar to the alkene
moiety (Figure 2). The alternative conformation IIa (with R2 inside) shows a disfavoured 1,3-allylic
interaction between R2 and the silyl group and a 1,3-diaxial interaction between R2 and the Me group,
which would explain the preferred formation of 2,3-trans-tetrahydropyranes 2a–e.
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Figure 2. Stereochemical outcome of cyclization of alcohols 1a–e.
The decrease in stereoselectivity observed for arylsubstituted vinylsilyl alcohols 1i–l could be
explained using the same model, since now, besides a disfavoured 1,3-diaxial interaction in conformer
IIb, there is a competing 1,2-allylic interaction between R2 and R4 in conformer Ib. This interaction is
especially strong when the phenyl group is coplanar with the double bond, while the possibility of
rotating around would cause the loss of the resonance stabilization. For alcohols 1f–g R4 is a flexible
alkyl chain and this 1,2-allylic interaction seems to be rather small (Figure 3).
Figure 3. Chair-like reactive conformations for arylsubstituted vinylsilyl alcohols 1i–l.
In addition, the presence of a remaining silyl group in the final tetrahydropyrans offers the
attractive possibility of further functionalization. As known, Fleming-Tamao oxidation [29] permits
the transformation of the silyl group to a hydroxy group. To demonstrate the potential of these
tetrahydropyrans as key intermediates for the synthesis of tetrahydropyranyl marine natural products
and their synthetic analogues, we have transformed tetrahydropyran 2d into the corresponding alcohol
3d [30] (Scheme 4).
Scheme 4. Synthesis of 2-hydroxymethyltetrahydropyran 3d.
Finally, we decided to study the effect of the silyl group in the cyclization of silyl alkenols 1.
For this purpose, we synthesized an analogue of alcohol 1e lacking the silyl moiety (1m). Reaction of
alcohol 1m with p-TsOH in DCM did not occur at r.t., nor under reflux conditions, recovering after
5 hours the unreacted starting alcohol. This seems to indicate that the presence of an electron-rich
alkene, such as the vinylsilane, is needed for the cyclization to proceed (Scheme 5).
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Scheme 5. Influence of the silyl group in the cyclization.
3. Materials and Methods
3.1. General Procedures for the Acid-catalysed Cyclization of Vinylsilyl Alcohols
To a solution of the acid (1 mmol) in dry CH2Cl2 (10 mL) is added a solution of the alcohol (1 mmol)
in CH2Cl2. The mixture is stirred under N2 in the shown conditions (Tables 1–4) and quenched with
saturated solution of NaHCO3 (5 mL). The organic layer was washed 3 times with NaHCO3, dried over
MgSO4, evaporated in vacuo and purified by flash chromatography (EtOAc/hexane).
3.2. Trans-5,5-Dimethyl-2-Dimethylphenylsilylmethyl-3-Phenyl-Tetrahydropyran (2a)
Colourless oil (77%); 1H NMR (400 MHz, CDCl3) δ = 7.49–7.45 (m, 2H), 7.38–7.34 (m, 3H), 7.33–7.24
(m, 3H), 7.14–7.11 (m, 2H), 3.56 (dd, J = 11.4 and 2.4 Hz, 1H), 3.43 (td, J = 9.7 and 3.5 Hz, 1H), 3.23 (d,
J = 11.4 Hz, 1H), 2.73–2.64 (m, 1H), 1.67–1.59 (m, 1H), 1.54 (t, J = 13.0 Hz, 1H), 1.19 (s, 3H), 0.92–0.87
(m, 2H, CH2-Si), 0.88 (s, 3H), 0.33 (s, 3H, CH3-Si), 0.29 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ =
143.9 (C), 140.0 (C), 133.7 (CH), 128.6 (CH), 128.0 (CH), 127.6 (CH), 126.3 (CH), 80.4 (CH), 78.2 (CH2),
48.0 (CH), 46.3 (CH2), 31.0 (C), 27.2 (CH3), 24.2 (CH3), 20.8 (CH2-Si), −1.5 (CH3), −2.5 (CH3); HRMS
(ESI+) m/z calcd for C22H30NaOSi ([M + Na]+): 361.1958, found 361.1957.
3.3. 5,5-Dimethyl-2-Dimethylphenylsilylmethyl-Tetrahydropyran (2b)
Colourless oil (71%); 1H NMR (400 MHz, CDCl3) δ = 7.63–7.56 (m, 2H), 7.45–7.38 (m, 3H), 3.46 (dd,
J = 11.0 and 2.2 Hz, 1H), 3.35–3.26 (m, 1H), 3.14 (d, J = 11.0 Hz, 1H), 1.51–1.42 (m, 3H), 1.36–1.24 (m,
1H), 1.23–1.18 (m, 1H), 1.09 (dd, J = 14.5 and 7.0 Hz, 1H), 1.04 (s, 3H), 0.81 (s, 3H), 0.37 (s, 3H, CH3-Si),
0.35 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 139.5 (C), 133.6 (CH), 128.8 (CH), 127.7 (CH), 78.2
(CH2), 75.9 (CH), 37.1 (CH2), 31.2 (CH2), 29.6 (C), 27.2 (CH3), 24.1 (CH2), 23.6 (CH3), −1.8 (CH3), −2.2
(CH3); HRMS (ESI+) m/z calcd for C16H26NaOSi ([M + Na]+): 285.1645, found 285.1646.
3.4. 3,3,5,5-Tetramethyl-2-Dimethylphenylsilylmethyl-Tetrahydropyran (2c)
Colourless oil (70%); 1H NMR (400 MHz, CDCl3) δ = 7.59–7.53 (m, 2H), 7.39–7.31 (m, 3H), 3.49 (dd,
J = 11.1 and 2.5 Hz, 1H), 2.99–2.94 (m, 2H), 1.35 (dd, J = 13.6 and 2.5 Hz, 1H), 1.17–1.12 (m, 1H), 1.10 (s,
3H), 1.01 (s, 3H), 0.94–0.88 (m, 2H), 0.76 (s, 3H), 0.73 (s, 3H), 0.35 (s, 3H, CH3-Si), 0.33 (s, 3H, CH3-Si);
13C NMR (101 MHz, CDCl3) δ = 140.2 (C), 133.8 (CH), 128.6 (CH), 127.6 (CH), 84.0 (CH), 79.1 (CH2),
52.2 (CH2), 34.1 (C), 31.3 (C), 29.6 (CH3), 29.3 (CH3), 26.5 (CH3), 21.6 (CH3), 16.0 (CH2), −1.2 (CH3),
−2.8 (CH3); HRMS (ESI+) m/z calcd for C18H30NaOSi ([M + Na]+): 313.1958, found 313.1956.
3.5. Trans-3-Butyl-5,5-Dimethyl-2-Dimethylphenylsilylmethyl-Tetrahydropyran (2d)
Colourless oil (73%); 1H NMR (400 MHz, CDCl3) δ = 7.66–7.60 (m, 2H), 7.45–7.39 (m, 3H), 3.45 (dd,
J = 11.0 and 2.6 Hz, 1H), 3.02 (d, J = 11.0 Hz, 1H), 2.94 (td, J = 10.0 and 2.8 Hz, 1H), 1.61–1.56 (m, 1H)
1.50–1.20 (m,8H), 1.06 (s, 3H), 1.00–0.91 (m, 2H), 0.93 (t, J = 7.0, 3H) 0.83 (s, 3H), 0.38 (s, 6H, (CH3)2-Si);
13C NMR (101 MHz, CDCl3) δ = 140.5 (C), 133.7 (CH), 128.6 (CH), 127.6 (CH), 80.9 (CH), 77.8 (CH2),
43.2 (CH2), 39.4 (CH), 31.8 (CH2), 30.9 (C), 28.4 (CH2), 27.4 (CH3), 24.4 (CH3), 23.0 (CH2), 20.8 (CH2),
14.1 (CH3), −1.4 (CH3), −2.4 (CH3); HRMS (ESI+) m/z calcd for C20H34NaOSi ([M + Na]+): 341.2271,
found 341.2271.
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3.6. Trans-3-Isopropy-5,5-Dimethyl-2-Dimethylphenylsilylmethyl-Tetrahydropyran (2e)
Colourless oil (75%); 1H NMR (400 MHz, CDCl3) δ = 7.55–7.52 (m, 2H), 7.34–7.32 (m, 3H), 3.35 (dd,
J = 11.0 and 2.7 Hz, 1H), 3.06 (td, J = 10.3 and 3.1 Hz, 1H), 2.92 (d, J = 11.0, 1H), 1.89–1.82 (m, 1H),
1.38–1.32 (m, 1H), 1.30–1.25 (m, 1H), 1.17 (dd, J = 14.8 and 3.1 Hz, 1H), 0.98 (s, 3H, CH3), 1.00–0.97
(m, 1H), 0.90 (dd, J = 14.8 and 10.3 Hz, 1H), 0.81 (d, J = 7.0 Hz, 3H, CH3), 0.78 (s, 3H, CH3), 0.63 (d,
J = 6.9 Hz, 3H, CH3), 0.31 (s, 3H, CH3-Si), 0.30 (s, 3H, CH3-Si);13C NMR (101 MHz, CDCl3) δ = 140.5
(C), 133.6 (CH), 128.5 (CH), 127.6 (CH), 79.1 (CH), 77.9 (CH2), 44.1 (CH), 35.7 (CH2), 30.7 (C), 27.6 (CH),
26.9 (CH3), 24.4 (CH3), 21.0 (CH3), 20.3 (CH2-Si), 15.3 (CH3), −1.4 (CH3), −2.5 (CH3); HRMS (ESI+)
m/z calcd for C19H32NaOSi ([M + Na]+): 327.2110, found 327.2115.
3.7. 5,5-Dimethyl-2-Dimethylphenylsilylmethyl-3-Phenyl-2-Propyl-Tetrahydropyran (2f)
Colourless oil (71%); 1H NMR (400 MHz, CDCl3) δ = 7.58–7.19 (m, 10H), 3.21 (d, J = 11.6, 1H), 3.15
(dd, J = 11.6 and 2.4 Hz, 1H), 3.00 (dd, J = 13.5 and 3.7 Hz, 1H), 2.17–2.06 (m, 1H), 2.01 (t, J = 13.5 Hz,
1H), 1.24–1.17 (m, 2H), 1.34 (dt, J = 13.5 and 3.5 Hz,1H), 1.23 (d, J = 15.4, 1H, CHHSi), 1.13 (d, J = 15.4,
1H, CHHSi), 1.00 (s, 3H), 0.97–0.92 (m, 1H),0.88 (d, J = 7.3 Hz, 3H), 0.85 (s, 3H), 0.50 (s, 3H, CH3-Si),
0.35 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 142.9 (C), 141.8 (C), 133.7 (CH), 129.7 (CH), 128.3
(CH), 127.8 (CH), 127.5 (CH), 126.3 (CH), 78.8 (C), 71.1 (CH2), 48.4 (CH), 39.9 (CH2), 32.8 (CH2), 30.8
(C), 27.8 (CH3), 26.6 (CH2-Si), 24.8 (CH3), 15.4 (CH2), 14.7 (CH3), −0.3 (CH3), −0.4 (CH3); HRMS (ESI+)
m/z calcd for C25H36NaOSi ([M + Na]+): 406.2428, found 403.2435.
3.8. 5,5-Diethyl-3-Methyl-2-Dimethylphenylsilylmethyl-2-Propyl-Tetrahydropyran (2g)
Colourless oil (70%); 1H NMR (400 MHz, CDCl3) δ = 7.54–7.31 (m, 5H), 3.17 (d, J = 11.7 Hz, 1H),
3.08 (dd, J = 11.7 Hz, 1H), 1.95–1.89 (m, 1H), 1.55–1.41 (m, 7H), 1.31–1.24 (m, 3H), 1.07–0.99 (m, 2H),
0.90–0.82 (m 6H), 0.80 (t, J = 7.0 Hz, 3H), 0.73 (t, J = 7.5 Hz, 3H), 0.67 (d, J = 6.9 Hz, 3H), 0.37 (s, 3H,
CH3-Si), 0.31 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 141.2 (C), 133.4 (CH), 128.5 (CH), 127.6
(CH), 79.8 (C), 69.0 (CH2), 43.2 (CH2), 37.1 (CH2), 35.5 (C), 30.4 (CH), 28.7 (CH2), 23.6 (CH2), 17.6
(CH3), 17.1 (CH2), 16.1 (CH2), 14.6 (CH3), 7.5 (CH3), 6.9 (CH3), −0.4 (CH3), −1.0 (CH3); HRMS (ESI+)
m/z calcd for C22H38NaOSi ([M + Na]+): 369.2584, found 369.2582.
3.9. 3,5,5-Trimethyl-2-Dimethylphenylsilylmethyl-2-Phenyl-Tetrahydropyrans 2i and 3i
Chromatography gave tetrahydrofurans 2i and 3i as a mixture. Colourless oil (71%).
(2i): 1H NMR (400 MHz, CDCl3) δ = 7.53–7.51 (m, 2H), 7.49–7.46 (m, 2H), 7.34–7.26 (m, 5H),
7.23–7.19 (m, 1H), 3.26 (d, J = 11.8, 1H), 3.19 (dd, J = 11.8 and 2.3 Hz, 1H), 1.79–1.73 (m, 1H), 1.74 (d,
J = 15.4 Hz, 1H, CHHSi), 1.44 (d, J = 15.4 Hz, 1H, CHHSi), 1.35–1.23 (m, 2H), 1.13 (s, 3H), 0.80 (s, 3H),
0.68 (d, J = 6.8 Hz, 3H), 0.14 (s, 3H, CH3-Si), −0.13 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ =
147.5 (C), 141.1 (C), 133.4 (CH), 128.5 (CH), 127.6 (CH), 127.4 (CH), 126.3 (CH), 126.1 (CH), 81.6 (C), 71.9
(CH2), 42.7 (CH2), 39.0 (CH), 30.9 (C), 27.4 (CH3), 24.2 (CH3), 17.2 (CH3), 13.7 (CH2-Si), −1.4 (CH3),
−1.5 (CH3); HRMS (ESI+) m/z calcd for C23H32OSi ([M + Na]+): 375.2110, found 375.2115.
(3i): distinguishable signals: 1H NMR (400 MHz, CDCl3) δ = 3.32 (d, J = 11.7, 1H), 2.07–2.00 (m,
1H), 0.96 (s, 3H), 0.89 (s, 3H), 0.78 (d, J = 7.2 Hz, 3H), 0.22 (s, 3H), 0.07 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ = 28.2 (CH3), 26.4 (CH3), 19.0 (CH3).
3.10. 5,5-Dimethyl-2-Dimethylphenylsilylmethyl-2,3-Diphenyl-Tetrahydropyrans 2j and 3j
Chromatography gave tetrahydrofurans 2j and 3j as a mixture. Colourless oil (65%).
(2j): 1H NMR (400 MHz, CDCl3) δ = 7.44–7.13 (m, 13H), 6.74–6.71 (m, 2H), 3.46 (d, J = 11.8, 1H),
3.31 (dd, J = 11.8 and 2.3 Hz, 1H), 2.98 (dd, J = 13.7 and 1.5 Hz, 1H), 2.12–2.05 (m, 2H, CHHSi), 1.49 (dt,
J = 13.6 and 2.8 Hz, 1H), 1.27 (d, J = 14.9 Hz, 1H, CHHSi), 1.22 (s, 3H), 0.92 (s, 3H), 0.13 (s, 3H, CH3-Si),
−0.20 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 146.29 (C), 141.56 (C), 140.9 (C), 133.4 (CH),
129.9 (CH), 128.5 (CH), 127.6 (CH), 127.2 (CH), 126.9 (CH), 126.4 (CH), 126.4 (CH), 126.3 (CH), 81.4
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(C), 71.7 (CH2), 51.9 (CH), 40.3 (CH2), 31.1 (C), 27.5 (CH3), 24.0 (CH3), 15.4 (CH2-Si), −1.4 (CH3), −1.5
(CH3); HRMS (ESI+) m/z calcd for C28H35OSi ([M + H]+): 415.2450, found 415.2452.
(3j): distinguishable signals: 1H NMR (400 MHz, CDCl3) δ = 3.52 (d, J = 11.9, 1H), 3.38 (dd,
J = 11.9 and 1.5 Hz, 1H), 3.16 (dd, J = 13.6 and 2.1 Hz, 1H), 1.89 (d, J = 14.9 Hz, 1H, CHHSi), 1.84
(d, J = 14.9 Hz, 1H, CHHSi), 1.75 (dd, J = 13.6 and 13.1 Hz, 1H), 1.22 (s, 3H), 0.96 (s, 3H), 0.14 (s, 3H,
CH3-Si), −0.26 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 129.3 (CH), 128.3 (CH), 127.9 (CH),
127.5 (CH), 127.23 (CH), 126.5 (CH), 126.2 (CH), 126.1 (CH), 82.9 (C), 70.6 (CH2), 51.8 (CH), 38.2 (CH2),
32.8 (C), 29.3 (CH3), 28.1 (CH2), 25.0 (CH3), −2.1 (CH3).
3.11. 3-Isopropyl-5,5-Dimethyl-2-Dimethylphenylsilylmethyl-2-Phenyl-Tetrahydropyrans 2k and 3k
Chromatography gave tetrahydrofurans 2k and 3k as a mixture. Colourless oil (72%).
(2k):1H NMR (400 MHz, CDCl3) δ = 7.52–7.19 (m, 10H), 3.23 (d, J = 11.6, 1H), 3.15 (dd, J = 11.6
and 2.3 Hz, 1H), 1.85 (d, J = 15.3, 1H, CHHSi), 1.60–1.58 (m, 1H), 1.59 (dd, J = 13.1 and 5.4 Hz, 1H),
1.47 (d, J = 15.3, 1H, CHHSi), 1.33 (t, J = 13.1 Hz, 1H), 1.25–1.23 (m, 1H), 1.12 (s, 3H), 0.82 (s, 3H), 0.78
(d, J = 6.8 Hz, 3H), 0.48 (d, J = 6.8 Hz, 3H), 0.12 (s, 3H, CH3-Si), −0.10 (s, 3H, CH3-Si); 13C NMR (101
MHz, CDCl3) δ = 147.3 (C), 141.2 (C), 133.5 (CH), 128.4 (CH), 127.6 (CH), 127.3 (CH), 126.5 (CH), 126.3
(CH), 82.3 (C), 72.1 (CH2), 49.4 (CH), 34.0 (CH2), 30.6 (C), 27.8 (CH3), 25.2 (CH), 23.9 (CH3), 23.8 (CH3),
17.9 (CH3), 15.9 (CH2-Si), −1.1 (CH3), −1.3 (CH3); HRMS (ESI+) m/z calcd for C25H37OSi ([M + H]+):
381.2608, found 381.2610.
(3k): distinguishable signals: 1H NMR (400 MHz, CDCl3) δ = 2.00 (d, J = 15.2, 1H, CHHSi),
1.79–1.73 (m, 1H), 1.31(d, J = 15.2, 1H, CHHSi), 1.60–1.58 (m, 1H), 1.15 (s, 3H), 1.07–0.92 (m, 2H), 0.82 (d,
J = 6.7 Hz, 3H), 0.81 (s, 3H), 0.10 (s, 3H, CH3-Si), −0.18 (s, 3H, CH3-Si), −0.26 (d, J = 6.7 Hz, 3H); 13C
NMR (101 MHz, CDCl3) δ = 133.4 (CH), 128.3 (CH), 127.5 (CH), 127.4 (CH), 126.4 (CH), 82.1 (C), 70.2
(CH2), 50.6 (CH), 32.1 (C), 31.9 (CH2), 29.6 (CH3), 26.6 (CH2-Si), 25.9 (CH), 24.9 (CH3), 24.3 (CH3), 16.1
(CH3), −1.5 (CH3), −1.9 (CH3).
3.12. 5,5-Diethyl-3-Methyl-2-Dimethylphenylsilylmethyl-2-Phenyl-Tetrahydropyrans 2l and 3l
Chromatography gave tetrahydrofurans 2l and 3l as a mixture. Colourless oil (73%).
(2l): 1H NMR (400 MHz, CDCl3) δ = 7.51–7.18 (m, 10H), 3.31 (d, J = 11.8, 1H), 3.18 (dd, J = 11.8
and 2.2 Hz, 1H), 1.73 (d, J = 15.5, 1H, CHHSi), 1.70–1.60 (m, 3H), 1.42 (d, J = 15.5, 1H, CHHSi), 1.41–1.33
(m, 1H), 1.16–1.08 (m, 3H), 0.78 (t, J = 7.4 Hz, 3H,), 0.74 (t, J = 7.3 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H,),
0.13 (s, 3H, CH3-Si), −0.13 (s, 3H, CH3-Si); 13C NMR (101 MHz, CDCl3) δ = 147.7 (C), 141.1 (C), 133.4
(CH), 128.5 (CH), 127.6 (CH), 127.4 (CH), 126.2 (CH), 126.1 (CH), 81.7 (C), 69.0 (CH2), 38.3 (CH), 38.1
(CH2), 35.4 (C), 28.6 (CH2), 23.8 (CH2), 17.3 (CH3), 13.9 (CH2-Si), 7.5 (CH3), 7.0 (CH3), −1.4 (CH3),
−1.5 (CH3); HRMS (ESI+) m/z calcd for C25H36NaOSi ([M + Na]+): 406.2428, found 403.2436.
(3l): distinguishable signals: 13C NMR (101 MHz, CDCl3) δ = 144.2 (C), 128.3 (CH), 127.6 (CH),
127.5 (CH), 127.2 (CH), 68.6 (CH2), 38.5 (CH), 36.7 (CH2), 28.9 (CH2), 28.5 (CH2), 26.4 (CH2), 18.9 (CH3),
14.0 (CH3), 7.6 (CH3), −1.6 (CH3), −1.9 (CH3).
3.13. Procedure for the Fleming-Tamao Oxidation of Silyl Tetrahydropyran 2d
Mercuric acetate (0.466 mmol, 1.5 eq) was added to a solution of 2d (0.311 mmol) in peracetic acid
(35–40% solution in dilute acetic acid; 2 mL) and the mixture was stirred for 3 h at room temperature.
Toluene (6 mL) was added and the mixture of solvents was evaporated under reduced pressure.
The residue was taken up in ether, filtered and evaporated under reduced pressure. Purification by
flash column chromatography (hexane/EtOAc, 3:1 to pure EtOAc) yielded 3d (0.186 mmol, 60%) as a
white viscous liquid (melting point could not be measured). Rf = 0.4 (silica, hexane/EtOAc, 4:1).
3.14. Trans-2-Hydroxymethyl-3-Butyl-5,5-Dimethyl-Tetrahydropyran (3d)
1H NMR (400 MHz, CDCl3) δ = 3.80 (dd, J = 11.4, 2.8 Hz, 1H), 3.56 (dd, J = 11.4, 7.1 Hz, 1H),
3.48 (dd, J = 10.9, 2.5 Hz, 1H), 3.12 (d, J = 10.9 Hz, 1H), 3.04–2.95 (m, 1H), 2.10–1.97 (brs, 1H, OH),
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1.65–1.61 (m, 1H), 1.61–1.58 (m, 1H), 1.37–1.13 (m, 5H), 1.01 (s, 3H), 0.98–0.95 (m, 1H), 0.94–0.90 (m,
1H), 0.88 (t, J = 7.1 Hz, 3H), 0.82 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 82.4 (CH), 77.7 (CH2), 63.9
(CH2OH), 42.7 (CH2), 32.6 (CH, Bu), 31.2 (CH2), 30.9 (C), 28.3 (CH2), 27.2 (CH3), 24.0 (CH3), 22.9 (CH2),
14.0 (CH3, Bu); HRMS (ESI+) m/z calcd for C12H24NaO2 ([M + Na]+): 223.1669, found 223.1667.
4. Conclusions
In conclusion, a general and efficient methodology for the synthesis of tetrahydropyrans by the
acid-mediated cyclizations of vinylsilyl alcohols is described. The reaction leading to polysubstituted
tetrahydropyrans is highly stereoselective when R4 is either H or alkyl group. Worthy of note,
quaternary centres adjacent to the oxygen can be formed through the process. The formation of a
single diastereoisomer in these cases (THP with the phenyldimethylsilylmethyl group anti to the C-3
substituent) seems to be a consequence of an unfavourable 1,3-diaxial interaction in the alternative
reactive conformation. Moreover, the presence of the silyl group bonded to the alkenyl moiety seems
to be needed for the cyclization to take place. Further transformation of the silylated tetrahydropyrans
thus obtained into the corresponding hydroxymethyl tetrahydropyrans opens an attractive route for
the synthesis of marine drugs analogues.
Supplementary Materials: Copies of 1H-NMR and 13C-NMR are available online at http://www.mdpi.com/
1660-3397/16/11/421/s1.
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Abstract: Alotamide is a cyclic depsipetide isolated from a marine cyanobacterium and possesses
a unique activation of calcium influx in murine cerebrocortical neurons (EC50 4.18 μM). Due to
its limited source, the three stereocenters (C19, C28, and C30) in its polyketide fragment remain
undetermined. In this study, the first asymmetric synthesis of its polyketide fragment was achieved.
Four relative possible diastereomers were constructed with a boron-mediated enantioselective aldol
reaction and Julia–Kocienski olefination as the key steps. Comparison of 13C NMR spectra revealed
the relative structure of fragment C15–C32 of alotamide.
Keywords: alotamide; asymmetric synthesis; relative structural determination
1. Introduction
Recently, several active secondary metabolites have been isolated from marine cyanobacterium
and some of these metabolites demonstrate excellent bioactivities such as cytotoxic, antimicrobial,
and antiprotozoal properties [1,2]. For example, apratoxins display potent cytotoxicity against several
cancer cells at the nanoscale level and have become the new lead compounds in anticancer drug
discovery [3–6].
Alotamide was also isolated from the marine cyanobacterium Lyngbya bouillonii in 2009 [7].
It is a cyclic depsipeptide and structurally has two parts. The northern part is a tripetide that consists of
N-Me-Val, Cys-derived thiazolene ring, and Pro and the southern part is a special unsaturated
polyketide with three undetermined stereocenters (C19, C28, and C30). Functionally, alotamide is a
unique calcium influx activator in murine cerebrocortical neurons (EC50 4.18 μM). Given that calcium
overload is involved in physiological processes and may lead to several nervous diseases such as AD
and epilepsy, this compound has gained increasing attention as a new neurotoxin from the marine
resource [8]. In view of the limited natural source, a concise synthetic strategy of alotamide should be
developed. In this study, we described the first asymmetric synthesis of its polyketide fragment
C15–C32 and obtained four possible diastereomers. The relative stereochemistry was assigned after
the NMR comparison.
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Figure 1. Structure of alotamide.
2. Results
The chemical structure of alotamide is shown in Figure 1. The southern polyketide with three
undetermined stereocenters established eight possible isomers and only four needed to be evaluated
for relative stereochemical determination. In this regard, we set C19 as R and listed four diastereomers,
which are shown in Figure 2 (1a–1d).
Figure 2. Structures of four diastereomers 1a–1d.
According to the retrosynthetic analysis (Scheme 1), the dihydroxy unit would arise from an
asymmetric aldol reaction and the Julia–Kocienski olefination would be applied to form the diene part.
The polyketide fragment would be separated into two subunits, 2 and 3, which both could be prepared
from commercial compounds.
Scheme 1. Retrosynthetic analysis.
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Compound 2 was prepared from commercial lactone 4 and treated with LiOH to open the lactone
ring (Scheme 2) [9]. The resulting compound was subjected to TBS protection and condensation
with Evan’s protocol 6 [10] in sequence to obtain 7 in 71% yield over three steps. Compound 7 was
treated with NaHMDS/MeI at −78 ◦C to obtain the desired R-methyl 8 in 89% yield (dr = 12:1).
After the reduction of 8 by LiBH4 [11], alcohol 9 was oxidized into the corresponding aldehyde, which
was immediately refluxed with the Wittig reagent 10 to generate olefin 11. In this reaction, the E/Z
selectivity reached 30:1 and the little Z isomer was separated in the following DIBAL-H reduction.
The sequential oxidation with IBX and Pinnick reaction generated a free acid and the allyl protection
was conducted to acquire 12 in 64% yield for the above four steps. After the deprotection of the TBS
group, the Mitsunobu reaction was applied to convert the compound 13 into tetrazole 15 in 94% yield.
Then the SPT part was oxidized by H2O2 (20 eq) in the presence of (NH4)6Mo7O24 (0.2 eq) to obtain
the desired 2 without the Z isomer [12].
 
Scheme 2. Synthesis of subunit 2.
The preparation of subunit 3 was initiated with 4-hydroxy-2-butanone (Scheme 3).
The Wittig–Horner reaction was conducted after PMB protection to smoothly obtain the desired
product 17 (70% yield, E/Z = 3:1) while a complex mixture appeared when TBS protected alcohol
was applied in this HWE reaction [13,14]. After the removal of the PMB group followed by the TBS
protection, compound 19 was obtained and then converted into the corresponding aldehyde 3 by
sequential steps of DIBAL-H reduction and IBX oxidation prior to the Julia–Kocienski olefination.
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Scheme 3. Synthesis of subunit 3.
The different bases were tested through olefination (Table 1). When 1 eq KHMDS (entry 1) was
applied, the yield was 50% and numerous reactants 2 and 3 remained. The product diene was an
E/Z mixture with E/Z selectivity of up to 15:1. When the amount of KHMDS was increased to 1.5 eq,
the yield improved and the two reactants remained in small quantities. When 2 eq KHMDS was used,
the two reactants were completely consumed and the yield reached 86% while the high selectivity (15:1)
was maintained. Other bases such as LiHMDS were also tried, but the resulting E/Z selectivity was
low. We also exchanged the aldehyde and SO2PT functional groups and subjected them to olefination
(entry 5). The yield of the Z isomer greatly increased and the selectivity was 1.5:1 [15,16].
Table 1. Optimization of the Julia–Kocienski olefination.
Entry R 1 R 2 Base (equiv) Yield 1 21a:21b 2
1 CHO SO2PT KHMDS (1eq) 50% 15:1
2 CHO SO2PT KHMDS (1.5eq) 72% 15:1
3 CHO SO2PT KHMDS (2eq) 86% 15:1
4 CHO SO2PT LiHMDS (2eq) 83% 3.5:1
5 SO2PT CHO KHMDS (2eq) 94% 1.5:1
1 Combined yield of 21a and 21b. 2 Determined by LC-MS.
Having completed the construction of diene 21a, we started to prepare the dihydroxy unit
(Scheme 4). To our delight, under the condition of the HF/Py complex, we fairly achieved the alcohol 22
and oxidized it to corresponding aldehyde 23 by DMP prior to the aldol reaction (deprotection of PMB
group in this step led to a complex mixture).
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Scheme 4. Synthesis of compound 23.
IPCBCl-controlled aldol reaction [17,18] was selected to install the C28 stereo-center (Table 2).
The application of (−)-IPCBCl at −20 ◦C successfully generated 24b with the C28 (S) configuration in
59% yield (dr = 99:1). The chiral reactant was changed into (+)-IPCBCl, which afforded the C28 (R)
product as expected and maintained the high diastereoselectivity (dr = 98:2). LiHMDS also proceeded
and a 1:1 mixture was obtained in this aldol reaction.
Table 2. Boron-mediated aldol reaction.
Entry Reagent A Yield 1 24a:24b 2
1 (−)-IPCBCl 59% 1:99
2 (+)-IPCBCl 55% 98:2
3 LiHMDS 47% 1:1
1 Combined yield of 24a and 24b. 2 Determined by LC-MS.
After TBS protection followed by the reduction of the combination of BH3-DMS and CBS catalysts,
we obtained 26a (dr = 4:1, determined by 1H NMR) and 26b (dr = 17:1, determined by 1H NMR),
respectively. Compounds 26c (dr = 3.6:1, determined by 1H NMR) and 26d (dr = 14:1, determined by
1H NMR) were achieved from 25b with the similar dr value (Scheme 5).
Scheme 5. Cont.
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Scheme 5. Synthesis of 26a–26d.
The stereochemistries of the 1,3-diol part in 26a–26d were confirmed by their 13C NMR chemical
shifts of the corresponding acetonides 28a–28d (Scheme 6). Syn-diol acetonide preferred a chair
conformation and two ketal methyl groups were significantly different (e.g., 19.94 and 30.46 ppm
for 28a). Meanwhile anti-diol acetonide preferred a twist-boat conformation and two similar methyl
groups existed (e.g., 25.24 and 25.13 ppm for 28b) [19–21].
Scheme 6. Stereo-chemical assignments of 28a–28d.
After the sequential methylation and removal of the TBS group from 26a–26d, we successfully
furnished the four desired analogues 1a–1d (Scheme 7). The total yield was 2.5% for 1a from the
lactone and 2.7% for 1b, 2.5% for 1c, and 2.6% for 1d.
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Scheme 7. Synthesis of 1a–1d.
3. Discussion
A careful comparison between four isomers and alotamide was conducted. The differences in
13C NMR chemical shifts are shown in Figure 3a. From C15 to C28, several significant variations
(Δδ > 1 ppm) existed between all four isomers and alotamide possibly because of the difference
between the “straight-chain” mode in our analogues and the “ring” mode in the original structure.
From C28 to C32, the dihydroxy unit is a linear chain both in our analogues and natural compound.
Thus, comparing the data in this portion is suitable for relative stereochemistry determination.
At the same time, several obvious variations in 13C spectra were observed between 1,3-syn
isomers (1a and 1c) and 1,3-anti isomers (1b and 1d) from C29 to C32 (Figure 3a). Therefore, we chose
1a and 1b to represent the syn-analogues and anti-analogues to distinguish syn-configurations and
anti-configurations (Figure 3b,c).
 
Figure 3. (a) Δδ 13C (ppm) between alotamide and 1a–1d, (b) Δδ 13C (ppm) between alotamide and 1a
and 1b from C29–C32, (c) Δδ 1H (ppm) between alotamide and 1a and 1b in dihydroxy unit.
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A significant variation at C30 position of 1b (Δδ > 4 ppm) and a closer correlation of 1a at C29,
C31 and C32 in the 13C spectra revealed the syn configuration in the C28–C30 unit. In addition, smaller
variations with alotamide in 1H spectra were noticed for analogue 1a at protons H29A and H29B
(differences between alotamide and 1a and 1b at proton H30 were not plotted in Figure 3c because
the differences were all greater than 0.4 ppm and insignificant). This finding confirmed the 1,3-syn
structure in the dihydroxy unit.
Two 1,3-syn isomers 1a and 1c were also compared. Their 1H spectra were the same and the
differences in 13C NMR chemical shifts are listed in Table 3. A closer correlation of 1c was observed
especially at the sites C20, C29, and C31. Thus, it appeared that 1c (19R, 28S, 30R) most closely fit the
original natural alotamide. The total synthesis of alotamide with fragment 1c and another (19S, 28R,
30S) enantiomer is in progress.
Table 3. Δδ 13C (ppm) between alotamide and 1a and 1c.
Isomer C20 C21 C23 C26 C29 C31
1a 0.30 1.90 −1.67 1.40 −0.18 −0.06
1c 0.28 1.88 −1.65 1.41 −0.13 −0.04
4. Materials and Methods
All anaerobic and moisture-sensitive manipulations were carried out with standard Schlenk
techniques under argon. Solvents were dried and distilled by standard procedures. 1H- NMR and
13C-NMR spectra were recorded in CDCl3 on a Bruker Ascend-400 400 MHz or Bruker Ascend-500
500 MHz at room temperature. Chemical shifts (δ) are reported in ppm and are referenced to
chloroform (δ 7.26 ppm for 1H, δ 77.16 ppm for 13C). Data for NMR spectra are reported as follows:
s = singlet, d = doublet, t = triplet, q = quartet, quint. = quintet, sext. = sextet, m = multiplet,
br = broad signal, J = coupling constant in Hz. HRMS were recorded on an Agilent 6530-Q-TOF
mass spectrometer equipped with an Agilent 1260- HPLC. Optical rotations were measured on a
PerkinElmer 241 MC polarimeter.
4.1. (R)-3-(4-((Tert-Butyldimethylsilyl)Oxy)Butanoyl)-4-Phenyloxazolidin-2-One (7)
To a solution of the lactone (5 g, 58 mmol) in MeOH (50 mL) at room temperature was added
LiOH (2.44 g, 58 mmol) and stirred overnight. The solvent was removed from the reaction and the
residue was dissolved in dimethylformamide (50 mL) at 0 ◦C. Imidazole (8 g, 116 mmol) was added to
this solution, which was followed by TBSCl (8.7 g, 58 mmol) in two portions over 15 min. The reaction
mixture was warmed to room temperature overnight with stirring and then diluted with 1 M HCl and
extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine and dried
over Na2SO4. The organic layer was removed under vacuum and the crude acid was used without
further purification.
To a stirred solution of the acid in dry THF (200 mL) at 0 ◦C under argon, Et3N (20 mL, 145 mmol)
and PivCl (7.1 mL, 58 mmol) were added sequentially. After 1 h stirring at 0 ◦C, LiCl (0.62 g, 14.5 mmol),
followed by oxazolidinone 6 (9.4 g, 58 mmol), were added. The reaction was continued for 1 h at 0 ◦C
and another 2 h at room temperature prior to quenching with a saturated NH4Cl solution (50 mL)
and extracted with DCM (2 × 200 mL). The combined organic layers were washed with brine, dried
over Na2SO4, and concentrated in vacuum. Purification by column chromatography (PE/EA = 9:1)
afforded compound 7 (15 g, 71% for three steps) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.47–7.21 (m, 5H), 5.43 (dd, J = 8.7, 3.6 Hz, 1H), 4.69 (td, J = 8.8, 1.0
Hz, 1H), 4.28 (ddd, J = 8.9, 3.6, 1.3 Hz, 1H), 3.64 (t, J = 6.3 Hz, 2H), 3.03 (qt, J = 17.7, 7.4 Hz, 2H), 1.92–1.77
(m, 2H), 0.90 (s, 9H), 0.04 (d, J = 1.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 172.62, 153.76, 139.27,
129.18, 128.68, 125.93, 70.00, 62.25, 61.91, 57.56, 32.08, 27.09, 25.96, 18.32, −5.34, −5.62. [α]20D = −42.63,
(c 3.38, CHCl3). HRMS (ESI+): calcd. for C19H29NO4Si [M + H]+, 364.1939; found 364.1940.
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4.2. (R)-3-((R)-4-((Tert-Butyldimethylsilyl)oxy)-2-Methylbutanoyl)-4-Phenyloxazolidin-2-one (8)
To a stirred solution of compound 7 (15 g, 41.2 mmol) in dry THF (100 mL) at −78 ◦C under
argon, NaHMDS (2.0 M solution in THF, 24.7 mL, 49.4 mmol) was added dropwise. After 1 h,
MeI (7.7 mL, 123.5 mmol) was added and the mixture was stirred overnight at the same temperature.
The reaction mixture was quenched with a saturated NH4Cl solution (100 mL) and warmed up to
room temperature before being extracted with DCM (2 × 100 mL). The combined organic extracts
were washed with water and brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 13:1) gave pure 8 (13.8 g, 89%) as a white solid.
1H NMR (400 MHz, CDCl3) δ 7.45–7.23 (m, 5H), 5.44 (dd, J = 8.7, 3.7 Hz, 1H), 4.67 (t, J = 8.8 Hz,
1H), 4.25 (dd, J = 8.9, 3.7 Hz, 1H), 4.02–3.85 (m, 1H), 3.73–3.55 (m, 2H), 2.00 (td, J = 13.9, 6.4 Hz, 1H),
1.59 (dq, J = 12.2, 6.1 Hz, 1H), 1.15 (d, J = 7.0 Hz, 3H), 0.91 (s, 9H), 0.06 (s, 6H). 13C NMR (101 MHz,
CDCl3) δ 176.36, 153.35, 139.47, 129.28, 128.70, 125.75, 69.80, 61.02, 57.74, 35.72, 34.71, 26.00, 18.39, 17.83,
−5.33. [α]20D = −79.14, (c 2.34, CHCl3). HRMS (ESI+): calcd. for C20H31NO4Si [M + H]+, 378.2095,
found 378.2095.
4.3. (R)-4-((Tert-Butyldimethylsilyl)Oxy)-2-Methylbutan-1-Ol (9)
To an ice-cold solution of compound 8 (13.8 g, 36.6 mmol) in THF (100 mL) moist with a catalytic
amount of water, LiBH4 (1.2 g, 54.9 mmol) was added portion wise under argon. After 12 h of stirring
at room temperature, the reaction was quenched cautiously with a saturated NH4Cl solution (50 mL)
and then distilled under a reduced pressure followed by extraction with DCM. The combined organic
solution was dried over Na2SO4 and concentrated in vacuum. Purification by column chromatography
(PE/EA = 9:1) provided pure compound 9 (6.86 g, 86%) as a colorless oil [11].
1H NMR (400 MHz, CDCl3) δ 3.81–3.69 (m, 1H), 3.68–3.60 (m, 1H), 3.46 (s, 1H), 3.43–3.33 (m, 1H),
3.19 (s, 1H), 1.86–1.70 (m, 1H), 1.59–1.46 (m, 2H), 0.89 (m, 12H), 0.05 (s, 6H). 13C NMR (101 MHz,
CDCl3) δ 68.21, 61.82, 37.53, 34.46, 25.98, 18.34, 17.46, −5.33, −5.36. [α]20D = −10.98, (c 1.82, CHCl3).
HRMS (ESI+): calcd. for C11H26O2Si [M + H]+, 219.1775, found 219.1771.
4.4. Ethyl (R,E)-6-((Tert-Butyldimethylsilyl)Oxy)-2,4-Dimethylhex-2-Enoate (11)
To a stirred solution of 9 (6.86 g, 31.5 mmol) in DMSO (50 mL) IBX (10.6 g, 37.8 mmol) was added.
After 1 h stirring at 40 ◦C, the reaction was quenched with water (50 mL) and extracted with ether
(2 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, and removed
under vacuum. The residue was refluxed with 10 (22 g, 63 mmol) in toluene (100 mL) at 80 ◦C for 3 h
and the solvent was removed under vacuum. Purification by column chromatography (PE/EA = 40:1)
provided pure compound 11 (7 g, 75%) as a colorless oil [22].
1H NMR (400 MHz, CDCl3) δ 6.53 (dd, J = 10.1, 1.4 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.70–3.41
(m, 2H), 2.80–2.45 (m, 1H), 1.83 (d, J = 1.4 Hz, 3H), 1.66–1.44 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H),
1.00 (d, J = 6.7 Hz, 3H), 0.87 (s, 9H), 0.01 (d, J = 2.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.57,
147.56, 126.83, 61.02, 60.52, 39.83, 29.78, 26.04, 20.06, 18.37, 14.42, 12.59, −5.23, −5.25. [α]20D = −2.167,
(c 0.1, CHCl3). HRMS (ESI+): calcd. for C16H32O3Si [M + H]+, 301.2193, found 301.2194.
4.5. Allyl (R,E)-6-((Tert-Butyldimethylsilyl)oxy)-2,4-Dimethylhex-2-Enoate (12)
To a stirred solution of compound 11 (7 g, 23.6 mmol) in dry DCM (60 mL) at −78 ◦C under argon,
DIBAL-H (1.5 M solution in toluene, 18.0 mL, 27.0 mmol) was added dropwise. After 1 h, the reaction
mixture was quenched with aqueous sodium-potassium tartrate solution (20 mL) and warmed up to
room temperature before being extracted with DCM (2 × 100 mL). The combined organic extracts
were washed with water and brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 8:1) gave alcohol (4.8 g, 79%) as a colorless oil.
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To a stirred solution of above alcohol in DMSO (50 mL), IBX (6.2 g, 22 mmol) was added. After 1 h
stirring at 40 ◦C, the reaction was quenched with water (50 mL) and extracted with ether (2 × 100 mL).
The combined organic layers were washed with brine, dried over Na2SO4, and removed under vacuum.
The crude anhydride was used without further purification.
To the solution of above crude aldehyde in tBuOH (40 mL), NaH2PO4 (11 g, 93 mmol) in H2O
(40 mL), 2-methyl-2-butene (19 mL, 186 mmol), and NaClO2 (3.1 g, 28 mmol, >79.0% purity) were
added. After stirring for 2 h at room temperature, the mixture was extracted with EA (50 mL × 3) and
the combined organic layers were washed with brine, dried over Na2SO4, filtrated, and concentrated.
The crude acid was taken into the next step without future purification.
To a stirred solution of above acid in dry DMF (50 mL) allylBr (3.2 g, 37.2 mmol) and K2CO3
(5.1 g, 37.2 mmol) were added separately. After being stirred for 12 h, the mixture was quenched
with a saturated aqueous solution of NH4Cl and extracted with EA (100 mL × 3). The combined
organic layers were washed with brine, dried over Na2SO4, filtrated, and concentrated. The residue
was purified by column chromatography on silica gel (PE/EA = 40:1) to give 12 (4.7 g, 81%) for three
steps as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.58 (dd, J = 10.1, 1.4 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz,
1H), 5.32 (ddd, J = 17.2, 3.0, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (dt, J = 5.6, 1.4 Hz, 2H),
3.66–3.42 (m, 2H), 2.82–2.58 (m, 1H), 1.86 (d, J = 1.4 Hz, 3H), 1.68–1.55 (m, 2H), 1.01 (d, J = 6.7 Hz,
3H), 0.88 (s, 10H), 0.02 (d, J = 2.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.16, 148.14, 132.76, 126.60,
117.84, 65.27, 61.00, 39.80, 29.82, 26.04, 20.02, 18.38, 12.62, −5.22. [α]20D = −53.365, (c 0.52, CHCl3). HRMS
(ESI+): calcd. for C17H32O3Si [M + H]+, 313.2193, found 313.2186.
4.6. Allyl (R,E)-6-Hydroxy-2,4-Dimethylhex-2-Enoate (13)
To a stirred solution of 12 (4.7 g, 15 mmol) in dry THF (10 mL), the HF/Py complex (2 mL)
was added at 0 ◦C. After being stirred for 1 h, the mixture was quenched with a saturated aqueous
solution of NaHCO3 and extracted with DCM (20 mL × 3). The combined organic layers were washed
with 1 M HCl brine, dried over Na2SO4, filtrated, and concentrated. The residue was purified by
column chromatography on silica gel (PE/EA = 6:1) to give 13 (2.3 g, 77%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.59 (dd, J = 10.1, 1.4 Hz, 1H), 5.97 (ddt, J = 17.1, 10.6, 5.6 Hz, 1H),
5.34 (dq, J = 17.2, 1.5 Hz, 1H), 5.24 (ddd, J = 10.5, 2.6, 1.3 Hz, 1H), 4.65 (dt, J = 5.6, 1.4 Hz, 2H), 3.75–3.44
(m, 2H), 2.78–2.63 (m, 1H), 1.88 (d, J = 1.4 Hz, 3H), 1.75–1.62 (m, 1H), 1.62–1.50 (m, 2H), 1.05 (d, J = 6.7
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.07, 147.61, 132.63, 126.88, 117.97, 65.34, 60.94, 39.55, 29.97,
20.09, 12.62. [α]20D = −55.72, (c 0.79, CHCl3). HRMS (ESI+): calcd. for C11H18O3 [M + H]+, 199.1329,
found 199.1328.
4.7. Allyl (R,E)-2,4-Dimethyl-6-((1-Phenyl-1H-Tetrazol-5-yl)Thio)Hex-2-Enoate (15)
To a stirred solution of 13 (2.3 g, 11.6 mmol) in anhydrous dry THF (50 mL) at 0 ◦C under
argon, PPh3 (6.1 g, 23.2 mmol), 14 (2 g, 11.6 mmol), and DIAD (4.6 mL, 23.2 mmol) were added
sequentially. The reaction was continued further for 1 h at room temperature prior to quenching with
the saturated NH4Cl solution (50 mL) and extracted with DCM (2 × 100 mL). The combined organic
layers were washed with brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 15:1) afforded compound 15 (3.9 g, 94%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.67–7.46 (m, 5H), 6.55 (dd, J = 10.1, 1.4 Hz, 1H), 5.94 (ddt, J = 17.1,
10.5, 5.6 Hz, 1H), 5.42–5.29 (m, 1H), 5.22 (dd, J = 10.4, 1.3 Hz, 1H), 4.62 (dt, J = 5.6, 1.4 Hz, 2H), 3.41–3.13
(m, 2H), 2.77–2.60 (m, 1H), 2.06–1.90 (m, 1H), 1.89–1.74 (m, 4H), 1.05 (d, J = 6.7 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ 167.69, 154.18, 146.10, 133.74, 132.49, 130.22, 129.89, 127.82, 123.90, 118.07, 65.40,
35.95, 32.63, 31.37, 19.89, 12.76. [α]20D = −58.87, (c 1.47, CHCl3). HRMS (ESI+): calcd. for C18H22N4O2S
[M + H]+, 359.1536, found 359.1532.
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4.8. Allyl (R,E)-2,4-Dimethyl-6-((1-Phenyl-1H-Tetrazol-5-yl)sulfonyl)Hex-2-Enoate (2)
To a stirred solution of 15 (3.9 g, 10.1 mmol) in ethanol (100 mL) at 0 ◦C, (NH4)6Mo7O24 (2.9 g,
2.2 mmol) and H2O2 (20 mL) were added sequentially. The reaction was continued further for 12 h
at room temperature prior to quenching with saturated NH4Cl solution (50 mL) and extracted with
DCM (2 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, and
concentrated in vacuum. Purification by column chromatography (PE/EA = 8:1) afforded compound
2 (3.6 g, 94%) as a white solid.
1H NMR (400 MHz, CDCl3) δ 7.76–7.51 (m, 5H), 6.53 (dd, J = 10.1, 1.4 Hz, 1H), 5.97 (ddt, J = 17.1,
10.5, 5.6 Hz, 1H), 5.48–5.32 (m, 1H), 5.25 (dd, J = 10.4, 1.3 Hz, 1H), 4.65 (dt, J = 5.6, 1.3 Hz, 2H), 3.77–3.58
(m, 2H), 2.95–2.62 (m, 1H), 2.24–2.04 (m, 1H), 2.01–1.92 (m, 1H), 1.88 (d, J = 1.4 Hz, 3H), 1.11 (d, J = 6.7
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 167.47, 153.49, 144.44, 133.12, 132.42, 131.64, 129.88, 128.93,
125.17, 118.32, 65.61, 54.40, 32.31, 28.74, 19.98, 12.86. [α]20D = −13.87, (c 0.79, CHCl3). HRMS (ESI+):
calcd. for C18H22N4O2S2 [M + H]+, 391.1435, found 391.1435.
4.9. 4-((4-Methoxybenzyl)Oxy)Butan-2-One (16)
To a stirred solution of 4-hydroxy-2-butanone (1.1 mL ,12.8 mmol) in dry THF (20 mL)
at 0 ◦C, 4-methoxybenzyl 2,2,2-trichloroacetimidate (2 mL, 10.7 mmol) and triphenylcarbenium
tetrafluoroborate (cat.) were added sequentially. The reaction was continued further for 1 h at
room temperature prior to quenching with the saturated NH4Cl solution (50 mL) and extracted with
DCM (2 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4,
and concentrated in vacuum. Purification by column chromatography (PE/EA = 6:1) afforded
compound 16 (1.8 g, 82%) as a colorless oil [14].
1H NMR (400 MHz, CDCl3) δ 7.33–7.18 (m, 2H), 6.94–6.81 (m, 2H), 4.45 (s, 2H), 3.81 (s, 3H), 3.72
(t, J = 6.3 Hz, 2H), 2.71 (t, J = 6.3 Hz, 2H), 2.18 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 207.51, 159.27,
130.16, 129.42, 113.84, 72.91, 64.96, 55.31, 43.81, 30.48. HRMS (ESI+): calcd. for C12H16O3 [M + H]+,
209.1172, found 209.1170.
4.10. Ethyl (E)-5-((4-Methoxybenzyl)Oxy)-3-Methylpent-2-Enoate (17)
To a stirred solution of triethyl phosphonoacetate (3.5 mL, 17.5 mmol) in dry THF (50 mL) at 0 ◦C,
NaH (0.7 g, 17.5 mmol) was added. After stirring at room temperature for 1 h, 16 (1.8 g, 8.8 mmol)
in THF (5 mL) was added at 0 ◦C. The reaction was continued further for 12 h at room temperature
prior to quenching with a saturated NH4Cl solution (50 mL) and extracted with DCM (2 × 100 mL).
The combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuum.
Purification by column chromatography (PE/EA = 20:1) afforded compound 17 in the E/Z mixture
(1.7 g, 70%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.99–6.72 (m, 2H), 5.82–5.63 (m, 1H), 4.47
(d, J = 2.8 Hz, 2H), 4.23–4.08 (m, 2H), 3.82 (d, J = 2.1 Hz, 3H), 3.70–3.51 (m, 2H), 2.98 (t, J = 6.6 Hz,
1H), 2.45 (t, J = 6.4 Hz, 2H), 2.19 (d, J = 1.2 Hz, 2H), 1.96 (d, J = 1.3 Hz, 1H), 1.29 (td, J = 7.1, 5.4 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 166.73, 166.34, 159.33, 159.19, 157.81, 156.72, 130.70, 130.30, 129.38,
129.27, 117.46, 117.10, 113.90, 113.81, 72.76, 72.46, 68.74, 67.59, 59.60, 55.35, 40.89, 33.73, 26.16, 19.00,
14.42. HRMS (ESI+): calcd. for C16H22O4 [M + H]+, 279.1591; found 279.1589.
4.11. Ethyl (E)-5-Hydroxy-3-Methylpent-2-Enoate (18)
To a stirring solution of 17 (1.7 g, 6.1 mmol) in DCM (20 mL) and water (4 mL) DDQ (1.67 g,
7.3 mmol) was added at room temperature. After 1 h, the reaction mixture was quenched with saturated
aqueous NaHCO3 (10 mL) and 1 M aqueous NaHSO3 (10 mL) and extracted with DCM (30 mL × 3).
The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The crude
product was purified by column chromatography (PE/EA = 3:1) to give the desired compound 18 as a
colorless oil (672 mg, 70% yield) [13].
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1H NMR (400 MHz, CDCl3) δ 5.71 (d, J = 1.2 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.76 (t, J = 6.4 Hz,
2H), 2.47–2.30 (m, 2H), 2.16 (d, J = 1.2 Hz, 3H), 1.92 (s, 1H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 166.67, 156.12, 117.73, 60.22, 59.78, 43.82, 18.82, 14.37. HRMS (ESI+): calcd. for C8H14O3
[M + H]+, 159.1016, found 159.1014.
4.12. Ethyl (E)-5-((Tert-Butyldimethylsilyl)Oxy)-3-Methylpent-2-Enoate (19)
To a stirred solution of 18 (672 mg, 4.3 mmol) in anhydrous DMF (10 mL) at 0 ◦C, imidazole
(7.7 g, 11.4 mmol) and TBSCl (1.1 g, 6.84 mmol) were added sequentially. The reaction was continued
further for 12 h at room temperature prior to quenching with saturated NH4Cl solution (20 mL) and
extracted with EA (2 × 20 mL). The combined organic layers were washed with brine, dried over
Na2SO4, and concentrated in vacuum. Purification by column chromatography (PE/EA = 40:1) created
compound 19 (1.05 g, 90%) as a colorless oil [13].
1H NMR (400 MHz, CDCl3) δ 5.66 (d, J = 1.1 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 2.32 (t, J = 6.6 Hz,
2H), 2.15 (d, J = 1.2 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H), 0.86 (s, 9H), 0.02 (s, 6H). 13C NMR (101 MHz,
CDCl3) δ 166.74, 156.92, 117.34, 61.41, 59.53, 44.12, 25.97, 19.21, 18.36, 14.42, −5.29. HRMS (ESI+): calcd.
for C14H28O3Si [M + H]+, 273.1880, found 273.1880.
4.13. (E)-5-((Tert-Butyldimethylsilyl)Oxy)-3-Methylpent-2-En-1-Ol (20)
To a stirred solution of compound 19 (1.05 g, 3.87 mmol) in dry DCM (15 mL) at −78 ◦C under
argon, DIBAL-H (1.5 M solution in toluene, 3.9 mL, 5.8 mmol) was added dropwise. After 1 h,
the reaction mixture was quenched with the aqueous sodium-potassium tartrate solution (20 mL)
and warmed up to room temperature before being extracted with DCM (2 × 20 mL). The combined
organic extracts were washed with water and brine, dried over Na2SO4, and concentrated in vacuum.
Purification by column chromatography (PE/EA = 7:1) gave 20 (680 mg, 76%) as a colorless oil [23].
1H NMR (400 MHz, CDCl3) δ 5.45 (td, J = 6.9, 1.2 Hz, 1H), 4.16 (d, J = 6.9 Hz, 2H), 3.71 (t, J = 7.0 Hz,
2H), 2.25 (t, J = 7.0 Hz, 2H), 1.71 (s, 3H), 1.53 (s, 1H), 0.90 (s, 9H), 0.06 (s, 6H). 13C NMR (101 MHz,
CDCl3) δ 136.95, 125.38, 62.20, 59.42, 42.91, 26.05, 18.45, 16.80, −5.17. HRMS (ESI+): calcd. for
C12H26O2Si ([M + H]+, 231.1775, found 231.1775.
4.14. Allyl (R,2E,6E,8E)-11-((Tert-butyldimethylsilyl)Oxy)-2,4,9-Trimethylundeca-2,6,8-Trienoate (21a)
To a stirred solution of 20 (680 mg, 3.0 mmol) in DMSO (10 mL) IBX (990 mg, 3.5 mmol) was
added. After 1 h of stirring at 40 ◦C, the reaction was quenched with water (10 mL) and extracted
with ether (2 × 20 mL). The combined organic layers were washed with brine, dried over Na2SO4,
and removed under vacuum. The crude aldehyde 3 was used without further purification.
To a stirred solution of crude 3 and compound 2 (1.3 g, 3.3 mmol) in dry THF (30 mL) at −78 ◦C
under argon, KHMDS (1.0 M solution in THF, 27.0 mL, 27.0 mmol) was added dropwise. After 1 h,
the reaction mixture was quenched with the saturated NH4Cl solution (20 mL) and warmed up to
room temperature before being extracted with DCM (2 × 100 mL). The combined organic extracts
were washed with water and brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 40:1) gave 21a (1.0 g, 86%, 2 steps) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.61 (dd, J = 10.0, 1.4 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H),
5.97 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.79 (d, J = 10.8 Hz, 1H), 5.48 (dt, J = 14.8, 7.3 Hz, 1H), 5.33 (ddd,
J = 17.2, 3.1, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 3.68 (t, J = 7.0 Hz, 2H),
2.64–2.47 (m, 1H), 2.24 (t, J = 7.0 Hz, 2H), 2.14 (t, J = 7.1 Hz, 2H), 1.85 (d, J = 1.3 Hz, 3H), 1.74 (s, 3H),
1.02 (d, J = 6.7 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 168.13, 147.84, 134.13,
132.75, 129.61, 128.53, 126.49, 126.40, 117.83, 65.27, 62.39, 43.29, 40.02, 33.96, 26.09, 19.68, 18.47, 17.20,
12.73, −5.14. [α]20D = −32.72, (c 0.38, CHCl3). HRMS (ESI+): calcd. for C23H40O3Si [M + H]+, 293.2819,
found 293.2819.
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4.15. Allyl (R,2E,6E,8E)-11-Hydroxy-2,4,9-Trimethylundeca-2,6,8-Trienoate (22)
To a stirred solution of 21a (1.0 g, 2.6 mmol) in dry THF (5 mL), HF/Py complex (1 mL) was added
at 0 ◦C. After being stirred for 1 h, the mixture was quenched with a saturated aqueous solution of
NaHCO3 and extracted with DCM (20 mL × 3). The combined organic layers were washed with 1
M HCl, brine, dried over Na2SO4, filtrated, and concentrated. The residue was purified by column
chromatography on silica gel (PE/EA = 6:1) to give 22 (550 mg, 76%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.4 Hz, 1H), 6.24 (dd, J = 15.0, 10.8 Hz, 1H),
5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.85 (d, J = 10.8 Hz, 1H), 5.52 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (ddd,
J = 17.2, 3.0, 1.5 Hz, 1H), 5.22 (dd, J = 10.4, 1.3 Hz, 1H), 4.63 (d, J = 5.6 Hz, 2H), 3.69 (t, J = 6.3 Hz, 2H),
2.65–2.51 (m, 1H), 2.29 (t, J = 6.3 Hz, 2H), 2.15 (t, J = 7.0 Hz, 2H), 1.84 (d, J = 1.4 Hz, 3H), 1.75 (s, 3H),
1.54 (s, 1H), 1.01 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.09, 147.69, 132.93, 132.70, 130.49,
128.14, 127.38, 126.53, 117.82, 65.26, 60.49, 42.95, 39.97, 33.84, 19.67, 16.50, 12.72. [α]20D = −38.23, (c 0.96,
CHCl3). HRMS (ESI+): calcd. for C17H26O3 [M + H]+, 279.1955, found 279.1954.
4.16. Allyl (2E,4R,6E,8E,11R)-11-Hydroxy-2,4,9-Trimethyl-13-Oxotetradeca-2,6,8-Trienoate (24a)
To the above alcohol 22 (200 mg, 0.72 mmol) in dry DCM (5 mL, 0 ◦C), DMP (610 mg, 1.44 mmol)
and NaHCO3 (240 mg, 2.9 mmol) was added sequentially. After being stirred for 30 min, the mixture
was carefully quenched with a solution of saturated aqueous NaHCO3 and Na2S2O3. The resulting
mixture was extracted with DCM (20 mL × 3) and the combined organic layers were washed with brine,
dried over Na2SO4, and concentrated. The crude aldehyde 23 was used without future purification.
To a stirred solution of (+)-IPCBCl (1.8 M in heptane, 1.08 mmol, 0.6 mL) in dry ether (3 mL) at
−0 ◦C under argon, Et3N (0.2 mL, 1.44 mmol) and acetone (80 uL, 1.08 mmol) were added sequentially.
After 1 h stirring at −0 ◦C, aldehyde 23 in ether (2 mL) was added at −78 ◦C. The reaction was
continued further for 1 h at −78 ◦C and another 12 h at −20 ◦C prior to quenching with a mixture of
PH 7 buffer (1 mL), methanol (1 mL), and H2O2 (1 mL). The mixture was warmed up to room
temperature before being extracted with ether (2 × 10 mL). The combined organic extracts were
washed with water and brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 4:1) created 24a (132 mg, 55%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.2 Hz, 1H), 6.22 (dd, J = 15.0, 10.8 Hz, 1H),
5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.83 (d, J = 10.8 Hz, 1H), 5.52 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd,
J = 17.2, 1.4 Hz, 1H), 5.23 (dd, J = 10.4, 1.1 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.20 (tt, J = 11.6, 5.9 Hz, 1H),
2.79 (s, 1H), 2.66–2.47 (m, 3H), 2.24 (dd, J = 13.4, 7.5 Hz, 1H), 2.19–2.07 (m, 6H), 1.84 (d, J = 1.2 Hz, 3H),
1.75 (s, 3H), 1.02 (d, J = 6.7 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 209.56, 168.10, 147.68, 132.82, 132.72,
130.79, 128.10, 127.99, 126.58, 117.85, 65.91, 65.29, 49.62, 47.13, 40.02, 33.86, 30.98, 19.72, 16.89, 12.75.
[α]20D = −33.92, (c 0.34, CHCl3). HRMS (ESI+): calcd. for C20H30O4 [M + H]+, 335.2217, found 335.2217.
4.17. Allyl (2E,4R,6E,8E,11S)-11-Hydroxy-2,4,9-Trimethyl-13-Oxotetradeca-2,6,8-Trienoate (24b)
To a stirred solution of (−)-IPCBCl (1.7 M in heptane, 1.08 mmol, 0.64 mL) in dry ether (3 mL) at
0 ◦C under argon, Et3N (0.2 mL, 1.44 mmol) and acetone (80 uL, 1.08 mmol) were added sequentially.
After 1 h stirring at 0 ◦C, aldehyde 23 in ether (2 mL) was added at −78 ◦C. The reaction was continued
further for 1 h at −78 ◦C and another 12 h at −20 ◦C prior to quenching with a mixture of PH 7 buffer
(1 mL), methanol (1 mL), and H2O2 (1 mL). The mixture was warmed up to room temperature before
being extracted with ether (2 × 10 mL). The combined organic extracts were washed with water and
brine, dried over Na2SO4, and concentrated in vacuum. Purification by column chromatography
(PE/EA = 4:1) provided 24b (142 mg, 59%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.2 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H),
5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.83 (d, J = 10.8 Hz, 1H), 5.53 (dt, J = 14.8, 7.3 Hz, 1H),
5.32 (dd, J = 17.2, 1.4 Hz, 1H), 5.23 (dd, J = 10.4, 1.1 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.29–4.12
(m, 1H), 2.66–2.51 (m, 3H), 2.23 (dd, J = 13.5, 7.6 Hz, 1H), 2.19–2.08 (m, 6H), 1.84 (d, J = 1.2 Hz, 3H),
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1.75 (s, 3H), 1.02 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 209.53, 168.10, 147.67, 132.83, 132.72,
130.76, 128.12, 127.98, 126.57, 117.86, 65.92, 65.29, 49.66, 47.11, 39.97, 33.86, 30.98, 19.69, 16.91, 12.74.
[α]20D = −26.04, (c 0.37, CHCl3). HRMS (ESI+): calcd. for C20H30O4 [M + H]+, 335.2217, found 335.2216.
4.18. Allyl (2E,4R,6E,8E,11R)-11-((Tert-Butyldimethylsilyl)oxy)-2,4,9-Trimethyl-13-Oxotetradeca-2,6,8-Trienoate (25a)
To a stirred solution of compound 24a (132 mg, 0.4 mmol) in dry DCM (3 mL) at −78 ◦C under
argon, 2,6-lutidine (0.23 mL, 2 mmol) and TBSOTf (0.35 mL, 1.5 mmol) were added sequentially.
After 1 h, the reaction mixture was quenched with aqueous NaHCO3 (5 mL) and warmed up to room
temperature before being extracted with DCM (2 × 10 mL). The combined organic extracts were
washed with 1 M HCl and brine, dried over Na2SO4, and concentrated in vacuum. Purification by
column chromatography (PE/EA = 40:1) created 25a (160 mg, 89%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.3 Hz, 1H), 6.19 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.75 (d, J = 10.8 Hz, 1H), 5.48 (dt, J = 14.8, 7.3 Hz, 1H), 5.33 (dd, J =
17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz, 1H), 4.64 (d, J = 5.6 Hz, 2H), 4.38–4.20 (m, 1H), 2.67–2.41
(m, 3H), 2.29–2.20 (m, 1H), 2.19–2.00 (m, 6H), 1.84 (d, J = 1.1 Hz, 3H), 1.73 (s, 3H), 1.01 (d, J = 6.7 Hz,
3H), 0.85 (s, 9H), 0.03 (d, J = 8.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 208.04, 168.10, 147.75, 133.24,
132.74, 130.28, 128.31, 128.07, 126.53, 117.86, 68.06, 65.29, 50.86, 48.64, 40.00, 33.93, 31.85, 25.96, 19.67,
18.12, 17.30, 12.74, −4.41, −4.71. [α]20D = −40.90, (c 0.26, CHCl3). HRMS (ESI+): calcd. for C26H44O4Si
[M + H]+, 449.3082, found 449.3078.
4.19. Allyl (2E,4R,6E,8E,11S)-11-((Tert-Butyldimethylsilyl)oxy)-2,4,9-Trimethyl-13-Oxotetradeca-2,6,8-Trienoate (25b)
The procedure was identical to 25a. Compound 25b (160 mg, 85%) was obtained as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.3 Hz, 1H), 6.19 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.74 (d, J = 10.8 Hz, 1H), 5.48 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2,
1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.35–4.23 (m, 1H), 2.66–2.42 (m, 3H),
2.23 (dd, J = 13.2, 5.7 Hz, 1H), 2.19–2.05 (m, 6H), 1.84 (d, J = 1.2 Hz, 3H), 1.73 (s, 3H), 1.01 (d, J = 6.7 Hz,
3H), 0.84 (s, 9H), 0.02 (d, J = 7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 208.07, 168.09, 147.76, 133.25,
132.74, 130.27, 128.31, 128.04, 126.52, 117.85, 68.09, 65.28, 50.84, 48.60, 40.04, 33.92, 31.84, 25.95, 19.71,
18.11, 17.33, 12.73, −4.42, −4.74. [α]20D = −17.13, (c 0.51, CHCl3). HRMS (ESI+): calcd. for C26H44O4Si
[M + H]+, 449.3082, found 449.3079.
4.20. Allyl (2E,4R,6E,8E,11R,13S)-11-((Tert-Butyldimethylsilyl)Oxy)-13-Hydroxy-2,4,9-Trimethyltetradeca-2,6,8-Trienoate (26a)
To a solution of (R)-Me-CBS (1 M in toluene, 0.05 mL, 0.05 mmol) in dry THF (5 mL) was slowly
added BH3·DMS (12 uL, 0.13 mmol) at −40 ◦C. After being stirred for 30 min at the same temperature,
a solution of 25a (57 mg, 0.13 mmol) in THF (2 mL) was slowly added. After being stirred for 2 h at
−40 ◦C, the mixture was diluted with MeOH. The resulting mixture was concentrated and extracted
with DCM (30 mL × 3). The combined organic layers were washed with brine, dried, filtrated,
and concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 15:1)
to give a mixture of 26a and 26b (4:1, 48 mg, 83%) as a colorless oil (pure major isomer 26a can be
obtained by repeating the purification on silica gel).
1H NMR (400 MHz, CDCl3) δ 6.60 (d, J = 9.9 Hz, 1H), 6.18 (dd, J = 14.7, 11.0 Hz, 1H), 5.96 (ddt,
J = 17.1, 10.5, 5.6 Hz, 1H), 5.77 (d, J = 10.8 Hz, 1H), 5.49 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2,
1.4 Hz, 1H), 5.23 (dd, J = 10.5, 1.0 Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H), 4.27–4.06 (m, 2H), 2.66–2.47 (m, 1H),
2.35 (dd, J = 13.4, 6.3 Hz, 1H), 2.23 (dd, J = 13.3, 7.6 Hz, 1H), 2.16 (dd, J = 20.8, 13.7 Hz, 2H), 1.84 (s, 3H),
1.71 (s, 3H), 1.61 (ddd, J = 14.0, 10.0, 3.7 Hz, 1H), 1.48 (ddd, J = 14.5, 9.4, 3.7 Hz, 1H), 1.14 (d, J = 6.2 Hz,
3H), 0.99 (d, J = 11.9 Hz, 3H), 0.88 (s, 9H), 0.07 (d, J = 18.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ
168.12, 147.74, 133.01, 132.72, 130.26, 128.29, 127.95, 126.52, 117.86, 70.36, 65.29, 64.58, 46.98, 43.26, 40.03,
33.91, 25.95, 23.98, 19.68, 18.06, 17.15, 12.76, −4.51, −4.70. [α]20D = −17.67, (c 0.1, CHCl3). HRMS (ESI+):
calcd. for C26H46O4Si [M + H]+, 451.3238, found 451.3241.
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4.21. Allyl (2E,4R,6E,8E,11R,13R)-11-((Tert-Butyldimethylsilyl)Oxy)-13-Hydroxy-2,4,9-Trimethyltetradeca-2,6,8-Trienoate (26b)
To a solution of (S)-Me-CBS (1 M in toluene, 0.1 mL, 0.1 mmol) in dry THF (5 mL), BH3·DMS
(24 uL, 0.25 mmol) was slowly added at −40 ◦C. After being stirred for 30 min at the same temperature,
a solution of 25a (110 mg, 0.24 mmol) in THF (2 mL) was slowly added. After being stirred for 2 h at
−40 ◦C, the mixture was diluted with MeOH. The resulting mixture was concentrated and extracted
with DCM (30 mL × 3). The combined organic layers were washed with brine, dried, filtrated, and
concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 15:1) to
create 26b (92 mg, 85%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.3 Hz, 1H), 6.19 (dd, J = 15.0, 10.8 Hz, 1H),
6.04–5.92 (m, 1H), 5.77 (d, J = 10.8 Hz, 1H), 5.51 (dd, J = 14.9, 7.4 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz,
1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.01 (dq, J = 13.0, 4.3 Hz, 1H), 3.96–3.83
(m, 1H), 3.18 (s, 1H), 2.66–2.50 (m, 1H), 2.32 (dd, J = 13.1, 4.6 Hz, 1H), 2.12 (dt, J = 13.2, 7.9 Hz, 3H),
1.84 (d, J = 1.1 Hz, 3H), 1.72 (s, 3H), 1.59–1.52 (m, 1H), 1.47–1.37 (m, 1H), 1.14 (d, J = 6.2 Hz, 3H), 1.02
(d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 0.12 (d, J = 8.4 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.12, 147.73,
132.79, 132.72, 130.34, 128.23, 127.93, 126.54, 117.86, 72.22, 67.43, 65.29, 49.26, 44.82, 40.01, 33.91, 25.95,
23.70, 19.70, 18.03, 17.28, 12.75, −3.77, −4.55. [α]20D = −40.33, (c 0.35, CHCl3). HRMS (ESI+): calcd. for
C26H46O4Si [M + H]+, 451.3238, found 451.3241.
4.22. Allyl (2E,4R,6E,8E,11S,13R)-11-((Tert-Butyldimethylsilyl)Oxy)-13-Hydroxy-2,4,9-Trimethyltetradeca-2,6,8-Trienoate (26c)
To a solution of (S)-Me-CBS (1 M in toluene, 0.05 mL, 0.05 mmol) in dry THF (5 mL), BH3·DMS
(12 uL, 0.13 mmol) was slowly added at −40 ◦C. After being stirred for 30 min at the same temperature,
a solution of 25b (55 mg, 0.12 mmol) in THF (2 mL) was slowly added. After being stirred for 2 h at
−40 ◦C, the mixture was diluted with MeOH. The resulting mixture was concentrated and extracted
with DCM (30 mL × 3). The combined organic layers were washed with brine, dried, filtrated, and
concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 15:1) to give
a mixture of 26c and 26d (3.6:1, 44 mg, 80%) as a colorless oil (pure major isomer 26c can be obtained
by repeating the purification on silica gel).
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.3 Hz, 1H), 6.19 (dd, J = 15.0, 10.9 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.77 (d, J = 10.8 Hz, 1H), 5.49 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2,
1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.23–4.07 (m, 2H), 3.36 (s, 1H),
2.67–2.49 (m, 1H), 2.35 (dd, J = 13.3, 6.2 Hz, 1H), 2.29–2.21 (m, 1H), 2.14 (t, J = 7.0 Hz, 2H), 1.84 (d,
J = 1.1 Hz, 3H), 1.71 (s, 3H), 1.64–1.56 (m, 1H), 1.49 (ddd, J = 14.5, 9.5, 3.7 Hz, 1H), 1.14 (d, J = 6.2 Hz,
3H), 1.01 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H), 0.06 (d, J = 20.4 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.09,
147.74, 133.01, 132.71, 130.27, 128.27, 127.94, 126.52, 117.86, 70.43, 65.29, 64.58, 46.92, 43.25, 40.04, 33.93,
25.95, 23.98, 19.73, 18.06, 17.21, 12.73, −4.52, −4.71. [α]20D = −14.83, (c 0.1, CHCl3). HRMS (ESI+): calcd.
for C26H46O4Si [M + H]+, 451.3238, found 451.3240.
4.23. Allyl (2E,4R,6E,8E,11S,13S)-11-((Tert-Butyldimethylsilyl)Oxy)-13-Hydroxy-2,4,9-Trimethyltetradeca-2,6,8-Trienoate (26d)
To a solution of (R)-Me-CBS (1 M in toluene, 0.1 mL, 0.1 mmol) in dry THF (5 mL), BH3·DMS
(24 uL, 0.25 mmol) was slowly added at −40 ◦C. After being stirred for 30 min at the same temperature,
a solution of 25b (113 mg, 0.25 mmol) in THF (2 mL) was slowly added. After being stirred for 2 h at
−40 ◦C, the mixture was diluted with MeOH. The resulting mixture was concentrated and extracted
with DCM (30 mL × 3). The combined organic layers were washed with brine, dried, filtrated, and
concentrated. The residue was purified by column chromatography on silica gel (PE/EA = 15:1) to
provide 26d (100 mg, 88%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 10.0, 1.3 Hz, 1H), 6.19 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.76 (d, J = 10.8 Hz, 1H), 5.50 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2,
1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.11–3.98 (m, 1H), 3.95–3.82 (m, 1H),
3.12 (s, 1H), 2.67–2.51 (m, 1H), 2.32 (dd, J = 13.2, 4.7 Hz, 1H), 2.19–2.06 (m, 3H), 1.84 (d, J = 1.2 Hz, 3H),
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1.71 (s, 3H), 1.56 (dt, J = 14.4, 3.2 Hz, 1H), 1.46–1.38 (m, 1H), 1.14 (d, J = 6.2 Hz, 3H), 1.02 (d, J = 6.7 Hz,
3H), 0.89 (s, 9H), 0.11 (d, J = 8.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.10, 147.74, 132.78, 132.71,
130.32, 128.22, 127.91, 126.53, 117.84, 72.26, 67.41, 65.28, 49.21, 44.81, 40.03, 33.90, 25.95, 23.70, 19.72,
18.02, 17.33, 12.74, −3.78, −4.56. [α]20D = −15.29, (c 0.63, CHCl3). HRMS (ESI+): calcd. for C26H46O4Si
[M + H]+, 451.3238, found 451.3228.
4.24. Synthetic Procedure of 27a–27d
To a stirred solution of 26a (35 mg) in dry THF (2 mL), the HF/Py complex (0.7 mL) was added
at 0 ◦C. After being stirred for 1 h, the mixture was quenched with a saturated aqueous solution of
NaHCO3 and extracted with DCM (10 mL × 3). The combined organic layers were washed with
1 M HCl, brine, dried over Na2SO4, filtrated, and concentrated. The residue was purified by a column
chromatography on silica gel (PE/EA = 2:1) to create 27a (22 mg, 84%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.64–6.56 (m, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1,
10.5, 5.6 Hz, 1H), 5.84 (d, J = 10.8 Hz, 1H), 5.54 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.4 Hz, 1H),
5.23 (dd, J = 10.5, 0.9 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.13–4.02 (m, 1H), 4.02–3.92 (m, 1H), 2.65–2.51
(m, 1H), 2.24–2.10 (m, 4H), 1.84 (d, J = 1.3 Hz, 3H), 1.75 (s, 3H), 1.61–1.55 (m, 1H), 1.55–1.47 (m, 1H),
1.20 (d, J = 6.2 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.11, 147.65, 132.71,
132.58, 130.99, 128.31, 128.00, 126.60, 117.87, 70.45, 68.91, 65.30, 48.84, 44.80, 40.00, 33.83, 24.07, 19.72,
16.88, 12.75. [α]20D = −29.76, (c 0.34, CHCl3). HRMS (ESI+): calcd. for C20H32O4 [M + Na]+,337.2373,
found 337.2375.
Compound 27b (20.9 mg, 80%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.60
(dd, J = 10.0, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.85
(d, J = 10.7 Hz, 1H), 5.54 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz,
1H), 4.64 (d, J = 5.5 Hz, 2H), 4.21–4.12 (m, 1H), 4.08 (ddd, J = 12.4, 7.8, 5.3 Hz, 1H), 2.65–2.51 (m, 1H),
2.22–2.18 (m, 2H), 2.16 (d, J = 7.2 Hz, 2H), 1.84 (d, J = 1.3 Hz, 3H), 1.76 (s, 3H), 1.67–1.54 (m, 2H),
1.23 (d, J = 6.3 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.11, 147.65, 133.00,
132.71, 130.92, 128.15, 128.03, 126.59, 117.86, 66.73, 65.47, 65.30, 48.14, 44.09, 40.01, 33.84, 23.69, 19.72,
16.81, 12.75. [α]20D = −14.00, (c 0.05, CHCl3). HRMS (ESI+): calcd. for C20H32O4 [M + Na]+,337.2373,
found 337.2377.
Compound 27c (22 mg, 84%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.60
(dd, J = 10.0, 1.3 Hz, 1H), 6.23 (dd, J = 14.9, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.84
(d, J = 10.8 Hz, 1H), 5.54 (dt, J = 14.9, 7.3 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz,
1H), 4.64 (d, J = 5.5 Hz, 2H), 4.10–4.02 (m, 1H), 4.01–3.94 (m, 1H), 2.62–2.52 (m, 1H), 2.20–2.11 (m, 4H),
1.84 (d, J = 1.3 Hz, 3H), 1.75 (s, 3H), 1.61–1.55 (m, 1H), 1.54–1.46 (m, 1H), 1.20 (d, J = 6.2 Hz, 3H), 1.02
(d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.12, 147.64, 132.71, 132.57, 130.99, 128.32, 128.01,
126.60, 117.87, 70.45, 68.91, 65.31, 48.84, 44.81, 39.99, 33.85, 24.07, 19.70, 16.88, 12.75. [α]20D = −29.37,
(c 0.32, CHCl3). HRMS (ESI+): calcd. for C20H32O4 [M + Na]+,337.2373, found 337.2374.
Compound 27d (21.4 mg, 82%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.86 (d, J = 10.8 Hz, 1H), 5.54
(dt, J = 14.8, 7.3 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz,
2H), 4.21–4.11 (m, 1H), 4.12–4.02 (m, 1H), 2.65–2.51 (m, 1H), 2.23–2.18 (m, 2H), 2.15 (t, J = 7.2 Hz, 2H),
1.84 (d, J = 1.3 Hz, 3H), 1.76 (s, 3H), 1.65–1.56 (m, 2H), 1.23 (d, J = 6.3 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 168.12, 147.64, 132.99, 132.72, 130.95, 128.18, 128.04, 126.60, 117.87, 66.72,
65.48, 65.31, 48.14, 44.10, 39.99, 33.86, 23.69, 19.70, 16.82, 12.76. [α]20D = −17.62, (c 0.32, CHCl3). HRMS
(ESI+): calcd. for C20H32O4 [M + Na]+, 337.2373, found 337.2374.
4.25. Synthetic Procedure of 28a–28d
To a stirred solution of compound 27a (22 mg, 0.065 mmol) in dry acetone (2 mL) under argon,
PTSA· H2O (1.14 mg, 0.006 mmol) and 2,2-dimethylpropane (0.08 mL, 0.65 mmol) were added
sequentially. After 1 h, the reaction mixture was quenched with a saturated aqueous solution of
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NaHCO3 and extracted with DCM (2 × 10 mL). The combined organic extracts were washed with water
and brine, dried over Na2SO4, and concentrated in vacuum. Purification by column chromatography
(PE/EA = 20:1) provided 28a (23 mg, 93%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.61 (dd, J = 9.9, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.80 (d, J = 10.8 Hz, 1H), 5.50 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2,
1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.04–3.88 (m, 2H), 2.65–2.50 (m, 1H),
2.30 (dd, J = 13.6, 5.9 Hz, 1H), 2.15 (t, J = 7.1 Hz, 2H), 2.06 (dd, J = 13.6, 7.0 Hz, 1H), 1.84 (d, J = 1.1 Hz,
3H), 1.74 (s, 3H), 1.49–1.42 (m, 4H), 1.41–1.34 (m, 4H), 1.15 (d, J = 6.1 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 168.11, 147.77, 133.12, 132.72, 129.98, 128.39, 127.15, 126.52, 117.83, 98.61,
67.97, 65.34, 65.27, 46.85, 40.00, 38.60, 33.90, 30.46, 22.38, 19.94, 19.69, 17.34, 12.74. [α]20D = −30.22, (c 0.26,
CHCl3). HRMS (ESI+): calcd. for C23H36O4 [M + Na]+,377.2686, found 377.2689.
Compound 28b (20.8 mg, 89%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.61
(dd, J = 10.0, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.81
(d, J = 10.7 Hz, 1H), 5.49 (dt, J = 14.8, 7.3 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3
Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.04–3.88 (m, 2H), 2.64–2.51 (m, 1H), 2.31 (dd, J = 14.1, 6.9 Hz, 1H),
2.22–2.07 (m, 3H), 1.84 (d, J = 1.3 Hz, 3H), 1.74 (s, 3H), 1.63–1.57 (m, 2H), 1.35 (s, 6H), 1.18 (d, J = 6.3 Hz,
3H), 1.02 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.13, 147.79, 133.39, 132.74, 129.93, 128.43,
126.83, 126.52, 117.84, 100.32, 65.40, 65.28, 62.94, 46.16, 40.00, 39.83, 33.93, 25.24, 25.13, 21.86, 19.70,
17.07, 12.75. [α]20D = −47.32, (c 0.11, CHCl3). HRMS (ESI+): calcd. for C23H36O4 [M + Na]+, 377.2686,
found 377.2684.
Compound 28c (22 mg, 90%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.61
(dd, J = 9.9, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.80
(d, J = 10.8 Hz, 1H), 5.50 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4,
1.2 Hz, 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.02–3.88 (m, 2H), 2.66–2.50 (m, 1H), 2.30 (dd, J = 13.6, 5.9 Hz, 1H),
2.15 (t, J = 7.1 Hz, 2H), 2.06 (dd, J = 13.7, 7.0 Hz, 1H), 1.84 (d, J = 1.2 Hz, 3H), 1.74 (s, 3H), 1.49–1.42
(m, 4H), 1.41–1.34 (m, 4H), 1.15 (d, J = 6.1 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3)
δ 168.10, 147.76, 133.12, 132.72, 129.96, 128.39, 127.11, 126.51, 117.83, 98.60, 67.97, 65.34, 65.27, 46.81,
40.00, 38.60, 33.89, 30.45, 22.38, 19.94, 19.70, 17.35, 12.73. [α]20D = −25.76, (c 0.69, CHCl3). HRMS (ESI+):
calcd. for C23H36O4 [M + Na]+, 377.2686, found 377.2685.
Compound 28d (21.5 mg, 90%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
6.61 (dd, J = 10.0, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H),
5.49 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.3 Hz, 1H), 4.64
(d, J = 5.5 Hz, 2H), 4.04–3.86 (m, 2H), 2.65–2.48 (m, 1H), 2.31 (dd, J = 14.1, 7.0 Hz, 1H), 2.20–2.06
(m, 3H), 1.84 (d, J = 1.3 Hz, 3H), 1.74 (s, 3H), 1.68–1.57 (m, 2H), 1.35 (s, 6H), 1.18 (d, J = 6.3 Hz, 3H), 1.02
(d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.11, 147.78, 133.38, 132.73, 129.90, 128.42, 126.79,
126.51, 117.83, 100.31, 65.38, 65.27, 62.93, 46.13, 40.00, 39.84, 33.92, 25.23, 25.11, 21.85, 19.70, 17.07, 12.74.
[α]20D = −17.71, (c 0.23, CHCl3). HRMS (ESI+): calcd. for C23H36O4 [M + Na]+, 377.2686, found 377.2692.
4.26. Synthetic Procedure of 29a–29d
To a stirred solution of compound 26a (48 mg, 0.11 mmol) in dry DCM (3 mL) and 4A molecular
sieve under argon, the Proton Sponge (107 mg, 0.5 mmol) and trimethyloxonium tetrafluoroborate
(60 mg, 0.4 mmol) were added sequentially. After 1 h, the reaction mixture was quenched with 1 M HCl
(10 mL) and extracted with DCM (2 × 10 mL). The combined organic extracts were washed with water
and brine, dried over Na2SO4, and concentrated in vacuum. Purification by column chromatography
(PE/EA = 40:1) created 29a (38 mg, 77%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (d, J = 9.9 Hz, 1H), 6.20 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.75 (d, J = 10.8 Hz, 1H), 5.47 (dt, J = 14.8, 7.3 Hz, 1H), 5.28 (ddd, J = 13.8,
11.6, 1.3 Hz, 2H), 4.64 (d, J = 5.6 Hz, 2H), 4.00 (tdd, J = 8.7, 5.4, 3.2 Hz, 1H), 3.54–3.37 (m, 1H), 3.28
(d, J = 2.2 Hz, 3H), 2.71–2.44 (m, 1H), 2.36–2.21 (m, 1H), 2.21–2.01 (m, 3H), 1.84 (d, J = 1.2 Hz, 3H), 1.72
(s, 3H), 1.62–1.54 (m, 1H), 1.37–1.28 (m, 1H), 1.11 (d, J = 6.1 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H),
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0.05 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.12, 147.85, 133.80, 132.75, 129.65, 128.52,
127.56, 126.47, 117.85, 73.13, 67.86, 65.27, 55.62, 49.18, 44.92, 39.99, 33.96, 26.08, 19.64, 19.38, 18.20, 17.36,
12.72, −3.96, −4.53. [α]20D = −38.67, (c 0.05, CHCl3). HRMS (ESI+): calcd. for C27H48O4Si [M + H]+,
465.3395, found 465.3388.
Compound 29b (72 mg, 76%) was obtained as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 6.61
(dd, J = 9.9, 1.1 Hz, 1H), 6.20 (dd, J = 14.9, 10.9 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.77
(d, J = 10.8 Hz, 1H), 5.46 (dt, J = 14.8, 7.3 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz,
1H), 4.64 (dd, J = 5.5, 1.1 Hz, 2H), 3.93–3.83 (m, 1H), 3.41 (dd, J = 12.5, 6.3 Hz, 1H), 3.29 (s, 3H), 2.64–2.47
(m, 1H), 2.28–2.05 (m, 4H), 1.84 (d, J = 1.3 Hz, 3H), 1.72 (s, 4H), 1.48–1.39 (m, 1H), 1.11 (d, J = 6.1 Hz,
3H), 1.01 (d, J = 6.7 Hz, 3H), 0.86 (s, 9H), 0.02 (d, J = 9.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 168.14,
147.87, 133.66, 132.73, 129.73, 128.47, 127.73, 126.45, 117.85, 74.24, 68.48, 65.28, 55.97, 48.38, 44.21, 40.01,
33.97, 26.01, 19.64, 19.43, 18.16, 17.33, 12.74, −4.15, −4.47. [α]20D = −34.83, (c 0.38, CHCl3). HRMS (ESI+):
calcd. for C27H48O4Si [M + H]+, 465.3395, found 465.3391.
Compound 29c (32 mg, 71%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
6.59 (d, J = 9.7 Hz, 1H), 6.18 (dd, J = 15.0, 10.9 Hz, 1H), 5.94 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.73
(d, J = 10.7 Hz, 1H), 5.45 (dt, J = 14.7, 7.2 Hz, 1H), 5.31 (dd, J = 17.2, 1.1 Hz, 1H), 5.21 (d, J = 10.5 Hz, 1H),
4.62 (d, J = 5.5 Hz, 2H), 3.98 (dt, J = 16.1, 6.0 Hz, 1H), 3.51–3.35 (m, 1H), 3.26 (s, 3H), 2.62–2.44 (m, 1H),
2.27 (ddd, J = 19.7, 13.8, 9.4 Hz, 1H), 2.18–2.01 (m, 3H), 1.82 (s, 3H), 1.70 (s, 3H), 1.60–1.52 (m, 1H),
1.37–1.25 (m, 1H), 1.09 (d, J = 6.1 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.86 (s, 9H), 0.03 (d, J = 6.8 Hz,
6H). 13C NMR (101 MHz, CDCl3) δ 168.11, 147.86, 133.79, 132.74, 129.66, 128.51, 127.55, 126.46, 117.84,
73.13, 67.86, 65.27, 55.63, 49.18, 44.91, 40.05, 33.97, 26.08, 19.71, 19.38, 18.20, 17.39, 12.72, −3.96, −4.54.
[α]20D = −26.17, (c 0.1, CHCl3). HRMS (ESI+): calcd. for C27H48O4Si [M + H]+, 465.3395, found 465.3389.
Compound 29d (72 mg, 70%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.61
(dd, J = 10.0, 1.2 Hz, 1H), 6.20 (dd, J = 15.0, 10.9 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.77 (d, J =
10.8 Hz, 1H), 5.46 (dt, J = 14.7, 7.2 Hz, 1H), 5.33 (dd, J = 17.2, 1.5 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz, 1H),
4.64 (d, J = 5.5 Hz, 2H), 3.94–3.79 (m, 1H), 3.51–3.36 (m, 1H), 3.29 (s, 3H), 2.70–2.50 (m, 1H), 2.25–2.07
(m, 4H), 1.85 (d, J = 1.3 Hz, 3H), 1.79–1.67 (m, 4H), 1.45 (m, 1H), 1.12 (d, J = 6.1 Hz, 3H), 1.01 (d, J =
6.6 Hz, 3H), 0.86 (s, 9H), 0.01 (d, J = 9.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.12, 147.87, 133.67,
132.75, 129.73, 128.47, 127.72, 126.47, 117.84, 74.25, 68.54, 65.28, 55.97, 48.39, 44.20, 40.07, 33.96, 26.02,
19.70, 19.44, 18.17, 17.37, 12.74, −4.15, −4.47. [α]20D = −16.46, (c 0.41, CHCl3). HRMS (ESI+): calcd. for
C27H48O4Si [M + H]+, 465.3395, found 465.3389.
4.27. Synthetic Procedure of 1a–1d
To a stirred solution of 29a in dry THF (2 mL), the HF/Py complex (0.4 mL) was added at 0 ◦C.
After being stirred for 1 h, the mixture was quenched with a saturated aqueous solution of NaHCO3
and extracted with DCM (10 mL × 3). The combined organic layers were washed with 1 M HCl, brine,
dried over Na2SO4, filtrated, and concentrated. The residue was purified by column chromatography
on silica gel (PE/EA = 4:1) to create 1a (20 mg, 70%) as a colorless oil.
1H NMR (400 MHz, CDCl3) δ 6.60 (dd, J = 9.9, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96
(ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.83 (d, J = 10.8 Hz, 1H), 5.59–5.42 (m, 1H), 5.32 (dd, J = 17.2, 1.5 Hz,
1H), 5.22 (dd, J = 10.4, 1.2 Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H), 4.10–3.98 (m, 1H), 3.69–3.61 (m, 1H),
3.34 (s, 3H), 2.57 (m, 1H), 2.17 (m, 4H), 1.84 (d, J = 1.3 Hz, 3H), 1.75 (s, 3H), 1.59–1.55 (m, 2H), 1.17
(d, J = 6.2 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.11, 147.75, 133.68, 132.71,
130.36, 128.23, 127.58, 126.52, 117.85, 74.75, 66.38, 65.28, 56.34, 48.36, 42.82, 40.00, 33.89, 19.70, 18.94,
16.91, 12.73. [α]20D = −25.83, (c 0.46, CHCl3). HRMS (ESI+): calcd. for C21H34O4 [M + Na]+, 373.2349,
found 373.2346.
Compound 1b (40 mg, 74%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.60
(dd, J = 9.9, 1.1 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.95 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.82
(d, J = 10.8 Hz, 1H), 5.50 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.22 (dd, J = 10.4, 1.2
Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H), 3.98–3.87 (m, 1H), 3.61–3.49 (m, 1H), 3.33 (s, 3H), 2.65–2.47 (m, 1H),
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2.26–2.05 (m, 4H), 1.83 (s, 3H), 1.75 (s, 3H), 1.59–1.50 (m, 2H), 1.17 (d, J = 6.0 Hz, 3H), 1.01 (d, J = 6.7 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 168.10, 147.78, 133.68, 132.70, 130.13, 128.30, 127.42, 126.48, 117.82,
77.98, 69.74, 65.25, 55.89, 48.24, 43.29, 40.00, 33.88, 19.68, 19.20, 17.00, 12.71. [α]20D = −29.17, (c 0.80,
CHCl3). HRMS (ESI+): calcd. for C21H34O4 [M + Na]+, 373.2349, found 373.2348.
Compound 1c (18 mg, 75%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.60
(dd, J = 9.9, 1.3 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.96 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.83
(d, J = 10.8 Hz, 1H), 5.59–5.42 (m, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.22 (dd, J = 10.4, 1.2 Hz, 1H),
4.63 (d, J = 5.5 Hz, 2H), 4.10–3.98 (m, 1H), 3.69–3.61 (m, 1H), 3.34 (s, 3H), 2.57 (m, 1H), 2.17 (m, 4H),
1.84 (d, J = 1.3 Hz, 3H), 1.75 (s, 3H), 1.59–1.55 (m, 2H), 1.17 (d, J = 6.2 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 168.11, 147.74, 133.68, 132.71, 130.34, 128.24, 127.58, 126.52, 117.85, 74.74,
66.38, 65.28, 56.34, 48.36, 42.87, 39.98, 33.89, 19.68, 18.96, 16.91, 12.73. [α]20D = −21.89, (c 0.52, CHCl3).
HRMS (ESI+): calcd. for C21H34O4 [M + Na]+, 373.2349, found 373.2349.
Compound 1d (40 mg, 74%) was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.60
(dd, J = 9.9, 1.1 Hz, 1H), 6.23 (dd, J = 15.0, 10.8 Hz, 1H), 5.95 (ddt, J = 17.1, 10.5, 5.6 Hz, 1H), 5.82
(d, J = 10.8 Hz, 1H), 5.50 (dt, J = 14.8, 7.3 Hz, 1H), 5.32 (dd, J = 17.2, 1.5 Hz, 1H), 5.22 (dd, J = 10.4, 1.2
Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H), 3.98–3.87 (m, 1H), 3.61–3.49 (m, 1H), 3.33 (s, 3H), 2.65–2.47 (m, 1H),
2.26–2.05 (m, 4H), 1.83 (s, 3H), 1.75 (s, 3H), 1.59–1.50 (m, 2H), 1.17 (d, J = 6.0 Hz, 3H), 1.01 (d, J = 6.7 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 168.10, 147.78, 133.69, 132.70, 130.11, 128.31, 127.41, 126.48, 117.83,
77.96, 69.75, 65.26, 55.89, 48.22, 43.30, 39.96, 33.88, 19.66, 19.20, 17.04, 12.71. [α]20D = −38.68, (c 0.76,
CHCl3). HRMS (ESI+): calcd. for C21H34O4 [M + Na]+, 373.2349, found 373.2350. Detailed NMR data
tables of 1a–1d are in the Supplementary Material.
5. Conclusions
Asymmetric synthesis of the alotamdie fragment C15–C32 was established and four
diastereomers were achieved concisely. Boron-mediated enantioselective aldol reaction led to a
good diastereoselectivity and Julia-Kocienski olefination constructed the diene part in excellent E/Z
selectivity and yield. A careful NMR comparison between four isomers and natural alotamide
suggested the relative structure.
Supplementary Materials: A supplementary file is available online at http://www.mdpi.com/1660-3397/16/
11/414/s1. Supplementary Information shows the NMR spectra of the synthetic compounds and the NMR data
tables of 1a–1d.
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Abstract: Smenamides are an intriguing class of peptide/polyketide molecules of marine origin
showing antiproliferative activity against lung cancer Calu-1 cells at nanomolar concentrations
through a clear pro-apoptotic mechanism. To probe the role of the activity-determining structural
features, the 16-epi-analogue of smenamide A and eight simplified analogues in the 16-epi series
were prepared using a flexible synthetic route. The synthetic analogues were tested on multiple
myeloma (MM) cell lines showing that the configuration at C-16 slightly affects the activity,
since the 16-epi-derivative is still active at nanomolar concentrations. Interestingly, it was found
that the truncated compound 8, mainly composed of the pyrrolinone terminus, was not active,
while compound 13, essentially lacking the pyrrolinone moiety, was 1000-fold less active than the
intact substance and was the most active among all the synthesized compounds.
Keywords: smenamides; marine natural products; peptide/polyketide molecules;
synthetic analogues; functional-analogues; antiproliferative activity; MM cell line
1. Introduction
Marine sponges, together with their symbiotic microorganisms, have proven to be a rich source
of skeletally new substances [1–3], which have often inspired novel strategies in anticancer drug
discovery. Targeted cancer therapies consist of “drugs” which interfere with specific molecules
necessary for tumor growth and progression. A primary goal of these therapies is to fight cancer
cells with more precision without hitting normal cells. These drugs are classified into monoclonal
antibodies, directed against antigens expressed on the neoplastic cell surface, and small molecules,
usually designed to interfere with protein targets [4].
Smenamides A (1) and B (2) (Figure 1) are highly functionalized peptide/polyketide substances
isolated by our group in 2013 from the Caribbean sponge Smenospongia aurea [5]. They have proven to
be interesting for their structural features, such as the unusual N-methylacetamide western terminus,
the dolapyrrolidone eastern terminus, typical of dolastatin-15 (3), a potent antimitotic agent derived
from Dolabella auricularia [6], and the chlorovinyl functional group, common to some cyanobacterial
metabolites, such as jamaicamides (4–6, Figure 1), isolated from Lyngbiamajuscula [7]. The only
difference between the two smenamides resides in the configuration of the C-13/C-15 double bond
positioned close to the middle part of the polyketide portion of the molecule. It has been speculated
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that this could determine a different overall shape and, as a consequence, the different biological
behavior observed for smenamides [5].
Figure 1. Smenamide A (1) and B (2), dolastatin-15 (3), and jamaicamides (4–6). Configuration at C-16
in smenamide A as determined by synthesis [8].
Smenamides have proven to be active in blocking the proliferation of the Calu-1 cancer cell line at
nanomolar concentrations, working, however, with a different mechanism of action. Smenamide A,
more interestingly, acts with a clear pre-apoptotic mechanism proving to be the more promising as
a lead compound. It is worth stating that the configuration at C-16 in both smenamides remained
unassigned in the original study due to the limited amount of the natural substances available.
In a recent study, a chiral protocol strategy aimed at the total synthesis of the smenamide family
was designed, starting from commercially available S-citronellene, a cheap starting material [8].
Two stereoisomers of smenamide A, namely ent-smenamide A and 16-epi-smenamide A (7, Figure 2),
were synthesized. This synthetic effort allowed us to determine the C-16 configuration of smenamide
A as R (Figure 1), as well as to develop a flexible synthetic route towards this class of substances.
In the present study, the antiproliferative activity of 16-epi-smenamide A has been evaluated
on multiple myeloma (MM) cell lines. MM is a clonal plasma cell malignancy accounting for
approximately 13% of all hematological cancers [9]. It originates from post-germinal centre B
cells that accumulate somatic hypermutation and immunoglobulin heavy-chain class switching [8].
Several novel agents have been introduced into clinical practice but, after an initial response,
most patients relapse or progress with a treatment-refractory disease [10]. For this reason, MM still
proves to be incurable for most patients. In this scenario, it is necessary to develop new agents targeting
novel pathways relevant for the MM cells, thereby increasing the range of available therapies.
In addition to 16-epi-smenamide A, the eight simplified synthetic analogues 8–15 (Figure 2)
have also been synthesized. They were conceived as “functional-analogues” of smenamide A,
incorporating some of the potential activity-determining structural features of the natural product.
They were easily prepared thanks to the flexible nature of the previously developed synthetic route,
with the aim of probing the importance of the main structural features of the smenamides, that is,
the pyrrolinone, chlorovinyl and N-methylacetamido functional groups. In this paper, we illustrate
a case-example of the application of this strategy to the design and study of functional-analogues of
complex natural lead compounds.
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Figure 2. 16-epi-smenamide A (7) and its analogues 8–15. For structural comparison, numeration of
analogues is in agreement with that of 16-epi-smenamide A.
2. Results and Discussion
2.1. Compounds 7–15
16-epi-smenamide A (7, Figure 2) is the C-16 epimer of the natural smenamide A (1, Figure 1).
It was synthesized starting from S-citronellene using the chiral protocol previously reported.
16-epi-smenamide A was tested on SKM-M1 and RPMI-8226 cells, two MM cell lines, showing it to be
able to reduce cell viability in a dose-dependent way at nanomolar concentrations (see Section 2.2).
We demonstrated that 16-epi-smenamide A, despite possessing the opposite configuration at
C-16, retains the potent antiproliferative activity shown by the natural compound, smenamide-A,
thus suggesting that this configuration does not affect the nature of its activity. Therefore, as a
working hypothesis for the design of simplified analogues of 16-epi-smenamide A (7), this compound
was hypothetically disconnected into two main building blocks, corresponding to the polyketide
and the peptide moieties. To probe the importance of the main structural features of smenamides,
eight “functional-analogues” of 16-epi-smenamide-A were prepared. In particular, the truncated
compound 8, retaining the C1–C18 portion of smenamide A, was synthesized to investigate the role
of the pyrrolinone moiety. Compounds 9–12, in turn, represent the simplified C15–C27 polyketide
portion and retain only the chlorovinyl and N-methylacetamide functional groups. They also served
to investigate the role of the geometric isomerism around the C20/C21 double bond. The modulation
of the polarity within the 9/11 and 10/12 pairs was achieved by acetylation. Ester 13, only lacking the
pyrrolinone moiety, was prepared to simulate the entire polyketide portion, while compound 14 and
its acetyl-derivative 15 allowed us to investigate the role of the chlorine atom. In fact, it is well known
that the presence of halogens in natural products is important for the modulation of the biological
activity [11,12], as previously reported.
Thus, the activation of 2,4-dimethyl-2-pentenoic acid as the pentafluorophenylester (16)
(Figure 3) and its subsequent coupling with the previously synthesized pyrrolinone subunit 17 [8],
afforded compound 8 in an 85% yield.
Ketone 18 (Figure 4) is a versatile intermediate to access 16-epi-smenamide analogues. It was easily
prepared from commercially available S-citronellene, as depicted in Figure 4, and used as the starting
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material to obtain the seven analogues 9–15 by the introduction of the chlorovinyl, methylene and
α,β-unsaturated ethyl ester functionalities (Figure 5). Thus, the Wittig olefination of 18 gave the two
isomeric chlorovinyl derivatives 19 and 20 in a 3:2 ratio in favor of 19, which could be separated by
column chromatography.
Figure 3. Preparation of pyrrolinone derivative 8.
Figure 4. Synthesis of the ketone intermediate 18.
Figure 5. Preparation of compounds 9–13.
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Deprotection of both 19 and 20 with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran
(THF) afforded alcohols 9 and 10, respectively, whose acetylation with Ac2O/pyridine gave
the corresponding acetyl derivatives 11 and 12, respectively. In order to introduce the
α,β-unsaturated ethyl ester function, the oxidation of 9 was accomplished with the Ley-Griffith method
[tetrapropylammonium perruthenate (TPAP) (cat)/N-Methylmorpholine N-oxide (NMO)] [13–15] to
give aldehyde 21 that was used in the subsequent Wittig reaction without further purification. Finally,
the reaction with Ph3P=CH(Me)-CO2Et led to ethyl ester 13 in a 70% yield.
The methylene derivatives 14 and 15 were prepared by Wittig olefination of 18 using
methylenetriphenylphosphorane (Figure 6). In particular, the first obtained product 22 was deprotected
with TBAF in THF to give the desired alcohol 14 whose acetylation with Ac2O/pyridine finally afforded
the acetyl-derivative 15.
Figure 6. Preparation of methylene derivatives 14 and 15.
All synthesized compounds were tested on RPMI-8226 cell lines, as described in Section 2.2.
Compound 8, lacking the great part of the polyketide moiety, was not active at all. As for the truncated
polyketide compounds 9–15, it was shown that only compound 13, essentially lacking the pyrrolinone
terminus, retained a certain degree of activity. In particular, a 1000-fold decreased EC50 value resulted,
compared to the intact parent substance 7. Equally, neither alcohols 9 and 10 nor the corresponding
acetates 11 and 12, not the dechlorinated analogues 14 and 15 showed significant activities. On the
other hand, when the activity data of compounds 9–12 are compared with those of 13, it is evident
that the α,β-unsaturated ethyl ester function plays a role in the activity. In addition, even if it seems
that the pyrrolinone terminus does not represent a crucial functional part of the molecule, its absence
reduces the activity of 13 suggesting that it, or the entire C1–C15 unsaturated moiety, may be equally
important for the full activity of smenamides, conferring rigidity to the molecule, possibly needed to
exert the activity. However, these data alone do not allow us to speculate about the importance of the
chlorine atom as well as of the configuration of the C20/C21 double bond on the activity.
2.2. In Vitro Evaluation of Activity on Multiple Myeloma Cell Lines
In order to study the in vitro effects of 16-epi-smenamide A (7) and its synthetic analogues 8–15,
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt] assays were performed on SKM-M1 and RPMI-8226, MM cell lines, to evaluate their effects
on cell viability. Compound 7, tested at increasing concentrations (10–300 nM) for 48 h, was shown
to reduce cell viability in both MM cell lines in a dose-dependent way (Figure 7). More than 50% of
viability reduction was observed between 30 and 50 nM concentration. EC50 for compound 7 was
calculated as 44 nM in SKM-M1 cells, and 24 nM in RPMI-8226 cells, after 48 h of treatment.
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Figure 7. Viability of SKM-M1 and RPMI-8226 multiple myeloma (MM) cell lines was evaluated
by MTS assay after treatment with compound 7 at different concentrations (10, 30, 50, 100 and
300 nM) for 48 h. Results are expressed as percent of cell viability normalized to dimethylsulfoxide
(DMSO)-treated control cells. The line-graphs represent average with standard deviation (SD) from
three independent experiments.
Likewise, compound 8 was used to treat SKM-M1 and RPMI-8226 cell lines at 50 nM, 100 nM,
1 μM, 5 μM and 10 μM concentrations, for 24, 48 and 72 h. MTS assays showed that compound 8
had no effect on cell viability on SKM-M1 cell line and negligible effect on RPMI-8226 cell viability
(Figure 8). For this compound, EC50 was not calculated.
Figure 8. Cell viability was evaluated by MTS assay after treatment at different concentrations (50 nM,
100 nM, 1 μM, 5 μM, 10 μM) for 24, 48 and 72 h with compound 8 on SKM-M1 and RPMI-8226 cell lines.
Results are expressed as percent of cell viability normalized to DMSO-treated cells. The line-graphs
represent average with SD from three independent experiments.
Because compound 7 resulted more active on the RPMI-8226 cell line, its synthetic analogues 9–15
were tested on this cell line at increasing concentrations (50 nM, 100 nM, 1 μM, 5 μM) for all time points
(24, 48 and 72 h). As shown in Figure 9, compound 9–12, 14 and 15 have negligible effect on RPMI-8226
cell viability; while compound 13 was able to reduce cell viability reaching 80% of reduction at 5 μM,
after 72 h of treatment. EC50 of compound 13 at 72 h was calculated as 1.1 μM.
Further investigation of the cell death mechanism was carried out using compound 13 (at 1 and
5 μM) to treat RPMI-8226 cells. Control experiments were carried out with dimethylsulfoxide (DMSO)
as vehicle control, or with untreated cells. After 72 h of treatment, Annexin-V fluorescein isothiocyanate
(FITC)/propidium iodide (PI) analyses were performed to evaluate whether the cytotoxic activity of
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compounds 13 was related to apoptosis induction. Data obtained showed that a significant increase
of apoptotic cells at both concentrations occurred when cells are treated with compound 13 (5% of
increase at 1 μM respect to control (* p < 0.05) and 66% at 5 μM (*** p < 0.001) (Figure 10a,b)). Moreover,
compound 13 was able to significantly decrease the number of cell in G0/G1 phase and increase those
in S phase at both concentrations (Figure 10c,d).
Figure 9. Cell viability was evaluated by MTS assay after treatment at different concentrations (50 nM,
100 nM, 1 μM, 5 μM) for 24, 48 and 72 h with compounds 9–15 on RPMI-8226 cell line. Results are
expressed as percent of cell viability normalized to DMSO-treated cells. The line-graphs represent
average with SD from three independent experiments.
Figure 10. Compound 13: cytofluorimetric evaluation of apoptosis/necrosis by the Annexin-V
fluorescein isothiocyanate (FITC)/propidium iodide (PI) test (a,b) and cell cycle analysis by PI staining
(c,d) on RPMI-8226 cell line, at 1 μM and 5 μM for 72 h. (a) Dot plots and (c) cell cycle histograms
show a single representative experiment; (b,d) the bar-graphs represent average with S.D. (* p < 0.05,
** p < 0.01, *** p < 0.001).
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3. Experimental Section
3.1. General Experimental Procedures
All reagents and anhydrous solvents were purchased (Aldrich and Fluka) at the highest
commercial quality and used without further purification. Where necessary, flame-dried and
argon-charged glassware was used. The reactions were monitored using thinlayer chromatography
(TLC) carried out on precoated silica gel plates (Merck 60, F254, 0.25 mm thick). Merck silica gel
(Kieselgel 40, particle size 0.063–0.200 mm) was used for the column chromatography. Na2SO4 was
used as a drying agent for aqueous workup. Nuclear magnetic resonance (NMR) experiments were
performed using Varian Unity Inova spectrometers at 400, 500, and 700 MHz in CDCl3. Proton chemical
shifts were referenced to the residual CHCl3 signal (7.26 ppm). 13C-NMR chemical shifts were
referenced to the solvent (77.0 ppm). Abbreviations for signal coupling are as follows: s = singlet,
d = doublet, t = triplet, q = quartet, m = multiplet, and b = broad. Optical rotations were measured
using a JASCO P-2000 polarimeter at the sodium D line. High resolution mass spectra were recorded
by infusion on a Thermo Linear Trap Quadrupole (LTQ) Orbitrap XL mass spectrometer equipped
with an electrospray source in the positive mode using MeOH as the solvent.
See Supplementary Materials for all NMR spectra.
Compound 8. To a solution of 2,4-dimethyl-2-pentenoic acid (114 mg, 0.889 mmol) in EtOAc
(4.0 mL), pentafluorophenol (188.2 mg, 1.02 mmol) and DCC (210.5 mg, 1.02 mmol) were added at 0 ◦C.
The reaction mixture was stirred for 1 h at 0 ◦C and 3 h at room temperature and evaporated under
reduced pressure to give 16 (185.9 mg, 0.632 mmol) that was used in the next step without further
purification. 1H-NMR: (400 MHz, CDCl3): δ 6.90 (1H, d, J=9.75), 2.8–2.6 (1H, m), 1.95 (3H, s), 1.07 (6H,
d, J = 6.6).
To a stirred solution of pyrrolinone 17 (126.6 mg, 0.624 mmol) [8] in THF (5.0 mL),
nBuLi (0.390 mL, 0.632 mmol, 1.6 M soln in hexane) was added dropwise at −78 ◦C. After 15 min,
a solution of pentafluorophenyl ester 16 (183.45 mg, 0.624 mmol) in THF (0.1 mL) was added via
syringe. After 2 h, the reaction was quenched with a saturated aqueous NH4Cl solution (5 mL) and
extracted with EtOAc (3 × 15 mL). The organic phase was washed with water (15 mL) and brine (15 mL),
dried, and concentrated in vacuo. The crude was purified by preparative TLC (CHCl3/CH3OH, 98:2)
to give 8 (166.2 mg, 0.530 mmol, 85%) as colourless oil. [α]20D = +22.1 (c = 10, CHCl3);
1H-NMR:
(400 MHz, CDCl3): δ 7.23–7.17 (3H, m, ArH), 7.0–6.9 (2H, m, ArH), 5.62 (1H, d, J = 9.47), 5.01–4.96 (1H,
m), 4.84 (1H, s), 3.87 (3H, s, OCH3), 3.39 (1H, dd, J = 14.1, 5.4, Ha-7), 3.15 (1H, dd, J = 14.1, 2.0, Hb-7),
2.68–2.54 (1H, m), 1.8 (3H, s), 0.99 (6H, d, J = 6.5); 13C-NMR (100 MHz, CDCl3): δ 177.2, 171.3, 168.8,
145.2, 134.4, 129.8, 129.4, 128.1, 127.0, 94.8, 59.1, 58.3, 33.9, 27.4, 21.9, 21.5, 13.3; HRMS (ESI) m/z calcd.
for C13H25ClNO2 [M + H]+ 262.1568, found 262.1566.
78
Mar. Drugs 2018, 16, 206
A mixture of compounds 19 and 20 was prepared as previously described [8]. Pure 19 and 20 were
obtained by silica gel chromatography (hexane-EtOAc, 1:2). Deprotection of 19, as reported [5] afforded
alcohol 9 as colourless oil. [α]20D = −63.4 (c = 1.5, CHCl3); 1H-NMR: (400 MHz, CDCl3, mixture of
rotamers): δ 5.86 (0.4H, s, vinyl proton), 5.82 (0.6H, s, vinyl proton), 3.46 (2H, t, J = 5.3), 3.42–3.24
(2H, m’s), 2.99 (1.8H, s, H3-27), 2.89 (1.2H, s, H3-27), 2.27–2.02 (7H, overlapped signals including
two singlets at 2.09 and 2.07 for H3-26), 1.78–1.52 (4H, m), 1.30–1.15 (1H, m), 0.93, 0.91 (overall 3H,
overlapped d’s, both J = 6.0, H3-17); 13C-NMR (100 MHz, CDCl3): δ 170.6, 170.4, 142.0, 141.3, 113.2,
112.6, 67.8, 67.7, 50.5, 47.3, 36.1, 35.2, 33.2, 32.3, 32.2, 31.1, 31.0, 27.4, 27.3, 25.8, 24.6, 21.9, 21.2, 16.44,
16.38; HRMS (ESI) m/z calcd. for C13H25ClNO2 [M + H]+ 262.1568, found 262.1566.
To a solution of 20 (3.9 mg, 0.008 mmol) in THF (0.6 mL), TBAF (0.012 mL, 0.012 mmol,
1.0 M solution in THF) was added at 0 ◦C. The reaction mixture was allowed to reach room temperature
and stirred for 1 h. Then, the reaction was quenched with a satd. aq. solution of NH4Cl (0.5 mL).
The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 3 mL). The combined
organic phases were dried and evaporated in vacuo. The crude was subjected to High Performance
Liquid Chromatography (HPLC) separation [column Ascentis Si (Supelco), 25 cm × 4.6 mm, 5 μm;
eluent: n-hexane/isopropanol 7:3, flow rate 1 mLmin−1] to give alcohol 10 (1.0 mg, 48%, tR = 14.5 min)
as colourless oil. [α]20D = +12.1 (c = 0.13; CHCl3);
1H-NMR (400 MHz, CDCl3, mixture of rotamers):
δ 5.83 (0.4H, s, vinyl proton), 5.81 (0.6H, s, vinyl proton), 3.50 (2H, bt, J = 5.7), 3.34, 3.26 (1H each, both t,
J = 7.5, H2-24), 2.98 (1.8H, s, H3-27), 2.92 (1.2H, s, H3-27), 2.31–2.17 (2H, m), 2.11–2.05 (5H, overlapped
signals including a singlet at 2.08 for H3-26); 1.75–1.53 (4H, overlapped multiplets); 1.29–1.19 (1H, m),
0.98, 0.96 (overall 3H, overlapped doublets, both J = 6.1, H3-17); 13C-NMR (100 MHz, CDCl3): δ 170.7,
170.5, 142.0, 141.4, 113.0, 112.5, 67.9, 50.2, 47.4, 36.25, 36.0, 35.7, 35.6, 33.2, 32.2, 31.7, 30.33, 30.28, 27.6,
27.5, 26.2, 25.2, 22.0, 16.4; HRMS (ESI) m/z calcd. for C13H25ClNO2 [M + H]+ 262.1568; found 262.1566.
To a stirred solution of alcohol 9 (1.4 mg, 0.005 mmol) in pyridine (0.6 mL), excess acetic anhydride
(0.4 mL) was added at rt. After 2 h the reaction mixture was evaporated under reduced pressure.
The crude was subjected to HPLC separation [column Ascentis Si (Supelco), 25 cm × 4.6 mm, 5 μm;
eluent: n-hexane/isopropanol 75:25, flow rate 1 mLmin−1] to give acetyl derivative 11 as a colourless
oil (1.5 mg, 0.0047 mmol, 95%). [α]20D = +5.1 (c = 0.12, CHCl3);
1H-NMR: (400 MHz, CDCl3, mixture of
rotamers): δ 5.87 (0.4H, s, vinyl proton), 5.82 (0.6H, s, vinyl proton), 3.98–3.85 (2H, m), 3.39 (1.2H, t,
J = 6.7, H2-24), 3.29 (0.8H, t, J = 6.7, H2-24), 3.00 (1.8H, s, H3-27), 2.93 (1.2H, s, H3-27), 2.27–2.03 (10H,
overlapped signals including singlets at 2.10, 2.09 and 2.07 for acetates), 1.80–1.54 (4H, m), 1.57–1.47
(1H, m), 1.31–1.21 (1H, m), 0.95, 0.93 (overall 3H, overlapped d’s, both J = 6.0, H3-17); 13C-NMR
(100 MHz, CDCl3): δ 141.9, 141.7, 141.3, 141.0, 113.5, 112.7, 68.92, 68.83, 50.5, 47.2, 36.0, 33.2, 32.12,
32.11, 32.09, 32.08, 31.31, 31.29, 31.27, 31.26, 27.45, 27.40, 27.38, 25.8, 24.7, 21.2, 20.9, 16.7; HRMS (ESI)
m/z calcd. for C15H27ClNO3 [M + H]+ 304.1674, found 304.1669.
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To a stirred solution of alcohol 10 (1.2 mg, 0.004 mmol) in pyridine (0.5 mL), excess acetic
anhydride (0.4 mL) was added at room temperature. After 2 h the reaction mixture was evaporated
under reduced pressure. The crude was subjected to HPLC separation [column Ascentis Si (Supelco),
25 cm × 4.6 mm, 5 μm; eluent: n-hexane/isopropanol 75:25, flow rate 1 mLmin−1] to give acetyl
derivative 12 as colourless oil (1.0 mg, 0.003 mmol, 75%). [α]20D = +12.88 (c = 0.06; CHCl3);
1H-NMR:
(500 MHz, CDCl3, mixture of rotamers): δ 5.83 (0.4H, s, vinyl proton), 5.82 (0.6H, s, vinyl proton),
3.99–3.88 (2H, m), 3.34 (1.2H, t, J = 7.6, H2-24), 3.26 (0.8H, t, J = 7.6, H2-24), 2.98 (1.8H, s, H3-27),
2.91 (1.2H, s, H3-27), 2.27–2.20 (3H, m,), 2.10–2.03 (7H, overlapped signals including singlets at 2.08,
2.07 and 2.06 for acetates), 1.85–1.45 (5H, m), 1.32–1.23 (1H, m), 0.99, 0.98 (overall 3H, overlapped d’s,
both J = 6.0, H3-17); 13C-NMR (100 MHz, CDCl3): δ 171.4, 171.3, 170.6, 141.7, 141.0, 113.24, 112.7, 112.6,
69.0, 68.9, 50.2, 47.2, 36.2, 33.2, 32.44, 32.40, 31.7, 30.5, 27.5, 27.4, 26.1, 25.2, 22.0, 21.1 16.7; HRMS (ESI)
m/z calcd. for C15H27ClNO3 [M + H]+ 304.1674; found 304.1671.
Compound 13 was prepared from alcohol 9 as previously described [8]. [α]20D = +127.4 (c = 0.5,
CHCl3); IR (neat) νmax: 2957, 2927, 2858, 1707, 1651, 1596, 1459, 1424, 1373, 1262, 1122 cm−1; 1H-NMR
(400 MHz, CDCl3, mixture of rotamers): δ 6.49 (1H, d, J = 10.1, H-15), 5.82 (0.5H, s, vinyl proton),
5.76 (0.5H, s, vinyl proton), 4.18 (2H, q, J = 7.0, OCH2CH3), 3.37, 3.27 (1H each, both t, J = 7.6, H2-24),
2.99 (1.5H, s, H3-27), 2.91 (1.5H, s, H3-27), 2.46 (1H, m, H-16), 2.18 (2H, m), 2.09 (1.5H, s, H3-26),
2.08 (1.5H, s, H3-26), 2.01 (2H, t, J = 8.6), 1.83 (1.5H, d, J = 1.2, H3-14), 1.82 (1.5H, d, J = 1.2, H3-14),
1.30 (3H, t, J = 7.0, OCH2CH3), 1.02 (1.5H, d, J = 6.6, H3-17), 1.00 (1.5H, d, J = 6.6, H3-17); 13C-NMR
(100 MHz, CDCl3) δ 170.5, 170.3, 168.3, 168.2, 146.9, 146.6, 141.6, 140.8, 132.1, 132.0, 131.94, 131.91, 128.5,
128.4, 127.2, 127.0, 113.4, 112.7, 60.6, 60.5, 50.4, 47.1, 36.0, 34.7, 34.6, 33.1, 32.7, 27.4, 27.3, 25.7, 24.6, 21.9,
21.3, 20.01, 19.98, 14.3, 12.63, 12.61; HRMS (ESI) m/z calcd. for C18H30ClNNaO3 [M + Na]+ 366.1812;
found 366.1802.
To a stirred suspension of methylenetriphenylphosphorane (6.6 mg, 0.024 mmol) in THF (0.5 mL),
nBuLi (0.015 mL, 0.024 mmol, 1.6 M sol. in hexane) was added dropwise at 0 ◦C under argon.
After 30 min at 0 ◦C, a solution of ketone 18 (5.5 mg, 0.012 mmol) in dry THF (0.3 + 0.3 mL rinse)
was added, and the mixture was allowed to reach room temperature. After 4 h, the reaction was
quenched with a saturated aqueous NH4Cl solution (2 mL) and extracted using Et2O (3× 5 mL).
The organic phase was washed with brine, dried, and evaporated under reduced pressure. The crude
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was purified by preparative TLC (chloroform/methanol 95:5) affording compound 22 colourless oil
(4.5 mg, 0.096 mmol, 80%) as a colourless oil. 1H-NMR (400 MHz, CDCl3, mixture of rotamers): δ 7.66
(4H, J = 6.9, ArH), 7.44–7.35 (6H, m, ArH), 4.76 (0.5H, s, methylene proton), 4.72 (0.5H, s, methylene
proton), 4.71 (1H, s, methylene protons), 3.53–3.44 (2H, m), 3.34, 3.23 (1H each, both t, J = 7.6, H2-24),
2.96 (1.5H, s, H3-27), 2.90 (1.5H, s, H3-27), 2.07 (3H, s, H3-26), 2.05–1.92 (4H, m), 1.74–1.56 (4H, m),
1.32–1.17 (1H, m), 1.05 (9H, s, C(CH3)3), 0.93 (3H, d, J = 6.5, H3-17); 13C-NMR (100 MHz, CDCl3):
δ 170.4, 149.2, 148.4, 135.6, 134.0, 133.9, 129.52, 129.48, 109.5, 108.9, 68.8, 68.7, 50.5, 47.4, 36.1, 35.4, 33.45,
33.38, 33.2, 32.8, 31.2, 29.7, 26.9, 26.1, 25.3, 21.9, 21.2, 19.3, 16.7; HRMS (ESI) m/z calcd. for C29H43NO2Si
[M + H]+ 466.3136; found 466.3124.
To a solution of 22 (5.4 mg, 0.012 mmol) in THF (0.8 mL), TBAF (0.017 mL, 0.017 mmol, 1.0 M
solution in THF) was added at 0 ◦C. The reaction mixture was allowed to reach rt and stirred for 1 h.
Then, the reaction was quenched with a satd. aq. solution of NH4Cl (1 mL). The phases were separated,
and the aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic phases were dried
and evaporated in vacuo. The crude was subjected to HPLC separation [column Ascentis Si (Supelco),
25 cm × 4.6 mm, 5 μm; eluent: ethyl acetate/isopropanol 9:1, flow rate 1 mLmin−1] to give alcohol 14
(1.9 mg, 0.008 mmol, 70%) as colourless oil. [α]20D = +7.24 (c = 0.07; CHCl3);
1H-NMR (400 MHz, CDCl3,
mixture of rotamers): δ 4.79 (0.5H, s, methylene proton), 4.75 (1.5H, bs, methylene protons), 3.54–3.43
(2H, m), 3.41–3.30 (1H, m, H2-24), 3.27 (1H, t, J=7.4, H2-24), 2.99 (1.5H, s, H3-27), 2.92 (1.5H, s, H3-27),
2.12 1.98 (overall 7H, including singlets at 2.09 and 2.07 for H3-26), 1.75–1.50 (4H, m), 1.32–1.19 (1H,
m), 0.95, 0.93 (overall 3H, overlapped d’s, J = 6.5, H3-17); 13C-NMR (100 MHz, CDCl3): δ 170.6, 150.8,
148.8, 148.3, 109.6, 109.2, 68.14, 68.10, 50.4, 47.5, 36.3, 35.4, 33.4, 33.2, 33.1, 33.0, 32.1, 31.08, 31.03, 29.7,
26.0, 25.1, 21.3, 16.6, 16.5; HRMS (ESI) m/z calcd. for C13H26NO2 [M + H]+ 228.1958; found 228.1956.
To a stirred solution of alcohol 14 (1.5 mg, 0.006 mmol) in pyridine (0.2 mL), excess acetic
anhydride (0.2 mL) was added at rt. After 2 h the reaction mixture was evaporated under reduced
pressure. The crude was subjected to HPLC separation [column Ascentis Si (Supelco), 25 cm × 4.6 mm,
5 μm; eluent: n-hexane/isopropanol 75:25, flow rate 1 mLmin−1] to give acetyl derivative 15 as a
colourless oil (1.0 mg, 0.004 mmol, 62%). [α]20D = +13.63 (c = 0.07; CHCl3);
1H-NMR (400 MHz, CDCl3,
mixture of rotamers): δ 4.78 (0.5H, s, methylene proton), 4.75 (0.5H, s, methylene proton), 4.74 (1H, s,
methylene protons), 3.99–3.84 (2H, m), 3.36, 3.26 (1H each, both t, J = 7.6, H2-24), 2.98 (1.5H, s, H3-27),
2.92 (1.5H, s, H3-27), 2.12–1.96 (10H, overlapped signals including singlets at 2.09, 2.08 and 2.06 for
acetates) 1.82–1.60 (4H, m), 1.34–1.22 (1H, m), 0.95, 0.94 (overall 3H, overlapped d’s, J = 6.5, H3-17);
13C-NMR (175 MHz, CDCl3): δ 170.42, 171.36, 170.6, 141.7, 141.05, 113.24, 112.6, 112,65, 69.0, 68.9, 50.2,
47.2, 36.2, 33.2, 32.43, 32.40, 31.9, 31.7, 30.5, 27.5, 27.4, 26.1, 25.2, 22.0, 21.4, 21.1, 16.7; HRMS (ESI) m/z
calcd. for C15H27NO3 [M + H]+ 270.2063; found 270.2061.
81
Mar. Drugs 2018, 16, 206
3.2. Biological Activity
3.2.1. Cell Lines and Chemical
Human MM cell lines, SKM-M1 and RPMI-8226, were cultured in RPMI 1640 (Gibco,
Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS. Gibco,
Life Technologies, Carlsbad, CA, USA), 1% of penicillin-streptomycin (Gibco) at 37 ◦C and 5% CO2.
All chemical compounds were dissolved in DMSO (Sigma Aldrich, St. Louis, MO, USA) and
diluted in FBS for cell treatments.
3.2.2. Cell Viability
SKM-M1 and RPMI-8226 cell lines were seeded into 96-well plates (3 × 104 cells/100 μL) and
incubated with all compounds at increasing concentrations for different time points. In particular,
compound 7 was used at concentrations 10–300 nM for 48 h; compound 8 at 50–10 μM for 24, 48 and
72 h; compounds 9–15 at 50–5 μM for 24, 48 and 72 h. Cells treated with the DMSO vehicle were used
as control. Cell viability was determined using the CellTiter 96 Aqueous One Solution assay kit (MTS,
Promega, Madison, WI, USA). The optical density was measured at 492 nm by plate reader (Das srl,
Rome, Italy). Cellular viability was calculated as percentage of viable cells compared with DMSO
control. All experiments were conducted in triplicate. EC50 values were obtained by GraphPad Prism
(GraphPad Prism, San Diego, CA, USA).
3.2.3. Functional Tests
RPMI-8226 cell line was treated with 1 μM and 5 μM of compound 13 or with DMSO vehicle or
not treated for 72 h (cell density 3×105 cells/mL) and used in:
- Apoptosis assay
Apoptosis of RPMI-8226 was evaluated by cytometric analysis of Annexin V and PI-stained cells
using fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection kit I (Becton Dickinson, BD,
Franklin, NJ, USA) [16]. Samples were prepared following the manufacturer’s instructions; stained cells
were acquired using NAVIOS flow cytometer (Beckman Coulter, Brea, CA, USA) and analyzed by
Kaluza software (Beckman Coulter). 10,000 events were acquired for each samples; single positive for
Annexin V and double positive for Annexin V and PI cells were interpreted as signs of early and late
phases of apoptosis respectively. Percent of apoptotic cells was obtained from the sum of early and
late apoptosis.
- Cell cycle analysis
After treatment RPMI-8226 cells were fixed in cold ethanol 70% for 1 h, then labeled with PI
(Sigma Aldrich, St. Louis, MO, USA)/RNase A (EuroClone S.p.a., Pero, MI, Italy) staining solution
for 30 min. Samples were acquired by NAVIOS flow cytometer and analyzed by Kaluza software
(Beckman Coulter). 10,000 events were acquired for each sample.
3.2.4. Statistical Analysis
Statistical significance was determined using a paired t test by GraphPad Prism. All error bars
represent the standard deviation (SD) of the average.
4. Conclusions
This study adds new knowledge about the antiproliferative activity and the possible role of
smenamides, chlorinated peptide/polyketide substances originally isolated from the Caribbean sponge
Smenospongiaaurea, as lead compounds in anticancer drug research. Our results have shown that
the configuration at C-16 slightly affects the activity, since the 16-epi-analogue 7 was still active
at nanomolar concentrations. Interestingly, it has been found that the truncated compound 8,
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containing the pyrrolinone terminus, was not active while compound 13, composed of the intact
C12–C27 portion, retained the activity, even though its EC50 value was 1000 times smaller compared
with the parent 16-epi-smenamide 7. In addition, compound 13 was able to block the cell cycle at
the G0/G1 phase. It is worth noting that smenothiazoles [17], biogenetically related but structurally
different from smenamides, possess the same activity. This study provides the basic knowledge needed
to design simplified and synthetically easily accessible analogues that could target MM cells.
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spectrum of compound 8 (CDCl3, 100 MHz), Figure S5: 1H NMR spectrum of compound 10 (CDCl3, 400 MHz),
Figure S6: 13C NMR spectrum of compound 10 (CDCl3, 100 MHz), Figure S7: 1H NMR spectrum of compound
11 (CDCl3, 400 MHz), Figure S8: 13C NMR spectrum of compound 11 (CDCl3, 100 MHz), Figure S9: 1H NMR
spectrum of compound 12 (CDCl3, 400 MHz), Figure S10: 13C NMR spectrum of compound 12 (CDCl3, 100 MHz),
Figure S11: 1H NMR spectrum of compound 22 (CDCl3, 400 MHz), Figure S12: 13C NMR spectrum of compound
22 (CDCl3, 100 MHz), Figure S13: 1H NMR spectrum of compound 14 (CDCl3, 400 MHz), Figure S14: 13C NMR
spectrum of compound 14 (CDCl3, 100 MHz), Figure S15: 1H NMR spectrum of compound 15 (CDCl3, 400 MHz),
Figure S16: 13C NMR spectrum of compound 15 (CDCl3, 100 MHz).
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Abstract: Encouraged by the promising antitumoral, antiangiogenic, and antilymphangiogenic
properties of toluquinol, a set of analogues of this natural product of marine origin was synthesized
to explore and evaluate the effects of structural modifications on their cytotoxic activity. We decided
to investigate the effects of the substitution of the methyl group by other groups, the introduction
of a second substituent, the relative position of the substituents, and the oxidation state. A set of
analogues of 2-substituted, 2,3-disubstituted, and 2,6-disubstituted derived from hydroquinone were
synthesized. The results revealed that the cytotoxic activity of this family of compounds could rely on
the hydroquinone/benzoquinone part of the molecule, whereas the substituents might modulate the
interaction of the molecule with their targets, changing either its activity or its selectivity. The methyl
group is relevant for the cytotoxicity of toluquinol, since its replacement by other groups resulted in a
significant loss of activity, and in general the introduction of a second substituent, preferentially in the
para position with respect to the methyl group, was well tolerated. These findings provide guidance
for the design of new toluquinol analogues with potentially better pharmacological properties.
Keywords: toluquinol; thymoquinone; marine hydroquinone; antitumor; natural compound analogues
1. Introduction
Hydroquinones and quinones are ubiquitous in nature, playing essential roles in oxidative
metabolism, including in electron transport chains and photosynthesis, and are produced as primary
or secondary metabolites by many organisms. A myriad of hydroquinones and quinones have been
isolated from marine sources, including microbes, algae, and marine invertebrates, such as ascidians,
sponges, cnidarians, and mollusks [1,2]. Some of them display a wide range of biological activities,
including cytotoxicity to cancer cells, probably related to their involvement in redox cycling and/or
Michael-1,4-addition reactions [3]. In many cases, the molecules responsible for the biological activities
detected in some marine macroorganisms derive from the complex secondary metabolite relationship
between the marine microorganisms and their hosts [4]. Marine fungi are a rich source of structurally
diverse compounds with a high pharmaceutical potential [5]. In the course of our ongoing research
program aimed at the search and characterization of new drug candidates of a marine origin, toluquinol
(2-methylhydroquinone, compound 1) was isolated from the culture broth of the marine fungus
Penicillium sp. HL-85-ALS5-R004 [6]. The antitumoral, antiangiogenic, and antilymphangiogenic
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activities of toluquinol [6,7] make this compound a good example of the potential of marine-derived
compounds in the treatment of cancer. Encouraged by these results, we decided to explore the
effects of structural modifications of toluquinol on its antitumoral properties in order to establish a
structure-activity relationship as a guide to identify and develop either more potent or more specific
analogues based on this natural product. These structural modifications included the substitution of
the methyl group of toluquinol by different substituents (derivatives 2–7), the introduction of a second
substituent (derivatives 8–11), the effect of the position of this second substituent (derivatives 12–13),
and, finally the oxidation state of the hydroquinone, such as the case of toluquinol (1) and toluquinone
(14), and thymoquinol (15) and thymoquinone (16) (Figure 1).
Figure 1. Structures of toluquinol (1) and programmed set of analogues 2–16.
2. Results and Discussion
2.1. Synthesis of Compounds 2–15
For the synthesis of analogues 2 and 3, we used the procedures described in the literature [8,9], according
to which the trifluoromethyl derivative 2 and the prenyl derivative 3 were prepared by direct treatment
of 1,4-hydroquinone (17) with 5-(trifluoromethyl)-dibenzothiophenium trifluoromethanesulfonate
(Umemoto’s reagent) and prenol, respectively, under acidic conditions (Scheme 1). Whereas the
preparation of 2 proceeded without further issues, the synthesis of 3 was more complicated due to
the low yield of the coveted prenyl derivative 3, obtained at a poor 15% yield, and the formation
of sub-products that could be identified as the disubstituted derivative 18 and the benzopyrane 19,
obtained in 3% and 2.7% yields, respectively. The three compounds obtained from this reaction could be
separated by flash column chromatography and sub-products 18 and 19 were considered for inclusion
in the biological studies (Scheme 1).
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Scheme 1. Synthesis of analogues 2 and 3.
For the synthesis of analogues 4–7, we considered a Suzuki coupling reaction as a straightforward
and powerful method [10] to install a vinyl-type substituent via direct coupling of the 2-bromo-1,4-
hydroquinone 20, prepared by bromination of 17 [11], with the corresponding pinacol boronic ester.
The optimization of this coupling reaction led us to establish Pd[PPh3]4 and K2CO3 as the most
suitable catalyst and base, respectively. On the other hand, the solvent, temperature, and reaction
time depended on the boronic ester employed. Thus, when the reactions were undertaken using the
solvent system 1,4-dioxane/H2O at 80 ◦C, which are the usual reaction conditions for Suzuki couplings
(Conditions A), we observed an important degree of degradation of the reaction mixture, detecting
only small amounts of the corresponding coupling products. In light of these discouraging results,
we found that reactions undertaken in THF instead of 1,4-dioxane produced better results in terms
of the resulting yields of the coupling products. With this new solvent system, products 4 and 5
were obtained in 92 and 32% yields, requiring a reaction time for completion of 48 h (Conditions B),
and products 6 and 7 were obtained in 79 and 56% yields, respectively, after 15 h for the completion of
the coupling reactions (Conditions C) (Scheme 2).
Scheme 2. Synthesis of analogues 4–7 via Suzuki couplings (* Conditions A: Pd[PPh3]4, solid K2CO3,
dioxane, H2O, 80 ◦C, 15 h; conditions B: Pd[PPh3]4, 2 M aq. K2CO3, THF, 80 ◦C, 48 h; conditions C:
Pd[PPh3]4, 2 M aq. K2CO3, THF, 80 ◦C, 15 h).
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For the cases of the 2,6-disubstituted 1,4-hydroquinone derivatives 8–11, we devised their syntheses
based again on a Suzuki coupling reaction as the most suitable method for rapid access to the targeted
molecules. To this end, the bromo derivative of toluquinol 22 was prepared according to the procedures
described in the literature [12] from o-cresol (21), and the corresponding Suzuki couplings were
achieved following the modified conditions previously established for the synthesis of derivatives
4–7. However, on this occasion we found that, for some cases (compounds 8 and 11), the solvent
system 1,4-dioxane/H2O provided better results compared with the use of THF as solvent, whereas for
compounds 9 and 10, THF was the solvent of choice for the Suzuki coupling (Scheme 3).
Scheme 3. Synthesis of disubstituted analogues 8–11 via Suzuki couplings (* Conditions A: Pd[PPh3]4,
solid K2CO3, dioxane, H2O, 80 ◦C, 15 h; conditions B: Pd[PPh3]4, 2 M aq. K2CO3, THF, 80 ◦C, 48 h).
As a continuation of the synthetic strategy based on a Suzuki reaction for the installation of
new substituents, the synthesis of the corresponding 2,5-disubstituted analogues requires the bromo
derivative 24 as the key starting material. The synthesis of this bromo derivative was achieved
according to the procedure described in the literature [13], starting from toluquinol (1) and proceeding
through bromo toluquinone 23, prepared in three steps from 1. The reduction of this bromo quinone by
the action of sodium thiosulfate provided the bromo precursor 24 at a 44% yield. The Suzuki coupling
reaction of 24 with the corresponding pinacol boronic ester afforded the desired 2,5-disubstituted 12 at
a reasonable 50% yield (Scheme 4).
 
Scheme 4. Synthesis of the p-disubstituted analogue 12 via a Suzuki reaction.
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Finally, compounds 2,3-dimethyl-1,4-hydroquinone (13) and toluquinone (14) were commercially
available and, in the case of thymoquinol (15), its preparation was achieved from commercial
thymoquinone (16) by reduction with sodium thiosulfate [14].
2.2. Antitumoral Properties of the Compounds
The synthesized 1,4-hydroquinone derivatives 2–12 and 15 and the commercially available
compounds 13, 14, and 16 were subjected to biological evaluation with regard to their effect on cell
growth against a panel of various human cancer cell lines. They included MDA-MB-231 (human breast
adenocarcinoma), HL-60 (human promyelocytic leukemia), U87-MG (human glioblastoma), HT-1080
(human fibrosarcoma), and HT-29 (human colorectal adenocarcinoma). In these studies, toluquinol (1)
was used as a control, for comparison purposes.
To elucidate the effect of the toluquinol analogs on the growth of tumors, logarithmically
proliferating cells were treated with serial dilutions of the compounds for 72 h. Then, the number
of viable cells was evaluated by the addition of MTT, and results were expressed as a percentage of
viable cells versus the untreated controls. Representative dose-response curves are presented in the
Supplementary Materials. In those figures each point represents the mean of quadruplicates, and SD
values were typically lower than 10% of the mean values and were omitted for clarity. The half-maximal
inhibitory concentration (IC50) value was calculated from each dose-response curve as the concentration
of compound yielding 50% of the control cells’ survival. Table 1, containing the IC50 values (means ±
SD of three independent experiments with quadruplicate samples each one), summarizes the results of
these biological evaluations.
Table 1. In vitro antitumor activities of toluquinol and analogues (IC50, μM) [a].
Structure Compound
Tumor Cell Line
MDA-MB-231 [b] HL-60 [c] U87-MG [d] HT-1080 [e] HT-29 [f]
 
 Toluquinol (1) 2.3 ± 0.8 1.7 ± 0.5 5.6 ± 1.5 1.4 ± 0.6 4.1 ± 0.4
 
 Compound 2 14.5 ± 1.8 13.9 ± 1.1 31.7 ± 5.6 41.2 ± 11.4 29.7 ± 7.1
 
 Compound 3 >100 50.0 ± 3.4 >100 >100 >100
 
 
Compound 18 >100 7.0 ± 1.2 >100 >100 >100
 
 
Compound 4 4.1 ± 1.1 3.0 ± 0.7 10.4 ± 3.6 3.7 ± 1.8 7.9 ± 0.1
 
 
Compound 5 3.9 ± 1.5 5.3 ± 2.0 29.7 ± 4.9 8.4 ± 1.4 15.5 ± 4.5
 
 
Compound 6 6.7 ± 1.8 6.3 ± 1.3 15.9 ± 4.4 6.1 ± 2.5 12.3 ± 2.5
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MDA-MB-231 [b] HL-60 [c] U87-MG [d] HT-1080 [e] HT-29 [f]
 
 Compound 7 4.2 ± 1.8 6.2 ± 1.7 8.8 ± 0.8 3.2 ± 1.9 9.8 ± 3.2
Compound 8 2.2 ± 0.3 3.1 ± 1.7 10.0 ± 2.1 3.3 ± 0.1 8.1 ± 0.6
 Compound 9 2.6 ± 1.3 3.6 ± 1.5 15.8 ± 2.3 5.5 ± 1.9 14.2 ± 4.3
 Compound 10 3.2 ± 1.2 4.7 ± 0.8 16.0 ± 1.3 5.0 ± 1.5 15.6 ± 1.2
 Compound 11 2.4 ± 0.3 3.1 ± 1.3 9.6 ± 1.3 2.9 ± 1.0 7.7 ± 1.6
 Compound 12 1.6 ± 0.5 2.9 ± 1.4 5.2 ± 1.2 1.1 ± 0.2 7.9 ± 2.0




1.0 ± 0.1 1.6 ± 0.5 10.2 ± 2.0 2.0 ± 1.1 8.2 ± 1.4
 Thymoquinone
(16)




3.4 ± 0.1 5.6 ± 1.9 8.8 ± 0.9 4.9 ± 1.7 9.5 ± 0.5
Compound 19 >100 82.0 ± 5.9 >100 >100 >100
[a] Half-maximal inhibitory concentration (IC50) values calculated from dose-response curves as the concentration
of compound yielding 50% of control cell survival. They are expressed as means + SD of three independent
experiments with quadruplicate samples each. [b] MDA-MB-231: Human breast adenocarcinoma. [c] HL-60: Human
promyelocytic leukemia. [d] U87-MG: Human glioblastoma. [e] HT-1080: Human fibrosarcoma. [f] HT-29: Human
colorectal adenocarcinoma.
2.2.1. Antitumor Properties with Structure-Activity Relationship (SAR) of 2-Substituted
Hydroquinones 2–7
Relevant conclusions can be derived from the results presented in Table 1. At first sight, they clearly
indicate a relevant role of the methyl group of toluquinol in the cytotoxic activity of this compound,
since compounds lacking this methyl group (2–7) exhibited significantly increased IC50 values for all
the tested cell lines. In this regard, substitution of the methyl group of toluquinol by a trifluoromethyl
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group (compound 2) caused a 6- to 30-fold increase in the IC50 values for all the cell types, approaching
the recently reported IC50 values for 1,4-hydroquinone in tumor cell lines [15]. These results are also in
agreement with our previous results showing that substitution of the methyl group of toluquinol with
either a carboxylic acid (as in gentisic acid) or a sulfonic acid (as in calcium dobesilate) provoked a
notable decrease in the growth inhibitory activity of the compounds, as deduced from the higher IC50
values obtained for them in endothelial and tumor cells [6].
Many bioactive quinones and hydroquinones derived from marine organisms have one or more
prenyl groups in their molecules [1–3]. Our results show that the substitution of a prenyl group
(compound 3) for a toluquinol methyl group practically abrogated the generic antitumor activity of the
compound that only exerted a moderate cytotoxic effect against the HL60 human leukemia cell line.
This activity is consistent with that already described in P388 murine leukemia cells for this natural
marine compound, first isolated from the tunicate Aplidium californicum [16,17]. Disubstituted prenyl
hydroquinones are also frequently found in marine organisms. Although a correlation between their
substitution pattern and the producing organism has been proposed, there is some evidence that the
pharmacophore responsible for the cytotoxicity of these naturally occurring secondary metabolites
could be the quinone, hydroquinone, or naphthoquinone nucleus [1,18]. As shown in Table 1,
the inclusion of a second isoprenyl group in the molecule (compound 18, obtained as a sub-product in
the synthesis of compound 3, as shown in Scheme 1) caused a 7-fold increase in the antileukemic activity
of the new compound, which remained noncytotoxic for the other tumor cell lines. This suggests that
the structural modification of the natural isoprenyl hydroquinone can effectively increase its activity,
maintaining the interesting putative specificity of this compound to leukemia cells.
It is worth noting that, when substituted vinyl groups were introduced instead of the methyl group,
their corresponding derivatives (compounds 4–7) retained some antitumor activities, with compound 7
being the most active in this series and compound 6 the least active, as an indication of the detrimental
effect of the steric hindrance when either a bulky substituent is present, such as the tert-butyl group
(compound 6), or an increased number of methyl groups are included in the aliphatic chain (compound
5). In any case, all of them showed significantly lower cytotoxicity than toluquinol, indicating that
these structural changes are not well tolerated with regard to their antiproliferative properties and
again suggesting the important role of the methyl group for the cytotoxicity of this compound.
2.2.2. Antitumor Properties with SAR of 2,6-Disubstituted Hydroquinones 8–11
Our results show that good tolerance was displayed after the inclusion of a second substituent in
the biological properties of the resulting disubstituted 1,4-hydroquinones (compounds 8–13). All those
toluquinol derivatives presented antitumoral activities in the same low μM range as the original
molecule. The biological evaluation of the subset comprised by the 2,6-disubstituted-1,4-hydroquinones
(compounds 8–11) revealed a number of intriguing findings. Although the resulting cytotoxicity values
showed that the introduction of a second substituent in the toluquinol molecule was well tolerated,
a significant decrease in the cytotoxic activity was only observed as the steric volume of the substituent
increased (compounds 9 and 10). This is in agreement with the abovementioned results obtained with
the monosubstituted vinyl derivatives. We analyzed the effect of the position of the second substituent
in the 1,4-hydroquinone.
2.2.3. Antitumor Properties with SAR of 2,3-Disubstituted Hydroquinone 13 and 2,5-Disubstituted
Hydroquinones 12 and 15
A comparison of the IC50 values obtained for 2,3-dimethyl-1,4-hydroquinone (13), the 2,5-
disubstituted derivatives (compounds 12 and 15), and the 2, 6-disubstituted derivatives (compounds 8
and 11) indicates that, although no major differences were observed when non-bulky groups were
included in any of those positions, in general, 2,5-disubstituted compounds seemed to exhibit higher
cytotoxic activity. In this regard, compound 12 proved to be one of the most potent analogues,
exhibiting cytotoxic activity higher than that of the 2,6-disubstituted counterpart (compound 11).
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Special mention should be made of thymoquinol (compound 15), which in our assays demonstrated
very similar activity to that of toluquinol. Several thymoquinol glycosides have been isolated from plants
used in folk medicine to treat infections [19,20]. The main reason that we included thymoquinol in this
study is that it is the reduced form of thymoquinone (compound 16), the major active ingredient of Nigella
sativa, known as black seed or black cumin, which has been used as a traditional remedy to treat a variety
of diseases for more than 2000 years [21]. Known as “the miracle herb of the century,” its impressive
biological activities include antibacterial, antifungal, antiviral, antihelminthic, anti-inflammatory,
immunomodulatory, and anticancer, as well as curative properties against cardiovascular diseases,
diabetes, asthma, and oral or kidney diseases [22]. Thymoquinone, also found in many other
medicinal plants, presents a wide range of biological activities of pharmacological value, including an
interesting antitumor activity derived from its antiproliferative, anti-oxidant, cytotoxic, apoptogenic,
and antimetastatic effects [21,23]. Thymoquinone has been recently identified as a potent anticancer
compound capable of inducing apoptotic cell death by upregulating the expression of apoptotic
genes p53 and caspase 9 and downregulating the expression of anti-apoptotic genes such as Bcl2 [24].
The antiangiogenic activity of thymoquinone may also contribute to enhancing the pharmacological
potential of this compound in oncology [25,26].
2.2.4. Antitumor Properties with SAR of Benzoquinones 14, 16, and Benzopyrane 19
To shed light on the effect of the oxidation state of the toluquinol derivatives on their biological
properties, we compared the activities of toluquinol (1) and thymoquinol (15) with those of their
respective quinones, toluquinone (14) and thymoquinone (16). Our results show that the reduced
compounds have better activities than those of their corresponding quinones, although these differences
were not very significant. Although this contradicts the previous statement that the keto form of
thymoquinone could be responsible for the pharmacological properties of the compound [27], it is
in agreement with recent reported data showing that the reduction of thymoquinone, toluquinone,
and other quinones to their respective hydroquinones increased their cytotoxic potency and selectivity
on four cell lines of ovarian cancer [28]. In any case, it cannot be ruled out that both species might
play a role in the toxicity of the compounds, which could generate a redox cycle in the tumor cell,
responsible for the ROS production leading to cell death, in a similar mechanism to that proposed to
explain the cytotoxic activities of marine terpenoquinones [3]. Supporting this hypothesis, the cytotoxic
activity of thymoquinone has been related to the induction of oxidative damage in cancer cells,
resulting in apoptosis [29]. Thymoquinone has a dual effect, with antioxidant properties at low
concentration, but pro-oxidant ones at higher concentrations, derived from ROS generation [30].
Acting as a redox-cycler, the quinone can be metabolized by enzymatic or non-enzymatic reactions
to hydroquinone or semiquinone, generating superoxide anion radicals [31]. The relevance of the
cyclic interconversion of quinones and hydroquinones in the activity of these compounds might also
explain the negligible cytotoxic activity of compound 19 (obtained as a subproduct in the synthesis of
compound 3, as shown in Scheme 1), in which this interconversion between the two forms is prevented.
3. Experimental Section
3.1. General Techniques
All reactions were carried out under an argon atmosphere with dry, freshly distilled solvents
under anhydrous conditions, unless using aqueous reagents or otherwise noted. All solvents used in
reactions were dried and distilled using standard procedures. Tetrahydrofuran (THF) was distilled
from sodium benzophenone, and methylene chloride (CH2Cl2) from calcium hydride. Yields refer
to chromatographically and spectroscopically (1H NMR) homogeneous materials, unless otherwise
stated. All solutions used in workup procedures were saturated unless otherwise noted. All reagents
were purchased at highest commercial quality and used without further purification unless otherwise
stated. All reactions were monitored by thin-layer chromatography (TLC) using 0.25-mm silica
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gel plates (60F-254), using UV light (254 nm) as the visualizing agent and acidic ceric ammonium
molybdate/phosphomolybdic acid or potassium permanganate solutions and heat as the developing
agents. Flash column chromatography (FCC) was performed using silica gel (60 Å, particle size
230–400 mesh) under air pressure. All solvents used for chromatographic purifications were distilled
prior to use. 1H and 13C NMR spectra were recorded on a Bruker DPX-400 MHz instrument (Fällanden,
Switzerland) and calibrated using residual undeuterated solvent as an internal reference. Chemical
shifts are reported in ppm, with the resonance resulting from incomplete deuteration of the solvent as
the internal standard (13CDCl3: 7.26 ppm, s and 77.0 ppm, t; 13CD3OD: 4.87 ppm, s, 3.31 ppm, quin
and 49.1 ppm, sep; 13C2D6OS: 2.49 ppm, quin and 39.52 ppm, sep). Data are reported as follows:
chemical shift δ/ppm (multiplicity, coupling constants J (Hz) and integration (1H only)). The following
abbreviations were used to explain the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet;
quin = quintet; b = broad; m = multiplet or combination thereof. 13C signals are singles, unless
otherwise stated. High-resolution mass spectrometry (HRMS) was performed on a Thermo Fisher
Scientific H-ESI and APCI mass spectrometer (Waltham (MA), USA) in positive mode and using an ion
trap (Orbitrap) as the mass analyzer type. HRMS signals are reported to four decimal places and are
within ± 5 ppm of theoretical values. Melting points were collected using a Gallenkamp melting point
apparatus (London, UK), using a gradient of 0.5 ◦C per min.
3.2. Biological Material and Methods
All the cancer cell lines used in this study were obtained from the American Type Culture Collection
(ATCC, Manassas, Virginia, USA). Human fibrosarcoma HT-1080 and human glioblastoma U87-MG
cells were maintained in Eagle’s Minimum Essential Medium (EMEM), supplemented with 10% FBS.
Human colon adenocarcinoma HT-29 cells were maintained in DMEM containing glucose (4.5 g/L)
supplemented with 10% FBS. Human breast cancer carcinoma MDA-MB-231 cells were maintained
in a RPMI1640 medium supplemented with 10% FBS. Acute promyelocytic leukemia HL-60 cells
were maintained in a RPMI1640 medium supplemented with 20% FBS. All culture media contained
glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 μg/mL), and amphotericin (1.25 μg/mL),
and all cell lines were grown at 37 ◦C in a humidified 5% CO2 atmosphere.
3.3. Synthesis
3.3.1. 2-(Trifluoromethyl)benzene-1,4-diol (2)
Hydroquinone 17 (50 mg, 0.45 mmol, 1.0 equiv.), 5-(Trifluoromethyl) dibenzothiophenium
trifluoromethanesulfonate (362 mg, 0.9 mmol, 2.0 equiv.) and pyridine (0.04 mL, 0.45 mmol, 1.0 equiv.)
were dissolved in DMF (2 mL) and the reaction mixture was stirred for 72 h at 25 ◦C. After this time,
the reaction mixture was diluted with water and the aqueous phase was extracted with Et2O twice.
The combined organic phases were washed sequentially with a saturated aqueous CuSO4 solution
and brine, dried over MgSO4, filtered, and the solvent removed under reduced pressure. The crude
mixture was purified by flash column chromatography (silica gel, 5% EtOAc in hexanes→ 20% EtOAc
in hexanes) to obtain 2 (39 mg, 49%) as a yellow oil [8]: Rf = 0.23 (silica gel, 30% EtOAc in hexanes);
1H NMR (400 MHz, CD3OD) δ 6.88 (d, J = 2.9 Hz, 1 H), 6.81 (ddd, J = 8.8, 2.9, 0.6 Hz, 1 H), 6.76 (dd,
J = 4.9, 4.4 Hz, 1 H); 19F NMR (400 MHz, CD3OD) δ −63.78; HRMS (H-ESI) m/z: [M +H]+ calculated
for C7H6F3O2 179.0320; found 179.0318.
3.3.2. 2-(3-Methylbut-2-en-1-yl)benzene-1,4-diol (3), 2,5-bis-(3-Methylbut-2-en-1-yl)benzene-1,4-diol
(18) and 2,2-dimethyl-6-chromanol (19): Reaction of 17 with Prenol
Hydroquinone 17 (300 mg, 2.72 mmol, 1.0 equiv.) and 3-methyl-2-buten-1-ol (0.55 mL, 5.45 mmol,
2.0 equiv.) were dissolved in a 1:1 mixture of Et2O:CH2Cl2 (10 mL). Then, BF3•OEt2 (0.1 mL, 0.54 mmol,
0.2 equiv.) was added at 0 ◦C and the reaction mixture was stirred for 48 h at 25 ◦C. After this time,
cold water was added and the aqueous phase was extracted with EtOAc. The organic phase was
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washed with brine, dried over MgSO4, filtered, and the solvent removed under reduced pressure.
The residue was purified by flash column chromatography (silica gel, 15% EtOAc in hexanes→ 25%
EtOAc in hexanes) to obtain 3 (72 mg, 15%), together with side products 18 (21 mg, 3%) and 19 (13 mg,
2.7%) [9]. [3]: white solid, Rf = 0.30 (silica gel, 50% EtOAc in hexanes); m.p. = 101–103 ◦C; 1H NMR
(400 MHz, CDCl3) δ 6.68 (d, J = 8.3 Hz, 1 H), 6.63–6.54 (m, 2 H), 5.29 (t, J = 7.3 Hz, 1 H), 3.29 (d,
J = 7.0 Hz, 2 H), 1.77 (s, 3 H), 1.76 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 149.7, 147.5, 131.6, 128.8, 122.6,
115.7, 115.1, 112.4, 27.8, 24.5, 16.4; HRMS (H-ESI) m/z: [M + H]+ calculated for C11H15O2 179.1072;
found 179.1064. [18]: white solid; 1H NMR (400 MHz, CDCl3) δ 6.70–6.45 (m, 4 H), 5.29 (t, J = 7.9 Hz, 1
H), 3.31–3.24 (m, 1 H), 2.71 (dd, J = 13.0, 6.4 Hz, 1 H), 1.82–1.69 (m, 12 H); 13C NMR (100 MHz, CDCl3)
δ 147.2, 131.4, 125.8, 122.9, 115.6, 27.5, 24.6, 16.5; HRMS (H-ESI) m/z: [M + H]+ calculated for C16H23O2
247.1698; found 247.1708. [19]: red oil; 1H NMR (400 MHz, CDCl3) δ 6.65 (d, J = 8.6 Hz, 1 H), 6.62–6.53
(m, 2 H), 2.72 (t, J = 6.8 Hz, 2 H), 1.77 (t, J = 6.8 Hz, 2 H), 1.31 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ
149.8, 146.9, 121.3, 117.1, 114.8, 113.9, 73.2, 32.5, 25.6, 22.2; HRMS (H-ESI) m/z: [M + H]+ calculated for
C11H15O2 179.1072; found 179.1071.
3.3.3. Synthesis of Compounds 20 and 22
2-Bromobenzene-1,4-diol (20). Bromine (0.56 mL, 10.90 mmol, 1.2 equiv.) was added dropwise to
a solution of 1,4-hydroquinone (17) (1.0 g, 9.08 mmol, 1.0 equiv.) in tBuOMe (20 mL) at -15 ◦C and
the reaction mixture was stirred for 2 h. After this time, the reaction mixture was quenched by the
addition of 10% aqueous sodium thiosulfate solution and extracted with Et2O twice. The combined
organic phases were washed with brine, dried over MgSO4, filtered, and the solvent removed under
reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% EtOAc in
hexanes) to obtain 20 (1.3 g, 78%) as a colorless solid [11]: Rf = 0.35 (silica gel, 30% EtOAc in hexanes);
1H NMR (400 MHz, CD3OD) δ 6.89 (d, J = 2.8 Hz, 1 H), 6.72 (d, J = 8.7 Hz, 1 H), 6.60 (dd, J = 8.7, 2.9 Hz,
1 H); 13C NMR (100 MHz, CD3OD) δ 152.0, 148.2, 120.3, 117.7, 116.4, 110.7.
2-Bromo-6-methylbenzene-1,4-diol (22). Bromine (2.8 mL, 55.48 mmol, 2.0 equiv.) was added
dropwise over 15 min to a solution of o-cresol (21) (2.9 mL, 27.74 mmol, 1.0 equiv.) in AcOH (30 mL) at
0 ◦C and the reaction mixture was stirred at 25 ◦C for 1 h. After this time, cold water was added and the
resulting white precipitate was filtered and washed with cold water to obtain 2,4-dibromo-6-methyl
phenol (S1) (5.8 g, 80%) as a colorless solid that did not require further purification [12]: Rf = 0.60
(20% EtOAc in hexanes); m.p. = 56–57 ◦C; 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 2.3, 0.6 Hz,
1 H), 7.21–7.19 (m, 1 H), 2.27 (t, J = 0.7 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 149.8, 133.1, 131.3,
127.7, 112.0, 110.4, 16.5. A solution of CrO3 (1.5 g, 15.31 mmol, 1.1 equiv.) in H2O (4 mL) was added
to a solution of 2,4-dibromo-6-methyl phenol (3.7 g, 13.91 mmol, 1.0 equiv.) in Ac2O (7 mL)/CH3CN
(3.5 mL) and the resulting mixture was heated at 60 ◦C for 1.5 h. After this time, the reaction mixture
was cooled to 25 ◦C and diluted with water. Then, the aqueous phase was extracted with CH2Cl2 three
times, and the combined organic phases were washed with brine, dried over MgSO4, filtered, and the
solvent removed under reduced pressure to obtain 2-bromo-6-methyl-p-benzoquinone (S2) (2.3 g, 85%)
as an orange solid that did not require further purification: Rf = 0.45 (silica gel, 20% EtOAc in hexanes);
m.p. = 92–93 ◦C; 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 2.4 Hz, 1 H), 6.65 (dq, J = 2.4, 1.6 Hz, 1 H),
2.14 (d, J = 1.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 184.8, 179.9, 145.7, 138.1, 137.3, 133.4, 16.8.
The resulting p-benzoquinone derivative (1.0 g, 4.97 mmol, 1.0 equiv.) was dissolved in a mixture
of EtOH (10 mL)/H2O (2 mL) and the mixture was heated at 50 ◦C. Then, Na2S2O4 (1 g, 5.97 mmol,
1.2 equiv.) was added and the reaction mixture was heated at 50 ◦C for 1.5 h. After this time, EtOH was
removed under reduced pressure, the crude mixture was diluted with water, and the aqueous phase
was extracted with EtOAc. The organic phase was washed with brine, dried over MgSO4, filtered,
and the solvent removed under reduced pressure to obtain a solid that was washed with cold CH2Cl2
to obtain 22 (585 mg, 57%) as a pale yellow solid that did not require further purification: Rf = 0.25
(silica gel, 20% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ 6.82 (dd, J = 2.9, 0.5 Hz, 1 H), 6.60 (dd,
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J = 2.9, 0.7 Hz, 1 H), 2.25 (t, J = 0.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.8, 144.8, 126.5, 117.7,
115.7, 109.6, 16.9; HRMS (H-ESI) m/z: [M + H]+ calculated for C7H8BrO2 202.9708; found 202.9726.
3.3.4. General Procedures for Suzuki Couplings: Synthesis of the 2-Substituted and 2,6-Disubstituted
Hydroquinones 4–11
Condition A: To a solution of boronic acid pinacol ester derivative (2.0 equiv.), bromo derivative
(1.0 equiv.), Pd[PPh3]4 (0.2 equiv.), and K2CO3 (3.6 equiv.) in 1,4-dioxane was added a drop of water
and the reaction mixture was heated at 80 ◦C for 15 h. After this time, a saturated aqueous NH4Cl
solution was added and the aqueous phase was extracted with EtOAc three times. The combined
organic phases were washed with brine, dried over MgSO4, filtered, and the solvent removed under
reduced pressure. The residue was purified by flash column chromatography (silica gel) to obtain
the corresponding product. Condition B: Boronic acid pinacol ester derivative (1.1 equiv.), bromo
derivative (1.0 equiv.), Pd[PPh3]4 (0.05 equiv.), and K2CO3 (2.0 M aqueous solution, 6.6 equiv.) were
dissolved in THF and the reaction mixture was heated at 80 ◦C for 48 h. After this time, a saturated
aqueous NH4Cl solution was added and the aqueous phase was extracted with EtOAc three times.
The combined organic phases were washed with brine, dried over MgSO4, filtered, and the solvent
removed under reduced pressure. The residue was purified by flash column chromatography (silica gel)
to obtain the corresponding product. Conditions C: Boronic acid pinacol ester derivative (1.1 equiv.),
bromo derivative (1.0 equiv.), Pd[PPh3]4 (0.05 equiv.), and K2CO3 (2.0 M aqueous solution, 6.6 equiv.)
were dissolved in THF and the reaction mixture was heated at 80 ◦C for 15 h. After this time, a saturated
aqueous NH4Cl solution was added and the aqueous phase was extracted with EtOAc three times.
The combined organic phases were washed with brine, dried over MgSO4, filtered, and the solvent
removed under reduced pressure. The residue was purified by flash column chromatography (silica
gel) to obtain the corresponding product.
2-(2-Methylprop-1-en-1-yl)benzene-1,4-diol (4). Compound 4 was prepared from bromohydroquinone
20 (50 mg, 0.29 mmol, 1.0 equiv.) by treatment with 2-methyl-1-propenylboronic acid pinacol ester
(0.06 mL, 0.29 mmol, 1.1 equiv.), Pd[PPh3]4 (15 mg, 0.01 mmol, 0.05 equiv.), and K2CO3 (0.9 mL, 2.0 M
aqueous solution, 1.72 mmol, 6.6 equiv.) in THF (2 mL), according to the general procedure for Suzuki
couplings (conditions B), as described above. Purification by flash column chromatography (silica gel,
20% EtOAc in hexanes) afforded 4 (39 mg, 92%) as a pale yellow oil: Rf = 0.48 (silica gel, 50% EtOAc in
hexanes); 1H NMR (400 MHz, MeOD) δ 6.60 (d, J = 8.6 Hz, 1 H), 6.56 (d, J = 3.0 Hz, 1 H), 6.49 (ddd,
J = 8.6, 3.0, 0.4 Hz, 1 H), 6.21–6.14 (m, 1 H), 1.88 (d, J = 1.4 Hz, 3 H), 1.76 (d, J = 1.1 Hz, 3 H); 13C NMR
(100 MHz, MeOD) δ 150.7, 148.7, 136.3, 127.6, 121.9, 117.7, 116.8, 114.9, 26.5, 19.6; HRMS (H-ESI) m/z:
[M + H]+ calculated for C10H13O2 165.0916; found 165.0938.
2-(3-Methylbut-2-en-2-yl)benzene-1,4-diol (5). Compound 5 was prepared from bromohydroquinone
20 (50 mg, 0.26 mmol, 1.0 equiv.) by treatment with 3-Methyl-2-buten-2-ylboronic acid pinacol ester
(0.06 mL, 0.29 mmol, 1.1 equiv.), Pd[PPh3]4 (15 mg, 0.01 mmol, 0.05 equiv.), and K2CO3 (0.9 mL, 2.0 M
aqueous solution, 1.72 mmol, 6.6 equiv.) in THF (2 mL), according to the general procedure for Suzuki
coupling (conditions B). Purification by flash column chromatography (silica gel, 5% EtOAc in hexanes
→ 15% EtOAc in hexanes) gave 5 (15 mg, 32%) as a pale yellow oil: Rf = 0.40 (silica gel, 50% EtOAc
in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.61 (d, J = 8.7 Hz, 1 H), 6.50 (dd, J = 8.6, 3.0 Hz, 1 H),
6.37 (d, J = 2.9 Hz, 1 H), 1.86 (dd, J = 1.4, 1.0 Hz, 3 H), 1.79 (d, J = 0.5 Hz, 3 H), 1.50 (dd, J = 2.7, 1.3 Hz,
3 H); 13C NMR (100 MHz, CD3OD) δ 149.7, 146.1, 132.4, 128.1, 126.2, 115.7, 115.6, 113.4, 20.7, 18.7, 18.6;
HRMS (H-ESI) m/z: [M + H]+ calculated for C11H15O2 179.1072; found 179.1065.
(E)-2-(3,3-Dimethylbut-1-en-1-yl)benzene-1,4-diol (6). Compound 6 was prepared from
bromohydroquinone 12 (100 mg, 0.53 mmol, 1.0 equiv.) by treatment with 2-t-Butyl-E-vinylboronic acid
pinacol ester (0.14 mL, 0.58 mmol, 1.1 equiv.), Pd[PPh3]4 (31 mg, 0.03 mmol, 0.05 equiv.), and K2CO3
(1.75 mL, 2.0 M aqueous solution, 3.49 mmol, 6.6 equiv.) in THF (4 mL), according to the general
procedure for Suzuki coupling (conditions C). Purification by flash column chromatography (silica gel,
15% EtOAc in hexanes) afforded 6 (80 mg, 79%) as a pale yellow oil: Rf = 0.33 (silica gel, 50% EtOAc
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in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.81 (t, J = 3.0 Hz, 1 H), 6.58 (dd, J = 12.4, 3.9 Hz, 2 H),
6.47 (dd, J = 8.6, 2.9 Hz, 1 H), 6.14 (d, J = 16.3 Hz, 1 H), 1.11 (s, 9 H); 13C NMR (100 MHz, CD3OD) δ
151.2, 148.6, 141.9, 127.2, 120.8, 117.3, 115.5, 112.9, 34.3, 30.1; HRMS (H-ESI) m/z: [M +H]+ calculated
for C12H17O2 193.1229; found 193.1238.
(E)-2-(3-Methoxyprop-1-en-1-yl) benzene-1,4-diol (7). Compound 7 was prepared from
bromohydroquinone 20 (50 mg, 0.26 mmol, 1.0 equiv.) by treatment with trans-3- Methoxy-1-
propenylboronic acid pinacol ester (0.06 mL, 0.29 mmol, 1.1 equiv.), Pd[PPh3]4 (15 mg, 0.01 mmol,
0.05 equiv.), and K2CO3 (0.90 mL, 2.0 M aqueous solution, 1.72 mmol, 6.6 equiv.) in THF (2 mL),
according to the general procedure for Suzuki coupling (conditions C). Purification by flash column
chromatography (silica gel, 25% EtOAc in hexanes) gave 7 (26 mg, 56%) as a pale yellow oil: Rf = 0.30
(silica gel, 50% EtOAc in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.88–6.82 (m, 2 H), 6.62 (d, J = 8.5 Hz,
1 H), 6.54 (dd, J = 8.6, 2.9 Hz, 1 H), 6.22 (dt, J = 16.0, 6.3 Hz, 1 H), 4.07 (dd, J = 6.3, 1.4 Hz, 2 H), 3.36
(s, 3 H); 13C NMR (100 MHz, CD3OD) δ 151.2, 149.2, 129.4, 126.1, 125.6, 117.5, 116.7, 113.6, 74.7, 57.9;
HRMS (H-ESI) m/z: [M + H]+ calculated for C10H13O3 181.0865; found 181.0884.
2-Methyl-6-(2-methylprop-1-en-1-yl)benzene-1,4-diol (8). Compound 8 was prepared from bromo
derivative 22 (58 mg, 0.29 mmol, 1.0 equiv.) by treatment with 2-methyl-1-propenylboronic acid
pinacol ester (0.12 mL, 0.58 mmol, 2.0 equiv.), Pd[PPh3]4 (66 mg, 0.06 mmol, 0.2 equiv.), and K2CO3
(142 mg, 1.03 mmol, 3.6 equiv.) in 1,4-dioxane (1.5 mL), according to the general procedure for Suzuki
coupling (conditions A). Purification by flash column chromatography (silica gel, 20% EtOAc in
hexanes) afforded 8 (29 mg, 58%) as a yellow oil: Rf = 0.50 (silica gel, 30% EtOAc in hexanes); 1H NMR
(400 MHz, CD3OD) δ 6.44 (dd, J = 3.0, 0.5 Hz, 1 H), 6.38–6.36 (m, 1 H), 6.17 (s, 1 H), 2.14 (s, 3 H), 1.89 (d,
J = 1.2 Hz, 3 H), 1.73 (d, J = 1.0 Hz, 3 H); 13C NMR (100 MHz, CD3OD) δ 149.1, 145.0, 135.9, 126.4, 125.7,
120.5, 115.3, 113.6, 24.9, 18.2, 15.4; HRMS (H-ESI) m/z: [M + H]+ calculated for C11H15O2 179.1072;
found 179.1081.
2-Methyl-6-(3-methylbut-2-en-2-yl)benzene-1,4-diol (9). Compound 9 was prepared from bromo
derivative 22 (50 mg, 0.24 mmol, 1.0 equiv.) by treatment with 3-methyl-2-buten-2-ylboronic acid
pinacol ester (0.06 mL, 0.26 mmol, 1.1 equiv.), Pd[PPh3]4 (14 mg, 0.01 mmol, 0.05 equiv.) and K2CO3
(0.8 mL, 2.0 M aqueous solution, 1.72 mmol, 6.6 equiv.) in THF (2 mL), according to the general
procedure for Suzuki coupling (conditions B). Purification by flash column chromatography (silica gel,
10% EtOAc in hexanes) gave 9 (16 mg, 35%) as a pale yellow oil: Rf = 0.60 (silica gel, 30% EtOAc in
hexanes); 1H NMR (400 MHz, CDCl3) δ 6.52 (dd, J = 3.0, 0.7 Hz, 1 H), 6.33 (dd, J = 3.1, 0.5 Hz, 1 H),
2.21 (t, J = 0.6 Hz, 3 H), 1.89 (dd, J = 1.5, 1.0 Hz, 3 H), 1.85 (d, J = 0.7 Hz, 3 H), 1.55 (q, J = 1.4 Hz, 3 H);
13C NMR (100 MHz, CDCl3) δ 148.4, 143.8, 132.1, 130.7, 124.7, 124.6, 116.1, 112.2, 21.7, 20.1, 20.0, 16.3;
HRMS (H-ESI) m/z: [M + H]+ calculated for C12H17O2 193.1229; found 193.1234.
(E)-2-(3,3-Dimethylbut-1-en-1-yl)-6-methylbenzene-1,4-diol (10). Compound 10 was prepared
from bromo derivative 22 (100 mg, 0.53 mmol, 1.0 equiv.), by treatment with 2-t-Butyl-E-vinylboronic
acid pinacol ester (0.14 mL, 0.58 mmol, 1.1 equiv.), Pd[PPh3]4 (31 mg, 0.03 mmol, 0.05 equiv.), and K2CO3
(1.75 mL, 2.0 M aqueous solution, 3.50 mmol, 6.6 equiv.) in THF (4 mL), according to the general
procedure for Suzuki coupling (conditions B). Purification by flash column chromatography (silica
gel, 15% EtOAc in hexanes) gave 10 (40 mg, 79%) as a pale yellow oil: Rf = 0.40 (silica gel, 30% EtOAc
in hexanes); 1H NMR (400 MHz, CDCl3) δ 6.67–6.65 (m, 1 H), 6.52 (dd, J = 3.0, 0.6 Hz, 1 H), 6.43 (d,
J = 16.2 Hz, 1 H), 6.16 (d, J = 16.2 Hz, 1 H), 2.20 (t, J = 0.6 Hz, 3 H), 1.12 (s, 9 H); 13C NMR (100 MHz,
CDCl3) δ 148.8, 144.9, 144.9, 125.6, 125.2, 118.8, 116.3, 110.9, 33.7, 29.5, 16.1; HRMS (H-ESI) m/z: [M +
H]+ calculated for C13H19O2 207.1385; found 207.1367.
(E)-2-(3-Methoxyprop-1-en-1-yl)-6-methylbenzene-1,4-diol (11). Compound 10 was prepared
from bromo derivative 22 (50 mg, 0.25 mmol, 1.0 equiv.) by treatment with trans-3-methoxy-1-
propenylboronic acid pinacol ester (0.10 mL, 0.49 mmol, 2.0 equiv.), Pd[PPh3]4 (57 mg, 0.05 mmol,
0.2 equiv.), and K2CO3 (122 mg, 0.89 mmol, 3.6 equiv.) in 1,4-dioxane (1.5 mL), according to the general
procedure for Suzuki coupling (conditions A). Purification by flash column chromatography (silica gel,
25% EtOAc in hexanes) afforded 11 (24 mg, 51%) as a pale yellow oil: Rf = 0.30 (silica gel, 50% EtOAc
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in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.97–6.90 (m, 1 H), 6.71 (d, J = 3.0 Hz, 1 H), 6.50 (dd, J = 3.0,
0.7 Hz, 1 H), 6.16 (dt, J = 15.9, 6.3 Hz, 1 H), 4.08 (dd, J = 6.3, 1.4 Hz, 2 H), 3.37 (s, 3 H), 2.15 (s, 3 H); 13C
NMR (100 MHz, CD3OD) δ 150.1, 145.2, 128.2, 127.1, 125.6, 124.9, 116.9, 109.3, 73.2, 56.6, 15.5; HRMS
(H-ESI) m/z: [M + H]+ calculated for C11H15O3 195.1021; found 195.1023.
3.3.5. Synthesis of Compounds 23, 24, and 2,5-Disubstituted Hydroquinones 12 and 15
2-Bromo-5-methylcyclohexa-2,5-diene-1,4-dione (23). To a solution of toluquinol (1) (2.5 g, 20.14 mmol,
1.0 equiv.) in acetone (15 mL) was added K2CO3 (14 g, 100.70 mmol, 5.0 equiv.) and Me2SO4 (5.7 mL,
60.41 mmol, 3.0 equiv.) and the reaction mixture was stirred for 3 h. After this time, the reaction
mixture was diluted with water and the aqueous phase was extracted with Et2O. The organic phase
was washed with brine, dried over MgSO4, filtered, and the solvent removed under reduced pressure
to obtain the corresponding dimethoxy derivative (~20 mmol), which was used in the next steps
without purification. To a solution of the dimethoxy derivative obtained above (~20 mmol) and NaOAc
(3.3 g, 40.28 mmol, 2.0 equiv.) in AcOH (20 mL) was added bromine (1.2 mL, 2.15 mmol, 1.1 equiv.)
over 25 min and, after the addition, the reaction mixture was stirred for 1 h. Then, the reaction mixture
was quenched by a slow addition of a saturated aqueous NaHCO3 solution at 0 ◦C. The aqueous
phase was then extracted with EtOAc and the organic phase washed with brine, dried over MgSO4,
filtered, and the solvent removed under reduced pressure to obtain the corresponding bromo derivative
(~20 mmol), which was used in the next step without purification. The bromo derivative obtained
above (~20 mmol) was dissolved in CH3CN (35 mL). Then, CAN (28 g, 50.34 mmol, 2.5 equiv.) and H2O
(20 mL) were added and the reaction mixture was stirred for 1 h at 25 ◦C. After this time, the reaction
mixture was diluted with water and the aqueous phase was extracted with Et2O twice. The combined
organic phases were washed with brine, dried over MgSO4, filtered, and the solvent removed under
reduced pressure. The residue was purified by flash column chromatography (silica gel, 1% EtOAc in
hexanes) to obtain compound 23 (1.5 g, 37% over 3 steps) as an orange solid [13]: Rf = 0.45 (silica gel,
20% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ 7.29 (s, 1 H), 7.26 (s, 2 H), 2.08 (d, J = 1.6 Hz,
3 H); 13C NMR (100 MHz, CDCl3) δ 185.1, 179.5, 146.5, 138.1, 137.5, 132.6, 15.7.
2-Bromo-5-methylbenzene-1,4-diol (24). Quinone 23 (264 mg, 1.31 mmol, 1.0 equiv.) was dissolved
in a mixture of EtOH/H2O (3/0.5 mL) and heated to 50 ◦C. Then, Na2S2O4 (264 mg, 1.57 mmol, 1.2 equiv.)
was added and the reaction mixture was stirred at 50 ◦C for 1.5 h. After this time, the reaction mixture
was cooled to 25 ◦C and the EtOH was removed under reduced pressure. The resulting residue was
diluted with water and extracted with EtOAc twice and the combined organic phases washed with
brine, dried over MgSO4, filtered, and the solvent removed under reduced pressure to obtain a yellow
solid. This solid was washed with cold CH2Cl2 to afford pure compound 24 (118 mg, 44%) as a pale
yellow solid that did not require further purification: Rf = 0.52 (silica gel, 50% EtOAc in hexanes);
1H NMR (400 MHz, CD3OD) δ 6.83 (s, 1 H), 6.64 (d, J = 0.7 Hz, 1 H), 2.08 (s, 3 H); 13C NMR (100 MHz,
CD3OD) δ 148.7, 146.4, 124.9, 117.9, 117.8, 105.6, 14.6; HRMS (H-ESI) m/z: [M + H]+ calculated for
C7H8BrO2 202.9708; found 202.9715.
(E)-2-(3-Methoxyprop-1-en-1-yl)-5-methylbenzene-1,4-diol (12). Compound 12 was prepared
from bromo derivative 24 (113 mg, 0.56 mmol, 1.0 equiv.) by treatment with trans-3-Methoxy-1-
propenylboronic acid pinacol ester (0.24 mL, 1.11 mmol, 2.0 equiv.), Pd[PPh3]4 (129 mg, 0.11 mmol,
0.2 equiv.), and K2CO3 (277 mg, 2.00 mmol, 3.6 equiv.) in 1,4-dioxane (3 mL), according to the general
procedure for Suzuki coupling (conditions A). Purification by flash column chromatography (silica gel,
5% EtOAc in hexanes→ 20% EtOAc in hexanes) gave compound 12 (54 mg, 50%) as a pale yellow oil:
Rf = 0.50 (silica gel, 50% EtOAc in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.85–6.78 (m, 2 H), 6.52
(d, J = 0.6 Hz, 1 H), 6.15 (dt, J = 15.9, 6.5 Hz, 1 H), 4.06 (dd, J = 6.4, 1.3 Hz, 2 H), 3.35 (s, 3 H), 2.11 (s,
3 H); 13C NMR (100 MHz, CD3OD) δ 147.9, 147.5, 128.2, 125.4, 123.4, 121.4, 117.6, 111.7, 73.5, 56.5, 14.8;
HRMS (H-ESI) m/z: [M + H]+ calculated for C11H15O3 195.1021; found 195.1017.
Thymoquinol 15. To a solution of thymoquinone (16) (100 mg, 0.61 mmol, 1.0 equiv.) in MeOH
(2 mL) was added a solution of Na2S2O4 (225 mg, 1.29 mmol, 2.1 equiv.) in H2O (2 mL). The reaction
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mixture was stirred for 2 h at 25 ◦C and, after this time, the organic solvent was removed under reduced
pressure. Then, the crude mixture was diluted with water and the aqueous phase was extracted
with EtOAc. The organic phase was washed with brine, dried over MgSO4, filtered, and the solvent
removed under reduced pressure. The residue was purified by flash column chromatography (silica
gel, 20% EtOAc in hexanes) to obtain 15 (50 mg, 49%) as a pale brown solid [14]: Rf = 0.50 (silica gel,
30% EtOAc in hexanes); 1H NMR (400 MHz, CD3OD) δ 6.56 (s, 1 H), 6.48 (s, 1 H), 3.17 (dt, J = 13.8,
6.9 Hz, 1 H), 1.17 (s, 3 H), 1.15 (s, 3 H); 13C NMR (100 MHz, CD3OD) δ 147.8, 146.6, 132.8, 121.6, 116.9,
112.1, 26.3, 21.8, 14.5; HRMS (H-ESI) m/z: [M + H]+ calculated for C10H15O2 167.1072; found 167.1058.
3.4. Cell Growth Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT dye reduction assay
in 96-well microplates was used [32]. This assay is dependent on the reduction of MTT by
mitochondrial dehydrogenases of a viable cell to a blue formazan product, which can be measured
spectrophotometrically. 3 × 103 HL-60, and 2 × 103 HT-1080, HT-29, MDA-MB-231, and U87MG cells in
a total volume of 100 μL of their respective growth medium were incubated with serial dilutions 1:1 of
the tested compounds. After three days of incubation (37 ◦C and 5% CO2 in a humid atmosphere), 10 μL
of MTT (5 mg/mL in phosphate-buffered saline) were added to each well, and the plate was incubated
for a further 4 h at 37 ◦C. The resulting formazan was dissolved in 150 μL of 0.04 N HCl/2-propanol
and read at 550 nm. IC50 values were calculated from semi-logarithmic dose-response plots as those
concentrations of the compound yielding 50% cell survival, taking the values obtained for the control
to be 100%. IC50 results are expressed as means ± S.D. of at least three independent experiments.
4. Conclusions and Future Perspectives
Bioactive marine compounds can serve as the basis for the synthesis of derivatives with improved
pharmacological properties. The synthesis of a set of analogues of the natural product toluquinol has
been described and their in vitro cytotoxicity against a panel of cancer cell lines was compared.
Our results indicate that the cytotoxic activity of this family of compounds could rely on the
hydroquinone part of the molecule, probably due to its capability to undergo redox cycling. Although
the hydroquinones seemed to be more cytotoxic than their quinone counterparts, the differences
between them were not very significant. Substituents in the ring may modulate the interaction of
the molecule with their targets, changing either the activity or the selectivity. Tolerance for biological
activity was much more restricted for the methyl group of the molecule, whose replacement by other
groups resulted in a significant loss of cytotoxic activity. An increased selectivity was obtained when
prenyl groups were used as substituents. The inclusion of a second substituent group in the toluquinol
molecule was well tolerated and originated a series of derivatives with cytotoxic activities that were
similar to or even higher than that of the natural product. These findings provide guidance for the
design of new toluquinol analogues with potentially better pharmacological properties. Two of the
compounds studied here (toluquinol and thymoquinone) have been reported to inhibit angiogenesis
in vitro and in vivo. Further optimization and development of the new compounds and biochemical
studies to determine the mechanism of the biological actions of this family of compounds, with an
emphasis on their putative antiangiogenic activity and their undesired toxic effects, are currently
in progress.
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Abstract: Five hybrid polyketides (1a, 1b, and 2–4) containing tetramic acid core including a new
hybrid polyketide, cladosin L (1), were isolated from the marine fungus Cladosporium sphaerospermum
SW67, which was isolated from the marine hydroid polyp of Hydractinia echinata. The hybrid
polyketides were isolated as a pair of interconverting geometric isomers. The structure of 1
was determined based on 1D and 2D NMR spectroscopic and HR-ESIMS analyses. Its absolute
configuration was established by quantum chemical electronic circular dichroism (ECD) calculations
and modified Mosher’s method. Tetramic acid-containing compounds are reported to be derived
from a hybrid PKS-NRPS, which was also proved by analyzing our 13C-labeling data. We investigated
whether compounds 1–4 could prevent cell damage induced by cisplatin, a platinum-based anticancer
drug, in LLC-PK1 cells. Co-treatment with 2 and 3 ameliorated the damage of LLC-PK1 cells induced
by 25 μM of cisplatin. In particular, the effect of compound 2 at 100 μM (cell viability, 90.68 ± 0.81%)
was similar to the recovered cell viability of 88.23 ± 0.25% with 500 μM N-acetylcysteine (NAC),
a positive control.
Keywords: hybrid polyketides; tetramic acid; Cladosporium sphaerospermum; hybrid PKS-NRPS;
LLC-PK1 cells
1. Introduction
Marine invertebrates host a diverse assemblage of mostly beneficial microbes that play important
roles in host development, fitness, and protection [1,2]. To ensure propagation within these often extreme
and highly competitive host-specific microenvironments, microorganisms have developed unique
metabolic and physiological capabilities that aid in their survival [3,4]. Amongst many other important
biochemical traits, marine microorganisms are well known to produce structurally diverse and unique
secondary metabolites, which often show important pharmacological activities, such as antioxidant,
antibiotic, anticancer, or anti-inflammatory activities [5–9]. Previous reports have shown interesting
marine natural products, e.g., hypochromins A and B were isolated from Hypocrea vinisa; penicillinolide
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A, a 10-membered lactone, was purified from Penicillium sp., and p-hydroxyphenopyrrozin was
identified from Chromocleista sphaerospermum [10–12].
As a part of our continuing endeavor to discover novel bioactive natural products from various
natural sources [13–17], we recently analyzed the marine fungus Cladosporium sphaerospermum sp.
SW67, which was obtained from the polyp surface of the marine invertebrate Hydractinia echinata
(Cnidaria). Subsequent co-culture assays and comparative metabolomics studies led to the isolation and
characterization of three novel spirocyclic natural products containing a tetramic acid core—namely,
cladosporicin A and cladosporiumins I and J—as well as the isolation of previously reported
stereoisomers [18]. Based on our acquired whole genome sequence of C. sphaerospermum sp. SW67 and
gene expression studies, we proposed a putative PKS-NRPS hybrid gene cluster (cls) as a genetic basis
for the tetramic acid-derived metabolites [18].
Intriguingly, a previous study exploring the metabolites of the related deep-sea-derived fungus
C. sphaerospermum sp. 2005-01-E3 led to the characterization of structurally-related hybrid polyketides
containing 2,4-pyrrolidinedione (tetramic acid) derivatives, named cladosins A-E [19]. In addition,
cladosins H-K, featuring tetramic acid derivatives with aniline moiety, were identified from the
deep-sea-derived fungus C. sphaerospermum L3P3 [20]. These studies and the intriguing HPLC-UV
profiles of our fungal extract prompted us to re-analyze our culture extracts resulting in the isolation of
five hybrid polyketides (1a, 1b, and 2–4) containing tetramic acid core including a new fungal hybrid
polyketide named cladosin L (1). Herein, we describe the isolation and structural characterization of
the hybrid polyketides and their plausible biogenetic pathway, as well as their bioactivity screening.
2. Results and Discussions
2.1. Isolation and Structural Characterization
C. sphaerospermum SW67 was cultivated on a large scale on PDA and MEA agar plates for 14 days
at 25 ◦C. Mycelium-covered plates were then extracted with MeOH and then filtered and evaporated
to afford the crude culture extract. Subsequent solvent-partitioning of the extract and LC/MS-guided
chemical analysis of the fractions combined with semi-preparative C18 reverse-phase HPLC yielded
five hybrid polyketides (1a, 1b, and 2–4) with a very similar NMR signal pattern (Figure 1).
 
Figure 1. Chemical structures of compounds 1–4 from C. sphaerospermum SW67.
Compound 1 was isolated as a yellowish oil with a negative optical rotation, [α]25D −25.5 (c 0.05,
MeOH) and as an inseparable mixture of two geometric isomers (1a:1b) present in an approximate
ratio of 1:1. The mixture (1a/1b) was determined to have the same molecular formula of C13H22N2O4,
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requiring five degrees of unsaturation by the adduct ion of m/z 271.1658 [M+H]+ (calcd. for C13H23N2O4,
271.1658) detected in HR-ESI-MS. The IR spectrum showed absorption bands for the hydroxyl groups
at 3435 cm−1 and carbonyl groups at 1634 cm−1. The 1H and 13C NMR data (Table 1) exhibited three
methyls, two methylenes, and four methines including two oxygenated methines, an amide-like
carbonyl, an α/β-unsaturated ketone, and two non-protonated sp2 carbons. Its NMR spectral features
were very similar to those of the previously described cladosins B (2) and F (3), which were also isolated
in the present work, except for the apparent difference in the chemical shifts of the methyl groups
and one additional methine signal set at δH 3.59/3.66 and δC 68.0/67.0. The gross structure of 1a was
assembled by extensive 2D NMR analysis (Figure 2). The COSY correlations from H2-7 (δH 2.85 and
3.17)/H-8 (δH 4.14)/H2-9 (δH 1.59 and 1.60)/H-10 (δH 3.99)/H3-11 (δH 1.18) unambiguously established
the spin system from C-7 to C-11 with the oxygen attached to C-8 and C-10. This partial structure was
connected to the Δ3(6) double bond as evidenced by the key HMBC correlations from H-7 (δH 2.85 and
3.17) to C-3 (δC 99.1) and C-6 (δC 172.3). The HMBC correlations from H3-13 (δH 0.77) and H3-14 (δH
1.01) to C-5 (δC 68.0) and C-12 (δC 32.1) led to the identification of an isobutyl moiety in the molecule.
That the isobutyl unit was linked to the 2,4-pyrrolidinedione (tetramic acid) scaffold was based on
the HMBC correlations from H-5 (δH 3.59) to the amide carbonyl (C-2, δC 178.3), olefinic carbon (C-3,
δC 99.1), and α/β-unsaturated ketone carbon (C-4, δC 199.8). Finally, the amino group was placed on
C-6 as deduced by the molecular formula of C13H22N2O4. Comparison of the NMR data of 1a and 1b
suggested that they had a similar planar structure. The only significant differences between 1a and 1b
were the chemical shifts of carbons attributable to the 2,4-pyrrolidinedione scaffold (Table 1), indicating
that 1 existed as a pair of interconverting geometric isomers in solution [19]. The probability of the
geometric isomers of 1 could be explained by the interconversion of keto-enamine and enol-imine
forms [21,22]. However, the isomers 1a/1b existed only in the keto-enamine form (Figure 1), which was
explained through a conversion via tautomerism of the 3-acyltetramic acids. The geometric forms of 1a
and 1b were determined as exo-form A (Δ3(6): Z) and exo-form B (Δ3(6): E) since the chemical shift of
a carbonyl group forming the hydrogen-bond with amine group, is more downshifted when compared
to that of the corresponding free carbonyl group in 13C NMR data [21,22].
Table 1. 1H (800 MHz) and 13C (200 MHz) NMR data of 1 in CD3OD.
Position
1
Exo-Form A (a) Exo-Form B (b)
δH (J in Hz) δC, typ δH (J in Hz) δC, typ
2 178.3, CO 176.5, CO
3 99.1, C 97.7, C
4 199.8, CO 202.0, CO
5 3.59, d (3.0) 68.0, CH 3.66 d (3.0) 67.0, CH
6 172.3, C 172.7, C
7 2.85, m;3.17, dd (13.0, 4.0) 41.1, CH2
2.82 m;
3.13 dd (13.5, 4.5) 42.1, CH2
8 4.14, m 69.6, CH 4.13 m 69.2, CH
9 1.59, m; 1.60, m 48.0, CH2 1.59 m; 1.60 m 47.8, CH2
10 3.99, m 66.1, CH 3.99 m 66.1, CH
11 1.18, d (6.0) 25.0, CH3 1.18 d (6.0) 25.1, CH3
12 2.13, m 32.1, CH 2.12 m 32.1, CH
13 0.77, d (7.0) 16.4, CH3 0.78 d (7.0) 16.7, CH3
14 1.01, d (7.0) 20.7, CH3 1.01 d (7.0) 20.6, CH3
 
Figure 2. Key COSY ( ) and HMBC (→) correlations for 1.
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The relative configuration of the stereogenic carbons of the pentan-1,3-diol (C-8 and C-10) of 1 was
determined based on the characteristic signals for C-9 methylene protons (methylene group between
the 1,3-diol), which were overlapped in anti-1,3-diols whereas, they appeared as two sets of multiplets
in syn-1,3-diols [19,23]. Since the signals of the methylene protons of C-9 in 1 were overlapped at δH
1.58–1.60, the 1,3-diol was determined as anti. The absolute configuration of the anti-1,3-diol system
was determined by the modified Mosher’s method. A detailed analysis of 1H NMR and TOCSY
spectra of the (R)- and (S)-di-MTPA ester derivatives of 1 indicated that the distributed Δδ values were
negative (ΔδL), negative (ΔδC), and negative (ΔδR), which implied that the absolute configurations
of both C-8 and C-10 were (R) (Figure 3A) [24]. To establish the absolute configuration of C-5 in 1,
the experimental ECD spectrum of 1 was compared to the calculated ECD spectra of two possible
epimers (1A, 5(R); 1B, 5(S), Figure 3B). Since 1 exists as 1:1 mixture of two geometric isomers, total four
ECD spectra of 1Aa, 1Ab, 1Ba, and 1Bb were simulated (Figure S22) and the ECD spectra of the two
geometric isomers (1Aa and 1Ab; 1Ba and 1Bb) were averaged to generate two ECD spectra of 1A and
1B (Figure 3C). The experimental ECD spectrum of 1 showed two negative Cotton effects at 241 and
297 nm, which corresponded to two negative Cotton effects at 235 and 277 nm of 1B spectrum whereas
1A spectrum exhibited two positive Cotton effects at 230 and 274 nm. Therefore, the C-5 configuration
was assigned as (S), which is in agreement with previously reported structures of cladosporiumins
G and H; both were reported to be built up by L-valine. Accordingly, the complete structure of 1,
named cladosin L, is shown in Figure 1.
 
Figure 3. (A) Analysis of the modified Mosher’s method for 1. Δδ (δS–δR) values are shown. (B) Four
diastereomers of 1. (C) Experimental ECD spectrum of 1 and calculated ECD spectra of 1A/1B.
The known hybrid polyketides, isolated from C. sphaerospermum SW67, were identified as cladosin
B (2), cladosin F (3), and cladosin C (4) by comparison of their NMR data with those reported in the
literature [19,25].
2.2. Proposed Biogenesis of 1–4
It is generally assumed that tetramic acid-containing compounds, such as cladosins and structurally
related natural products [26], are built up by polyketide synthases (PKS)–non ribosomal peptide
synthetases (NRPS) hybrid megaenzymes, which catalyze the formation and condensation of
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a tetraketide or a related unsaturated or reduced polyketide unit and an activated amino acid
to yield the 1,3-dione-5,7-diol conjugate (Figure 4) [27–29].
Figure 4. Fungal iterative hybrid PKS–NRPS megaenzymes are responsible for the formation of tetramic
acid derivatives and often require a discrete ER to be completely functional. The R-domain catalyzes
a non-reductive Dickmann condensation to release the product from the enzyme. Tetramic acids exists
often as mixture of rapidly interconverting tautomers in solution arising from C–C bond rotation of the
acyl side chain.
In fungi, these PKS/NRPS hybrid gene clusters generally consist of a single iterative PKS module
(incorporating acetate building blocks), which is followed by a single NRPS module (attaching the
polyketide chain to an amino acid) and an offloading domain. The domain architecture of the iterative
PKS module closely resembles the mammalian fatty acid synthases (FAS) with the following domain
organization: KS (ketosynthase), AT (acyltransferase), DH (dehydratase), CMeT (C-methyltransferase),
*KR (a structural domain variant of a ketoreductase), ER (enoylreductase), KR (ketoreductase), and ACP
(acyl carrier protein). In contrast to FAS, modules of an iterative PKS within hybrid organizations are
more promiscuous and produce individual and diverse polyketide chains with different reduction
and methylation patterns [27–29]. In particular, enoyl reduction carried out by the ER domain in
polyketide biosynthesis adds diversity to the growing PKS chain. However, sequence alignments of
fungal ER domains in iterative PKS–NRPSs showed that almost all ERs are predicted to be inactive
(ER0) due to a variety of significant sequence differences, e.g., missing a typical GGVG motif for
NADPH binding. In most cases, trans-acting ERs were found to be necessary for the respective product
formation [27–29]. The NRPS modules of iterative NRPS/PKS hybrids have the general domain
organization of C (condensation), A (adenylation) and T (thiolation, also known as PCP peptide
carrier protein). Different release mechanisms are responsible for offloading from PKS, NRPS or their
respective hybrids, which are catalyzed by the respective enzymatic domains such as R (reductase),
DKC (Dieckmann cyclase) or TE (thioesterase) [30].
A previous genome mining approach of the cladosin producing organism Cladosporium sp. SW67
and the related strain Cladosporium sp. UM843 revealed a putative PKS-NRPS cluster (clsA-clsL),
which is proposed to be responsible for the formation of cladosins, cladosporiumins and cladosporicins.
The region of the gene cluster cls encodes for five genes: a siderophore esterase (clsA), an AMP dependet
synthetase/ligase (clsD), a γ-glutamyl transferase (clsF), a cytochrome P450 (clsK) and a PKS-NRPS
hybrid gene (clsI), of which, only the cytochrome P450 (clsK) and the PKS-NRPS hybrid (clsI) gene
appear to be necessary for tetramic acid formation. The possible roles of clsA-F remain unclear.
The domains of the putative PKS-NRPS were predicted as KS-AT-X-Y-KR-C-A-PCP-TD using
PKS/NRPS analysis predictor [31], Blast searches [32] and Antismash [33]. Here, two domains (X, Y)
located between the AT and the KS domain of the PKS-NRPS hybrid enzyme ClsI could not be assigned
despite intensive manual database analyses of the three most similar genes using e.g., MIBig [34] and
UniProt [35]. Here, it needs to be acknowledged that until today only limited numbers of fungal
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PKS/NRPS domains have been fully characterized, which clearly limits the assignments based on
homology searches.
To identify possible conserved motifs within the unknown domains, the corresponding areas were
extracted by using ClustalW implemented in Bioedit 7.2.0 [36] and aligned against each other (Table 2).
Based on different motif alignments, we found that the first unidentified domain (X) within clsI shows
weak homologies to known dehydratase (DH) domains. In general, dehydratase (DH) domains carry
a characteristic catalytic proline and aspartic acid residues within a characteristic conserved HPALLD
motif [37]. Alignment of the unknown domain within ClsI and a related domain in CluI detected in
Cladosporium sp. UM843 revealed a TPMAAD motif, which is in weak accordance with so far reported
homologous (Table S8).
Table 2. Sequence alignment of the first unknown domain of Cladosporium SW67 and Cladosporium sp.
UM843 with DH-domains of known NRPS-PKSs with high identities (Tables S8 and S9). Red marked
lines indicate conserved DH motif. Accession numbers are derived from the UniProt database.
Amino Acid Sequence
SW67_clsI_unknown_1 R E W E T Q F Q L T P M A A D S R Y N F R L M I C G P S E S
UM843_cluI_unknown_1 R E W E T Q F Q L T P M A A D S R Y N F R L M I C G P S E S
ACLA_078660_DH F N H S Q P L L I H P A T L D A A I Q S I M L A Y C Y P G D
A0A0C6E017_DH D M Q I D N Y V V N P G F L D V A F Q S V Y T A F S S P A S
ANIA_08412_DH V P D A D E L L V H P I D L D A A F Q S V M L A Y S Y P G D
A0A0C6E0I7_DH P V S W T H T L T H P A P I D T A V Q G L L T A F S F P G D
FFUJ_12239_DH F N H S Q P L L I H P A T L D A A I Q S I M L A Y C Y P G D
ACLA_078660_DH C L S D T G L L V H P A F L D M T L H A T L A A F A S P G D
B1GVX7_DH P V S W T H T L T H P A P I D T A V Q G L L T A F S F P G D
A0JJU1_DH A D L N D C Y L V H P A I L D V A F Q T I F V A R A H P D S
S0EET5_DH V V P D F P A M I H P A L I D G A F Q S I F A A Y C Q P D D
Subsequently, we analyzed the second unknown domain by different motif alignments. Genes
with the highest identities for already described PKS-NRPSs mainly contained methyltransferase
(C-MT) domains at the corresponding sites. Regions of sequence similarities within SAM dependent
MTs are divided into three different motifs (I, II and II) [38,39] and comparative alignments
between the unknown second domains (Y) and known C-MT domains showed that neither Motif I
[(L/I/V)(V/L)(E/D)(V/I)G(C/G)G(P/T)G] nor Motif III [(G/P)(T/Q)(A/Y/F)DA(Y/V/I)(I/F)(L/V/C)] was
detectable within the second domain (Y). However, weak homologies to Motif II [LL(K/R)PGG(L/I/R)
(I/L)(V/I/F/L)(L/I)] could be detected in both unknown domains (Y) of Cladosporium sp. SW67 and
UM843 (Table 3).
Table 3. Sequence alignment of the second unknown domain of Cladosporium sp. SW67 and Cladosporium
sp. UM843 and C-MT-domains of known NRPS-PKSs with high identities (Tables S8 and S9). Colored
lines indicate conserved MT-domain motif II. Accession numbers are derived from the UniProt database.
Amino Acid Sequence
SW67_clsI_unknown_2 - - - - - - - F D Q E N H R V S P G G C I C V L H S R T - -
UM843_cluI_unknown_2 - - - - - - - F D Q E N H R V S P G G C I C V L H S R T - -
ACLA_078660_C-MT T R D L A Q T V R N V R R L L K P G G Y L L L L E I T E N -
A0A0C6E017_C-MT C A R L D E A V A N L R K L L K P G G L L V L G E G A S D G
ANIA_08412_C-MT T H S L E N T L R Q C R K L L R P G G R L V L L E I T R - -
A0A0C6E0I7_C-MT T R D L A Q T V R N V R R L L K P G G Y L L L L E I T E N -
FFUJ_12239_C-MT T E F L E K T M R N V R T L L K P G G Y L C L L E C T G - -
ACLA_078660_C-MT T H S L E N T L R Q C R K L L R P G G R L V L L E I T R - -
B1GVX7_C-MT T R N L G V T L G N V R S L L K P G G Y L L L N E K T G P -
A0JJU1_C-MT T K S L T V T M R N T R K L L K P G G Q L L L L E V T S - -
S0EET5_C-MT T P D L E K T M A H A R S L L K P G G Q M V I L E I T H K -
In a last step, we analyzed the catalytic domain responsible for product-release from the
PKS-NRPS enzyme. The formation of the 1,3-dione-5,7-diol conjugate requires a Dieckmann-type
condensation/cyclization of a polyketide unit and a valine residue (Figure 5). To analyze if the proposed
PKS-NRPS enzymes harbors the necessary release domain [30,40]. Thus, amino acid sequences
of NR-PKSs enzymes with known product release mechanisms were again collected from NCBI
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and UniProt databases [35] and closest homologues were obtained by identity search in the MiBIG
database [34] and the first three matches were individually evaluated by BLAST. The product-release
enzyme domains of clsI and cluI were extracted by PKS/NRPS Analyzer and manually aligned using
the ClustalW tool implemented in Bioedit 7.2.0 and partial sequences were manually compiled,
assembled and trimmed (Tables S8 and S9). Initial tree(s) for the heuristic search were obtained
automatically by applying neighbor joining approach. The robustness of branches was assessed by
bootstrap analysis with 1000 replicates. The tree is drawn to scale with branch lengths measured in the
number of substitutions per site and evolutionary analyses were conducted in MEGA7 [41].
 
Figure 5. Phylogenetic tree of different fungal product-releasing and their functional classification.
The different types of product-releasing enzyme domains in NR-PKSs have been highlighted with
different color code [42]. Phylogenetic analysis was conducted using neighbor joining method [43,44].
Bold text represents the Cladosporium sp. SW67 and UM843 group (accession number/gene name, type
of release reaction, group of product-release enzyme). Probability values > 50% are shown at the nodes
based on 1000 bootstraps. The tree is drawn to scale with branch lengths measured in the number of
substitutions per site.
Due to similarities and cluster grouping, the product release domain of Cladosporium SW67 and
UM843 can be classified as reductase (R) domain (Figure 4). This domain was initially found to
catalyze an NAD(P)H-dependent reductive release of fungal iterative PKS–NRPSs products based on
sequence homology to SDR (shortchain dehydrogenase/reductase) family proteins. Detailed studies on
tenellin [45,46] and aspyridone A [47] biosynthesis showed that R domains also catalyze non-reductive
Dieckmann-type condensation reactions yielding the tetramic acids derivatives peraspyridone A and
pretenellin A (Figure 6A) [48]. In case of peraspyridone A, subsequent oxidation by an additional
P450 monooxygenase yields aspyridone A; a similar mechanism was proposed for the biosynthesis of
tenellin A.
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Figure 6. (A) TenS and ApDA as examples of fungal iterative hybrid PKS–NRPS that
include a non-reductive Dieckmann-type condensation reactions yielding peraspyridone A and
pretenellin A, respectively. (B) Proposed biosynthetic pathway of the core structure formation of
cladosporiumin and cladosin-type natural products. Domains of PKS-NRPS are putatively assigned as
KS-AT-(*DH)-(*C-MT)-KR-C-A-PCP-TE (* weak homologies).
In summary, we propose the following domain arrangement of the putative PKS-NRPS
(KS-AT-*DH-*cMT-KR-C-A-PCP-R) (Figure 6B). Whether or not the poorly assigned domains
(-*DH-*cMT-) are fully functional, cannot be deduced at this stage. Here, we also propose that
the identified terminal reductase (R) domain in clsI and cluI performs a non-reductive Dieckmann-type
cyclisation to yield the 2,4-pyrrolidinedione skeleton, which after oxidation of the valine unit
(cytochrome P450 clsK) and (spontaneous) elimination of H2O results in derivative 7 bearing
a thermodynamically stable tetra-substituted double bond (Figure 6B). Whether or not the cytochrome
P450 clsK [49] is also responsible for the elimination of H2O cannot be deduced at this stage.
Tetramic acids of types 5 and 7 exist in both, keto and enol form, which allows for the (spontaneous)
reaction with NH3 yielding enamines 8 and 10, respectively. Due to a tautomeric equilibrium,
enols and imines were found as interconverting E/Z-mixtures. To confirm the biosynthetic origin,
we re-analyzed our 13C-labeling data (addition of 13C-valine and 13C-acetate to a growth medium,
Figure 7). As expected, an LC/MS based analysis of the enriched 13C-labeled compound mixture
revealed the incorporation of one valine residue and a PKS-typical CH3CO2-dependent pattern
(incorporation of four acetate units) into 1 (Figure S15) confirming once more the biosynthetic proposal.
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Figure 7. The proposed 13C-labeling pattern of 1–4 based on a hybrid PKS-NRPS assembly line.
2.3. Biological Evaluation of 1–4
In our ongoing studies to explore biologically active unique natural products, we particularly
focused on the discovery of renoprotective natural products for protection against cisplatin-induced
nephrotoxicity [50–52], which is a major issue in the clinical use of cisplatin in cancer
patients [53–55]. It has been reported in the literatures that some natural products
exhibit effective protection against cisplatin-induced nephrotoxicity [55–57]. In our recent
studies, it was found that 1-O-(2-aminobenzoyl)-α-L-rhamnopyranoside from a termite-associated
Streptomyces sp. RB1 [50], dehydroeburicoic acid monoacetate from Poria cocos [51], and sterols,
(22E,24S)-ergosta-7,22-diene-3β,5α,6β-triol and (22E,24R)-ergosta-8(14),22-diene-3β,5α,6β,7α-tetrol
from Pleurotus cornucopiae [52] showed the renoprotective effects. Despite the continued publications
of these effects, these studies failed to achieve clinical success. Therefore, there is an urgent need to
develop effective agents to save the lives of cancer patients having impaired renal functions.
To identify active compounds having protective effects against cell damage caused by cisplatin,
the LLC-PK1 cells were pre-treated with 1–4 for 2 h before treatment with 25 μM of cisplatin.
After treatment with cisplatin, the cell viability was 63.01 ± 2.47% when compared to the control.
The reduction in cell viability in response to cisplatin-induced cell death was recovered to 80.14 ± 4.16%
and 90.68± 0.81% after pretreatment with 50 μM and 100 μM of 2, respectively (Figure 8B). Cell viability
was reduced by 61.93 ± 0.72% after treatment with 25 μM of cisplatin, whereas it was increased by
77.65 ± 2.43% and 85.6 ± 2.47% after treatment with 50 μM and 100 μM of 3, respectively (Figure 8C).
Although the protective effects of 2 and 3 were similar, 2 showed a better effect. In addition, the effect
of 2 at 100 μM was similar to the recovered cell viability of 88.23 ± 0.25% with 500 μM N-acetylcysteine
(NAC), a positive control (Figure 8E). Compound 4 showed no protective effect and 1 showed minor but
insignificant protective effect (Figure 8A,D). In the structure activity relationship (SAR), the comparison
of protective effects of active compounds (1, 2 and 3) vs inactive compounds (4) suggested that the
presence of hydroxy group at C-8 may be essential for the renoprotective effect against cisplatin-induced
nephrotoxicity in LLC-PK1 cells. Therefore, there is a need to further evaluate the mechanisms of
action of 2 and 3 against cisplatin-induced damage to LLC-PK1 cells.
109
Mar. Drugs 2019, 17, 606
 
Figure 8. Comparison of the protective effects of 1–4 (A–D) and NAC (E, positive control) on the
viability of LLC-PK1 cells exposed to 25 μL of cisplatin for 24 h by MTT assay. The control cells were
treated with the vehicle only (mean ± SD, * p < 0.05 vs. control).
3. Materials and Methods
3.1. General Experimental Procedures
Optical rotations were measured using a Jasco P-1020 polarimeter (Jasco, Easton, MD, USA). The IR
spectra were recorded on a Bruker IFS-66/S FT-IR spectrometer. The ESI and HR-ESI mass spectra were
recorded on an SI-2/LCQ DecaXP Liquid chromatography (LC)-mass spectrometer. The experimental
ECD spectra in MeOH were acquired in a quartz cuvette of 1 mm optical path length on a JASCO
J-1500 spectropolarimeter (Tokyo, Japan). NMR, including COSY, HSQC, and HMBC, experiments
were conducted utilizing a Varian UNITY INOVA 800 NMR spectrometer operating at 800 MHz (1H)
and 200 MHz (13C) with chemical shifts given in ppm (δ). The preparative high-performance liquid
chromatography (HPLC) utilized a Waters 1525 Binary HPLC pump with Waters 996 Photodiode
Array Detector (Waters Corporation, Milford, CT, USA). Semi-preparative HPLC was carried out using
a Shimadzu Prominence HPLC System with SPD-20A/20AV Series Prominence HPLC UV-Vis Detectors
(Shimadzu, Tokyo, Japan). LC/MS analysis was carried out on an Agilent 1200 Series HPLC system
(Agilent Technologies, Santa Clara, CA, USA) equipped with a diode array detector and a 6130 Series
ESI mass spectrometer using an analytical Kinetex (4.6 × 100 mm, 3.5 μm). Merck precoated Silica gel
F254 plates and RP-18 F254s plates were used for thin-layer chromatography (TLC). The spots were
detected on TLC under UV light or by heating after spraying with anisaldehyde-sulfuric acid.
3.2. Biological Material
The fungus was obtained as previously described [18]. In brief, polyps of H. echinata (Alfred
Wegener Institute, Sylt, Germany) were aseptically homogenated, diluted with sterile filtered seawater,
and plated onto potato dextrose agar (PDA) plates. The plates were incubated for 1–3 weeks at room
temperature, and colonies showing fungal morphologies were selected. The isolate SW67 was identified
as C. sphaerospermum based on the analysis of the internal transcribed spacer (ITS) gene sequence.
3.3. Extraction and Isolation
Overall, approximately 400 PDA and 400 MEA plates were inoculated with a 100 μL aliquot of
a turbid fungal spore suspension of C. sphaerospermum SW67 in sterile PBS. The suspension was evenly
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distributed over the agar surface, and the plates were incubated at 25 ◦C in the dark for 14 days. The agar
was then cut into squares, consolidated, and macerated overnight in MeOH. The MeOH solution was
filtered and removed under reduced pressure to obtain the crude MeOH extract. The MeOH extract (6 g)
was dissolved in distilled water (700 mL) and then partitioned with EtOAc (700 mL), yielding 0.25 g of
EtOAc-soluble fraction. The EtOAc-soluble fraction was fractionated by preparative reversed-phase
HPLC (Phenomenex Luna C18, 250 × 21.2 mm i.d., 5 μm) using CH3CN-H2O (1:9–3:2, v/v, gradient
system, flow rate: 5 mL/min) to afford six subfractions (A–F). Compound 1 (2.0 mg, tR = 29.0 min)
was purified from subfraction B (15 mg) by semi-preparative reversed-phase HPLC (Phenomenex
Luna C18, 250 × 10.0 mm i.d., 5 μm) with an isocratic solvent system of 29% MeOH. The subfraction C
(14 mg) was purified by semi-preparative reversed-phase HPLC (Phenomenex Luna C18, 250 × 10.0
mm i.d., 5 μm) with an isocratic solvent system of 31% MeOH to afford 2 (3.0 mg, tR = 36.0 min) and 3
(7.4 mg, tR = 40.0 min). Compound 4 (1.7 mg, tR = 39.0 min) was isolated from subfraction D (8 mg) by
semi-preparative reversed-phase HPLC (Phenomenex Luna C18, 250 × 10.0 mm i.d., 5 μm) with an
isocratic solvent system of 38% MeOH.
Cladosin L (1)
Yellowish oil; [α]25D −25.5 (c 0.05, MeOH); IR (KBr) νmax 3435, 2966, 2843, 1634, 1521, and 1060 cm−1;
UV (MeOH) λmax (log ε) 198 (2.5), 236 (1.9), and 296 (3.9) nm; ECD (MeOH) λmax (ε) 211 (1.7), 241
(−3.2), 266 (−1.6), and 297 (−2.5) nm; 1H (800 MHz) and 13C NMR (200 MHz), see Table 1; (+)-HRESIMS
m/z 271.1658 [M + H]+ (calcd. for C13H23N2O4, 271.1658).
3.4. Preparation of Mosher Ester Derivatives from Cladosin L (1)
Cladosin L (1) (0.5 mg) was dissolved in deuterated pyridine (0.25 mL) and transferred
to a clean NMR tube and then a small quantity of 4-(dimethylamino)pyridine was added.
(S)-(+)-α-methoxy-α-(trifluoromethyl) phenylacetyl (MTPA) chloride (5 μL) was added into the
NMR tubes under an N2 gas stream and the NMR tube was shaken carefully to mix the sample
with added reagents. The NMR tube was stored at room temperature overnight, which afforded the
(R)-MTPA ester derivative of 1. The (S)-MTPA ester derivative of 1 was also prepared using (R)-MTPA
chloride according to the procedure described above. The 1H NMR and TOCSY spectra were directly
obtained from the Mosher’s ester derivatives of 1 in NMR tube.
(R)-MTPA Ester of 1. 1H NMR (Pyridine-d5, 800 MHz): δ 3.44 (H-7), 4.99 (H-8), 2.04 (H-9), 4.59 (H-10),
1.37 (H-11); ESIMS m/z 725.2 [M + Na]+.
(S)-MTPA Ester of 1. 1H NMR (Pyridine-d5, 800 MHz): δ 3.41 (H-7), 4.97 (H-8), 2.02 (H-9), 4.58 (H-10),
1.36 (H-11); ESIMS m/z 725.2 [M + Na]+.
3.5. Computational Analysis
All conformers of 1Aa, 1Ab, 1Ba, and 1Bb used in this study were found using the Macromodel
(version 2015-2, Schrödinger LLC, New York, NY, USA) module with “Mixed torsional/Low-mode
sampling” in the MMFF force field. The searches were implemented in the gas phase with a 5 kJ/mol
energy window limit and 10,000 maximum number of steps to explore all potential conformers.
The Polak–Ribiere Conjugate Gradient (PRCG) method was utilized to minimize conformers with
10,000 iterations and a 0.001 kJ (mol Å)−1 convergence threshold on the Root Mean Square (RMS)
gradient. All the conformers were subjected to geometry optimization using the Gaussian 16 package
(Gaussian Inc., Wallingford, CT, USA) in the gas phase at B3LYP/6-31+G(d,p) level and proceeded to
calculation of excitation energies, oscillator strength, and rotatory strength at B3LYP/6-31+G(d,p) level
in the Polarizable Continuum Model (PCM, methanol). The ECD spectra were Boltzmann-averaged
based on the calculated Gibbs free energy of each conformer (Tables S2–S5) and visualized with SpecDis
software (Version 1.71) [58] with a σ/γ value of 0.30 eV. The calculated ECD spectra of 1A and 1B were
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obtained by averaging those of 1Aa and 1Ab, and 1Ba and 1Bb, respectively, since the compound 1
exists as a 1:1 mixture of two geometric isomers (1a and 1b) as described in the Section 2.1 above.
3.6. Isotope Labeling
For 13C labeling experiments, 2 g/L of sodium [1-13C] acetate, sodium [2-13C] acetate, or [1-13C]
valine was each added separately to 1 L of PDA medium (6.6 g/L). Each plate was inoculated with
100 μL of a spore suspension (SW67) in sterile PBS, and the plates were incubated for 14 d at room
temperature in the dark. The plates were cut into pieces and extracted with 100% MeOH (if not
mentioned otherwise, mixtures refer to MeOH in ddH2O) at 4 ◦C overnight. The extracts were filtrated
and the solvent was evaporated under reduced pressure. The remaining extract was re-dissolved in
10% MeOH and loaded on a pre-activated and equilibrated C18 cartridge (100 mg C18, 10% MeOH).
The loaded SPE column was washed with 20% MeOH, and then the metabolites were eluted using
100% MeOH. The extracts were then concentrated under reduced pressure. Finally, the organic extract
was dissolved with 100% MeOH to yield a 1.0 mg/mL stock solution for the UHPLC-MS analysis.
For compound 1 (m/z = 271.15 [M − H]−), feeding with [1-13C] sodium acetate and [2-13C]
sodium acetate, respectively, resulted in the detection of the corresponding mass shift of up to +4 m/z.
Similar, addition of [1-13C] valine resulted in the detection of the corresponding mass shift of +1 m/z.
However, it needs to be noted that a dominant signal (m/z 270) of the closely related cladosporiumin F
overlapped with the respective signal of compound 1 due to their similar retention times. If the high
detection level of cladosporiumin F was due to heat/acid-induced hydrolysis during measurement,
it could not be excluded at this stage. Both the signal sets showed the same 13C incorporation pattern.
3.7. Renoprotective Effects against Cisplatin-Induced Kidney Cell Damage
The protective effects of compounds 1–4 against cisplatin-induced renal cell death were
determined by Ez-Cytox cell viability assay kit (DOGEN, Seoul, Korea) using LLC-PK1 pig kidney
epithelium cells (American Type Culture Collection, Rockville, MD, USA). The LLC-PK1 cells were
cultured in Dulbecco’s modified Eagle medium (Manassas, VA, USA) supplemented with 10% FBS,
1% penicillin/streptomycin, and 4 mM L-glutamine at 37 ◦C with 5% CO2 in a humidified incubator and
with 5% CO2 in air at 37 ◦C. The cells were seeded onto 96-well culture plates at 1 × 104 cells per/well
and incubated for 24 h to adhere. Thereafter, the cells were pre-treated with 25, 50, and 100 μM of
compounds 1–4, and then 25 μM of cisplatin was added to the wells. After 24 h, the medium containing
the compounds 1–4 and/or cisplatin was removed, and a serum-free medium containing Ez-Cytox
reagent was added to the wells. After incubation for 2 h at 37 ◦C, the cell viability was measured by
absorbance at 450 nm using a microplate reader (PowerWave XS; Bio-Tek Instruments, Winooski, VT,
USA). N-acetyl cysteine (NAC) was used as a positive control.
3.8. Statistical Analyses
All data described in this study were repeated at least three times and are represented as the
mean ± S.E.M. The statistical significance was determined by one-way analysis of variance (ANOVA).
p-values of < 0.05 were considered statistically significant.
4. Conclusions
Marine invertebrates host a diverse assemblage of mostly beneficial microbes that can produce
novel natural products. Herein, we isolated the marine fungus C. sphaerospermum SW67 from the
hydroid polyp of H. echinata. LC/MS-guided chemical analysis of the marine fungus C. sphaerospermum
SW67 led to the isolation and characterization of five hybrid polyketides (1a, 1b, and 2–4) containing
tetramic acid core including a previously unreported cladosin L (1), which was isolated as a pair of
interconverting geometric isomers. As indicated by biosynthetic gene cluster analysis and 13C-labeling
studies, compounds 1–4 are formed via the generally assumed biosynthesis of microbial tetramic
acids. Although the timing of the putative oxygenation and dehydration of the valine residue is
112
Mar. Drugs 2019, 17, 606
unknown, the compound 1 could be regarded as a putative precursor of previously and herein reported
cladosin F (3). Compounds 2 and 3 ameliorated the damage of LLC-PK1 cells induced by 25 μM of
cisplatin. In particular, 2 at 100 μM (cell viability, 90.68 ± 0.81%) exhibited a significant protective
effect against cell damage, which was similar to that of the positive control, 500 μM NAC (cell viability,
88.23 ± 0.25%). These findings provide experimental evidence that 2 could be an adjunct candidate to
treat cisplatin-induced adverse effects and/or to prevent anticancer drug-induced nephrotoxicity.
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Abstract: Short chain fatty acids (SCFAs) are valued as a functional material in cosmetics.
Cyanobacteria can accumulate SCFAs under some conditions, the related mechanism is unclear. Two
potential genes Synpcc7942_0537 (fabB/F) and Synpcc7942_1455 (fabH) in Synechococcus sp. PCC 7942
have homology with fabB/F and fabH encoding β-ketoacyl ACP synthases (I/II/III) in plants. Therefore,
effects of culture time and cerulenin on SCFAs accumulation, expression levels and functions of these
two potential genes were studied. The results showed Synechococcus sp. PCC 7942 accumulated high
SCFAs (C12 + C14) in early growth stage (day 4) and at 7.5g/L cerulenin concentration, reaching to
2.44% and 2.84% of the total fatty acids respectively, where fabB/F expression was down-regulated.
Fatty acid composition analysis showed C14 increased by 65.19% and 130% respectively, when
fabB/F and fabH were antisense expressed. C14 increased by 10.79% (fab(B/F)−) and 6.47% (fabH−)
under mutation conditions, while C8 increased by six times in fab(B/F)− mutant strain. These results
suggested fabB/F is involved in fatty acid elongation (C <18) and the elongation of cis-16:1 to cis-18:1
fatty acid in Synechococcus sp. PCC 7942, while fabH was involved in elongation of fatty acid synthesis,
which were further confirmed in complementary experiments of E. coli. The research could provide
the scientific basis for the breeding of SCFA-rich microalgae species.
Keywords: microalgae; Synechococcus sp. PCC 7942; short chain fatty acids; β-ketoacyl ACP Synthase
1. Introduction
Short chain fatty acids (SCFAs) are usually defined as the carbon number of fatty acids between 6
and 14 [1]. Due to corresponding glycerides with extraordinary characteristics such as low viscosity,
high extensibility, low freezing point, low surface tension, high transparency and oxidation stability,
SCFAs have very broad application in cosmeceuticals, nutraceuticals, nutritional supplements, chemical
industry, etc. [2]. Currently, main sources of SCFAs are tropical plants, such as coconut and palm
trees [3,4]. However, people have to turn their attention to the potential oleaginous microorganisms
because of the high cost of vegetable oils and the limitation of climate and land resources [5]. It is widely
reported that bacteria, mold, yeast and microalgae are important oleaginous microorganisms [5], of
which microalgae has received much attention for its unique advantages such as fast growth rate, high
oil content, high photosynthetic efficiency, low land requirements and environmental protection [6].
There are abundant algae in the ocean, the unique ecological environment of which causes the
special bioactive metabolites accumulation in the algae. These metabolites have a series of biological
effects, such as moisturizing [7], bacteriostasis [8], anti-inflammatory [9], antivirus [10], inhibiting the
growth of tumor cells [11], and resisting ultraviolet radiation [12]. It was found that a kind of ancient
cyanobacteria has antioxidant, immune and other biological activities [13]. In recent years, safety
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problems are often exposed in the cosmetics industry, when algae bioactive substances could be used
as raw materials for new cosmeceuticals due to their low toxicity and high safety. Therefore, algae
would be increasingly valued as a functional material in the field of cosmetics. At present, research on
algae focuses on the active substances such as minerals, bioactive peptides, natural pigments, enzymes,
polysaccharides and unsaturated fatty acids, etc. [14], while little research are about short carbon chain
fatty acids. It was found that short carbon chain fatty acids were widely used in cosmetics, where
they could replace white oil, lanolin and squalane. Compared with squalane, short carbon chain fatty
acids are more easily absorbed by the skin and can be rapidly oxidized and metabolized. In addition,
short carbon chain fatty acids have emulsifying stability and antioxidant properties, which can make
cosmetics more uniform and delicate, improve product quality and storage period. In suntan lotion,
short carbon chain fatty acids are non-greasy and uncomfortable feeling. In lipsticks, the short carbon
chain fatty acids can eliminate the unique smell of lanolin, making the matrix tissue delicate, the
pigment dispersion uniform and improving the surface gloss and spread ability [15].
Microalgae, as a high-quality oleaginous aquatic microorganism, are primarily used for biodiesel,
polyunsaturated fatty acids and pigments, but rarely for SCFAs. The content of SCFAs in microalgae
was not high under normal growth conditions [16–21]. Some microalgae can accumulate SCFAs when
cultivated in stressed conditions [22], but the related mechanism of this is unclear. Studies on the
synthesis mechanisms of SCFAs are mostly conducted in plants and bacteria [4], and mainly focused on
the key enzymes such as thioesterases (TEs) and β-ketoacyl ACP (Acyl Carrier Protein) synthases (KAS).
TEs are mainly present in plants and some eukaryotic microalgae, associated with the termination
of the fatty acid synthesis cycle by catalyzing ACPs to remove from acyl-ACPs, producing free fatty
acids [23,24]. Past efforts to increase medium chain fatty acid (MCFA) production in microalgae by
genetic modifications of chain-length specific TEs have met with limited success, because of high
specifics and substrate preferences of TEs. β-ketoacyl ACP synthases are associated with the carbon
chain elongation of fatty acids, which are classified as KAS I, KAS II and KAS III, encoded by fabB, fabF
and fabH, respectively [25,26]. It is reported that KAS III could catalyze the combination of acetyl-CoA
with malonyl-CoA to generate 4:0-ACP, KAS I could catalyze 4:0-ACP to generate 16:0-ACP and KAS
II could catalyze 16:0-ACP to generate 18:0-ACP as well as control the ratio of 16:0-ACP/18:0-ACP [27].
Verwoert et al. [28] overexpressed the KAS III gene from E. coli in rapeseed, causing changes in fatty
acid composition, which decreased the content of C18:1 and increased the content of C18:2 and C18:3.
Dehesh et al. [29] overexpressed the KAS III gene from spinach in three kinds of plants (Tobacco,
Arabidopsis thaliana, Rape), leading to C16:0 fatty acid accumulation. Research on cyanobacteria
Synechococcus sp. PCC 7002 revealed that KAS III initialized the synthesis of fatty acids circle, causing
the condensation of malonyl ACP and acetyl CoA to form acetyl–acetyl ACP, which was thought of the
only rate-limiting step in fatty acid synthesis of cyanobacteria [30]. The result is different from that of
E. coli, where KAS III was not rate-limiting.
Although the fatty acids composition of microalgae varied with species and strains [31], but some
cyanobacteria had strong ability to synthesize short carbon chain fatty acids. In the past, filamentous
cyanobacteria Trichodesmium erythraeum has been found to produce 27% to 50% C10 fatty acids [32].
Later, Karatay et al. [33] reported Synechococcus sp. could accumulate about 23.8% of caprylic acid
(C10:0) and myristic acid (C14:0) under nitrogen deficiency condition. Therefore, cyanobacteria may
be an ideal species for the production of short carbon fatty acids. In addition, cyanobacteria, as
prokaryotes, are more suitable for gene manipulation than eukaryotic microalgae, and some of which
have completed whole genome sequencing. The sequencing information could also provide guidance
for our research. Thus, Synechococcus sp. PCC 7942, whose genome have been sequenced, was used in
the present study to explore the effects of cerulenin and culture time on the synthesis of SCFAs, the
functions and expression regulation of genes related to the SCFAs synthesis were further investigated.
The results may provide scientific guidance for the future development of short chain fatty acids
resources in microalgae by means of metabolic engineering and molecular biology.
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2. Results and Discussion
2.1. Fatty Acid Compositions of Synechococcus sp. PCC7942 under Different Conditions
Microalgae synthesize and store different types of lipids in a single cell [32]. In contrast to the
conventional fatty acids (FAs) composition of microalgae that contain long chain fatty acids (LCFAs)
from C16 to C18, SCFAs (from C8 to C14) are generally classified to be unusual. Generally, the content
of SCFAs in microalgae is relatively low under normal growth conditions. In order to better understand
the synthesis mechanism of SCFAs in microalgae from a physiological perspective preliminarily, the
fatty acid profiles of Synechococcus sp. PCC 7942 under different culture time periods was investigated.
Table 1 shows the dynamic variations of fatty acids during the whole culture process. As shown
in Table 1, the main fatty acid was C16 under different culture time periods, accounting for about
70%–80% of the total fatty acids, while little contents of LCFAs from C20 to C22 were detected. At
the early growth stage (2 days–6 days), high content of SCFAs (C14 + C12) were observed, reaching
highest content (2.44%) at day 4, among which C14:1 was 1.70% and C14:0 was 0.74% (Table 1). After
day 8, contents of C14:0 and C14:1 did not change significantly, which were in the range of 0.3%–0.6%
and 0.5%–0.9%, respectively, while C12 fatty acid could not be detected. These results suggested that
the accumulation of SCFAs mainly occurred in the early growth stage (2 days–6 days), with C14 and
C12 as the main composition. To our knowledge, this was the first report of SCFAs accumulation in the
early growth stage in cyanobacteria.
Table 1. Fatty acid profile of Synechococcus sp. PCC 7942 under different culture time.
Fatty Acid (%)
Time (day)
2 4 6 8 10 12 14 16 18 20
12:0 0.02 ± 0.01 ND 0.02 ± 0.00 ND ND ND ND ND ND ND
14:0 0.63 ± 0.03 0.74 ± 0.15 0.56 ± 0.06 0.45 ± 0.03 0.62 ± 0.03 0.27 ± 0.03 0.33 ± 0.01 0.42 ± 0.03 0.34 ± 0.03 0.36 ± 0.03
14:1 0.98 ± 0.02 1.70 ± 0.19 1.17 ± 0.19 0.87 ± 0.10 0.90 ± 0.06 0.48 ± 0.03 0.55 ± 0.04 0.67 ± 0.06 0.57 ± 0.03 0.60 ± 0.06
16:0 42.14 ± 3.96 39.98 ± 2.67 45.42 ± 2.64 41.71 ± 2.22 38.65 ± 2.68 47.93 ± 2.00 45.41 ± 2.11 46.56 ± 2.04 46.63 ± 3.08 46.20 ± 2.05
16:1 34.72 ± 2.04 38.20 ± 1.89 36.80 ± 1.74 31.03 ± 1.25 31.32 ± 0.71 26.96 ± 1.71 31.94 ± 1.87 29.89 ± 0.89 29.60 ± 1.60 30.48 ± 1.89
16:2 ND ND ND ND ND ND ND ND 0.13 ± 0.03 0.13 ± 0.02
17:0 0.13 ± 0.03 0.22 ± 0.03 0.09 ± 0.03 0.12 ± 0.03 0.11 ± 0.02 0.18 ± 0.04 0.11 ± 0.03 0.10 ± 0.00 0.13 ± 0.01 0.11 ± 0.00
17:1 0.22 ± 0.01 0.41 ± 0.01 0.14 ± 0.03 0.24 ± 0.05 0.27 ± 0.02 0.30 ± 0.00 0.33 ± 0.00 0.34 ± 0.03 0.32 ± 0.01 0.33 ± 0.03
18:0 1.70 ± 0.34 3.00 ± 0.21 0.24 ± 0.05 2.49 ± 0.24 3.11 ± 0.25 2.57 ± 0.25 1.89 ± 0.37 1.08 ± 0.11 1.85 ± 0.11 1.61 ± 0.03
18:1 2.51 ± 0.33 3.89 ± 0.29 1.80 ± 0.08 3.79 ± 0.11 4.48 ± 0.31 7.14 ± 0.75 6.42 ± 0.57 4.90 ± 0.36 6.15 ± 0.36 5.82 ± 0.23
18:2 0.31 ± 0.047 0.24 ± 0.09 3.16 ± 0.32 0.34 ± 0.04 0.39 ± 0.03 0.35 ± 0.02 0.68 ± 0.03 0.21 ± 0.03 0.41 ± 0.02 0.43 ± 0.03
20:0 0.04 ± 0.00 0.03 ± 0.00 0.04 ± 0.00 0.08 ± 0.03 0.12 ± 0.01 0.05 ± 0.01 ND ND 0.06 ± 0.01 0.13 ± 0.02
22:0 0.04 ± 0.01 0.04 ± 0.01 0.05 ± 0.01 ND 0.19 ± 0.01 ND ND ND 0.26 ± 0.02 0.27 ± 0.04
22:1 0.05 ± 0.00 0.04 ± 0.00 0.04 ± 0.00 ND 0.11 ± 0.01 0.10 ± 0.00 0.07 ± 0.00 ND ND 0.06 ± 0.00
The fatty acid synthesis system of plants and bacteria belonged to the type II, where the KASs
were related to the fatty acid carbon chain elongation and generally divided into KAS I (FabB), KAS II
(FabF) and KAS III (FabH) [25,26]. It was reported that fatty acid synthase inhibitors have effects on
the fatty acids carbon chain elongation in bacteria [34,35], among which cerulenin mainly played its
role on KAS I and KAS II. In order to further understand the SCFAs synthesis in Synechococcus sp. PCC
7942, effects of different cerulenin concentrations on SCFAs accumulation were studied.
As shown in Table 2, the content of SCFAs (C12 + C14) accumulated as high as 2.84% of the
total fatty acids under cerulenin concentration of 7.5 g/L, among which the content of C14 fatty acids
increased from 1.58% (0 g/L) to 2.75% (7.5 g/L), increasing by 74.05% (p < 0.05), and C12 fatty acids
increased from 0.04% to 0.09%, increasing by 125% (p < 0.05). At this time, C16 fatty acids decreased
from 63.49% to 57.35%, decreasing by 9.67%, C18 fatty acids decreased from 18.44% to 13.7%, decreasing
by 25.7%, respectively. Israel et al. [36] found that after 40 min of adding cerulenin into the medium
with E. coli, 90% of oil synthesis and 25% of RNA and DNA synthesis were inhibited, but the protein
synthesis was not affected. In addition, a previous study [37,38] on antibacterial drug targets showed
that cerulenin has specific inhibition on KAS I and KAS II, which are responsible for the carbon chain
elongation of C4–C16 fatty acids in bacteria. As shown in Table 2, the contents of longer chain fatty
acids (C18 + C16) decreased and the contents of SCFAs (C12 + C14) increased, with the increase of
cerulenin concentration. These results suggested that KAS I/II in Synechococcus sp. PCC 7942 might be
inhibited, which resulted in the increase of SCFAs (C12 + C14).
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Table 2. Effects of different cerulenin concentrations on fatty acid profile in Synechococcus sp. PCC 7942
after 16 days cultivation.
Fatty Acid (%)
Cerulenin Concentration (g/L)
0 1 2.5 5 7.5
12:0 0.04 ± 0.00 0.05 ± 0.00 0.04 ± 0.01 0.07 ± 0.00 0.09 ± 0.01
14:0 0.71 ± 0.08 0.98 ± 0.09 0.77 ± 0.04 0.84 ± 0.09 1.25 ± 0.31
14:1 0.87 ± 0.15 1.1 ± 0.26 0.82 ± 0.08 1.35 ± 0.17 1.5 ± 0.31
15:0 0.07 ± 0.02 0.07 ± 0.01 ND ND ND
16:0 31.47 ± 2.48 41.74 ± 1.85 34.76 ± 1.68 35.43 ± 1.53 31.84 ± 2.46
16:1 31.75 ± 2.39 32.97 ± 2.56 25.66 ± 2.90 26.57 ± 3.38 25.43 ± 2.45
16:2 0.27 ± 0.03 0.07 ± 0.02 ND 0.06 ± 0.01 0.08 ± 0.01
17:0 0.49 ± 0.03 0.16 ± 0.04 0.16 ± 0.02 0.21 ± 0.02 0.47 ± 0.01
17:1 0.81 ± 0.12 0.43 ± 0.02 0.52 ± 0.06 0.51 ± 0.04 0.76 ± 0.11
18:0 1.79 ± 0.10 2.14 ± 0.42 3.33 ± 0.33 2.7 ± 0.15 3.57 ± 0.26
18:1 15.84 ± 0.98 8.02 ± 0.14 14.05 ± 1.47 12.13 ± 1.49 5.69 ± 0.04
18:2 0.81 ± 0.08 1.15 ± 0.11 0.69 ± 0.03 0.9 ± 0.10 4.44 ± 0.27
20:0 0.04 ± 0.03 0.05 ± 0.00 ND ND ND
Based on the above results, it is assumed that the low expression levels of the related genes fabB/F
(KAS I/II) in Synechococcus sp. PCC 7942 might inhibit the carbon chain elongation of fatty acids,
leading to the sufficient accumulation of SCFAs at this stage. Therefore, the related genes expression
levels under the above conditions were further investigated.
2.2. Genes Expression under Different Conditions in Synechococcus sp. PCC7942
Bioinformatic analysis showed that Synpcc7942_0537 and Synpcc7942_1455 in Synechococcus sp.
PCC 7942 might have homology with fabB/F and fabH of plants and bacteria.
As mentioned above, the influences of culture time period and cerulenin concentration on the fatty
acid compositions of microalgae were significant. In order to understand the relationship between genes
expression level and fatty acids (FAs) carbon chain elongation, the influences of cerulenin concentration
and culture time on transcriptional levels of the relative genes (fabB/F and fabH) were explored.
As shown in Figure 1a, the expression level of fabB/F was relatively low in the early growth stage
(2 days–6 days), and reached the highest expression level at day 8, then decreased in the later period
of culture time (10 days–16 days). The overall trend of expression level of fabB/F increased first and
then decreased, which was consistent with the variations of fatty acid composition (Table 1), that is
to say, the SCFAs mainly accumulated in early growth stage. The result indicated that fabB/F played
an important role on the synthesis of SCFAs. On the other side, during the whole cultivation phase,
the expression level of fabH was not high enough, and showed a trend of gradual decrease, only with
relatively high expression level in the early growth stage (2 days–6 days) (Figure 1b). Inhibition of the
expression of fabB/F will hinder the transformation of SCFAs (C12, C14) to relatively longer chain fatty
acids (C16, C18), leading to SCFAs accumulation, which also verified the previous hypothesis that
fabB/F is a key gene promoting the synthesis of SCFAs (C12, C14) to longer chain fatty acids (C16, C18).
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Figure 1. Dynamic change of expression levels of two related genes in Synechococcus sp. PCC 7942
under different conditions. (a) Expressions of Synpccw7942_0537 (fabB/F) under different culture
time periods; (b) Expressions of Synpccw7942_1455 (fabH) under different culture time periods;
(c) Expressions of Synpccw7942_0537 (fabB/F) under cerulenin concentration of 7.5 g/L; (d) Expressions
of Synpccw7942_1455 (fabH) under cerulenin concentration of 7.5 g/L. The expression levels of genes
Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) at 16 day (a,b) and cerulenin concentration
of 0 g/L (c,d) were set to 1.
As shown in Figure 1c, under cerulenin concentration of 7.5 g/L, the expression level of fabB/F was
relatively high at the early growth stage (2 days–8 days), then decreased significantly with the extension
of culture time and reached the lowest expression level in the late growth stage (12 days–16 days).
These results suggested that cerulenin could change the expression levels of fabB/F in Synechococcus
sp. PCC 7942. Ter Beek et al. [39] also found that cerulenin could change the expression levels of
fab (fatty acid biosynthesis) genes in fatty acid synthesis of Bacillus subtilis. The dynamic trend of
fabB/F expression at 7.5 g/L of cerulenin was consistent with variation of SCFAs composition, compared
with that in the absence of cerulenin or at low concentration of cerulenin (Table 2). The expression
level of fabH gene did not change significantly during the whole cultivation period under 7.5 g/L
cerulenin concentration (Figure 1d), which indicated that cerulenin also has specific inhibition on
KAS I and KAS II in Synechococcus sp. PCC 7942. However, high cerulenin concentration could cause
the inhibition of the growth of Synechococcus sp. PCC 7942. When the cerulenin concentrations were
between 0 g/L and 7.5 g/L, the OD730 value of the same culture time period decreased with the increase
of the concentration of cerulenin. At 7.5 g/L cerulenin concentration, the OD730 value was the lowest,
which was about one third of that at 0 g/L (Figure S1, Supplementary Materials). Therefore, although
there was no significant change during the whole cultivation period, the fabH expression level at 7.5 g/L
cerulenin was much lower (Figure 1d) compared with that in the absence of cerulenin (Figure 1b). This
is probably caused by the growth inhibition at 7.5 g/L cerulenin concentration (Figure S1). So, the
above dynamic expressions of two related genes in Synechococcus sp. PCC 7942 may be the result of
both growth and gene inhibition.
2.3. Fatty Acid Compositions in fabB/F and fabH Sense/Antisense Expression Strains
It is reported that deletion of some important enzymes in the fatty acid synthesis pathway may
lead to cell death [40]. Therefore, sense and antisense expression strains of fabB/F and fabH were
constructed first to investigate the functions of the two genes in the process of fatty acids synthesis.
Chen et al. [41] reported that inhibiting the expression of phosphoenol pyruvate carboxylase (PEPC)
gene in rapeseed by antisense RNA led the oil content of transgenic rapeseed to 6.4%–18%, which was
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higher than that of the control group. Song et al. [42] successfully antisense expressed the encoding
gene (pcc) of PEPC in Synechococcus sp. PCC 7002, resulting in an oil content increase. It can be seen
that antisense expression is very feasible in improving the oil content of microalgae.
As shown in Table 3, the SCFAs contents were not significantly changed in Synechococcus sp.
PCC 7942 harboring sense plasmids pRL-Sense-fabB/F (Synpccw7942_0537) and pRL-Sense-fabH
(Synpccw7942_1455) (The sense and antisense plasmids were all derived from pRL 489). Research
in plants showed fabB/F was responsible for the longer chain fatty acids elongation, while fabH was
related to the initiation of fatty acids synthesis and extending C2 to C4 [27]. The present study
suggested that acyl-ACPs for longer chain fatty acids synthesis may enter the next step of fatty acid
synthesis, which could not result in a massive accumulation of SCFAs (Table 3). It was also found
that overexpression of KAS IV in a MCFA-producing strain of Dunaliella tertiolecta could allow MCFA
accumulation [43], which lies in the control of a KAS enzyme to generate MCFA acyl-ACP substrates.
We believed that enlargement of the MCFA acyl-ACP substrate pool by overexpressing KAS IV and
concentration of MCFA acyl-ACP substrate pool caused by KAS enzyme all could lead to MCFAs
accumulation [24]. Although the overexpression of KAS III gene in E. coli could change the fatty acid
profile of E. coli, when C14:0 increased and C18:1 decreased [26], which were different from our results
of Synechococcus sp. PCC 7942 with pRL-Sense-fabH (Table 3), indicating that the Synpccw7942_1455
(KAS III) gene had species difference. Furthermore, eukaryotic microalgae (Dunaliella tertiolecta) and
bacteria/cyanobacteria are innately different, given that eukaryotic microalgae are capable to store free
FAs in the form of SCFAs.
Table 3. Fatty acid profile of sense and antisense expression of Synpccw7942_0537 (fabB/F) and
Synpccw7942_1455 (fabH) in Synechococcus sp. PCC 7942 after 16 days cultivation.
Fatty Acid (%) Wild Type a Sense-fabB/F b Sense-fabH c Antisense-fabB/F d Antisense-fabH e
C12:0 0.04 ± 0.01 0.06 ± 0.01 0.05 ± 0.00 0.06 ± 0.00 0.05 ± 0.01
C14:0 0.71 ± 0.08 0.71 ± 0.06 0.65 ± 0.04 1.09 ± 0.16 1.35 ± 0.35
C14:1 0.87 ± 0.07 0.75 ± 0.07 0.66 ± 0.03 1.52 ± 0.12 2.28 ± 0.46
C15:0 0.07 ± 0.00 0.29 ± 0.03 0.44 ± 0.02 0.10 ± 0.00 0.06 ± 0.01
C16:0 31.47 ± 0.63 32.04 ± 1.38 38.06 ± 0.55 34.99 ± 0.72 36.09 ± 2.31
C16:1 31.75 ± 2.40 33.16 ± 0.53 34.26 ± 1.68 37.2 ± 1.35 39.4 ± 1.19
C16:2 0.27 ± 0.02 0.16 ± 0.03 0.05 ± 0.01 0.13 ± 0.02 0.07 ± 0.02
C17:0 0.49 ± 0.02 0.32 ± 0.05 0.39 ± 0.06 0.10 ± 0.01 0.24 ± 0.03
C17:1 0.81 ± 0.01 0.56 ± 0.02 0.49 ± 0.02 0.77 ± 0.01 0.39 ± 0.03
C18:0 1.79 ± 0.21 6.83 ± 0.74 8.3 ± 0.36 0.72 ± 0.11 0.82 ± 0.03
C18:1 15.84 ± 2.00 8.05 ± 0.10 8.49 ± 0.32 1.25 ± 0.05 4.52 ± 0.65
C18:2 0.81 ± 0.08 3.33 ± 0.20 0.33 ± 0.03 0.18 ± 0.07 0.13 ± 0.03
C20:0 0.04 ± 0.01 0.06 ± 0.00 ND 0.72 ± 0.03 ND
a Wild type strain of Synechococcus sp. PCC 7942; b Synechococcus sp. 7942 harboring pRL-Sense-fabB/F
(Synpccw7942_0537); c Synechococcus sp. 7942 harboring pRL-Sense-fabH (Synpccw7942_1455); d Synechococcus sp.
7942 harboring pRL-Antisense-fabB/F (Synpccw7942_0537); e Synechococcus sp. 7942 harboring pRL-Antisense-fabH
(Synpccw7942_1455).
The content of C18 of Synechococcus sp. PCC 7942 containing pRL-Antisense-fabB/F decreased
from 18.44% of wild-type to 2.15% of antisense expression strain (Table 3), with a decrease of 88.34%.
Meanwhile, the content of C14 in Synechococcus sp. PCC7942 containing pRL-Anti-fabB/F increased
from 1.58% of the wild type to 2.61% of antisense expression strain (Table 3), with an increase of
65.19% (p < 0.05). This is because that the antisense gene fragment could inhibit the expression level of
fabB/F. The expression levels of fabB/F in antisense expression of fabB/F strains were down-regulated
(p < 0.05) as compared with that in the wild type strain during the whole growth period (Figure S2,
Supplementary Materials). In addition, as shown in Table 3, C16:2 in fabB/F antisense expression strain
decreased from 0.27% to 0.13%, C18:2 decreased from 0.81% to 0.18%, C17 (17:0 and 17:1) fatty acids
decreased from 1.3% to 0.87%. By referring to the studies of other microorganisms [3], fabB/F might
be related to the extension of longer chain fatty acids. Further analysis showed that C16:1 of the
antisense expression strain increased from 31.75% to 37.20% and C18:1 decreased from 15.84% to 1.25%
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(Table 3), which was consistent with the function of fabF for extending cis-16:1 into cis-18:1 mentioned
in a previous report [44]. In E. coli, both KAS I (fabB) and KAS II (fabF) have the ability for longer chain
elongation of saturated fatty acids. KAS I is one of the key enzymes involved in the de novo synthesis
of unsaturated fatty acids, while KAS II only extends the cis-hexadecenoyl to cis-octadecanoyl and
does not participate in de novo synthesis of unsaturated acyl [45]. Combined with the studies above, we
speculated that fabB/F was involved in the synthesis of unsaturated fatty acids. Leonard et al. [46] have
found that the gene with KAS II activity in Cuphea wrightii could regulate FA chain length regulation,
and was co-expressed with specific thioesterases, leading the content of C10:0 and C12:0 accumulation.
Besides, Pidkowich et al. [47] proved that KAS II had the function of extention 16:0-ACP to 18:0-ACP
in plant. Our results suggested that Synpccw7942_0537 (fabB/F) also performed the function of fabF
and fabB in microalgae.
The antisense expression fabH also caused the change of fatty acid composition. As Table 3 shows,
the content of C18 of Synechococcus sp. PCC 7942 containing pRL-Antisese-fabH decreased from 18.44%
of the wild-type strain to 5.47% of antisense expression strains, with a decrease of 70.34%. At the same
time, the content of C14 increased from 1.58% of the wild type to 3.63% of the antisense expression
strain (Table 3), with an increase of 130% (p < 0.05). In addition, C16:2, C17:0, C17:1 and C18:2 content
of fabH antisense expression strain all decreased, when C16:2 decreased from 0.27% to 0.07%, C18:2
decreased from 0.81% to 0.13%, C17 (17:0 and 17:1) fatty acids decreased from 1.3% to 0.63%. It is
generally believed that fabH was related to the initiation of fatty acid elongation and a rate-limiting
step of fatty acid synthesis [30]. González-mellado et al. [48] found that KAS III in sunflower had a
new substrate specificity, which could participate in the synthesis of C6 to C10 fatty acids. Our present
results showed that the C18 fatty acid decreased with the increase of C14 fatty acid when the gene
fabH was inhibited, suggesting that the Synpccw7942_1455 (fabH) in Synechococcus sp. PCC 7942 may
only participate in the carbon chain extension (C < 18) (not the first condensation step in the fatty acid
synthesis circle) and had acyl-ACP carbon chain substrate specificity. While antisense expression fabB/F
and fabH are able to redirect FA synthesis from long to short chain lengths, the increases in yield are
still not as high as those achieved in plants and some bacteria. It is thought that high content of SCFAs
could be poisonous for microalgae growth. Therefore, SCFAs accumulation is not only governed by
KAS, but also by the tolerance of SCFAs concentration in microalgae cells.
2.4. Fatty Acid Compositions of fabB/F and fabH Deletion Mutants
The functions of Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) were further explored
by gene deletion mutants. Table 4 showed that C16 was the main fatty acid component in the fab(B/F)−
mutant strain, accounting for about 60%–70% of the total fatty acid. The content of C8 increased by six
times and C14 increased by 10.79%, while the content of C18 decreased by 9.87% (Table 4). In addition,
the content of C15:0 fatty acid in the fab(B/F)− mutant strain was 0.48% of the total fatty acids, which
was not detected in the wild type (Table 4). These results suggested that the mutation of fabB/F gene
might block fatty acid elongation. It was reported that the homologous protein of FabB could not found
in some bacteria, but the homologous protein of FabF (FabY) had the dual functions of KAS I and KAS
II, but this is not common [40]. The above results suggested that fabB/F in Synechococcus sp. PCC 7942
might have the function of fatty acid carbon chain elongation (C < 18), which were consistent with the
functions of fabB and fabF in E. coli, where they carried out the elongation steps in fatty acid synthesis.
The fabB/F in Synechococcus sp. PCC 7942 was also involved in the de novo synthesis of the unsaturated
fatty acids of the microalgae and forming cis-11-octadecenoyl ACP by extending palmitoyl-ACP.
123
Mar. Drugs 2019, 17, 255
Table 4. Fatty acid profile of Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) deletion mutants
of Synechococcus sp. PCC 7942 after 16 days cultivation.
Fatty Acid (%) Wild Type a fab(B/F)− fabH−
C8:0 0.01 ± 0.00 0.06 ± 0.02 0.02 ± 0.00
C14:0 0.54 ± 0.04 0.63 ± 0.02 0.67 ± 0.07
C14:1 0.85 ± 0.02 0.91 ± 0.02 0.81 ± 0.00
C15:0 ND 0.48 ± 0.05 0.41 ± 0.03
C16:0 34.30 ± 0.25 36.21 ± 0.40 33.16 ± 0.04
C16:1 32.43 ± 0.63 30.93 ± 0.32 34.86 ± 0.70
C16:2 0.51 ± 0.01 0.64 ± 0.04 0.06 ± 0.00
C17:0 0.26 ± 0.06 0.69 ± 0.03 0.38 ± 0.05
C17:1 0.78 ± 0.14 0.74 ± 0.04 0.52 ± 0.05
C18:0 1.85 ± 0.03 1.93 ± 0.03 6.23 ± 0.58
C18:1 15.69 ± 0.90 13.71 ± 0.39 8.17 ± 0.35
C18:2 0.69 ± 0.05 0.79 ± 0.03 2.51 ± 0.54
C20:0 0.05 ± 0.00 0.02 ± 0.01 0.04 ± 0.00
a Wild type strain of Synechococcus sp. PCC 7942.
Table 4 also showed that the content of C18 decreased from 18.23% in the wild type to 16.91% in
fabH− mutant, with a decrease of 7.24%. Meanwhile, the content of C14 increased from 1.39% of the
wild type to 1.48% of the mutant, with an increase of 6.47%, and 0.41% content of C15 was obtained
(Table 4). These results indicated that the longer chain fatty acids decreased and shorter chain fatty
acids increased when fabH was mutated. Previous studies showed that fabH was a rate-limiting step
and also the first condensation step in the fatty acid synthesis circle in plants and bacteria [29,49]. The
present results suggested that Synpccw7942_1455 (fabH) might only participate in the fatty acid carbon
chain elongation (C < 18).
Nonetheless, the increment of SCFAs in mutants we observed was modest, far from our expectation.
It was also reported that some enzyme had the activity of KAS III, with the domain similar to FabH,
but whose molecular weight is larger than FabH, initializing fatty acid synthesis in Pseudomonas
aeruginosa [46]. Therefore, it is assumed that fab(B/F)− and fabH− mutants were considered as strains
deficient in fabB/F and fabH gene expression but not complete inactivation, or other proteins with
similar activity executed corresponding functions (KAS III).
2.5. Complementation of E. coli
In order to further verify the functions of the related genes, we attempted to construct mutant
strains of KAS I/II/III of E. coli and compared the fatty acid compositions of mutants with that of
their complementation.
As shown in Table 5, the content of C12, C14 and C16 in fab(B/F/H)− mutants of E. coli BL21 all
increased as compared with that of the wild type. These results were consistent with the results
that KAS III could catalyze acetyl-CoA with malonyl-CoA to generate 4:0-ACP, KAS I could catalyze
4:0-ACP to generate 16:0-ACP and KAS II could catalyze 16:0-ACP to generate 18:0-ACP as well as
regulate the ratio of 16:0-ACP/18:0-ACP [24]. Mutation of the genes might lead to changes in fatty acids.
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Table 5. Fatty acid profile of wild type, mutation and complementary mutation of E. coli.
Fatty Acid (%) E. coli BL21 fabB− fabF− fabH− Com-fabB a Com-fabF b Com-fabH c
C12:0 0.23 ± 0.02 0.3 ± 0.00 0.72 ± 0.10 0.78 ± 0.13 0.31 ± 0.12 0.50 ± 0.10 0.23 ± 0.01
C13:0 1.33 ± 0.11 ND ND 0.10 ± 0.00 1.19 ± 0.00 0.94 ± 0.23 1.87 ± 0.34
C14:0 2.88 ± 0.28 3.04 ± 0.23 3.69 ± 0.29 3.01 ± 0.46 2.88 ± 0.46 3.03 ± 0.33 3.87 ± 0.58
C14:1 ND 3.23 ± 0.20 0.21 ± 0.01 0.30 ± 0.00 ND ND ND
C15:0 8.25 ± 0.22 0.57 ± 0.03 1.02 ± 0.07 0.72 ± 0.15 6.32 ± 0.15 5.97 ± 0.55 12.45 ± 2.02
C16:0 33.98 ± 3.83 50.51 ± 2.75 48.59 ± 3.11 50.23 ± 3.64 33.82 ± 0.64 33.37 ± 2.50 34.76 ± 1.55
C16:1 2.78 ± 0.30 9.21 ± 0.22 9.94 ± 1.60 8.21 ± 0.94 2.60 ± 0.94 2.66 ± 0.35 3.08 ± 0.19
C17:0 5.02 ± 0.21 0.44 ± 0.04 0.60 ± 0.18 0.51 ± 0.07 3.56 ± 0.07 3.94 ± 0.42 7.57 ± 0.67
C17:1 2.69 ± 0.17 2.97 ± 0.31 2.46 ± 0.38 5.18 ± 0.56 3.71 ± 0.56 2.36 ± 0.34 1.99 ± 0.12
C18:0 2.30 ± 0.16 1.40 ± 0.15 2.93 ± 0.54 2.37 ± 0.40 2.62 ± 0.40 2.07 ± 0.23 2.20 ± 0.24
C18:1 20.57 ± 0.94 6.61 ± 0.51 7.12 ± 0.29 5.39 ± 0.68 20.51 ± 0.68 20.62 ± 2.83 5.55 ± 0.77
C18:2 0.17 ± 0.02 0.34 ± 0.02 0.52 ± 0.02 0.37 ± 0.03 0.16 ± 0.03 0.17 ± 0.03 8.36 ± 0.51
C19:0 1.11 ± 0.11 1.34 ± 0.05 1.22 ± 0.12 2.83 ± 0.29 5.20 ± 0.29 1.25 ± 0.15 0.96 ± 0.14
C20:0 0.03 ± 0.01 0.02 ± 0.00 0.04 ± 0.01 0.03 ± 0.00 0.04 ± 0.00 0.03 ± 0.00 0.03 ± 0.01
C20:1 1.59 ± 0.17 0.41 ± 0.04 0.73 ± 0.03 0.31 ± 0.03 1.76 ± 0.03 1.98 ± 0.17 1.03 ± 0.03
C21:0 0.01 ± 0.00 ND 0.02 ± 0.00 0.02 ± 0.01 0.01 ± 0.01 ND ND
C22:0 0.12 ± 0.01 0.03 ± 0.00 0.14 ± 0.02 0.07 ± 0.01 0.11 ± 0.01 0.09 ± 0.02 0.16 ± 0.01
C22:1 0.05 ± 0.00 0.02 ± 0.01 ND ND 0.08 ± 0.03 0.02 ± 0.00 ND
C23:0 0.10 ± 0.00 0.03 ± 0.01 0.05 ± 0.00 0.04 ± 0.01 0.06 ± 0.01 0.07 ± 0.00 0.17 ± 0.00
C24:0 0.09 ± 0.00 0.02 ± 0.00 0.05 ± 0.00 0.04 ± 0.01 0.06 ± 0.01 0.05 ± 0.00 0.15 ± 0.02
a E. coli BL21 fabB mutant complement with fabB/F of Synechococcus sp. PCC 7942. b E. coli BL21 fabF mutant
complement with fabB/F of Synechococcus sp. PCC 7942. c E. coli BL21 fabH mutant complement with fabH of
Synechococcus sp. PCC 7942.
Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) from Synechococcus sp. PCC 7942 were
used for E. coli mutants (fabB/F/H)− complementation. The results show that fatty acid compositions
of mutants were basically restored to that of the wild type after complementation (Table 5). These
suggested that the Synpccw7942_0537 (fabB/F) gene in Synechococcus sp. PCC 7942 has similar functions
of fabB and fabF of E. coli and was related to the elongation of fatty acids. Synpccw7942_1455 (fabH)
has similar function of fabH, which is also related to the elongation of fatty acid in Synechococcus sp.
PCC 7942.
2.6. Fluorescence Localization of the Related Proteins
In order to describe the SCFAs synthesis pathway in microalgae, cellular localization of
Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) by co-expressing green fluorescence protein
gene and potential genes were carried out. Figure 2 shows that the fusion expressed proteins of
eGFP-FabB/F and eGFP-FabH in Synechococcus sp. PCC 7942 were evenly dispersed on the cell
membrane, indicating that the enzymes corresponding to fabB/F and fabH were located on the cell
membrane. It is the first time to show the cell location of KASs.
 
Figure 2. The fusion expressed proteins of FabB/F-eGFP (a) and FabH-eGFP (b) in Synechococcus sp.
PCC 7942 observed under the confocal laser fluorescence microscope. (a) FabB/F labeled with eGFP in
Synechococcus sp. PCC 7942 for fluorescence localization; (b) FabH labeled with eGFP in Synechococcus
sp. PCC 7942 for fluorescence localization.
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Based on the above studies, a possible pathway for the SCFAs synthesis in Synechococcus sp. PCC
7942 is proposed. As shown in Figure 3, CO2 enters the microalgal cell and finally forms malonyl-ACP
through de novo fatty acids synthesis, then goes into the fatty acid synthesis pathway, where KAS
I/II (fabB/F) and KAS III (fabH) located on the cell membrane could catalyze condensation reactions to
accumulate different chain length fatty acids less than 18 carbon atoms. Previous research found that
fatty acids synthetic system started from acetyl-CoA carboxylase (ACCase), catalyzing the conversion
of acyl-CoA to malonyl CoA, which was thought to be a limiting step [50]. KAS III had also been proved
to be a limiting step in microalgae fatty acid biosynthesis. The above two limiting steps may affect the
fixation of CO2 in microalgae fatty acid biosynthesis. In the whole photosynthetic CO2 fixation process,
to increase the lipid productivity, ACCase and KAS III are the best options available for operation.
Overexpression of ACCase and KAS III genes has succeeded to regulate the lipid synthesis [29,51,52].
 
Figure 3. The proposed synthesis pathway of short carbon fatty acids (SCFAs) in Synechococcus sp.
PCC 7942.
3. Materials and Methods
3.1. Microalgae Cultures
Synechococcus sp. PCC 7942 used in the study was provided by Prof. Dingji Shi (Shanghai Ocean
University, Shanghai, China). Cells were preserved in the BG11 medium. The initial OD730 was
0.1, the initial pH was 7.8–8.0. The cultivation of Synechococcus sp. PCC 7942 was bubbled under
27 ± 1 ◦C and 140 mmol m−2 s−1 in 1 L Erlenmeyer flask with 500 mL working volume of BG11
medium. BG11 medium consists of (1 L) 1.5 g NaNO3; 0.03 g K2HPO4; 0.075 g MgSO4·2H2O; 0.036 g
CaCl2·2H2O; 0.006 g citric acid; 0.006 g ferric ammonium citrate; 0.001 g EDTA; 0.02 g Na2CO3 and 1 mL
micronutrient solution. The microelement solution consists of (1 L) 2.86 g H3BO3; 1.81 g MnCl2·4H2O;
0.222 g ZnSO4·7H2O; 0.39 g NaMoO4·5H2O; 0.079 g CuSO4·5H2O and 0.0494 g Co(NO3)2·6H2O.
Cell growth in BG11 medium was set as the normal growth condition. Different cerulenin
concentrations were set as follows: 0 g/L, 1 g/L, 2.5 g/L, 5 g/L and 7.5 g/L. Stock solution of cerulenin
(100 mg/L, preserved in ethyl alcohol, −20 ◦C) was added to BG11 medium with the final concentrations
at 0 day.
3.2. Genomic DNA Extraction and PCR Analysis
Genomic DNA of Synechococcus sp. PCC 7942 was isolated as described previously by Kuo
et al. [30]. Genomic DNA of Synechococcus sp. PCC 7942 transformant was prepared from exponential
growth phase cultures using a procedure based on cetyltrimethylammonium bromide (CTAB) method.
PCR analysis of transformants was carried out with genomic DNA as a template using primers as
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shown in Table S1 (Supplementary Materials). PCR amplification was performed for 30 cycles of 95 ◦C
for 1 min, 56 ◦C for 30 s, and 72 ◦C for 30 s, followed by 72 ◦C for 10 min.
3.3. Sense and Antisense Expression Vector Construction
Bioinformatics showed that two enzymes in Synechococcus sp. PCC 7942 were annotated with
β-ketoacyl ACP synthase activity. Alignments were proved that the sequence of Synpccw7942_0537
(Gene ID: 3774775) is similar to fabB and fabF in plants and bacteria, while the sequence of
Synpccw7942_1455 (Gene ID: 3773627) is similar to fabH in plants and bacteria. In this experiment, we
labeled them as fabF/B (Synpccw7942_0537) and fabH (Synpccw7942_1455), respectively.
The sequence Synpcc7942_0537 (fabB/F) and Synpcc7942_1455 (fabH) of Synechococcus sp.
PCC 7942 were amplified by PCR from total DNA, using 7942-anti-fabB/F-F, 7942-anti-fabB/F-R
and 7942-anti-fabH-F, 7942-anti-fabH-R (7942-sen-fabB/F-F, 7942-sen-fabB/F-R and 7942-sen-fabH-F,
7942-sen-fabH-R) primers (Table S1, Supplementary Materials) and then sub-cloned into pMD19-T
vector (pMD19-T Vector Cloning Kit, TaKaRa Biotech Co., Dalian, China), resulting in
pMD19T-antifabB/F (pMD19T-senfabB/F) and pMD19T-antifabH (pMD19T-senfabH) vectors. The
amplified DNA fragments were digested with restriction enzymes XhoI and KpnI, and ligated into the
corresponding sites of pRL489 vector to generate the antisense expression vectors (a) pRL-senfabB/F,
pRL-senfabH and antisense expression vectors (b) pRL-antisenfabB/F, pRL-antisenfabH, using kanamycin
as a selectable marker. These constructs were used for the natural transformation, then selected
transformants by gradient antibiotics screening. Plasmids were propagated and purified using a
standard procedure.
3.4. Deletion Mutant Construction
The plasmid pUC118 was constructed for gene deletion mutants of Synpcc7942_0537 (fabB/F) and
Synpcc7942_1455 (fabH). DNA fragments upstream and downstream of Synpcc7942_0537 (fabB/F) and
Synpcc7942_1455 (fabH) were amplified from Synechococcus sp. PCC 7942 genomic DNA using the
primers in Table S1 (Supplementary Materials). Chloromycetin gene was amplified from pET28a. These
upstream and downstream DNA fragments and chloromycetin gene were amplified by using overlap
PCR to form fabB/F-cat and fabH-cat fragments, and inserted into pUC118, replacing the corresponding
regions. The resulting plasmids (pUC118) contains homologous regions for gene deletion mutants of
Synpcc7942_0537 (fabB/F) and Synpcc7942_1455 (fabH), and chloromycetin antibiotic resistance was
used for selection. The deletion mutants were further confirmed by DNA sequence analysis (Figure S3,
Supplementary Materials).
3.5. Fusion Expression Vector of Green Fluorescence Protein Construction
The plasmid pRL489 was used for fusion expression vectors of green fluorescence protein gene
and Synpcc7942_0537 (fabB/F) and Synpcc7942_1455 (fabH). DNA sequences of Synpcc7942_0537
(fabB/F) and Synpcc7942_1455 (fabH) were amplified from Synechococcus sp. PCC 7942 genomic DNA
using the primers in Table S1 (Supplementary Materials). Enhanced green fluorescence protein
gene (egfp) fragment was from plasmid preserved in our laboratory. Synpcc7942_0537 (fabB/F) and
Synpcc7942_1455 (fabH) and egfp gene were amplified by using overlap PCR to form egfp-fabB/F and
egfp-fabH, and inserted into the pRL489, resulting pRL-egfp-fabB/F and pRL-egfp-fabH. Kanamycin
antibiotic resistance was used for selection.
3.6. Liquid Culture and Screening of Transgenic Microalgae
Monoalgal colonies screened under antibiotic were cultured in BG11 medium containing
kanamycin sulfate. Initially, transgenic microalgae was cultured in BG11 medium containing 25 g/L of
kanamycin, and then the concentration of kanamycin (50 g/L, 100 g/L, 150 g/L, 200 g/L, 250 g/L, and
300 g/L) was gradually increased. When the concentration of antibiotic was increased to 300 g/L, wild
type strains completely died under the pressure of antibiotic.
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3.7. RNA Extraction and cDNA Synthesis
Total RNA extraction was treated with Trizol reagent (Sangon Biotech, Shanghai, China).
Microalgal cells were harvested at different times (2 day intervals) by centrifugation. Approximately,
microalgal cells (0.1 g) were ground in liquid nitrogen to powder before adding 1 mL Trizol reagent.
After centrifugation at 12,000 r.p.m. for 10 min at 48 ◦C, 200 mL chloroform was added and mixed
thoroughly. The sample was centrifuged at 12,000 r.p.m. for 15 min, then 450 mL of the uppermost
layer was transferred into a fresh tube. Isopropanol (450 mL) was added to precipitated RNA and
then centrifuged at 12,000 r.p.m. for 15 min, washed with 1 mL ethanol (75%, v/v) twice, dissolved
in 30 mL diethyl pyrocarbonate treated distilled water. M-MLV (Moloney Murine Leukemia Virus)
reverse transcriptase (TaKaRa Biotech Co., Dalian, China) was used to synthesize the cDNA. Two fatty
acid synthetase genes (fabF/B and fabH) were investigated in this study. Genome annotation identified
putative components of fatty acid biosynthetic pathway including fabF/B and fabH. Primers were
designed according to the highly conserved regions obtained from the alignment of public database
and the deduced amino acid sequences. The primers used in the experiment were shown in Table S1
(Supplementary Materials). After amplification, the PCR products were purified and cloned into
pMD-19T vector for sequencing.
3.8. Quantitative Real-Time PCR
Real-time PCR was carried out on CFX96 Touch Real-Time PCR Detection System (Bio-Rad,
Hercules, CA, USA) using SYBR Premix Ex TaqTMII (TaKaRa Biotech Co., Dalian, China). The
reference gene was used as an internal standard, amplified with the rnpB-F/rnpB-R primers (Table S1,
Supplementary Materials). Real-time PCR was conducted following the procedure: 95 ◦C for 30 s
before performing 40 cycles of 95 ◦C for 5 s and 60 ◦C for 45 s, and a melting step at 60 ◦C–95 ◦C. PCR
efficiency of each gene was calculated by relative standard curve using sequential dilutions of the
cDNA. The 2−ΔΔCT method [53] was applied for the target gene expression calculation.
3.9. Lipid Extraction and Fatty Acid Analysis
Microalgal cells were harvested by centrifugation after cultivation. The total lipids were extracted
according to the following method. Lyophilized microalgae powder (0.2 g) was pulverized in a mortar
and extracted using 5 mL solvent mixture of chloroform:methanol (2:1, v/v). After shaking for 10 min,
the samples were centrifuged (5804R, Eppendorf, Germany) at 10,000 r.p.m. for 10 min. The procedure
was repeated three times to make sure the lipids were extracted completely. The solvent phase was
transferred by pipette and evaporated in a water bath at 60 ◦C.
The fatty acids component of the lipids was analyzed by GC-linked mass spectrometry (GC-MS).
Fatty acid methyl esters were obtained by acidic transesterification of the lipids. After reaction at 90 ◦C
for 2 h, 2.5 mL hexane and 1 mL water were added to the sample, then vibrated gently and centrifuged.
One milliliter of the organic upper phase was injected into an Auto System XL GC/Turbo Mass MS
(Perkin Elmer, Germany) using a DB-5MS (5% phenyl)-methylpolysiloxane nonpolar column (30 m ×
0.25 mm × 0.25 mm). At the beginning, the column temperature was kept at 60 ◦C for 4 min, then
increased to 220 ◦C, and finally reached to 280 ◦C with a temperature gradient of 10 ◦C min, maintained
for 10 min.
4. Conclusions
This study demonstrated that SCFAs synthesis of Synechococcus sp. PCC 7942 relied on β-ketoacyl
ACP synthase (KAS), where Synpccw7942_0537 (fabB/F) had the function of short chain fatty acids
elongation (C < 18) and elongation of C16:1 to C18:1, and Synpccw7942_1455 (fabH) could participate
the SCFAs elongation (C < 18). Moreover, cerulenin, which could inhibit the expression level of
Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH), led to SFCAs accumulation. Based on these
results, the SCFAs biosynthesis pathway in microalgae was proposed.
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Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/5/255/s1,
Table S1: Primers used in this experiment; Figure S1: Effects of different cerulenin concentrations on the growth of
Synechococcus sp. PCC 7942; Figure S2: The expression levels of fabB/F and fabH in Synechococcus sp. PCC 7942
with sense and antisense expression of Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH). The expression
levels of Synpccw7942_0537 (fabB/F) and Synpccw7942_1455 (fabH) in wild type strain were set to 1; Figure S3:
DNA sequence analysis of the deletion mutants. (a) Alignment of construction of fabB/F-cat deletion mutation; (b)
DNA fragment of fabB/F-cat; (c) alignment of construction of fabH-cat -cat deletion mutation; (d) DNA fragment of
fabH-cat.
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Abstract: The rapid emergence of multidrug-resistant pathogens makes an urgent need for discovering
novel antimicrobial agents as alternatives to conventional antibiotics. Towards this end, we designed
and synthesized a synthetic peptide of 23 amino acids (AAs) (1GWLIRGAIHAGKAIHGLIHRRRH23)
from a defense protein 3 cDNA sequence of Octopus minor. The sequence of the peptide, which
was named Octominin, had characteristic features of known antimicrobial peptides (AMPs) such
as a positive charge (+5), high hydrophobic residue ratio (43%), and 1.86 kcal/mol of Boman index.
Octominin was predicted to have an alpha-helix secondary structure. The synthesized Octominin
was 2625.2 Da with 92.5% purity. The peptide showed a minimum inhibitory concentration (MIC)
and minimum fungicidal concentration (MFC) of 50 and 200 μg/mL, respectively, against Candida
albicans. Field emission scanning electron microscopy observation confirmed that Octominin caused
ultrastructural cell wall deformities in C. albicans. In addition, propidium iodide penetrated the
Octominin-treated C. albicans cells, further demonstrating loss of cell membrane integrity that caused
cell death at both MIC and MFC. Octominin treatment increased the production of intracellular reactive
oxygen species and decreased cell viability in a concentration dependent manner. Cytotoxicity assays
revealed no significant influence of Octominin on the viability of human embryonic kidney 293T
cell line, with over 95% live cells in the Octominin-treated group observed up to 100 μg/mL.
Moreover, we confirmed the antifungal action of Octominin in vivo using a zebrafish experimental
infection model. Overall, our results demonstrate the Octominin is a lead compound for further
studies, which exerts its effects by inducing cell wall damage, causing loss of cell membrane integrity,
and elevating oxidative stress.
Keywords: anticandidal activity; antimicrobial peptides; Candida albicans; Octominin; Octopus minor
1. Introduction
Candida albicans is one of the most dominant fungal species of the human microbiota and
asymptomatically colonizes in the gastrointestinal and genitourinary tract in healthy people [1].
However, C. albicans is an opportunistic pathogen that can cause infections under certain pathological
and physiological conditions such as in diabetes, pregnancy, under steroidal chemotherapy,
and prolonged broad spectrum antibiotic administration, as well as in patients with acquired
immunodeficiency syndrome [2]. Multidrug resistance is considered to be the major cause for failures in
candidiasis treatment [3], and several pathogenic strains of C. albicans show multidrug resistance against
currently used antifungal drugs such as fluconazole, itraconazole, nystatin, caspofungin, ketoconazole,
flucytosine, and amphotericin B [4,5]. C. albicans shows a diversity of resistance mechanisms such as
a decrease in drug accumulation or drug affinity of its targets and changes in drug metabolism [6].
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Hence, it is important to identify and develop novel and less toxic anticandidal agents with high
therapeutic efficacy to effectively control infections with drug-resistant strains of C. albicans.
Antimicrobial peptides (AMPs) are short peptides that typically consist of less than 50 amino acids
(AAs) residues and exhibit antimicrobial activity [7]. To date, over 1200 AMPs have been identified or
predicted from bacteria, fungi, plants, invertebrates, nonmammalian vertebrates, and mammals [8,9].
The genes encoding AMPs are highly evolutionarily conserved components of the host defense system
against pathogenic microorganisms, and can thus be considered as “natural antibiotics” [10]. AMPs can
also be described as “host defense peptides” owing to their additional immunomodulatory functions
such as antitumor [11], antiendotoxin [12], cytokine and growth factor [6], immunomodulatory [9],
and wound healing functions [13]. The antimicrobial activity of AMPs has been reported against a
wide range of pathogens, including bacteria [14], yeast [15], fungi [16], viruses [17], and parasites [18].
Based on the secondary structure, AMPs can be classified into four major groups: α helical, β sheet,
loop, and extended peptide [19]. A common characteristic of AMPs is their amphipathic nature
with net positive charge due to the presence of multiple residues such as arginine (R), histidine (H)
and lysine (K) and hydrophobic residues such as alanine (A), leucine (L), isoleucine (I), tyrosine (Y),
and tryptophan (W) [20]. The ability of AMPs to kill microbial pathogens primarily depends on their
interaction and binding capacity with the cell membrane or cell wall, which vary according to the net
positive charge and ratio of hydrophobic AAs. This amphipathicity of AMPs is an important feature
for interacting with cell membranes or their mimics to induce antimicrobial functions, and binding of
AMPs to the cell membrane generally changes the membrane permeability and causes nonenzymatic
disruption [6], resulting in the efflux of intracellular materials to exert rapid bactericidal/fungicidal
activity [21].
Although various sources are available for isolating natural AMPs with different degrees of
functional activities, it is difficult to obtain sufficiently large quantities of the peptides with the purity
required for application in research or for therapeutic purposes. Therefore, the production of synthetic
AMPs is becoming an increasingly popular strategy, which can lead to the development of novel
therapeutic agents with a wide range of bioactivities [22]. Furthermore, intensifying the effort for
the identification and development of novel AMPs is essential to help suppress the rapid spread and
continued selection of multidrug-resistant pathogens.
Toward this end, the objective of this study was to screen for AMPs in the transcriptome of
Octopus minor, and synthesize the peptide to investigate its antifungal effect. A novel AMP was
screened and modified based on the defense protein 3 cDNA sequence of Octopus minor, which was
named Octominin. To evaluate its anticandidal function and mode of action, C. albicans was used as
a pathogenic model organism, and various parameters of Octominin in the presence of C. albicans
were determined, including the minimum inhibitory concentration (MIC), minimum fungicidal
concentration (MFC), and MFC/MIC ratios, along with the influence of the synthesized protein on
the fungal cell, including change of cell membrane structure, cell viability, reactive oxygen species
(ROS) production, propidium iodide (PI) uptake. Moreover, to establish the potential of Octominin for
development in therapeutic application, we assessed its cytotoxicity in the human embryonic kidney
HEK293T cell line. Based on the overall results and possible mode of action, we suggest that Octominin
is a potential lead molecule with fungicidal activity that can be developed for commercial use.
2. Results
2.1. Designing, Synthesis, and Characteristics of Octominin
Upon screening of the transcriptome database of O. minor for selection of AMPs, defense protein
3 cDNA sequence was considered as one of the candidates. Based on the antimicrobial peptide prediction
program [23], and subsequent modification of the sequence fragment, Octominin showed characteristics
of known AMPs, including a total net charge of +5, high number of positively charged residues (17%
R, 17% H), and hydrophobic residues (17% I, 8% L, 13% A, 4% W) with the total hydrophobic ratio of
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43% and protein binding potential (Boman index) of 1.86 kcal/mol. Moreover, the predicted grand
average hydropathy value (GRAVY) was −0.2696 and the predicted molecular weight of the peptide
was 2626.1 Da. Negatively charged AAs such as aspartate (D) and glutamate (E) were absent in the
Octominin sequence, and a total of eight hydrophobic residues were identified on the same surface of
the peptide. The predicted secondary and tertiary (three-dimensional) structures of Octominin are
shown in Figure 1, including an alpha-helix secondary structure. The molecular weight of synthesized
Octominin was 2652.2 Da with 92.5% purity (Supplementary Figure S1).
Figure 1. Predicted helical secondary and three-dimensional structures of Octominin. (A) Helical
wheel of Octominin shows the AAs arrangement and the residue numbers which are counted from
the amino (N) terminal of the peptide. The hydrophilic and hydrophobic residues are represented by
circles and diamonds, respectively. The potentially charged (positively charged) residues are marked as
pentagons in light blue. The most hydrophobic residue is green, and the amount of green is decreasing
proportionally to the hydrophobicity, with zero hydrophobicity coded as yellow. (B) Three-dimensional
structure and AA sequence of Octominin with positively charged residues.
2.2. MIC, MFC, and Growth Inhibition Profile of C. albicans Exposed to Octominin
We determined the MIC and MFC of Octominin to evaluate its ability for inhibiting the growth
of C. albicans as a candidate anticandidal agent. Octominin demonstrated a clear anticandidal effect
with a MIC and MFC of 50 and 200 μg/mL, respectively, representing a MFC/MIC ratio of 4.0.
Moreover, the time–kill kinetic analysis revealed clear growth inhibition of C. albicans above the
MIC level (Figure 2), which was similar to the growth inhibitory effect observed using the known
antifungal agent nystatin (10 μg/mL) as a positive control. In addition, Octominin showed partial
growth inhibition against C. albicans at a lower concentration (25 μg/mL) compared to that of the control.
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Figure 2. Time–kill kinetics of Octominin against C. albicans. C. albicans growth was assessed after
Octominin treatment (0, 25, 50, 75, and 100 μg/mL) at 3 h intervals by measuring the optical density
(OD) at 600 nm. The bars indicate the mean ± standard deviation (n = 3).
2.3. Effects of Octominin on Morphological Changes of C. albicans
To investigate the mode of action of Octominin, ultra-structural analysis of C. albicans was
conducted using field-emission scanning electron microscopy (FE-SEM) after Octominin treatment.
The SEM images clearly indicated membrane structural changes of C. albicans cells after treatment with
Octominin at the MIC and MFC (Figure 3). As expected, untreated C. albicans cells displayed a smooth
and undamaged cell surface (Figure 3A), whereas, swelling and severe cell wall alterations, including
a rough membrane and irregular shape, were observed in the C. albicans treated with 50 (Figure 3B)
and 200 μg/mL (Figure 3C) Octominin. Moreover, Octominin induced more severe morphological and
structural changes at the MFC level than at the MIC level.
 
Figure 3. Effect of Octominin on morphological and structural changes of C. albicans assessed by
field-emission scanning electron microscopy (FE-SEM). (A) Untreated C. albicans; (B) treated with 50
μg/mL (minimum inhibitory concentration; MIC;) Octominin; (C) treated with 200 μg/mL (minimum
fungicidal concentration; MFC) Octominin.
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2.4. Effects of Octominin on the Viability of C. albicans
The cell viability of C. albicans was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay after treatment with different concentrations of Octominin
(0–100 μg/mL). The cell viability was significantly decreased (P < 0.05) when C. albicans was treated
with Octominin in a concentration dependent manner (Figure 4). The control group showed the
highest cell viability, and the lowest cell viability of 9.25% was detected with treatment of Octominin at
100 μg/mL.
Figure 4. Effect of Octominin on the viability of C. albicans. Cell viability was assessed by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after treatment with different
concentrations of Octominin (0–100 μg/mL) until 24 h. * P < 0.05 compared to the control (untreated)
group. The error bars indicate the mean ± standard deviation (n = 3).
2.5. Effect of Octominin on the Membrane Permeability of C. albicans
The PI uptake assay was performed to evaluate the effect of Octominin on the membrane
permeability of C. albicans and its potential association with cell death. PI is an indicator stain
that can penetrate dead or damaged cells and subsequently bind with the nucleus, emitting red
fluorescence under a confocal laser scanning microscope (CLSM). The results of PI analysis showed
that Octominin induced clear membrane damage to the C. albicans cells in a concentration-dependent
manner (Figure 5). No PI-stained cells were detected in the untreated control group (Figure 5B,C).
Both PI-stained and nonstained cells could be observed after treatment of C. albicans with the MIC of
Octominin (Figure 5E,F), whereas all cells showed the red fluorescence signal after treatment with
Octominin at the MFC, indicating the highest degree of membrane permeability (Figure 5H,I).
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Figure 5. Effect of Octominin on membrane permeability in C. albicans. Confocal laser-scanning
microscope (CLSM) merged and fluorescence images representing the cell membrane permeability by
propidium iodide (PI) staining in C. albicans cells treated with Octominin at 30 ◦C for 6 h. (A–C) Untreated
control; (D–F) treatment with Octominin at the MIC (50 μg/mL); (G–I) treatment with Octominin at the
MFC (200 μg/mL).
2.6. Effects of Octominin on ROS Production in C. albicans
To investigate the mechanism of action of Octominin, we examined the change in the level of
endogenous ROS production in C. albicans after Octominin treatment, which was assessed by staining of
the fluorescent probe 5-(and-6)-carboxy-2,7-dihydrodichlorofluorescein diacetate (carboxy-H2DCF-DA).
The ROS level was increased in a concentration dependent manner when C. albicans was treated with
Octominin (Figure 6). Furthermore, C. albicans treated with 50 μg/mL (MIC) and 200 μg/mL (MFC) of
Octominin showed higher levels of ROS compared to those of untreated cells, indicating that Octominin
induced high oxidative stress in the cells.
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Figure 6. Effect of Octominin on reactive oxygen species (ROS) production of C. albicans. CLSM merged
and fluorescence images representing ROS production in C. albicans with Octominin treatment at the
MIC and MFC. (A–C) Untreated control; (D–F) treatment with Octominin at the MIC (50 μg/mL);
(G–I) treatment with Octominin at the MFC (200 μg/mL).
2.7. Cytotoxicity of Octominin to Mammalian Cells
To further explore the potential safety of Octominin in therapeutic application, its cytotoxicity
was tested using human embryonic kidney 293 (HEK293) cells with the EZ-Cytox enhanced cell
viability assay kit. No morphological changes of the cells were observed when treated with Octominin
up to 100 μg/mL (Figure 7B–D). There was no significant difference in cell viability between the
Octominin-treated samples and untreated control (P < 0.05), with over 95% of the HEK293 cells
remaining viable under all Octominin-treated concentrations up to 100μg/mL (Figure 7E). Overall, these
results confirmed that 100 μg/mL, which inhibits the growth of C. albicans by its anticandidal effects,
was not toxic to human cells, demonstrating its potential for use in vivo treatments after clinical trials.
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Figure 7. Cytotoxic effect of Octominin on HEK293 cells. (A–D) Representative images of Octominin-treated
HEK293 cells at 48 h post treatment. (A) Untreated (control), (B) 10 μg/mL Octominin, (C) 75 μg/mL
Octominin, (D) 100 μg/mL of Octominin. (E) Cell viability percentage of HEK293 cells treated with
Octominin at different concentrations (0, 10, 25, 50, 75, and 100 μg/mL). Data are expressed as the mean ±
standard error (n = 3).
2.8. Efficacy of Octominin Treatment on C. albicans Infection in a Zebrafish Model
C. albicans cells were injected to the dorsal muscle of adult zebrafish to study the effectiveness
of Octominin treatment under in vivo conditions. The cumulative mortality at 72 h post treatment
was 84% and 25% in the control and Octominin-treated (100 μg/fish per day) groups, respectively.
Moreover, superficial fungal growth and a wound around the infected site were clearly observed
in control (water-treated) fish (Figure 8A–C) at 24, 48, and 72 h post infection (hpi) compared
to Octominin-treated fish (Figure 8D–F). In addition, the histopathological data confirmed the
treatment effect against C. albicans, demonstrating less leukocyte infiltration around the infected
site of Octominin-treated fish (Figure 8I) than the infected and untreated fish (Figure 8H) at 72 hpi.
 
Figure 8. Anticandidal effect of Octominin in C. albicans-infected zebrafish. C. albicans growth and
wound area at 24, 48, and 72 h post treatment of Octominin compared with the control (water-treated) fish.
(A–C) C. albicans infected nontreated control. (D–F) C. albicans-infected Octominin treated fish.
Effect of Octominin treatment in zebrafish muscle tissue upon C. albicans infection evaluated by
periodic acid-Schiff-hematoxylin (PAS-H)-stained sections under microscope (400×). Muscle tissues of
uninfected (G), infected and untreated treated (H), and infected and Octominin-treated (I) zebrafish.
Black arrowhead shows the leukocyte infiltration in the muscle tissue of zebrafish.
140
Mar. Drugs 2020, 18, 56
3. Discussion
Discovery of novel AMPs is important to identify potential drug candidates for treating infections
with multidrug-resistant pathogens such as C. albicans. Several AMPs with diversified antimicrobial
functions have been identified from many species of the phylum Mollusk including abalone [14].
We previously reviewed the AMPs in marine mollusks and their potential biomedical applications [24];
thus, the present study represents a further extension of our AMPs research in different mollusk species
of the class Cephalopoda. Through screening of the transcriptome database of O. minor, we discovered
a defense protein 3 cDNA sequence, and a fragment of its AAs sequence was selected and modified,
and named Octominin for development of a novel AMP. Octominin shares 92% and 88% identity with
two related AMPs namely Chrysophsin-2 and Chrysophsin-1, respectively [25]. We further confirmed
that Octominin inhibits the growth of C. albicans with a MIC and MFC of 50 and 200 μg/mL, respectively.
A chemically synthesized porcine peptide PMAP-23 was reported to have marked antifungal activity
(MIC 2–5 μM) against C. albicans [26]. In addition, Nikawa et al. [27] synthesized three new cationic
peptides with an α-helical structure and amphipathic properties and their abilities to inhibit C. albicans
were compared to those of known antifungals. The authors suggested that the α-helicity of the peptides
has a limited contribution to the killing effect; however, the p-value was positively correlated with
greater antifungal activity. Although the MIC of Octominin is relatively high, C. albicans growth was
still delayed by about 3 h (in time–kill kinetics) as same to the 100 μg/mL. Moreover, 50 and 100 μg/mL
of Octominin treatment resulted 35% and 5% cell viability at 24 h, respectively. This indicates that
the viable cell number decreases rapidly under Octominin treatment, suggesting the efficient killing
of the C. albicans cells. Therefore, the anticandidal activity of Octominin could be associated with its
amphipathic nature, total hydrophobicity (43%), and net positive charge (+5).
Several peptides have been reported to cause ultrastructural damage to the cell wall of C. albicans.
For example, a short peptide bovine lactoferrin (FKARRWQWRM) showed efficient inhibitory activity
against Candida by damaging the cell wall via direct interaction with the cell surface, followed by
induction of the autolytic response [28]. Moreover, the chemically synthesized HP (2-20) peptide derived
from the N-terminus Helicobacter pylori ribosomal protein L1 showed free diffusion of PI suggesting
that the C. albicans cell membrane was damaged [29]. Similarly, PMAP-23 exerts its antifungal activity
by creating pores in the cell membrane rather than to the cell wall [26]. Another synthetic hybrid
peptide, HP(2-9)-magainin 2(1-12), showed strong antifungal activity via damage to the fungal cell
membrane, resulting in K+ release from the cells [18]. The FE-SEM images of Octominin-treated cells
clearly demonstrated its ability to damage the cell wall and the membrane based on the high number
of malformed cells. Moreover, free diffusion of PI into the cytoplasm of C. albicans suggested that
Octominin might have strong damaging effects on the C. albicans cell wall and/or cytoplasmic membrane.
Furthermore, we demonstrated that at least part of the mode of action of Octominin in C. albicans
cells was associated with the accumulation of ROS based on oxidation of the fluorescent dye DCFH-DA
(an indicator of ROS). The formation of ROS such as superoxide anion (O2−), hydroxyl radical (–OH),
hydrogen peroxide (H2O2), and singlet oxygen (1O2) can lead to oxidative stress in cells, consequently
inducing damage to the macromolecules such as DNA, RNA, and proteins. A state of oxidative stress
could activate degradation of the structural components, i.e., cellular membranes, and inactivate their
basic functions by increasing the permeability, ultimately resulting in exposure of the cellular contents
to the extracellular environment [30]. Indeed, the formation of ROS has been suggested as a critical
step in the fungicidal mechanism of several AMPs [31]. However, Veerman et al. [32] suggested that
ROS production did not play a role in the killing effect of the human salivary peptide histatin 5 in C.
albicans. Moreover, histatins bind to a receptor on the fungal cell membrane and enter the cytoplasm,
subsequently the mitochondrion, suggesting a role in oxidative stress [33]. Thus, the precise mode of
action of some of the antifungal peptides against C. albicans remains controversial or unclear.
Based on its physico-chemical properties (alpha-helical, amphipathic, hydrophobic, and cationic),
FE-SEM images, PI uptake, and ROS accumulation, we suggest that Octominin has multifactorial
effects on C. albicans, resulting in structural disruption of the cell wall and the membrane to ultimately
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kill the fungal cells. We propose that Octominin may directly interact with the cell wall and then
the phospholipid bilayer of the fungal cell membrane, leading to alterations of lipid organization in
the membrane or the formation of ion-permeable channels (i.e., pores) in the membranes allowing
for diffusion of the cell contents. Further, Octominin might directly interact with the cell membrane
of C. albicans to disrupt its function and enhance its permeability. Octominin could then reach
intracellular targets, the nucleus and DNA, leading to apoptosis. However, the exact mechanism by
which Octominin exerts its fungicidal activity will need to be explored and identified in future studies.
One of the crucial problems associated with the development of an antifungal therapeutic drug is
the cytotoxicity of the peptide that limits its safety and application. Here, we conformed that Octominin
does not influence the viability of mammalian cells. Further, the overall results of in vivo experiments
with a zebrafish infection model suggested that Octominin could effectively reduce the C. albicans
infection; however, complete recovery was not observed, which may have been due to loss of some
Octominin in the water after the treatment. Nevertheless, this result suggests that Octominin has
good potential for triggering the host defense against C. albicans, supporting its functional novelty.
Moreover, Octominin can be used safely as an anticandidal agent against C. albicans with maximum
efficacy. However, its safety and mechanism of action need to be elucidated more detail in future studies.
In summary, although the properties of Octominin are somewhat inconsistent with those of
previously reported anticandidal peptides, the basic characteristics as an AMP were confirmed. The net
positive (+5) charge of the novel peptide Octominin leads to its affinity towards the lipid plasma
membrane and specificity for Candida, and favors the interaction towards the anionic components in the
C. albicans plasma membrane. Octominin showed a potent anticandidal activity without mammalian
cell toxicity, demonstrating its potential for development as a novel anticandidal therapeutic agent.
Despite expanding knowledge of antifungal peptides in recent years, this study demonstrates the
untapped potential for discovering novel effective antifungal compounds, which can help to overcome
current challenges of the treatment of drug resistant infections.
4. Materials and Methods
4.1. Design and Synthesis of the Screened AMP in O. minor
We screened the immune functional gene sequences from our O. minor transcriptome database for
selection of candidate AMPs. The defense protein 3 cDNA sequence was selected and submitted to the
National Center for Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov/) database under
the accession number MN876862. The N-terminal region of the defense protein 3 AA sequence was
selected as a template for designing the Octominin peptide using the prediction tool of the antimicrobial
peptide database (APD) (http://aps.unmc.edu/AP), [23] according to the criteria of hydrophobicity,
net charge, total hydrophobic ratio, and protein binding potential. We modified the selected sequence
by increasing the number of hydrophobic (2 to 4 I, 1 to 2 L, 1 to 3 A, and 0 to 1 W) and positively charged
residues (3 to 4 R and 0 to 4 H) to obtain the characteristic features of an AMP, resulting in the novel
23-AA Octominin peptide (1GWLIRGAIHAGKAIHGLIHRRRH23). The peptide was synthesized by a
solid-phase peptide synthesis technique (AnyGen Co., Gwangju, Korea) and purified by reverse phase
high performance liquid chromatography using a SHIMADZU C18 analytical column (Shimadzu
HPLC LabSolution, Kyoto, Japan).
4.2. Culture of C. albicans
We used the C. albicans strain KCTC 27242 from the Korean Collection for Type Culture. A single
colony picked up from a potato dextrose agar (PDA) plate was cultured in potato dextrose broth (PDB)
under aerobic conditions at 30 ◦C for 24 h in a shaking incubator at 180 rpm. The C. albicans culture
was centrifuged at 3500 rpm for 10 min to harvest the cells and washed twice with phosphate buffered
saline (PBS, pH 7.4) followed by re-suspension in PBS (OD600 0.1) to adjust the concentration of 106
colony forming units per milliliter (CFU/mL), which was measured using a hemocytometer [30].
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4.3. Determination of MIC and MFC of Octominin for C. albicans
The MIC and MFC levels of Octominin on C. albicans were determined using the broth microdilution
susceptibility test and subculture, respectively according to the guidelines of the Clinical and Laboratory
Standards Institute (CLSI, 2008 M27-A3). Different concentrations (0–200 μg/mL) of Octominin were
tested with 10 μg/mL nystatin (Sigma-Aldrich, Saint Louis, USA) as a standard antifungal drug
(positive control) [33]. The MIC was determined as the minimal concentration required to inhibit the
visual growth of C. albicans. The MFC was determined by sub-culturing 10 μL of the medium collected
from the wells showing no microscopic growth after 48 h on PDA medium plates, representing the
lowest concentration that yielded no colonies after 24 h growth on agar. The calculated MFC/MIC
ratio was used to determine whether the AMPs Octominin had more fungistatic (MFC/MIC ≥ 4) or
fungicidal (MFC/MIC < 4) activity according to previously reported criteria [34]. For the time kill
kinetic analysis, C. albicans (106 CFU/mL) was incubated with Octominin at various concentrations
(0–100 μg/mL) in PDB at 30 ◦C, and the inhibitory effects were investigated after incubation at different
time intervals (0, 3, 6, 9, 12, 15, 18, and 21 h) by measuring the absorbance at 600 nm using a microplate
reader (Bio-Rad, Saint Louis, USA). The time–kill analysis experiment was performed in triplicate.
4.4. Determination of the Effect of Octominin on C. albicans Cell Viability
The effects of Octominin on the viability of C. albicans were tested by MTT assay as described by
Dananjaya et al. [30]. In brief, C. albicans was cultured in PDB (1 × 106 CFU/mL) and treated with the
different concentrations of Octominin at 30 ◦C for 24 h in a shaking incubator at 180 rpm. The culture
was then centrifuged at 3500 rpm for 10 min and the cells were washed with PBS. For the cell viability
assay, C. albicans cells were reacted with 20 μL of MTT reagent (Sigma Aldrich, Saint Louis, USA) for
30 min, and the samples were re-suspended with dimethyl sulfoxide (Sigma Aldrich, Saint Louis City,
USA). The cell viability was calculated based on the OD at 570 nm using a microplate reader (Bio- Rad,
Saint Louis, USA).
4.5. Analysis of Morphological Changes of C. albicans upon Octominin Treatment
To investigate the effect of Octominin on the cell morphology of C. albicans, FE-SEM analysis was
conducted as described by Dananjaya et al. [30] with some modifications. C. albicans cells (106 CFU/mL)
were treated with Octominin at the MIC (50 μg/mL) and MFC (200 μg/mL) for 6 h. As a control, C.
albicans cells were left untreated and cultured for the same period. The cells were pelleted, washed
with PBS, and prefixed with 2.5% glutaraldehyde for 30 min. The prefixed cells were then washed
with PBS, and serially (30%, 50%, 70%, 80%, 90%, and 100%) dehydrated using ethanol. The fixed cells
were dried and coated with platinum using an ion sputter (E-1030, Hitachi, Japan). Treated and control
C. albicans cells were observed by FE-SEM (Sirion FEI, Eindhoven, The Netherlands).
4.6. Determination of the Effect of Octominin on the Membrane Permeability of C. albicans
To determine the effect of Octominin on membrane permeability, a PI uptake assay was conducted
as described by Dananjaya et al. [30]. PI is a red-fluorescent nuclear and chromosome counterstain that
indicates changes of cell membrane permeability, and is commonly used to detect the presence of dead
cells. Octominin-treated (MIC; 50 μg/mL and MFC; 200 μg/mL levels) and control cell suspensions of
C. albicans were centrifuged (5000 rpm for 2 min) and the pellets were resuspended in PBS. The cells
were then incubated with 5 μg/mL of PI (Sigma Aldrich, Saint Louis, USA) at 30 ◦C for 15 min in the
dark, and then the excess stain was washed with PBS. Finally, one drop of each suspension was placed
on a cover slip, and fluorescence images were observed using a CLSM with a scan head integrated to
the Axiovert 200 M inverted microscope (Carl Zeiss, Jena, Germany). The PI fluorescence emission
was recorded at 585 nm.
143
Mar. Drugs 2020, 18, 56
4.7. Effect of Octominin on ROS Production in C. albicans
Accumulation of ROS in C. albicans was quantified using fluorescent probe carboxy-H2DCF-DA
(Invitrogen, Carlsbad, USA). In brief, C. albicans culture (106 CFU/mL) was treated with Octominin
(MIC; 50 μg/mL and MFC; 200 μg/mL) and incubated at 30 ◦C for 6 h. The cells were then harvested by
centrifugation at 5000 rpm for 2 min. To detect ROS levels, the cells were stained with H2DCF-DA
(30 μg/mL) and incubated for 30 min at room temperature (24 ± 1 ◦C) followed by centrifugation at
5000 rpm for 2 min. The cells were washed with×1 PBS and the dichloro-fluorescein (DCF) fluorescence
was measured using CLSM (LSM5 Live Configuration Variotwo VRGB, Zeiss, Germany) at an excitation
wavelength of 488 nm and an emission wavelength of 535 nm.
4.8. Analysis of Octominin Cytotoxicity on Mammalian Cells
To determine the cytotoxicity of Octominin, HEK293T cells (American Type Culture Collection
ATCC-11268) were treated with Octominin, and the cell viability was assessed. In brief, HEK293T
cells were seeded in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, USA) with 1%
antibiotic/antimycotic solution (Glibco, Carlsbad, USA) and 10% fetal bovine serum (Hyclone, Carlsbad,
USA). The cells were then seeded in 96-well flat bottom microtiter plates at a density of 1.5 × 104 cells
per well with 100 μL of medium, and incubated at 37 ◦C in a 5% CO2 atmosphere. After 24 h of culture,
the medium was aspirated out, and the cells were washed with PBS. Each well was treated with different
Octominin concentrations (0–100 μg/mL). Untreated cells were used as a control. Ultimately, cell
viability was determined at 48 h post treatment using EZ-Cytox Enhanced cell viability assay kit
(DoGenBio Co., Seoul, Korea) following the manufacturer’s protocol.
4.9. In Vivo Efficacy of Octominin upon C. albicans Infection in a Zebrafish Model
4.9.1. Zebrafish Husbandry
All zebrafish experiments were conducted in accordance with the institutional animal ethics
guidelines and under supervision and approval of the committees of Chungnam National University
(CNU-00866). Wild-type AB zebrafish were maintained under standard culturing conditions using an
automated water recirculating system (14 h:10 h light:dark cycle at 28 ± 0.5 ◦C, conductivity of 500 +
50 μS/sm, feeding equivalent to 4% of their body weight per day) throughout the experimental period.
4.9.2. Determination of In Vivo Efficacy of Octominin upon C. albicans Infection
The effectiveness of Octominin as an antifungal agent was tested using a zebrafish model of
C. albicans infection according to the method described by Kulatunga et al. [35]. In brief, a total of
18 zebrafish (average weight: 0.35 ± 0.05 g) were divided into three groups: (1) Uninfected control
with water treatment (Control), (2) C. albicans infected and water treated (Water treated), and (3) C.
albicans-infected and Octominin-treated (Octominin-treated). The fish were anesthetized using system
water containing 160 μg/mL of buffered tricaine (Ethyl 3-aminobenzoate methanesulfonate). C. albicans
(4 μL) was injected intramuscularly into the dorsal muscle of the water-treated and Octominin-treated
zebrafish groups at a dose of 1 × 106 cells/fish using Hamilton®syring (10 μL). Fish in the control group
were injected with 4 μL of autoclaved distilled water. Twenty microliters of Octominin (100 μg/fish)
was treated to the fish as a topical application by placing it at the site of fungal injection. Treatment was
administered after the infection (0 h) and then every 24 hpi up to 72 hpi. After the treatment, fish were
kept outside for 3 min to allow for Octominin absorption to the infection site and then released back to
the aquarium tanks. The water-treated group received the same treatment but with the same volume of
water. All fish were kept in individual tanks during the experiment period. To confirm the antifungal
effect of Octominin, photographs of both the water- and Octominin-treated fish were acquired for
comparing the infected/healed area at 24, 48, and 72 hpi. For histological examinations, fish were
euthanized with an over dose of tricaine, and then the muscle tissues at the infection site were collected
and preserved in 10% neutral buffered formalin for 24 h. Formalin fixed muscle tissues were processed
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(Leica® TP1020 Semi-enclosed Benchtop Tissue Processor, Nussloch, Germany), embedded (Leica
EG1150 Tissue Embedding Center, Nussloch, Germany), and sectioned into 4 μm thickness (Leica
RM2125 microtome, Nussloch, Germany). The tissue samples were stained by standard PAS staining.
Briefly, the sections were deparaffinized in xylene, and rehydrated in a series of ethanol using, distilled
water. The sections were then treated with periodic acid (0.5 mg/mL), washed well in distilled water,
and stained with Schiff’s reagent. Stained sections were then washed well in fast running lukewarm
tap water, the nuclei were stained with hematoxylin, and the sections were rinsed in tap water followed
by differentiation in acid alcohol and bluing in Scott’s tap water. Finally, the sections were dehydrated
in a series of ethanol, cleared in xylene, and mounted with a xylene based medium. Sections were
examined under a light microscope (Leica 3000 LED, Wetzlar, Germany) and the images were captured
with a Leica DCF450-C camera (400×).
4.10. Statistical Analysis
All experimental data were analyzed using GraphPad Prism software version 5 (GraphPad
Software Inc., La Jolla, USA). One way of analysis of variance and unpaired two-tailed t-test were
performed to find the significant (P < 0.05) differences between controls and peptide treated samples
and the data are presented as means ± standard deviations for replicates.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/1/56/s1,
Supplementary Figure S1.
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Abstract: Marine natural products are considered to be valuable resources that are furnished with
diverse chemical structures and various bioactivities. To date, there are seven compounds derived
from marine natural products which have been approved as therapeutic drugs by the U.S. Food and
Drug Administration. Numerous bromotyrosine derivatives have been isolated as a type of marine
natural products. Among them, psammaplin A, including the oxime groups and carbon–sulfur bonds,
was the first identified symmetrical bromotyrosine-derived disulfide dimer. It has been found to
have a broad bioactive spectrum, especially in terms of antimicrobial and antiproliferative activities.
The highest potential indole-derived psammaplin A derivative, UVI5008, is used as an epigenetic
modulator with multiple enzyme inhibitory activities. Inspired by these reasons, psammaplin
A has gradually become a research focus for pharmacologists and chemists. To the best of our
knowledge, there is no systematic review about the biological activity and structural modification of
psammaplin A. In this review, the pharmacological effects, total synthesis, and synthesized derivatives
of psammaplin A are summarized.
Keywords: psammaplin A; marine natural product; biological activity; structural modification
1. Introduction
Accumulating evidence indicates that natural products isolated from plants, animals, and
microorganisms have played irreplaceable roles in the development of new drugs for human
therapeutics [1–9]. It is noteworthy that marine natural products are considered to be extremely
valuable resources of natural products and are furnished with diverse chemical structures and
various bioactivities [10–12]. With the rapid development of technologies of scuba diving and
marine prospection, great interest has been shown in unexplored marine natural products, which are
considered to be potential sources for drug discovery [13–16]. To date, seven compounds derived
from marine natural products, including cytarabine [17], vidarabine [18], ziconotide [19], omega-3
acid ethyl esters [20], eribulin mesylate [21], brentuximab vedotin [22], and iota-carrageenan [17], have
been approved as therapeutic drugs by the U.S. Food and Drug Administration. The symmetrical
disulfide dimer psammaplin A (1, Figure 1), belonging to open-chain α-oximinoamidesis, was
originally isolated from Psammaplysilla (revised to Pseudoceratina) sp. and an unidentified sponge
in 1987 [23–25], which represents the first isolated natural product containing oxime and disulfide
moieties from marine sponge. Subsequently, biprasin, psammaplin C, psammaplin E, psammaplin F,
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psammaplin G, and psammaplin K (Figure 1) were also obtained [26–29]. Of these compounds,
psammaplin A has attracted much attention because of its strong antimicrobial and cytostatic
properties. Psammaplin A displays antibacterial activity mainly against Staphylococcus aureus (SA)
and methicillin-resistant Staphylococcus aureus (MRSA) due to DNA gyrase inhibition and bacterial
DNA synthesis arrest [30]. It was also reported that psammaplin A possesses antiproliferative
activities against various cancer cell lines, including triple-negative breast (TNBC, MDA-MB-231),
doxorubicin-resistant human breast (MCF-7/adr), colon (HCT15), ovarian (SK-OV-3), lung (A549,
LM4175), bone (BoM1833), endometria, brain (BrM-2a), skin (SK-MEL-2), and central nervous system
(XF498) cancer cell lines [29,31–34]. Additionally, the bactericidal and cytotoxic effects of psammaplin A
were related to multiple enzyme inhibition, such as DNA gyrase [30], topoisomerase II [35], chitinase [36],
farnesyl protein transferase [37], mycothiol-S-conjugate amidase [38], leucine aminopeptidase [37],
DNA polymerase α-primase [39], aminopeptidase N [40], and especially potent inhibitory effects on
histone deacetylases (HDAC) and DNA methyltransferase (DNMT) enzymes [28]. These enzymes
exert extremely important roles in the epigenetic regulation of gene expression. Moreover, psammaplin
A also exhibits potent enzyme inhibitory and antiproliferative activities under reduced conditions
in cells, which indicates that psammaplin A could be used as a natural prodrug [41]. Although
psammaplin A possesses a broad spectrum of bioactivities, its in-depth study has been hindered due
to the limited amount of the compound that can be isolated from marine microorganism sources, as
well its poor physiological stability. Inspired by this, many research groups have carried out its total
synthesis and synthesis of derivatives. For example, the most potential indole-derived psammaplin A
derivative, UVI5008 (Figure 1), was used as an epigenetic modulator with multiple enzyme inhibitory
activities [42].
 
Figure 1. The chemical structure of psammaplin compounds, biprasin and UVI5008.
Over the last two decades, more than ten reviews have covered the field of marine natural products
from various distinct viewpoints [43–57]. Hentschel et al. published an excellent paper on the synthesis
of oximinotyrosine-derived marine natural products, including psammaplin A, covering the literature
until 2009 [43]. Therefore, the synthetic methods of psammaplin A summarized in this review are
those reported after 2009. In addition, structural modification work, structure–activity relationships,
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and further mechanistic studies of psammaplin A in the field of antibacterial activity and cytotoxicity
have been studied by some research groups; these studies consistently confirm that the disulfide bond
and the oxime moieties are indispensable for the bioactivities of psammaplin A. However, there is no
systematic review of the biological activity and structural modification of psammaplin A. Thus, in this
review, the pharmacological effects, total synthesis, and derivatives of psammaplin A are summarized.
2. Synthetic Chemistry
Although psammaplin A possesses a broad bioactive spectrum, its in-depth study has been
hindered due to the limited amount of the compound that can be isolated from marine microorganism
sources. Consequently, many research groups have carried out its total synthesis. To the best of our
knowledge, Hentschel et al. have summarized the total synthesis of psammaplin A, covering the
literature until 2009 [43]. Therefore, here, we update the total synthesis methods.
Psammaplin A (1, Figure 1) consists of a symmetrical disulfide with a cystamine linker
functionalized on both sides by tyrosine-derived α-(hydroxyimino)acyl moieties [58]. Briefly, the
conventional total synthesis method of psammaplin A is initiated from tyrosine or phenylpyruvic
acid derivatives [59–62]. Then, the Lindel group optimized the synthetic method of psammaplin A
through the Horner–Wadsworth–Emmons (HWE) route (Scheme 1) [63]. The intermediate 4 was
synthesized by the HWE reaction of phosphonate 3 with aldehyde 2, then oxime 5 was formed after
desilylation of 4 under the condition of NEt3·3HF. Debenzylation of 5 in the presence of H2/Pd–C gave
the hydroxyimino isomers; later, methyl ester saponification with lithium hydroxide obtained acid 6.
Finally, the esterification of 6 with two equivalents of cystamine dihydrochloride under the condition of
NEt3, DCC, and N-hydroxysuccinimide (NHS) in DMF generated the natural product psammaplin A.
 
Scheme 1. Synthesis route of psammaplin A by the Lindel group. Reagents and conditions: (a) LDA,
THF, −78 ◦C, 15 h; (b) NEt3·3HF, MeOH, rt, 30 min; (c) (i) H2, Pd/C, dioxane, rt, 41 h; (ii) LiOH·H2O,
THF/H2O, rt, 40 h; (d) cystamine dihydrochloride, NHS, DCC, Et3N, DMF, rt, 15 h.
The Harburn group reported another synthetic route starting from the benzaldehyde 2
(Scheme 2) [64]. Firstly, 2 was converted to benzylidene rhodanine 7 in excellent yield. Then,
hydrolysis, acidification, and oximation of 7 afforded O-benzyl protected oximino acid 8. The coupling
of 8 with cystamine generated sponge metabolite 9 protected by the benzyl group. Finally, deprotection
of 9 proceeded successfully in CH2Cl2 using TMSI to provide psammaplin A.
The Park group developed a new efficient and concise synthetic method for preparing psammaplin
A (Scheme 3) [65,66]. Initially, the α,β-unsaturated ester 11 was obtained by Knoevenagel condensation
of 4-hydroxybenzaldehyde (10) with ethyl acetoacetate using acetic acid and piperidine. Then the
catalytic hydrogenation of 11 generated compound 12 through Pd/C and H2 in methanol. The
bromination of 12 with KBrO3 and KBr in methanol under the condition of 0.5 M-HCl provided 13.
The treatment of n-butylnitrite with 13 in ethanol under the condition of sodium ethoxide at 0 ◦C
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yielded α-NO substituted 13 analogue. After α-nitrosation, the fragmentation initiated by addition of
ethoxide anion to the acetyl group led to ethyl acetate release, followed by rearrangement to obtain the
α-oxime ester 14. The oxime hydroxyl group of 14 was protected with dihydropyran (DHP) under the
condition of catalytic amount p-toluenesulfonic acid (PTSA) to obtain 15. Then, 15 was hydrolyzed to
the acid 16 with 1 N potassium hydroxide in ethanol. 16 and N-hydroxyphthalimide were coupled
under the condition of EDC in 1,4-dioxane to synthesize 17, followed by adding cystamine to afford
the THP-protected psammaplin A. Finally, the THP-protected psammaplin A was deprotected in the
presence of the solution of methanolic hydrochloride to get psammaplin A.
Scheme 2. Synthesis route of psammaplin A of the Harburn Group. Reagents and conditions:
(a) Rhodanine, NH4OAc, toluene, reflux; or Rhodanine, NaOAc, AcOH, reflux; (b) (i) NaOH, H2O; (ii)
HCl (10%), 0 ◦C; (iii) HCl·NH2OBn, NaOAc, EtOH, 70 ◦C; (c) cystamine dihydrochloride, EDC, HOBt,
Et3N, CH2Cl2; (d) TMSI, CH2Cl2.
 
Scheme 3. Synthesis route of psammaplin A of the Park group. Reagents and conditions: (a) ethyl
acetoacetate, piperidine, AcOH; (b) H2, Pd/C, MeOH; (c) KBrO3, KBr, 0.5 M-HCl, MeOH; (d) n-BuONO,
AcOEt, NaOEt, EtOH, 0 ◦C; (e) DHP, PTSA, CH2Cl2; (f) 1 N-KOH, EtOH; (g) N-hydroxyphthalimide,
EDC, 1,4-dioxane; (h) (i) cystamine, Et3N, MeOH, 1,4-dioxane; (ii) 1 N HCl/Et2O CH2Cl2/MeOH.
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3. Pharmacological Activity
The pharmacological activities of psammaplin A and its derivatives include antibacterial, antiviral,
anticancer, insecticidal, embryo development promotive, chemical defensive eryptosis inducing, and
anticancer activities. These works can be classified as follows.
3.1. Antimicrobial Activity
Sortase enzymes, transpeptidases from Gram-positive bacteria, are responsible for anchoring
surface protein virulence factors to the peptidoglycan cell wall layer. In Gram-positive SA, sortase
isoform deletion results in significant reduction in infection potential and virulence. Psammaplin A
showed potent inhibition of Sortase A and B, and adhesion of SA cells to fibronectin (Figure 2) [67].
Figure 2. Schematic representation of the antimicrobial activity of psammaplin A.
The threat of multidrug-resistant bacterial strains against human health is increasing, and a large
number of people die every year from the spread of resistant strains. Studies by Kim et al. showed
that psammaplin A could inhibit Gram-positive bacteria, such as MRSA. Psammaplin A inhibited
DNA synthesis with an IC50 value of 2.83 μg/mL, and DNA gyrase activity with an IC50 value of
100 μg/mL. [30]. Franci et al. screened a group of previously identified epigenetic regulators, and some
could change the growth of Gram-positive bacteria. UVI5008 (Figure 1), a derivative of psammaplin A,
was identified. The growth inhibition activity against MRSA was caused by cell wall modification [68].
Lee et al. measured the inhibition of Gram-negative Vibrio vulnificus (V. vulnificus)-induced
cytotoxicity by 12 compounds from natural seafood in intestinal epithelial cells (INT-407). The results
showed that psammaplin A significantly inhibited V. vulnificus-induced cytotoxicity, which indicated
that psammaplin A could be developed for the prevention and treatment of V. vulnificus infection [69].
Tabudravu et al. tested the chitinase inhibition activity of psammaplin A in Bacillus, Streptomyces,
and Serratia marcescens. The results showed that psammaplin A noncompetitively inhibited
endochitinase activity with IC50 values of ranging from 50 to 100 μM [36].
3.2. Antiviral Activity
As a chronic infectious disease, hepatitis C can cause liver cancer; NS3 nucleoside triphosphatase
(NTPase)/helicase plays an important role in hepatitis C virus (HCV) replication. Salam et al. screened
inhibitors of NS3 helicase from marine organism extracts by a photo-induced electron transfer (PET)
system. Psammaplin A showed the apparent Km value of 0.4 μM of NS3 ATPase activity which
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indicated no influence. The inhibitory effect of psammaplin A on viral replication was verified by
experiments and it can be used as a potential antiviral agent [70]. Psammaplin A also shows anti-HIV
activity. Richard et al. reported that psammaplin A could induce the expression of latent HIV-1 provirus
in Jurkat full-length T cell lines (clones 8.4, 9.2, and 10.6). Psammaplin A synergistically enhanced
the expression of HIV-1 when combined with the protein kinase C (PKC) activator prostratin, but not
the histone deacetylase inhibitor (HDACi) panobinostat, indicating its latency to be a reversing agent
(LRA) to induce proviral expression [71].
3.3. Embryo Development Promotive Activity
Reprogramming of donor somatic nuclei to an omnipotent embryonic state is a major obstacle
to successful cloning, and treatment of cloned embryos with epigenetic modifiers such as HDACi
can improve cloning efficiency. Acting as a novel HDACi, the effects of psammaplin A on the
development and quality of cloned mouse embryos were investigated by Mallol et al. The experimental
results confirmed that psammaplin A increased the cloning efficiency of mice more than valproic acid
(VPA) [72].
For the development of somatic cell nuclear transfer (SCNT) embryos, the embryonic stem cell
(ESC)-derived rates from the obtained blastocysts and intracytoplasmic sperm injection (ICSI) fertilized
embryos were determined with or without treatment of psammaplin A. The results showed that
psammaplin A-treated SCNT exerted increased nuclear transfer ESC derivation and blastocyst rates,
and further increased embryo delay, which was not necessarily related to the epigenetic effects [73].
3.4. Insecticidal Activity
Chitinase is an interesting target that interferes with growth and develops alternative strategies
for controlling pests. Psammaplin A is a chitinase inhibitor and acts as an effective active ingredient
for the termite bait program. Husen et al. evaluated the impact of psammaplin A on Reticulitermes
flavipes (R. flavipes) by using a no-choice feeding bioassay of eastern underground termites. The
results indicated that chitinase inhibitor psammaplin A was toxic to R. flavipes and induced mortality
in a non-concentration-dependent manner [74]. After that, Husen et al. further designed a trial to
evaluate the palatability, feeding deterrence, consumption, and subsequent mortality. Psammaplin
A was incorporated into filter paper diets and the treated filter papers were used as food source or
bait for termite workers used in this study. In the no-selective feeding trial, the diet consumption of
termites fed a 0.3% (2–5 weeks) and 0.15% (4–5 weeks) psammaplin A treatment diet was significantly
reduced. In the double selection test, termites consumed almost the same amount of diet treated with
psammaplin A as an untreated diet (except for diets treated with 0.3% psammaplin A). Additionally, in
the no-select bioassay, termite mortality from diets treated with chitinase inhibitors was significantly
higher than in untreated diets; at the same time, the biological activity of psammaplin A-treated diets
in the double-select feeding arenas was reduced by more than 50%. These results indicate that chitinase
inhibitors have new potential [75].
Psammaplin A can also be used as an aphid management tool. In a previous study,
Saguez et al. reported the aphicidal effects of psammaplin A. Psammaplin A reduced fecundity,
increased larval mortality, and reduced body size. An artificial diet was used to provide M. persicae with
active (1, 10, 100 and 500 μg/mL) and inactive (500 μg/mL) bacterial (Serratia marcescens) chitinase. These
compounds increased the nymphal viability at all active chitinase doses compared to the control diet,
whereas inactive chitinase cannot [76]. Afterward, four chitinase inhibitors, cyclo-(histidine-valine),
cyclo-(valine-tyrosine), psammaplin A, and allosamidin, were selected for feeding experiments with
M. persicae (Sulzer), the peach-potato aphid. Artificial feed was used to supply 10, 50, and 100 μg/mL.
The results showed that psammaplin A was the most toxic compound, increasing the mortality of all
aphids at 50 and 100 μg/mL [77,78].
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3.5. Active Chemical Defense
Active chemical defense, which rapidly transforms precursor molecules of defensive compounds
after tissue damage, is widely found in terrestrial and marine plants, but is extremely rare in marine
invertebrates. Thoms et al. observed that wound activation converted psammaplin A sulfate to
psammaplin A in the tissue of the tropical sponge Aplysinella rhax. The same group, in a feeding test
of the puffer fish Canthigaster solandri, showed that the antifeeding activity of psammaplin A was
increased compared with the sulfate, which suggested that psammaplin A possessed defensive activity.
A series of observations on their response to other sponge species indicated that marine organisms
may have more active defenses [79].
3.6. Eryptosis Induction Acitivity
The cellular mechanisms that stimulate eryptosis include oxidative stress, cytosolic Ca2+ activity
([Ca2+]i), and increased ceramide; Abdulla Al Mamun Bhuyan et al. found that psammaplin A increased
ceramide abundance and dichlorodihydrofluorescein diacetate (DCFDA) fluorescence and triggered
cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, caused by induction of
oxidative stress, increase of [Ca2+]i, and enhanced appearance of ceramide [80].
3.7. Anticancer Effects
The underlying anticancer properties of psammaplin A may depend on its efficacy in regulating
enzymes that regulate apoptosis, differentiation, invasion, proliferation, angiogenesis, and DNA
replication and transcription (Figure 3). Jiang et al. found that psammaplin A showed significant
cytotoxic activity against the RAW264.7 cell line and could substantially inhibit SV40 DNA replication.
The polymerase α-primase was one of the main targets [39]. Psammaplin A radiosensitization of
glioblastoma U-373MG and lung cancer A549 cell lines might be due to the inhibition of DNA
repair [81]. Godert et al. found that psammaplin A was a potent DNMT inhibitor in vitro, but it failed
to alter the level of genomic DNA methylation in treated human colon carcinoma HCT116 cells [59].
Psammaplin A also inhibited cell growth of lung cancer NCI-H226 Bap1 null cells at a concentration
between 1/10,000 μL and 1/1000 μL, while exhibiting minimal toxicity to human neuroblastomal SKN
cells. When CPT was added, the performance strongly indicated that psammaplin A could exert a
synergetic DNA damaging effect [82]. Kim et al. reported the tissue distribution and pharmacokinetics
of psammaplin A as a DNMT and HDAC inhibitor in mice. The intravenous injection dose was
10 mg/kg and psammaplin A was rapidly eliminated, with the average half-life of 9.9 min and the
systemic clearance (CLs) was 925.1 ± 570.1 mL/min. Psammaplin A was highly distributed in lung
tissues, with lung-to-serum partition coefficients (Kp) of 49.9 to 60.2, while the concentrations in other
tissues were either comparable to or less than serum concentrations [83].
Epigenetic dysregulation is one of the causes of cancer, and epigenetic factors are condidered as
therapeutic targets. Nebbioso et al. pointed out that UVI5008 was an epigenetic modifier that inhibited
HDAC, DNMT, and sirtuins, which efficiently induced selective death of cancer cells and exerted its
activity in genetic mouse models of human breast cancer and several human tumor xenografts. Its
anticancer activity involved the activation of reactive oxygen species and death receptors. UVI5008
showed strong anticancer properties with IC50 values from 0.2 to 3.1 μM. It also showed activity in vivo
in HCT116- or MCF-7-xenografted mice (40 mg/kg) and ex vivo in acute myeloid leukemia (AML)
blasts (5 μM) [84].
Massague et al. found that psammaplin-based HDAC inhibitors differentially induced
hypoxia-inducible factor 1 (hif-1) activation, inhibited HDAC activity, and disrupted the growth
of organic metastatic TNBC subclones. The results showed that psammaplins significantly
inhibited the growth of bone (BoM1833) tumor spheres in the 3D culture system [31]. Peroxisome
proliferator-activated receptors (PPARs) are ligand-activated transcription factors which have been
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shown to inhibit the growth of human breast tumor cells, induce apoptosis, and promote terminal
differentiation. Psammaplin A can activate PPARγ and induces apoptosis in MCF-7 cells [85].
 
Figure 3. Schematic representation of the cytotoxic effects of psammaplin A.
Psammaplin A showed inhibitory activity in enzyme assays and antiproliferation assays with
IC50 values of 0.003 and 1 μM, respectively. It selectively induced high acetylation of histones,
resulting in upregulation of the well-known HDAC target gene gelsolin at the transcriptional level.
Furthermore, the reduced psammaplin A showed stronger inhibitory activity than the unreduced
one. It is noteworthy that glutathione-depleted cells were not sensitive to psammaplin A, which
indicated that cellular reduction was responsible for HDAC inhibition [41]. Baud et al. also reported
the cytotoxicity and enzyme inhibitory activity against recombinant HDAC1 by the active monomer
(thiol) form of psammaplin A [86]. DNMT1 inhibitory activity was not found in another study [60].
In addition, psammaplin A inhibits aminopeptidase N (APN), which plays an important role in
tumor progression and is involved in processes such as proliferation, adhesion, angiogenesis, and
tumor invasion [40]. Psammaplin A also has the ability to inhibit mycothiol-S-conjugate amidase
(MCA) [38], topoisomerase II [35], farnesyl protein transferase [37], and leucine aminopeptidase [37].
In addition, psammaplin C is a natural product of primary sulfonamide. Mujumdar et al. evaluated its
inhibitory properties for the treatment-related carbonic anhydrase (CA) zinc metalloenzyme. At the
same time, the analog psammaplin C showed unprecedented inhibition levels with a Ki of 0.79 nM
of isoenzyme hCA XII. They also proposed the protein X-ray crystal structure of psammaplin C
complexed with human CA and determined the binding posture with the hCA II, hCA IX, and hCA XII
mimetic active sites [26]. Psammaplin C also reduced the efflux of temozolomide by P-glycoprotein and
resensitizes the primary neurosphere to temozolomide. Salaroglio et al. revealed that the interaction of
CA XII and Pgp could ultimately block the efflux function of Pgp to improve the prognosis of patients
with glioblastoma [87].
Targeting the autophagic pathway plays a key role in chemotherapeutic approaches to treat
human cancers and preventing tumor-derived chemoresistance; at the same time, some marine-derived
compounds show this potency. Ratovitski et al. used psammaplin A to induce the expression of several
autophagic signaling intermediates in human glioblastoma, squamous cell carcinoma, and colorectal
cancer cells through transcriptional regulation by tumor protein p53 family members [34].
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Psammaplin A also shows anticancer activity by inducing cell cycle arrest and apoptosis.
Kim et al. reported that psammaplin A could significantly inhibit the proliferation of MCF-7/adr cells
in a dose-dependent manner, and the cells arrested at the G2/M phase [33]. Ahn et al. investigated the
antitumor effect on Ishikawa endometrial human cancer cells. The results showed that psammaplin
A could significantly inhibit Ishikawa cell proliferation in a dose-dependent manner. Psammaplin
A significantly induced the expression of acetylated H3 and H4 histones, resulted in significant
apoptosis associated with p53-independent p21WAF1 expression, and showed antiproliferative effects
by selectively inducing genes involved cell cycle arrest [32].
4. Medicinal Chemistry
Inspired by the unique symmetrical structure of bromotyrosine-derived disulfide dimer scaffolds,
a collection of derivatives was constructed and synthesized through structural modifications, aiming
to explore potential therapeutic value and study the structure–activity relationships. With this
consideration in mind, we reviewed the derivatives of psammaplin A (Figure 1) as follows, according
to their different activities.
4.1. Antibacterial Derivatives
Some homodimeric and heterodimeric analogues of psammaplin A were refined by Nicolaou and
coworkers utilizing combinatorial chemistry through a disulfide exchange strategy [61]. Combinatorial
chemistry techniques have played an important role in the synthesis and structural activity optimization
of bioactive natural products [88]. Among the synthetic homodimeric derivatives, compounds 18, 19,
20, and 21 (Figure 4) showed significant antibacterial effects against MRSA. Moreover, the heterodimeric
derivatives fell into three types (A–C) (Figure 5). Type A representative compound 22 consisted of
two similar psammaplin-like structures. Type B representative compounds 23–26 were comprised
of one psammaplin-like component conjugated to an alkyl or aryl group. Type C representative
compounds 27 and 28 had no resemblance to the original psammaplin A structure. Among these
heterodimeric derivatives, compounds 23–28, with MIC values of 1.22, 2.43, 1.61, 3.90, 4.10, and
3.14 μg/mL, respectively, possessed higher antibacterial activity than psammaplin A (MIC 5.47 μg/mL).
Especially, compound 23 showed similar activity to clinically used drugs vancomycin and ciprofloxacin,
with MIC values of 0.83 and 0.89 μg/mL, respectively.
 
Figure 4. Chemical structures of the synthetic homodimeric derivatives 18-21.
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Figure 5. Chemical structures of three types of psammaplin A derivatives 22-28.
In the same year, in order to obtain better antimicrobial agents, Nicolaou and coworkers continued
to optimize the heterodimeric lead compounds 23–26, mainly by studying the toxicity, potency, and
nonspecific protein-binding effects through molecular design, structural modification, and mechanism
of action [89]. Subsequently, a series of highly potent heterodimeric derivatives were afforded by
parallel synthesis. Some representative compounds 29–33 (Figure 6) possessed 50-fold higher activities
than their parent against both SA and MRSA. The average MIC values of compounds 30–33 were 0.09,
0.12, 0.29, and 0.12 μg/mL against SA, respectively, and 0.09, 0.11, 0.27, and 0.11 μg/mL against MRSA,
respectively. In an in vitro toxicity assay, a therapeutic index (TI) ratio, as an estimate of the selectivity
of the heterodimeric derivatives afforded the average IC50 value of a compound against fibroblast and
lymphocyte cells, and was divided by the average MIC value against SA and MRSA strains, and the
results showed that heterodimer 31, comprised of 3-bromo-phenyl alaine and 4’-fluorophenyl groups,
had a good TI of 37.5, which indicated low toxicity and good selectivity. The mechanism study failed
to confirm the reported inhibition of DNA gyrase [30] by psammaplin A and its derivatives. However,
their studies also propose a nonspecific redox-based mechanism for these heterodimers.
 
Figure 6. Chemical structures of the representative heterodimeric derivatives 29-33.
Recently, Blache et al. synthetized a series of psammaplin A analogues using click chemistry based
on a framework of bis-triazole (Scheme 4) [90]. Among them, the representative derivatives of the
dimethylaminoethyl chain 40 and the dimethylaminopropyl chain 41 possessed potent antibiofilm
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activity against three Gram-negative strains, including Pseudoalteromonas lipolytica (TC8), Paracoccus sp.
Strain (4 M6), and Pseudoalteromonas ulvae (TC14), with EC50 close to tributyltin oxide and ampicillin.
Furthermore, compounds 40 and 41 were not lethal to bacteria at low concentrations and showed
weak bactericidal effects at high concentrations, which indicated they might be used as coantibiotics or
nontoxic cobiocides.
 
Scheme 4. Synthesis of psammaplin A bis-triazole derivatives 40 and 41. Reagents and conditions:
(a) BBr3/CH2Cl2, 0 ◦C, rt, 4 h; (b) NaN3/DMF, 5 h, 90 ◦C; (c) K2CO3, 18-crown-6, 2-dimethylaminoethyl
chloride or 3-chloro-N,N-dimethylpropan-1-amine, acetone, reflux; (d) CuSO4/sodium ascorbate,
DMF/H2O (2:1), 24 h, rt.
4.2. Anticancer Derivatives
A collection of more than 70 psammaplin A analogues were synthesized by Fuchter and
coworkers [91]. The enzyme inhibitory activities against histone deacetylase 1 (HDAC 1) and
HDAC 6 were evaluated. The derivatives 46, 47, 53, and 54 (Scheme 5) showed more potent activity
than psammaplin A and current inhibitors including trichostatin A and SAHA. Moreover, these
compounds also displayed good selectivity for HDAC 1 over HDAC 6. In short, the structure−activity
relationship indicated that the derivatives with the electron withdrawing group or the electron donating
group in the benzene ring exhibited higher enzyme inhibitory activity than psammaplin A.
Subsequently, this group synthesized a library of psammaplin A derivatives (Figure 7) by
modifying the disulfide bond, the aromatic group substituents, and the oxime functionality, aiming to
study the enzymatic selectivity and mechanism of action against DNA methyltransferases and histone
deacetylases [92]. The HDAC assays showed that the disulfide analogues 55–62 were less potent than
their reduced products containing the free thiol. When the sulfur end group was protected, analogues
63–70 showed low to no inhibition of both HDAC 1 and HDAC 6. However, hydroxamic derivative 71
possessed highly potent activities against HDAC 1 (2 nM) and HDAC 6 (190 nM). Among the derivatives
changed by the oxime functionality, the oxime-containing analogue 72 and hydrazone analogues 73
and 74 were 444−611 and 80−183-fold more potent, respectively, than the α-ketoamide-containing
compounds 75 and 76 against HDAC 1. In the derivatives of aromatic group substituents, compound
77 exhibited the highest selectivity against HDAC 1. However, its potency was minor compared to the
presence of the oxime and the free thiol. Unfortunately, psammaplin A and its derivatives were found
to have weak inhibitory effects against DNA methyltransferases. On the other hand, the cytotoxicity
studies showed that compound 72 had the smallest IC50 values of 0.16 and 0.61 μM against human lung
carcinoma A549 and human breast carcinoma MCF-7, respectively. Amazingly, 73 was particularly
selective against MCF-7 (IC50 3.42 μM) with a ten-fold increase compared to the other cancer cell lines.
Besides, hydroxamic acid 55 showed significant antiproliferative activity against A549 and MCF-7,
which indicated that the cytotoxicity of derivatives might be related to HDAC inhibition. Western blot
analysis showed that treatment with compound 71 could upregulate histone acetylation levels and not
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affect the tubulin acetylation levels. According to docking studies with HDAC 1, psammaplin A and
its derivatives could bind to Zn2+.
 
Scheme 5. Synthesis of psammaplin A analogues 46, 47, 53, and 54. Reagents and conditions:
(a) NaOAc, N-Ac-Gly, Ac2O; (b) HCl; (c) HONH2·HCl, pyridine; (d) EDCI, N-hydroxy-succinamide
dioxane; nucleophile, NEt3, dioxane/MeOH; HCl, CH2Cl2/Et2O/MeOH; (e) Pd(OAc)2, P(o-Tol)3,
NEt3, DMF; (f) osmium(VIII) oxide, NMO, MeCN/water; (g) NBS, DMF; (h) p-TsOH·H2O, benzene;
HONH2·HCl, NaOAc, MeOH; (i) cystamine, AlMe3, CH2Cl2.
In order to focus on the structure–activity relationship of the antiproliferative activities of
psammaplin A derivatives, de Lera and coworkers synthesized five series of derivatives (Figure 8)
by modifications in the halo-tyrosine aryl ring, the oxime bond, the connecting chain length, and the
disulfide unit [60]. Subsequently, the HDAC inhibition tests showed that the derivatives 82 and 83
substituted on aryl rings possessed more potent inhibitory activity than psammaplin A. However,
compounds 84–89 showed no apparent inhibitory effect, which suggested the oxime and disulfide
bonds were indispensable for the HDAC inhibition activity. The cell-based assays on the U937 myeloid
leukemia cells indicated that derivatives 85, 82, and 83 lacking the oxime could cause cell cycle arrest at
G1 phase, and the spirocycle derivative 86 lacking the free oxime and flexibility could induce apoptosis
and arrest cell cycle at the G2 phase. The homologues 78–81, including three to six methylene units,
and dimer 84, containing an ethylene group replacing the disulfide bond, had weak apoptotic effects
against the U937 cells. Mechanically, compounds 78–81, 84, 86, 87, and 89 could decrease the expression
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levels of p21WAF1 and tubulin acetylation. The derivative 82 could upregulate the levels of p21WAF1
even higher than SAHA. Moreover, 82 and 83 could increase the acetylated histone H3 levels.
 
Figure 7. Chemical structures of the psammaplin A derivatives 55-77.
 
Figure 8. Chemical structures of the psammaplin A derivatives 78-89.
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With continued research by de Lera and coworkers [42], a number of indole-based psammaplin A
derivatives were designed and synthesized by replacing the o-bromophenol group with an indole ring
to pursue more potent molecules for epigenetic disorder modulation, such as cancer. Especially, the
induction ability of U937 acute myeloid leukemia (AML) cell apoptosis by compound 96 (Scheme 6)
was stronger than that of the parent. Cell-based assays affirmed that the presence of disulfide bridge
from 96 is essential for cell cycle arrest, differentiation, and induction of apoptosis. Besides, 96 could
more efficiently induce α-tubulin acetylation as a sign of HDAC6 inhibition and increase the expression
of histone H3 and p21 protein. Derivative 96 also induced cell cycle arrest and apoptosis in ex vivo AML
patient blasts. In enzyme-based assays, 96 not only possessed the stronger inhibitory activities against
HDAC and DNMT enzymes, but also inhibited the NAD+-dependent SIRT deacetylase enzymes.
In vivo pharmacokinetics study showed that 96, as a prodrug, could immediately transform into the
glutathione intermediate to exert multiple enzyme inhibitory activities [77]. More importantly, the
maximum tolerated dose of 96 was higher than that of listed HDAC inhibitors, which merited further
investigation for cancer therapy.
 
Scheme 6. Synthesis of indole-based psammaplin A derivative 96. Reagents and conditions: (a) K2CO3,
CH2Cl2, 25 ◦C, 20 h; (b) K2CO3, CH2Cl2, TrCl, 25 ◦C, 20 h; (c) LiOH·H2O, THF/H2O (1:1), 25 ◦C, 20 h;
(d) cystamine, EDC, NHS, dioxane, 25 ◦C, 2 h; (e) 1 M HCl in Et2O, CH2Cl2, 25 ◦C, 2 h.
Some psammaplin A fluorescent analogs were synthesized by Lindel and coworkers [63]. The
cytotoxicity studies showed the fluorescent 4-coumarinacetyl-α-(hydroxyimino)acyl derivatives 97 and
98 (Figure 9) with IC50 values of 0.93 and 1.10 μg/mL, respectively, were about two-fold stronger than
that of psammaplin A (IC50 0.42 μg/mL) against the mouse fibroblast L-929 cells. Furthermore, bis- and
mono (coumarinyl) derivatives 99 and 100 (Figure 9) lacking α-(hydroxyimino)acyl moieties were not
cytotoxic. The HDAC inhibitory activities of the coumarin–psammaplin hybrid 97 (IC50 0.011 μM) was
two-fold more potent than psammaplin A (IC50 0.028 μM) by a fluorometric HDAC assay. Afterwards,
fluorescence microscopy revealed that compounds 97 and 98 lacking α-(hydroxyimino)acyl units were
taken up into the cytoplasm, leading to fluorescence in the nuclear envelope, not in the nucleus, which
indicated the disulfide bonds were reduced to the thiol before the disulfide penetrated the nucleus [93].
Soon afterwards, Lindel and coworkers synthesized the first photoreactive psammaplin A
derivative 111 by adding 1-azi-2,2,2-trifluoroethyl moieties to benzene rings (Scheme 7) [94].
Photopsammaplin 111 showed antiproliferative activity in vitro with an average IC50 value of 1.4 μM
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against 42 human cancer cell lines, which was especially sensitive to lung cancer (LXFA 526), melanoma
(MEXF 276), mammary cancer (MAXF 401 and MCF-7), and bladder cancer (T-24), with IC50 values
below 0.6 μM. Furthermore, the fluorometric HDAC assay showed 111 was also a potent HDAC
inhibitor, with an IC50 value of 35 nM. With this information, photopsammaplin 111 might be
considered as a good candidate of photoaffinity labeling, which played an important role in new
targets identification of psammaplin A.
 
Figure 9. Chemical structures of the psammaplin A fluorescent derivatives 97-100.
Scheme 7. Synthesis of photopsammaplin 111. Reagents and conditions: (a) propane-1,3-diol, p-TsOH,
toluene, rt, 2.5 h; (b) Mg, THF, rt, 2 h; then 0 ◦C, 2,2,2-trifluoro-1-(piperidin-1-yl)ethanone, 2 h, rt;
(c) (i) HONH2·HCl, pyridine, rt, 9 h; (ii) NEt3, p-TsCl, 24 h, 0 ◦C to rt; (d) NH3, 6 h, −78 ◦C to rt;
(e) NEt3, I2, 15 min, 0 ◦C, then 3 h, rt, avoiding daylight; (f) 0.5 M H2SO4, acetone/H2O, rt, 12 h, quant;
(g) LDA, THF, −78 ◦C, 14 h; (h) (i) NEt3·3HF, MeOH, rt, 2 h; (ii) HONH2·HCl, MeOH, rt, 17 h, quant;
(i) LiOH·H2O, THF/H2O, rt, 20 h, quant; (j) cystamine dihydrochloride, NHS, DCC, NEt3, DMF, rt, 15 d.
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Innovative synthesis of psammaplin analogues is proposed by Bertrand and coworkers through
superacid, microwaves, and S-ene chemistry reactions as zinc-dependent HDAC inhibitors [95]. Among
them, the thiol derivative 119 (Scheme 8) was five-fold more selective for HDAC 6 compared to HDAC
2. Moreover, in the bioluminescent resonance energy transfer tests, the HDAC inhibition activity of
119 confirmed the oxidative process importance in cancer cells in the environment of biomolecules
being oxidized or reduced.
 
Scheme 8. Synthesis of psammaplin A analogue 119. Reagents and conditions: (a) CF3SO3H; (b) amine,
heating neat or microwave neat; (c) hν, R2-SH; (d) air.
Twenty-eight derivatives of psammaplin A were prepared by Park and coworkers using a new
concise approach [65]. Among them, compounds 120–124 (Figure 10) displayed comparable cytotoxicity
to the parent compound. Especially, 120 possessed the highest antiproliferative activity against A549
cells with an IC50 value of 1.20 μM. Study of the structure–activity relationship revealed the disulfide
bond and oxime group might be primary pharmacophores for high cytotoxicity. Furthermore, the
fluorometric HDAC assay showed that 120 could inhibit the HDAC enzyme activity and enhance the
expression of acetylated H3 in the A549 cells. The mechanism study showed 120 restrained the growth
of A549 cells through the AKT and ERK signaling pathways. The in vivo study reconfirmed that 120
could inhibit tumor size outgrowth.
 
Figure 10. Chemical structures of the psammaplin A derivatives 120-124.
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A collection of novel psammaplin A derivatives were synthesized by Zhao and coworkers [96].
The derivatives 133 and 134 (Scheme 9) showed potent cytotoxicity against four cancer cell lines
(PC-3, MCF-7, A549, and HL-60) and better HDAC inhibition than psammaplin A. Molecular docking
simulation showed that the hydrogen atom of the oxime group could interact with the active site of
Asp 99 of HDAC1 via hydrogen bonding, and the hydroxyl group which could interact with Glu 203 at
the entrance to the active site tunnel was optimally attached on the para-position of the benzene ring.
 
Scheme 9. Synthesis of psammaplin A analogues 133 and 134. Reagents and conditions: (a) hydantoin,
ethanolamine, EtOH, H2O, reflux, 5 h; (b) NaOH, H2O, reflux, 12 h; (c) NH2OH·HCl, NaOH, NaHCO3,
H2O, rt, overnight; (d) cystamine dihydrochloride, EDCI, HOBt, THF, rt, 24 h.
5. Conclusions
In summary, marine natural products, as extremely valuable resources, have become significant
enablers of new drug development due to their extensive chemical variability and diverse bioactivities.
Unfortunately, their in-depth study and application are restricted due to the low natural isolated
yield from marine microorganisms and their poor physiological stability. Therefore, a great deal of
interest has been shown in the total synthesis of marine natural products. The conventional total
synthesis methods of psammaplin A were initiated from tyrosine or phenylpyruvic acid derivatives.
Since 2009, improved synthesis methods have mainly used various substituted benzaldehydes as
the starting materials, which made psammaplin A easier to obtain. Moreover, the pharmacological
activities and structural modifications of the dimeric marine natural product psammaplin A were
comprehensively summarized. Psammaplin A possesses a wide range of pharmacological activities,
including antimicrobial, anticancer, antiviral, embryo development promotive, insecticidal, active
chemical defense, and eryptosis-inducing activities. More importantly, it displays antibacterial and
antiproliferative activities mainly through inhibiting multiple enzymes, including chitinase, HDAC,
and others. To further improve its drug-like properties, a collection of psammaplin A derivatives were
synthesized through structural modifications aimed to explore their potential therapeutic value and
to study the structure–activity relationships. Among them, some antibacterial derivatives showed
stronger antimicrobial activity against SA and MRSA via inhibiting DNA gyrase and bacterial DNA
synthesis enzymes. Furthermore, the promising anticancer derivatives not only possessed stronger
antiproliferative activities against various cancer cell lines, but also indicated higher HDAC 1 inhibitory
activity. Finally, the structure–activity relationships revealed that the disulfide bond and the oxime
moieties are indispensable pharmacophores for its bioactivities. Collectively, we hope this review will
aid researchers in further studying psammaplin A.
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